SUPPLEMENT
FY2023 — Annual financial statements
FY2023PDF · 217 pages4.7 MB
for the year ended 30 June 2023 ANNUAL FINANCIAL STATEMENTS -- 1 of 217 -- 1 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 HOW WE REPORT TO OUR STAKEHOLDERS CONTENTS Basis of preparation The consolidated and separate Annual Financial Statements have been prepared in accordance with IFRS Accounting Standards, its interpretations adopted by the IASB, the South African Institute of Chartered Accountants (SAICA) Financial Reporting Guides Limited as issued by the Accounting Practices Committee, Financial pronouncements as issued by the Financial Reporting Standards Council, the JSE Limited Listings Requirements, JSE Debt Listings Requirements as well as the South African Companies Act. They have been prepared in accordance with the going concern principle using the historical cost basis except where otherwise stated in the accounting policies (refer Annexure B). The Annual Financial Statements have been prepared under the supervision of Deon Viljoen CA(SA), Group Chief Financial Officer. The Annual Financial Statements are reviewed by management, the Discovery Limited Audit Committee and Board, and are audited by the external auditors of the Group. The embedded value statements has been prepared by Peter Bolink (FASSA) and supervised by Andrew Rayner (FASSA, FIA). A copy of the set of annual consolidated financial statements with the signatures of the directors is available at the Company’s registered office. DISCOVERY LIMITED Registration number 1999/007789/06 Our governance report includes information on our governance philosophy, leadership and our compliance with King IV™. GOVERNANCE REPORT An overview of the Group’s performance against our Integrated Sustainability Framework and, where appropriate, against relevant standards and frameworks. SUSTAINABILITY REPORT ANNUAL FINANCIAL RESULTS PRESENTATION AND BOOKLET Provides an overview of Discovery’s financial performance and can be accessed at www.discovery.co.za/corporate/investor-relations The consolidated financial results, embedded value and five-year review of the Discovery Group, as well as the separate financial results of Discovery Limited. GROUP ANNUAL FINANCIAL STATEMENTS THIS REPORT Our primary report to our shareholders, providers of financial capital and other key stakeholders, detailing how we created, preserved or eroded value for our stakeholder groups. INTEGRATED ANNUAL REPORT Discovery’s climate change response regarding governance, strategy, risk management, and metrics and targets related to the Group’s environmental impact. TASK FORCE ON CLIMATE-RELATED FINANCIAL DISCLOSURE (TCFD) REPORT Communicates material tax disclosure information to demonstrate our commitment to tax transparency and operating as a force for good through our tax contributions. TAX TRANSPARENCY REPORT Outlines our remuneration policy and implementation approach and factors influencing our remuneration-related decisions. REMUNERATION REPORT CONSOLIDATED FINANCIAL STATEMENTS 2 Directors’ responsibility statement 3 Group Chief Executive and Group Chief Financial Officer’s internal financial control responsibility statement 3 Certificate by the Company Secretary 4 Report of the Discovery Limited Audit Committee 10 Independent auditors’ report 15 Directors’ report 18 Group statement of financial position 19 Group income statement 20 Group statement of other comprehensive income 21 Group statement of cash flows 22 Group statement of changes in equity 23 Notes to the Group annual financial statements DISCOVERY LIMITED COMPANY 126 Company statement of financial position 127 Company income statement 127 Company statement of other comprehensive income 128 Company statement of cash flows 129 Company statement of changes in equity 130 Notes to the Company annual financial statements ANNEXURES 148 Annexure A – Group structure 150 Annexure B – Group accounting policies 195 Annexure C – Directorate 200 Annexure D – Unaudited analysis of shareholders 201 Annexure E – Embedded value statement 213 Annexure F – Unaudited five-year review 214 Glossary -- 2 of 217 -- 2 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Directors’ responsibility statement for the year ended 30 June 2023 The directors of Discovery are required by the Companies Act, No. 71 of 2008, as amended (Companies Act), to maintain adequate accounting records and to prepare financial statements for each financial year which fairly present the state of affairs of Discovery at the end of the financial year, and of the results and cash flows for the period. In preparing the accompanying Annual Financial Statements, International Financial Reporting Standards have been used and reasonable estimates have been made. The Annual Financial Statements incorporate full and responsible disclosure, in line with Discovery’s philosophy on corporate governance. The directors have reviewed Discovery’s budget and cash flow forecast for the year to 30 June 2024. On the basis of this review, and in light of the current financial position and available cash resources, the directors have no reason to believe that Discovery will not be a going concern for the foreseeable future. The going concern basis has therefore been adopted in preparing the Annual Financial Statements. The directors are responsible for Discovery’s systems of internal control, which include internal financial controls in the various subsidiaries that are designed to provide reasonable, but not absolute, assurance against material misstatement and loss. Discovery maintains internal financial controls to provide assurance regarding: Safeguarding of assets against unauthorised use or disposition, and The maintenance of proper accounting records, written or electronic and the reliability of financial information used within the business, or for the publication thereof, including submissions to the Companies and Intellectual Property Commission (CIPC). The controls contain self-monitoring mechanisms, and actions are taken to correct deficiencies as they are identified. Even an effective system of internal control, no matter how well designed, has inherent limitations, including the possibility of circumvention and the overriding of controls. An effective system of control therefore aims to provide reasonable assurance with respect to the reliability of financial information and, in particular, the presentation of Annual Financial Statements. To the best of their knowledge and belief, based on the above, the directors are satisfied that no material breakdown in the operation of the systems of internal control and procedures has occurred during the year under review. Discovery’s external auditors, PricewaterhouseCoopers Inc. and KPMG Inc., have audited the Annual Financial Statements and their unqualified report appears on pages 10 to 14. The Annual Financial Statements of Discovery for the year ended 30 June 2023, which appear on pages 18 to 199 have been approved by the Board of Directors on 20 September 2023 and are signed on its behalf by: Mark Tucker Chairperson Adrian Gore Group Chief Executive DIRECTORS’ RESPONSIBILITY TO THE SHAREHOLDERS OF DISCOVERY LIMITED AND ITS SUBSIDIARIES (DISCOVERY OR THE GROUP) -- 3 of 217 -- 3 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Group Chief Executive and Group Chief Financial Officer’s internal financial control responsibility statement for the year ended 30 June 2023 Certificate by the Company Secretary for the year ended 30 June 2023 After due, careful, and proper consideration, in accordance with the JSE Listings Requirements 3.84(k), each of the directors, whose names are stated below, hereby confirm that: The Annual Financial Statements set out on pages 18 to 199 fairly present, in all material respects, the financial position, financial performance and cashflows of the issuer in terms of IFRS; To best of our knowledge and belief, no facts have been omitted or untrue statements made that would make the Annual Financial Statements false or misleading; Internal financial controls have been put in place to ensure that material information relating to the issuer and its consolidated subsidiaries have been provided to effectively prepare the financial statements of the issuer; The internal financial controls are adequate and effective and can be relied upon in compiling the Annual Financial Statements, having fulfilled our role and function as executive directors with primary responsibility for implementation and execution of controls; Where we are not satisfied, we have disclosed to the Discovery Limited Audit Committee and the auditors any deficiencies in design and operational effectiveness of the internal financial controls, and have remediated or taken steps to remedy the deficiencies; and We are not aware of any fraud involving directors. Adrian Gore Deon Viljoen Group Chief Executive Group Chief Financial Officer 20 September 2023 20 September 2023 It is hereby certified in terms of section 88(2)(e) of the Companies Act, that Discovery Limited has for the year ended 30 June 2023 lodged with the Companies and Intellectual Property Commission (CIPC) all such returns as are required by a public company in terms of this Act and that all such returns are true, correct and up to date. Ayanda Ceba Company Secretary 20 September 2023 -- 4 of 217 -- 4 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Report of the Discovery Limited Audit Committee for the year ended 30 June 2023 We are pleased to present the Discovery Limited Audit Committee’s (DLAC) report for the financial year ended 30 June 2023. Our report details how we accomplished our various statutory obligations as well as our key focus areas and the significant audit matters we considered during the period. This report has been prepared based on the requirements of the Companies Act, the King Report on Corporate Governance™ for South Africa, 2016 (King IV™), the JSE Listings Requirements, the JSE Debt Listings Requirements and other applicable regulatory requirements. TERMS OF REFERENCE, ROLES AND RESPONSIBILITIES The DLAC is an independent statutory committee constituted under section 94 (7) of the Companies Act. The DLAC’s main objective, as set out in its Terms of Reference, is to assist the Board in fulfilling its oversight responsibilities and evaluating the adequacy and efficiency of accounting policies, internal financial controls (IFCs) and financial and corporate reporting processes. In addition, the DLAC assesses the effectiveness of the internal auditors and the independence and effectiveness of the joint external auditors, as well as considers and recommends to shareholders the appointment of the joint external auditors. Structure of the audit committees in Discovery Group The scope of the DLAC extends to all activities of the Discovery Limited Group and all its subsidiaries, both locally and internationally. Prior to implementing the revised Subsidiary Governance Framework (SGF), the DLAC also acted as the statutory Audit Committee of Discovery Life Limited and Discovery Insure Limited. Composition and governance The DLAC consists of a minimum of three independent non-executive directors of the Discovery Limited Board of Directors. During the financial year ended 30 June 2023, the committee held six meetings per the standard meeting cycle, one ad hoc meeting and an annual trilateral meeting with the Prudential Authority. The DLAC has the appropriate balance, diversity of knowledge, financial skills, and experience to execute its duties effectively. The membership, qualifications, and attendance of the members of the DLAC for the year ended 30 June 2023 are as follows: Committee member1 Qualifications Number of meetings eligible to attend Number of meetings attended D Macready (Chairperson) BCom (Hons), CTA, CA (SA) 6 6 M Hlahla BA (Hons) (Economics), MA 6 5 M Schreuder BCom (Hons), FIA, FASSA 6 6 1 L Chiume and KC Ramon were both appointed as independent non-executive directors and as members of the Discovery Limited Audit Committee, with effect from 18 September 2023. In addition to their membership on the DLAC, the committee members also serve across all key Board committees so as to ensure a collective and integrated oversight of key matters across the Discovery Group. Committee member Actuarial committee Risk and compliance committee Remuneration committee Social and Ethics committee D Macready x x M Hlahla x x M Schreuder x x The Chairperson of Discovery’s Board and other non-executive directors are entitled to attend any meetings upon request. The Group Chief Executive Officer, Group Chief Financial Officer, Chairperson of the Actuarial Committee, and executive directors attend meetings or parts of meetings by invitation only. Other members of management are invited to attend meetings to provide the DLAC with greater insights into specific issues or areas of the Group. The Chairperson has regular contact with the management team to discuss relevant matters directly. -- 5 of 217 -- 5 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Report of the Discovery Limited Audit Committee continued for the year ended 30 June 2023 MEETINGS CYCLE FOR THE YEAR For the financial year ended 30 June 2023, the DLAC held the following meetings and regulatory engagements: Committee meetings: The DLAC convened six scheduled meetings. This included an ad hoc meeting to specifically consider the Annual Financial Statements and results, which included the disclosures on the transition to IFRS 17 Insurance Contracts (IFRS 17). Management engagement: The DLAC Chairperson meets regularly with the Group Chief Financial Officer, the Heads of Actuarial, Risk and Compliance, and executive management where necessary. Auditor engagements: The internal and external auditors have direct access to the Chairperson, including closed sessions without management during the year, on any matter they consider relevant to fulfilling the DLAC’s responsibilities. In addition, the Chairperson meets regularly with internal audit and the external auditors before each meeting and at other times as necessary by either party before Committee meetings. Regulatory engagements: The DLAC participated in the annual bilateral and trilateral meetings as set up with the respective regulatory bodies. Subsidiary Audit Committee Engagement: The DLAC Chairperson meets regularly with the individual Chairpersons of the subsidiary audit committees and can attend their subsidiary meetings as an invitee. Subsidiary Chairpersons are invited formally to give feedback to the DLAC during reporting periods. Annual General Meeting: The DLAC Chairman attends Annual General Meetings and is available to answer any questions concerning matters pertaining to the Committee’s responsibilities. KEY FOCUS AREAS FOR THE FINANCIAL YEAR 2023 The section discusses how the DLAC delivered against its key focus areas for the financial year 2023 as set out in the DLAC’s last year’s report. Subsidiary Governance Framework During the financial year 2023, the DLAC was actively involved in the revision and implementation of Discovery’s revised SGF. Implementing the new framework has significantly enhanced and strengthened the governance and oversight of subsidiaries within the broader Discovery multi- national groupings whilst maintaining its common purpose, values and Shared-Value business model. The implementation of the SGF has resulted in the formation of new independent statutory Audit Committees for Discovery Life and Invest, Discovery Insure and Discovery Health. These new Subsidiary Audit Committees supplement the existing independent Audit Committees of the Discovery Group Europe Limited grouping which incorporates both VitalityLife and VitalityHealth, the Discovery Bank Holdings Limited grouping, as well as the Vitality Group International Audit and Finance Committee. IFRS 17 Insurance Contracts The successful transition and implementation of IFRS 17 was a key focus of the DLAC. The Chairperson of DLAC is also the Chairperson of the IFRS 17 Governance Committee, a subset of the various Discovery and UK Vitality Audit and Actuarial committees. The DLAC and the IFRS 17 Governance Committee receive detailed feedback from the respective IFRS 17 project groups which allows for appropriate debates on key policy and modelling elections. Note 30 of Annexure B sets out in more detail the governance structures of the IFRS 17 project. The DLAC has played an integral role in the overall governance oversight of the IFRS 17 project which included the appropriateness, integrity and veracity of key policy elections and interpretations as well as consideration of the disclosures, communication and overall assurance obtained of the impact on transition from IFRS 4 Insurance Contracts (IFRS 4) to IFRS 17. The past year has seen the final quantification of the transition position to IFRS 17 as at 1 July 2022, the summary of which is set out in note 30 of Annexure B. The following key activities were concluded under the IFRS 17 project: Discovery has modelled full retrospective application of IFRS 17 up to 30 June 2022 for all material insurance portfolios. The benefit of such a significant exercise has enabled a rigorous and informed debate on accounting policy elections and modelling. The fully retrospective approach has allowed Discovery to evaluate how its products behave during various scenarios, such as the financial crises of 2008, volatile periods of market movements in foreign exchange and interest rates, and the COVID-19 pandemic. Discovery subject matter experts on IFRS Accounting Standards, Tax and Actuarial actively partake in various insurance industry forums to keep close to recent market practices and developments. This ensures that debates on the various accounting policy elections and modelling are well thought through and benchmarked to best industry practices. In particular, Discovery has remained closely attuned to the developments in tax legislation in both South Africa and the United Kingdom to clearly understand any impacts the legislation could have on Discovery’s recognised assets and liabilities. The members of the Discovery Board, the DLAC and various other Board sub-committees, and executives of the various insurance business lines have had extensive training sessions on IFRS 17, including the practical interpretation and application within the context of the Discovery Group businesses. The DLAC was consulted and provided input into the IFRS 17 Investor communications to the market. KPMG Inc., as the current joint auditor, and Deloitte & Touche, as the proposed joint auditor following the mandatory audit firm rotation of PricewaterhouseCoopers Inc., have been engaged to provide the external audit assurance for IFRS 17 in their capacity as the external auditors for the financial year ending 30 June 2024, the first financial year that Discovery will apply IFRS 17. A combined assurance approach is being followed whereby group internal and external audits incrementally test the new IFRS 17 landscape. The focus in the next six months is finalising and producing IFRS 17 compliant financial statements for the first interim reporting period for the six months ending 31 December 2023, including restated information for the financial year ended 30 June 2023 and the interim reporting period for the six months ended 31 December 2022. A key consideration for DLAC going forward is to obtain assurance as to the ‘business-as-usual’ IFRS 17 financial, data, processes and financial reporting controls. -- 6 of 217 -- 6 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Report of the Discovery Limited Audit Committee continued for the year ended 30 June 2023 Implementation of the second phase of the audit firm rotation plan Discovery continued implementing the second phase of the audit firm rotation plan, which sees PricewaterhouseCoopers Inc. finalise its tenure as joint external auditor for the financial year ended 30 June 2023. As noted at the time, Discovery had early commenced its process for both the anticipated regulations by the Prudential Authority of the South African Reserve Bank for insurance groups that have joint external auditors and the required auditor rotation rules issued by the Independent Regulatory Board of Auditors (IRBA) in South Africa. Under its rotation plan, the shareholders approved KPMG Inc. as joint external auditor from the financial year ended 30 June 2022. As a result, KPMG Inc. will have had two years of continuity alongside the outgoing joint auditor PricewaterhouseCoopers Inc. At the Annual General Meeting of November 2022, the shareholders also approved the appointment of Deloitte & Touche as joint external auditors from 1 July 2023. The DLAC noted the Supreme Court of Appeal ruling in May 2023, which set aside the Mandatory Audit Firm Rotation (MAFR) rule issued by the IRBA. Despite this ruling, the DLAC considers it appropriate to continue with the rotation in auditors, supported by the following considerations: It is consistent with the vote at the Annual General Meeting, where shareholders overwhelmingly supported the appointment of Deloitte & Touche with effect from 1 July 2023 as joint auditors. Deloitte & Touche, having regard for the timing of audit firm rotation, were appointed with KPMG Inc. as the external audit assurance providers on IFRS 17. Therefore, Deloitte & Touche, with KPMG Inc., are best placed to continue as external auditors, with IFRS 17 being effective from 1 July 2023 for Discovery. Within Discovery Group, a conglomerate encompassing a diverse range of businesses, the significance of maintaining a strong independent oversight as well as business insight cannot be overstated. This insight is underpinned by the rigorous, disciplined, and fresh perspectives offered through rotational roles, ensuring a seamless transition whilst preserving the invaluable continuity offered by the incumbent team members. Effective functioning of the Group’s financial systems and control environment Discovery continues to maintain a strong risk culture and has implemented appropriate and effective IFCs to enable the integrity and reliability of the financial statements. These IFCs safeguard, verify, and maintain accountability of Discovery’s financial position and performance. The DLAC is responsible for assessing Discovery’s system of internal financial and accounting controls. In this regard, the DLAC has evaluated the adequacy and effectiveness of Discovery’s system of internal controls and made appropriate recommendations to the Board. This has included a formal documented review by the internal audit function of Discovery’s internal financial controls system’s design, implementation, and effectiveness. Discovery has successfully completed the third year of the internal financial control attestation process in terms of paragraph 3.84(k) of the JSE Limited Listings Requirements. Any deficiencies in design and operating effectiveness of IFCs identified via the Group’s three lines of defence are reported to the DLAC. The DLAC considered the identified deficiencies together with the appropriateness of management’s response, including remediation, reliance on compensatory controls, and additional review procedures. The DLAC noted and supports the Group Chief Executive Officer and Group Chief Financial Officer positive attestations under their names and signature. The DLAC believes that, based on the results of these reviews, Discovery’s IFCs effectively produce accurate financial information and a fair presentation of the financial performance of Discovery in the Annual Financial Statements. KEY ACTIVITIES OF THE DLAC FOR THE FINANCIAL YEAR 2023 Key audit matters The DLAC annually assesses the Key Audit Matters (KAMs) reported by the external auditors and considers the key judgements and estimates pertaining to the Annual Financial Statements. Accordingly, the KAMs of the joint auditors for the current period were addressed as follows. Key Audit Matter How the DLAC addressed the matter Valuation of assets and liabilities arising from insurance contracts The DLAC reviewed reports from the Group Chief Actuary and the external auditors on actuarial assumptions and basis changes. The DLAC evaluated the appropriateness of actuarial assumptions used in the setting of reserves, including negative Rand reserves, taking into account recommendations made by the Actuarial Committee. The annual assessment for impairment of goodwill and intangible assets The DLAC reviewed the impairment assessments based on the latest business planning inputs. It considered the sensitivity of these estimates to various scenarios. The most material of these is the valuation of Discovery Bank, which is sensitive to the discount rate, business plan performance and, most notably, the terminal growth rate. Management re-engaged an external valuator to perform an independent valuation. This valuation and the work performed by the auditors provided acceptable headroom at a Discovery Bank and Group levels against its respective carrying values Note 4 Significant accounting estimates and judgement in applying accounting policies of the financial statements sets out the respective significant accounting estimates and judgements. Further information is also included in note 10, Goodwill. -- 7 of 217 -- 7 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Report of the Discovery Limited Audit Committee continued for the year ended 30 June 2023 KEY ACTIVITIES OF THE DLAC FOR THE FINANCIAL YEAR 2023 continued Key audit matters continued Other significant matters considered Significant matters are those that the DLAC views as significant or material in nature, requiring either the exercise of judgement or matters otherwise considered subjective from an accounting or auditing perspective. The following areas received a key focus from the DLAC during the year: Evaluation of management’s assessment of impairment of specified assets under IAS 36 Impairment of Assets. In addition to focusing on the goodwill of Discovery Bank, as noted in the KAMs above, the DLAC also considered the goodwill of VitalityHealth and VitalityLife and the carrying value of material associates. The DLAC is satisfied that there was no risk of impairment of any material assets. Review of the supportability of deferred tax assets raised on assessed losses. Financial statement and accounting practices The DLAC has reviewed the accounting policies of all entities included in the consolidated Annual Financial Statements and is satisfied that they are appropriate, consistently applied and comply with IFRS Accounting Standards. The DLAC is satisfied that Discovery has established financial reporting procedures so as to ensure access to all financial information required by the issuer to prepare and report on the financial statements of Discovery effectively. The DLAC confirmed the going concern basis for the preparation of both Interim and Annual Financial Statements During the year, the DLAC reviewed the following financial reporting matters to ensure the integrity and fairness of financial information: Reviewed and debated the key accounting, actuarial and tax judgements and assumptions, including external audit’s KAMs and were satisfied with how these were addressed. Reviewed financial information included in the Group’s interim and year-end results announcements to ensure the accuracy and integrity of financial data disclosed externally. As part of its annual work plan, the DLAC evaluates management’s assessment of the findings in the most recent JSE’s Proactive Monitoring Report. Management performs a detailed assessment of the JSE’s findings against Discovery’s Annual Financial Statements to identify any potential areas of non-compliance or potential improvements or enhancements in disclosures. The review was completed in November 2022 with the release of the JSE’s Proactive Monitoring Report 2022. No significant deficiencies were identified, but smaller changes were incorporated into the interim results and Annual Financial Statements in light of recommendations from the report. Evaluated the consistent application of accounting policies for insurance reserves. An established DLAC process receives and appropriately considers any concerns or complaints relating to Discovery’s accounting and reporting practices. The DLAC immediately deals with any such issues raised. No issues have been raised during the course of the financial year. Finally, the DLAC has considered accounting treatments of significant or unusual transactions and accounting judgements. The DLAC has evaluated management’s judgements and reporting decisions in relation to the Integrated annual report and ensured all material disclosures have been included. In addition, it has reviewed both financial and non-financial information, forward-looking statements, and sustainability information. RESTATEMENT AS A RESULT OF PRIOR PERIOD ERROR – RECLASSIFICATION OF UNIT-LINKED INSURANCE CONTRACTS TO UNIT-LINKED INVESTMENT CONTRACTS As noted in note 45 of the Discovery consolidated results, Discovery has restated its previously published results for an error in the classification of certain unit-linked policies. As part of the IFRS 17 project, Discovery performed a full reassessment of all insurance contracts to ensure the products were correctly included in the scope of IFRS 17. Discovery identified that certain offshore unit-linked policies do not transfer significant insurance risk as required under IFRS 17. Instead of being classified as unit-linked insurance contracts, these policies should have been accounted for as unit- linked investment contracts under IFRS 9 Financial Instruments. As the definition of identification of significant insurance risk under IFRS 17 and IFRS 4 is the same; the change in treatment and restatement of previously published information is required under IFRS 4 in the current period. The DLAC has reviewed the proposed correction by management, the control environment to process the correction, and the external audit work to ensure the changes were made correctly. In addition, the DLAC considered the disclosures in the financial statements, required communication with the relevant regulatory bodies and confirmed it had discharged all its obligations as required. CLIMATE, NATURE AND BIODIVERSITY AND ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) The DLAC also: Performed review of the Sustainability Report, including understanding sources of data, metrics, methodologies and narrative. Considered the level of both internal and external assurance obtained on ESG reporting and disclosures, including reviews of the workplans and procedures. Performed review of the Task Force for Climate-Related Disclosures (TFCD) Report, focusing on the disclosure of climate-related risks, opportunities, and financial implications. -- 8 of 217 -- 8 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Report of the Discovery Limited Audit Committee continued for the year ended 30 June 2023 KEY ACTIVITIES OF THE DLAC FOR THE FINANCIAL YEAR 2023 continued External audit The DLAC is responsible for the appointment, compensation and oversight of the independent joint external auditors, namely KPMG Inc. and PricewaterhouseCoopers Inc, who were appointed as joint auditors effective 1 July 2022. The DLAC has assessed the independence and objectivity of the external auditors and is satisfied that the external auditors are independent of Discovery. The requisite assurance was sought and provided by the auditors that internal governance processes within each audit firm support and demonstrate its claim to independence. The DLAC has also reviewed the appropriate JSE accreditation of the individual audit partners responsible for the audit sign-off and the respective auditors’ most recent IRBA inspection reports. A formal policy exists in respect of the provision of non-audit services by the external auditors of Discovery and its subsidiaries, and a formal procedure governs the process whereby the auditors are appointed to provide any non-audit services, including a limitation on fees for non-audit services which shall not exceed 25% of each joint auditor audit fee. Non-audit services rendered by PricewaterhouseCoopers Inc. were less than 1% of the total audit fees. KPMG Inc. did not provide any non-audit services. In addition, as part of ensuring the independence of Deloitte & Touche as the proposed incoming auditor, the DLAC also considered any non-audit services rendered by Deloitte to the same standard as the existing auditors. During the period, Deloitte & Touche did not render any non-audit services. The Chairperson of the DLAC pre-approves the nature and extent of any non-audit services that the external auditors provide in terms of the agreed pre-approval policy, and the schedule of approved non-audit services is reviewed annually by the DLAC. The DLAC, following consultation with executive management, approved the engagement letter, terms, audit plan, main areas of focus, and budgeted audit fees for the year ended 30 June 2023. This approval of the audit plan included specific consideration as to the allocation of work between the joint auditors. The DLAC Chairperson met with both KPMG Inc. and PricewaterhouseCoopers Inc. lead partners prior to every DLAC meeting to discuss the 2022/23 audit plan, key areas of focus, scope and findings, including suitability of any reliance on Group Internal Audit. The DLAC met with the external auditors independently twice for the year under review. In terms of the conditions laid out in section 94(8) of the Companies Act and based on its assessment, taking consideration of the criteria of King IV™, the JSE and general guidance to Audit Committees, the DLAC is satisfied with the performance and quality of the external audit, the external auditor firms and lead partners for the year ended 30 June 2023. The DLAC received feedback from the external auditors on the audit of the Annual Financial Statements of the Group, the critical accounting estimates and judgements, and cross reviews, including the Summary of Audit Differences for the year ended 30 June 2023. The DLAC notes the unqualified independent auditors’ report in relation to Discovery Limited and the Group. Group Internal Audit (GIA) GIA provides independent objective assurance that the governance processes, including professional ethics, the management of risk and systems of internal controls, are both adequate and effective. The Chief Audit Executive (CAE) has a functional reporting line to the DLAC Chairperson and an administrative reporting line to the Group Chief Financial Officer. The DLAC is satisfied that the GIA displays high professional objectivity and professional ethics in performing its work. In assessing the quality, performance, and delivery of the internal audit plan, including the scope of the work performed, the level of resources and coverage of the audit plan, the DLAC took cognisance of the following: Reviewed and approved the internal audit charter and audit plan and evaluated the independence, effectiveness, and performance in line with its charter. Challenged the audit plan’s focus, relevance, and risk-based emphasis. Considered reports on the Group’s internal control systems, specifically focusing on the effectiveness of IFCs, including financial reporting controls. Reviewed significant issues raised by the internal audit processes and the adequacy of corrective action and accountability taken in response to such findings. Assessed the independence and effectiveness of the Chief Audit Executive, the internal audit function and the quality and extent of audit resources and found them satisfactory. Received the annual assessment provided by internal audit confirming the effectiveness of Discovery’s governance, risk management and control processes. Reviewed the external auditors’ annual assessment of the internal audit in terms of the requirements of ISA 610 Using the Work of Internal Auditors, reaffirming the extent of reliance that could be placed on the internal audit work. -- 9 of 217 -- 9 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Report of the Discovery Limited Audit Committee continued for the year ended 30 June 2023 OTHER MATTERS CONSIDERED BY THE DLAC In further fulfilling its duties and discharging its obligations for the year ended 30 June 2023, the DLAC also considered: Matter considered Outcome Evaluation of the expertise and experience of the finance function and financial director The DLAC reviewed and satisfied itself with the appropriateness of Discovery’s finance function’s expertise, resources, and experience, including the Group Chief Financial Officer, Mr Deon Viljoen. Combined assurance The combined assurance model provides an integrated plan of the various activities and sources of assurance, including risk and compliance, external and internal audit, corporate finance functions and the Actuarial Committees. The DLAC has reviewed and noted the combined assurance model, which has been implemented throughout the Group and considers that the model is appropriate in addressing Discovery’s risks. Whistleblowing The DLAC receives and deals with any complaints or whistleblowing, whether from within or outside Discovery, relating to Discovery’s accounting practices and internal audit, the content or auditing of Discovery’s financial statements, the internal financial controls of Discovery and related matters. No such whistleblowing was received during the financial year. Ethics and compliance The DLAC is responsible for reviewing any major breach of Discovery’s code of conduct and ethics and relevant legal, regulatory, and other obligations reported to the DLAC by the Social and Ethics Committee. The DLAC is satisfied that there has been no material breach of these standards or material non-compliance with laws and regulations. The DLAC is satisfied that it has complied with all its legal, regulatory, and other obligations during the period under review. KEY FOCUS AREAS FOR THE FINANCIAL YEAR 2024 The DLAC will remain focused on: Evaluating the effectiveness of the DLAC and its subsidiary Audit Committees relative to the SGF objectives, with particular emphasis on, skills, capacity, and workplans to ensure the members are enabled to fulfil their roles effectively. Enhance the capabilities, skills and oversight and effectiveness of the DLAC by expanding the audit committee with additional members. This expansion is intended to bring in diverse expertise and perspectives that can contribute to more robust decision-making, improved risk management, and a higher level of assurance in financial matters. A comprehensive analysis of Discovery’s ESG financial reporting practices in comparison to industry-leading standards and emerging trends. It aims to identify areas where Discovery can improve its ESG reporting, aligning it with best practices, the newly published IFRS Sustainability Disclosure Standards’ and staying ahead of evolving global expectations in ESG disclosure. The findings from this project will guide future reporting strategies and sustainability initiatives. Implement a specific project to ensure ongoing assurance for IFRS 17 systems, data, models, and reporting, as part of ‘business as usual’ processes. This includes the IFRS 17 restatement of comparative information, and investor presentations. Review the effectiveness of GIA and the appropriateness of the insourcing model. The review will assess whether the current insourcing model is suitable, especially in areas where risks are evolving rapidly, such as cybersecurity, IT General Controls (ITGCs), and core actuarial modeling within IFRS 17. The goal is to ensure that the GIA function is optimally structured to provide timely and comprehensive assessments of risk and compliance across these critical domains. Facilitate the audit firm rotation from PricewaterhouseCoopers Inc. to Deloitte & Touche. CONCLUSION The DLAC is satisfied that it has complied with all statutory duties and duties given to it by the Board under its Terms of Reference. The DLAC has reviewed the consolidated and separate financial statements of Discovery Limited for the year ended 30 June 2023 and, based on the information provided to the DLAC, considers that Discovery complies, in all material respects, with the requirements of the Companies Act and IFRS Accounting Standards. The DLAC has recommended the Annual Financial Statements to the Board for approval. The Board has subsequently approved the Annual Financial Statements, which will be open for discussion at the forthcoming Annual General Meeting. D Macready Chairperson: Discovery Limited Audit Committee 20 September 2023 -- 10 of 217 -- 10 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Independent Auditors’ report for the year ended 30 June 2023 To the shareholders of Discovery Limited REPORT ON THE AUDIT OF THE CONSOLIDATED AND SEPARATE FINANCIAL STATEMENTS Our opinion We have audited the consolidated and separate financial statements of Discovery Limited (the Group and Company), set out on pages 18 to 199 which comprise: the Group and Company statements of financial position at 30 June 2023; the Group and Company income statements for the year then ended; the Group and Company statements of other comprehensive income for the year then ended; the Group and Company statements of changes in equity for the year then ended; the Group and Company statements of cash flows for the year then ended; and the notes to the Group and Company annual financial statements (including Annexures A, B and C), including a summary of significant accounting policies. In our opinion, the consolidated and separate financial statements present fairly, in all material respects, the consolidated and separate financial position of Discovery Limited at 30 June 2023, and its consolidated and separate financial performance and consolidated and separate cash flows for the year then ended in accordance with IFRS Accounting Standards and the requirements of the Companies Act of South Africa. Basis for opinion We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors’ responsibilities for the audit of the consolidated and separate financial statements section of our report. We are independent of the Group and Company in accordance with the Independent Regulatory Board for Auditors’ Code of Professional Conduct for Registered Auditors (IRBA Code) and other independence requirements applicable to performing audits of financial statements in South Africa. We have fulfilled our other ethical responsibilities in accordance with the IRBA Code and in accordance with other ethical requirements applicable to performing audits in South Africa. The IRBA Code is consistent with the corresponding sections of the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (including International Independence Standards). We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. -- 11 of 217 -- 11 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Independent Auditors’ report continued for the year ended 30 June 2023 Key audit matters Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated and separate financial statements of the current period. These matters were addressed in the context of our audit of the consolidated and separate financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined that there are no key audit matters to communicate in respect of the separate financial statements of the Company. Valuation of assets and liabilities arising from individual life insurance contracts Refer to Section 13 of Annexure B – Group accounting policies, and notes 2, 4.1, 5 and 18 to the consolidated financial statements. Key audit matter How our audit addressed the key audit matter At 30 June 2023, the Group held assets arising from insurance contracts to the value of R63 865 million and liabilities arising from insurance contracts of R114 807 million. The assets and liabilities arising from insurance contracts related to both individual life and group life policies, with the key audit matter focusing on individual life policies (insurance contracts) underwritten by Discovery Life and Vitality Life. The actuarial value of those individual life assets and liabilities arising from insurance contracts that are long-term in nature is determined based on a prospective discounted cash flow valuation basis, calculated as the difference between the present value of future benefit payments plus expenses and the present value of future premiums. In valuing these assets and liabilities arising from insurance contracts, management applies significant judgement and various assumptions are made, including best estimate assumptions regarding the future expected claims experience, premium income, expenses and commission. Changes to these assumptions may result in a material change to the valuation. The most significant assumptions made in determining the value of these assets and liabilities arising from insurance contracts relate to: Impact of the Vitality status distribution on mortality, morbidity and the level of surrender and lapses. The Group is unique due to its Vitality programme as policyholders are provided access to several services and benefits that encourage healthy lifestyle choices and are awarded Vitality points, which ultimately determine their Vitality status. The mortality, morbidity and lapse assumptions within the valuation are specifically impacted by the Vitality status of the policyholder. Furthermore, the Vitality status informs future expected policyholder behaviour and adjustments are therefore made to the mortality, morbidity, and lapse assumptions to reflect the expected impact of the Vitality programme. Use of discretionary margins with respect to profit recognition. Discovery Life Limited writes profitable insurance products and applying the reserving basis using only compulsory margins as prescribed by regulations would result in a premature recognition of future profits at the inception of new business contracts; and therefore, certain discretionary margins are added to the best estimate assumptions. This is however limited to the extent of actual acquisition costs incurred and these discretionary margins are reset at each valuation date to reflect the underlying profitability of the portfolio. Changes to the discretionary margins have a direct impact on the profit recognition in a period and the Group has therefore established a framework as disclosed in Section 13 of Annexure B – Group accounting policies, to utilise the available discretionary margin in a specified order. We considered the valuation of assets and liabilities arising from insurance contracts to be a key audit matter in our audit of the consolidated financial statements, as it involves complex and subjective judgements about future events, including policyholder behaviour and economic conditions. The primary procedures we performed to address this key audit matter included the following: We involved our actuarial specialist to assist in: Gaining an understanding of the Group’s actuarial internal control environment and governance, including the functioning of the Group’s Actuarial Committee (and where applicable, the subsidiaries’ Actuarial Committees) and testing the design and implementation of key controls. Testing the design and implementation of the liability build-up control to support the sources of profit and corroborate the movements in the liability to relevant underlying information, from both internal and external sources. Evaluating the appropriateness of the valuation methodology applied by the Group to determine the value of assets and liabilities arising from insurance contracts. In doing so, we considered the principles and integrity of the Group’s models against acceptable industry standards. Challenging management with respect to the appropriateness of all significant assumptions adopted in the determination of the valuation of assets and liabilities arising from insurance contracts by comparing these assumptions to the results of historical actuarial experience investigations conducted by management, including benchmarking these assumptions against life insurance industry trends to determine whether they are reasonable and supportable. Evaluating the compliance of the valuation of the assets and liabilities arising from insurance contracts against the requirements of the Financial Soundness Valuation (FSV) basis as described in the Standard of Actuarial Practice (SAP) 104 and the Group’s accounting policies as set out in Section 13 of Annexure B – Group Accounting policies. In respect of the impact of the Vitality programme on the valuation of assets and liabilities arising from insurance contracts relating to individual life policies underwritten by the Group: Evaluating, on a sample basis, the reasonability of the Group’s assumptions in setting the Discovery Vitality status distribution, and the progression between statuses, by comparing these against historical trends; and Evaluating, on a sample basis, the integrity of the data inputs captured in the models by assessing whether the inputs used are consistent with historical actual experience. Use of discretionary margins with respect to profit recognition: Assessing whether all acquisition costs were appropriately captured in the determination of the discretionary margins at 30 June 2023 by comparing these input amounts to the audited acquisition cost amounts included in the Group’s income statement; and Evaluating the appropriateness of the calculation of the discretionary margin transfer against the requirements of the methodology set out in the Group’s accounting policies in Section 13 of Annexure B – Group Accounting policies. -- 12 of 217 -- 12 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Independent Auditors’ report continued for the year ended 30 June 2023 Impairment assessment of goodwill for the Discovery Bank cash-generating unit (CGU) Refer to Section 7 and 8 of Annexure B – Group accounting policies, and notes 4.2 and 10 to the consolidated financial statements. Key audit matter How our audit addressed the key audit matter At 30 June 2023, the Group held goodwill in relation to the Discovery Bank cash-generating unit (CGU) at a carrying value of R2 417 million. This goodwill arose from the acquisition of the DiscoveryCard business. In accordance with the requirements of IAS 36 Impairment of Assets (IAS 36), the Group annually assesses goodwill allocated to the Discovery Bank CGU for impairment. The recoverable amount of the Discovery Bank CGU is estimated on a fair value less costs to sell basis, using the income approach. Estimation uncertainty is inherent in the determination of fair value less costs to sell given the significant unobservable inputs into the calculation, which results in the fair value estimate being categorised as level 3 in terms of the fair value hierarchy in IFRS 13 Fair Value Measurement. Management has applied judgement in determining the inputs used in deriving their fair value estimate for the Discovery Bank CGU. These inputs include customer growth rates, customer behaviour assumptions and the expensing of system-build costs, which drive forecasts of future cashflows. In addition, management has applied judgement in the determination of their estimated discount rate, notably the beta factor used in deriving a cost of equity, and the terminal growth rate. We considered the impairment assessment of goodwill for the Discovery Bank CGU to be a key audit matter in our audit of the consolidated financial statements, as it involves complex and subjective judgements and is subject to estimation uncertainty. The primary procedures we performed to address this key audit matter included the following: Gaining an understanding of the process followed by management to assess goodwill for the Discovery Bank CGU for impairment, including the derivation of management’s key assumptions and testing the design and implementation of certain key controls related to this assessment. Assessing management’s attribution of assets and liabilities to the Discovery Bank CGU against the requirements of IAS 36. Assessing the appropriateness of disclosures included in the consolidated financial statements in accordance with the group accounting policies and the requirements of IAS 36. We involved our valuation and economic specialists to assist in: Evaluating the appropriateness of the valuation methodology applied by management to calculate the recoverable amount of the Discovery Bank CGU. In doing so, we considered the principles and integrity of the discounted cash flow model against the requirements of IAS 36 and acceptable industry standards. Evaluating the appropriateness of management’s assumptions against external market data or industry benchmarks, including the discount rate applied, customer growth rates and customer behavioural assumptions that drive forecasted cashflows. This includes an assessment of the reasonableness of the capital requirements and credit loss ratios applied in the future cashflows. We also assess the expensing of system build costs. Performing various sensitivity analyses over management’s forecast cash flows, customer growth rates, the terminal growth rate and discount rate applied to assess the impact of changes in these key assumptions on the recoverable amount of the Discovery Bank CGU. -- 13 of 217 -- 13 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Other information The directors are responsible for the other information. The other information comprises the information included in the document titled “Discovery Annual Financial Statements for the year ended 30 June 2023”, which includes the Directors’ report, the Report of the Discovery Limited Audit Committee and the Certificate by the Company Secretary as required by the Companies Act of South Africa, which we obtained prior to the date of this auditors’ report, and the document titled “Discovery Integrated Annual Report for the year ended 30 June 2023”, which is expected to be made available to us after that date. The other information does not include the consolidated and the separate financial statements and our auditors’ report thereon. Our opinion on the consolidated and separate financial statements does not cover the other information and we do not and will not express an audit opinion or any form of assurance conclusion thereon. In connection with our audit of the consolidated and separate financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated and separate financial statements, or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed on the other information obtained prior to the date of this auditors’ report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. Responsibilities of the directors for the consolidated and separate financial statements The directors are responsible for the preparation and fair presentation of the consolidated and separate financial statements in accordance with IFRS Accounting Standards and the requirements of the Companies Act of South Africa, and for such internal control as the directors determine is necessary to enable the preparation of consolidated and separate financial statements that are free from material misstatement, whether due to fraud or error. In preparing the consolidated and separate financial statements, the directors are responsible for assessing the Group and Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group and/or Company or to cease operations, or have no realistic alternative but to do so. Auditors’ responsibilities for the audit of the consolidated and separate financial statements Our objectives are to obtain reasonable assurance about whether the consolidated and separate financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated and separate financial statements. As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also: Identify and assess the risks of material misstatement of the consolidated and separate financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group’s and the Company’s internal control. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors. Conclude on the appropriateness of the directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group’s and the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors’ report to the related disclosures in the consolidated and separate financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors’ report. However, future events or conditions may cause the Group and/or the Company to cease to continue as a going concern. Evaluate the overall presentation, structure and content of the consolidated and separate financial statements, including the disclosures, and whether the consolidated and separate financial statements represent the underlying transactions and events in a manner that achieves fair presentation. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the Group audit. We remain solely responsible for our audit opinion. Independent Auditors’ report continued for the year ended 30 June 2023 -- 14 of 217 -- 14 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Auditors’ responsibilities for the audit of the consolidated and separate financial statements continued We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied. From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the consolidated and separate financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors’ report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication. Report on other legal and regulatory requirements In terms of the IRBA Rule published in Government Gazette Number 39475 dated 4 December 2015, we report that KPMG Inc. and PricewaterhouseCoopers Inc. have been the joint auditors of Discovery Limited for two years. Prior to the commencement of the joint audit relationship, PricewaterhouseCoopers Inc. was the sole auditor of Discovery Limited for twenty-one years. PricewaterhouseCoopers Inc. KPMG Inc. Director: Andrew Taylor Director: Mark Danckwerts Registered Auditor Registered Auditor Jukskei View KPMG Crescent 4 Lisbon Lane 85 Empire Road Waterfall City Parktown 2090 2193 South Africa South Africa 21 September 2023 21 September 2023 Independent Auditors’ report continued for the year ended 30 June 2023 -- 15 of 217 -- 15 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 NATURE OF BUSINESS Discovery Limited (the Company) is listed on the JSE Limited and is an integrated financial services organisation specialising in health insurance, life assurance, wellness, investments and savings, short-term insurance and banking. Discovery is a shared value insurance and banking company whose purpose and ambition are achieved through a pioneering business model that incentivises people to be healthier and enhances and protects their lives. Our unique and sophisticated Shared-value insurance model delivers better health and value for clients, superior actuarial dynamics for the insurer and a healthier society. It is a powerful platform of integrated assets and capabilities, which has positioned us well to respond to the following key trends that were accelerated by COVID-19 and remain relevant: a focus on health, wellness and resilience (nature of risk) accelerated use of technology and increased digitisation increased importance of purpose and trust YEAR UNDER REVIEW The year under review was characterised by significant macroeconomic uncertainty, with several issues coalescing. The period saw sustained inflationary pressures, rising interest rates, a particularly strong US dollar, increasing consumer pressure and a cost-of-living crisis in many regions. These pressures have constrained economic growth, following short-lived rebounds experienced by many countries post-COVID, with severe energy shortages in South Africa proving to be a further constraint. For the year ended 30 June 2023, normalised operating profit for the Group increased by 24% to R11 661 million (2022: R9 384 million) following a robust performance across each composite. Core new business annualised premium income (API) was up 6% to R23 025 million (up 12% to R22 788 million excluding products of VitalityInvest and Ping An Health Insurance Company of China Limited (PAHI) reinsurance business in rundown), with particularly strong growth from the South African (SA) and United Kingdom (UK) composites. Persistency continued to exceed expectations in all businesses. The Group continued to streamline some new initiatives with a focus on those businesses expected to generate significant value. In the previous financial year, the Group announced its decision to exit the UK investment market (VitalityInvest) and more recently has decided to terminate VitalityCar, extracting from the challenging UK motor insurance market. The following table demonstrates the contribution of key businesses to the growth in normalised profit from operations of 24% compared to the prior year. The weakening of the rand over the year contributed to the translated growth rate for the UK and Vitality Global (VG) composites with the latter also benefiting from a strong dollar over the year under review. Business Normalised Normalised profit from profit from operations operations (Current (Current period, in period, in R million) R million) % change % change (Current (Current period vs period vs prior period) prior period) Core new Core new business business API API22 (Current (Current period, in period, in R million) R million) % change % change (Current (Current period vs period vs prior period) prior period) Discovery Health 3 854 7% 8 678 19% Discovery Life 4 807 19% 2 838 12% Discovery Invest 1 560 30% 3 050 4% Discovery Insure – Personal 1 62 (138%) 1 249 0% Discovery Vitality 16 78% 372 45% Discovery Bank (767) 23% Other initiatives and central costs (436) 88% 631 (25%) – SA new initiatives (312) 28% 631 (25%) – Central costs (124) SA Composite 9 096 22% 16 818 11% VitalityHealth3 1 283 (3%) 2 064 19% VitalityLife 1 039 55% 1 721 37% Closure costs of VitalityInvest and VitalityCar in run down (455) (1%) Other initiatives and central costs (79) 32% UK Composite 1 788 21% 3 785 2 26% Vitality Health International – PAHI 596 76% 2 1852 (1%) Vitality Health International – Other (195) 1% Vitality Network 411 26% Other initiatives and central costs (35) 46% VG Composite 777 74% 2 185 (1%) 11 661 24% 22 788 1 Includes Discovery Insure’s share of equity accounted losses of R19 million (2022: R13 million). 2 Core new business API excludes products in rundown of VitalityInvest and PAHI reinsurance business. Core new business API for the UK composite increased 3% including VitalityInvest. Core new business API for PAHI decreased 18% including PAHI reinsurance business. 3 The difference between VitalityHealth normalised profit compared to that shown in the segment information is the accelerated write-off in the current year of the VitalityCar’s capitalised systems and intangible assets, with a pre-tax impact of R189 million. The write-off is disclosed in this table in Closure costs of VitalityInvest and VitalityCar in run down. Closure costs include – VitalityInvest R266 million (30 June 2022: R458 million) – VitalityCar R189 million (30 June 2022: nil). Directors’ report for the year ended 30 June 2023 -- 16 of 217 -- 16 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Directors’ report continued for the year ended 30 June 2023 Normalised headline earnings increased 32% to R7 678 million (2022: R5 816 million) while headline earnings increased 5% to R5 490 million (2022: R5 204 million) negatively impacted by the effect of a significant increase in both real and nominal interest rates in SA. The return on opening embedded value (RoEV) of 13.2%, benefited from translation and foreign exchange gains as a result of the weakening rand combined with strong local currency growth for Discovery’s offshore operations. R2.6 billion of positive non-economic experience variances were generated over the year, reflecting the positive dynamics of the shared value insurance model. However, this was offset by higher long-term rates in SA and UK which created a significant impact on the economic basis within the embedded value and constrained new business margins materially. SHARE CAPITAL Details of the authorised and issued share capital, together with details of shares issued during the year, are set out in note 8 to the Company Annual Financial Statements. OWNERSHIP For details of shareholders, refer to Annexure D. GROUP STRUCTURE The Company is directly and indirectly the holding company of subsidiaries and investments as set out in Annexure A. In addition, Discovery is required to consolidate certain unit trusts which are deemed to be under the Group’s control in terms of IFRS 10 Consolidated Financial Statements. These are also set out in Annexure A. DIVIDENDS Details of dividends paid and declared are set out in note 43 and note 44 to the Annual Financial Statements. CAPITAL Solvency and liquidity tests The directors have performed the requisite solvency and liquidity tests where required by the Companies Act as amended. Liquidity and solvency as well as the Group’s capital position remained strong and is robust under various stress scenarios across the Group. Statutory capital requirements With effect from 1 July 2018, the Insurance Act 18 of 2017 (Insurance Act), and the related Prudential Standards were implemented in South Africa. Discovery Life and Discovery Insure are regulated under the Insurance Act, while VitalityHealth and VitalityLife are regulated under the European Solvency II regulatory regime, which was implemented from 1 January 2016. The values below are estimated based on information extracted from the audited Annual Financial Statements. June 2023 June 2022 Statutory capital requirements Cover Statutory capital requirements Cover Discovery Life R20 809 million 1.9 times R20 322 million 1.7 times Discovery Insure R1 113 million 1.6 times R1 138 million 1.2 times Vitality Health GBP130.8 million GBP117.2 million (R3 138 million) 1.4 times (R2 344 million) 1.5 times Vitality Life GBP272.1 million GBP297.1 million (R6 528 million) 2.1 times (R5 943 million) 2.1 times -- 17 of 217 -- 17 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 DIRECTORS AND PRESCRIBED OFFICERS The following were directors and prescribed officers of the Company during the current financial year unless otherwise indicated: Executive directors Independent non-executive directors A Gore (Group Chief Executive) ME Tucker (Chairperson) T Mboweni Dr A Ntsaluba2 L Chiume4 KC Ramon5 A Pollard2 N Hlahla M Schreuder B Swartzberg FN Khanyile B van Kralingen DM Viljoen (Group Chief Financial Officer) D Macready SV Zilwa Dr TV Mapha Prescribed officers Non-executive directors HD Kallner2,3 HL Bosman1 NS Koopowitz2,3 R Farber 1 Retired effective 1 December 2022 following conclusion of the Company’s Annual General Meeting. This follows the unbundling by Rand Merchant Investment Holdings Limited of its shareholding in Discovery Limited earlier in 2022. He also resigned as chairperson and member of the Risk and Compliance Committee and as a member of the Remuneration Committee and the Nominations Committee. He has also retired as a non-executive director of Discovery Life Limited, Discovery Health (Pty) Limited and Discovery Vitality (Pty) Limited. 2 Stepped down from the Board effective 1 March 2023 as part of a change in governance structures. 3 Transitioned to Prescribed Officer with effect from 1 March 2023 as part of a change in governance structures. 4 Appointed with effect from 18 September 2023. She is also a member of the Discovery Limited Audit Committee and the Group and South African Risk and Compliance Committees. She brings a wealth of financial services and investment experience. 5 Appointed with effect from 18 September 2023. She is a member of the Discovery Limited Audit Committee and the Social and Ethics Committee. She brings diverse leadership and board experience in multiple sectors. The notice for the forthcoming Annual General Meeting of shareholders will include those names of individuals that retire by rotation and are eligible and available for re-election. DIRECTORS’ INTERESTS Details of the directors’ emoluments, participation in share incentive schemes and interests in the Company are reflected in Annexure C. No material contracts involving directors’ interests were entered into in the current year. The directors had no interest in any third party or company responsible for managing any of the business activities of Discovery. INDEMNIFICATION AND INSURANCE OF DIRECTORS AND OFFICERS The Company entered into agreements to indemnify its directors to the extent permitted by law against all liabilities including legal costs incurred by the director in connection with or as a consequence of the director acting in any capacity, including as an authorised representative of a Group company. During the financial year, the Company paid insurance premiums in respect of a Directors and Officers Liability insurance contract, which insures directors and officers of the Company against certain liabilities arising in the course of their duties to the Company or Group companies. Details of the nature of the liabilities covered and the amount of premium paid are not disclosed as such disclosure is prohibited under the terms of the contract. COMPANY SECRETARY Nobuhle Mbongo resigned as the Group Company Secretary with effect from 31 March 2023 to pursue another opportunity outside of the Group. In the interim, Ayanda Manqele, the current Deputy Company Secretary, was appointed Acting Group Company Secretary, with effect from 31 May 2023 until 31 August 2023. Ayanda Ceba was appointed as Group Company Secretary of Discovery with effect from 1 September 2023, following the resignation of the Group Company Secretary. Registered office Postal address 1 Discovery Place PO Box 786722 Sandton Sandton 2196 2146 BORROWING POWERS The directors may exercise all the powers of the Company to borrow money. In terms of the Memorandum of Incorporation, the borrowing powers of the Company are unlimited. In terms of the Insurance Act, both Discovery Life and Discovery Insure may not encumber its assets or directly or indirectly borrow. EVENTS AFTER THE REPORTING DATE Refer to Group note 44 for a list of the events after reporting date. AUDITORS It will be proposed at the Annual General Meeting of shareholders, that KPMG Inc. and Deloitte & Touche be appointed as joint external auditors in accordance with section 90(1) of the Companies Act. Directors’ report continued for the year ended 30 June 2023 -- 18 of 217 -- 18 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Group statement of financial position at 30 June 2023 R million Notes Group 2023 Restated 1 Group 2022 Restated1 Group 1 July 2021 Assets Goodwill 10 5 406 4 912 4 879 Intangible assets 7 6 982 6 539 6 371 Property and equipment 6 3 910 3 811 4 188 Assets arising from insurance contracts 5 63 865 56 645 50 483 Deferred tax asset 24 4 404 4 455 3 948 Deferred acquisition costs 8 799 640 585 Assets arising from contracts with customers 9A 2 201 1 692 1 375 Investment in equity-accounted investees 11 7 024 6 008 3 459 Financial assets – Loans and advances to customers at amortised cost 12 4 702 3 944 3 361 – Investments at amortised cost 12 9 910 7 161 5 604 – Investments at fair value through profit or loss 12 155 426 141 494 130 937 – Derivative financial instruments at fair value through profit or loss 13 119 276 249 Insurance receivables, contract receivables and other receivables 14 16 059 13 113 10 533 Non-current assets held for sale 11.2.1 – 171 – Current tax asset 41 220 391 Reinsurance contracts 15 709 511 445 Cash and cash equivalents 16 20 370 19 775 20 013 TOTAL ASSETS 301 927 271 367 246 821 Equity Capital and reserves Ordinary share capital and share premium 17.1 10 351 10 178 10 151 Perpetual preference share capital 17.2 779 779 779 Other reserves 8 622 3 621 1 935 Retained earnings 44 218 38 972 33 550 Equity attributable to equity holders of the Company 63 970 53 550 46 415 Non-controlling interest 4 5 4 TOTAL EQUITY 63 974 53 555 46 419 Liabilities Liabilities arising from insurance contracts 18 114 807 108 067 100 041 Liabilities arising from reinsurance contracts 19 14 669 13 192 12 525 Deferred tax liability 24 9 559 9 335 8 814 Contract liabilities to customers 9A 656 944 776 Financial liabilities – Borrowings at amortised cost 20 20 586 20 584 19 493 – Other payables 22 14 780 15 123 14 904 – Deposits from customers 23 14 333 10 881 8 985 – Investment contracts at fair value through profit or loss 21 48 044 38 637 33 354 – Derivative financial instruments at fair value through profit or loss 13 20 202 826 Employee benefits 25 334 320 315 Current tax liability 165 527 369 TOTAL LIABILITIES 237 953 217 812 200 402 TOTAL EQUITY AND LIABILITIES 301 927 271 367 246 821 1 The comparative information has been restated. Refer to note 45 for detail. The order in which individual line items are presented in the Statement of financial position has been amended to better reflect their respective liquidity, as far as possible, from least liquid to the most liquid items. No values were reclassified or restated between line items. -- 19 of 217 -- 19 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Group income statement for the year ended 30 June 2023 R million Notes Group 2023 Restated1 Group 2022 Insurance premium revenue 59 671 58 312 Reinsurance premiums (10 136) (8 262) Net insurance premium revenue 26 49 535 50 050 Fee income from administration business 9B 14 757 12 752 Vitality income 9B 3 891 3 495 Net banking fee and commission 965 645 Banking fee and commission income 9B 1 292 853 Banking fee and commission expense (327) (208) Net banking interest and similar income 574 318 Bank interest and similar income using the effective interest rate 1 318 811 Bank interest and similar expense using the effective interest rate (744) (493) Investment income using the effective interest rate method 27 772 296 Net fair value gains/(losses) on financial assets at fair value through profit or loss 28 14 373 (1 825) Other income 1 544 1 341 Net income 86 411 67 072 Net claims and policyholders’ benefits 29 (40 135) (30 715) Claims and policyholders’ benefits (46 746) (38 022) Insurance claims recovered from reinsurers 6 611 7 218 Recapture of reinsurance – 89 Acquisition costs 30 (6 213) (4 758) Marketing and administration expenses 31 (28 905) (25 209) Amortisation of intangibles from business combinations (56) (59) Expected credit losses (139) (67) Recovery of expenses from reinsurers 3 593 2 859 Net transfer to/from assets and liabilities under insurance contracts (322) (1 297) – Change in assets arising from insurance contracts 5 860 5 786 – Change in assets arising from reinsurance contracts 135 63 – Change in liabilities arising from insurance contracts (3 992) (6 738) – Change in liabilities arising from reinsurance contracts (328) (577) – Economic assumptions adjustments net of discretionary margins (1 997) 169 Fair value adjustment to liabilities under investment contracts (5 572) 32 Profit from operations 8 662 7 858 Finance costs 33 (1 941) (1 658) Foreign exchange gains 34 150 155 Impairment of goodwill (9) – (Losses)/gains on dilution and/or disposal of equity-accounted investments (5) 33 Reversal of impairment of equity-accounted investments – 134 Share of net profits from equity-accounted investments 515 422 Profit before tax 7 372 6 944 Income tax expense 35 (2 052) (1 465) Profit for the year 5 320 5 479 Profit attributable to: – Ordinary shareholders 5 258 5 422 – Preference shareholders 69 56 – Non-controlling interest (7) 1 5 320 5 479 Earnings per share for profit attributable to ordinary shareholders of the Company during the year (cents): 36 – Basic 785.4 825.5 – Diluted 781.5 817.8 1 The comparative information has been restated. Refer to note 45 for detail. -- 20 of 217 -- 20 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Group statement of other comprehensive income for the year ended 30 June 2023 R million Group 2023 Group 2022 Profit for the year 5 320 5 479 Items that are or may be subsequently reclassified to profit or loss: Currency translation differences 4 107 467 – Unrealised gains 4 222 467 – Tax on unrealised gains (115) – Cash flow hedges 76 309 – Unrealised gains 76 322 – Tax on unrealised gains – (2) – Gains recycled to profit or loss (1) (10) – Tax on recycled gains 1 (1) Share of other comprehensive income from equity-accounted investments 419 601 – Change in fair value of debt instruments at fair value through other comprehensive income (23) 17 – Currency translation differences 442 584 Items that may not be reclassified to profit or loss: Share of other comprehensive income from equity-accounted investments 7 – – Change in fair value of equity instruments at fair value through other comprehensive income 7 – Other comprehensive income for the year, net of tax 4 609 1 377 Total comprehensive income for the year 9 929 6 856 Attributable to: – Ordinary shareholders 9 867 6 799 – Preference shareholders 69 56 – Non-controlling interest (7) 1 Total comprehensive income for the year 9 929 6 856 -- 21 of 217 -- 21 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Group statement of cash flows for the year ended 30 June 2023 R million Notes Group 2023 Group 2022 Cash flow from operating activities 2 549 3 597 Cash generated by operations 37.1 8 308 20 943 Purchase of investments held to back policyholder liabilities (62 773) (56 588) Proceeds from disposal of investments held to back policyholder liabilities 55 908 38 411 Cash generated from operating activities 1 443 2 766 Dividends received 28 728 600 Interest received 27&28 3 718 2 824 Interest paid 37.4 (1 501) (1 412) Taxation paid 37.2 (1 839) (1 181) Cash flow from investing activities (2 236) (4 704) Purchase of financial assets (30 966) (32 878) Proceeds from disposal of financial assets 30 932 31 482 Purchase of property and equipment (551) (275) Proceeds from disposal of property and equipment 2 25 Purchase of software and other intangible assets (1 760) (1 567) Proceeds from disposal of software and other intangible assets – 2 Acquisition of business net of cash (3) – Additional investment in equity-accounted investments (182) (1 593) Proceeds from sale of non-current asset held for sale 184 – Dividends from equity-accounted investments 108 100 Cash flow from financing activities (1 234) 518 Dividends paid to preference shareholders (69) (56) Proceeds from borrowings 37.3 7 442 3 261 Repayment of borrowings 37.3 (8 607) (2 687) Net decrease in cash and cash equivalents (921) (589) Cash and cash equivalents at beginning of the year 19 619 20 013 Exchange gains on cash and cash equivalents 1 639 195 Cash and cash equivalents including bank overdraft at end of the year 16 20 337 19 619 Reconciliation to Statement of financial position Cash and cash equivalents 20 370 19 775 Bank overdraft included in borrowings at amortised cost 20 (33) (156) Cash and cash equivalents including bank overdraft at end of the year 16 20 337 19 619 -- 22 of 217 -- DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 22 Group statement of changes in equity for the year ended 30 June 2023 Attributable to equity holders of the Company R million Share capital and share premium Preference share capital Share-based payment reserve Investment reserve 1 Translation reserve Hedging reserve Retained earnings Total Non- controlling interest Total Equity Year ended 30 June 2023 At beginning of the year 10 178 779 798 35 2 823 (35) 38 972 53 550 5 53 555 Total comprehensive income for the year – 69 – (16) 4 549 76 5 258 9 936 (7) 9 929 Profit for the year – 69 – – – – 5 258 5 327 (7) 5 320 Other comprehensive income – – – (16) 4 549 76 – 4 609 – 4 609 Transactions with owners 173 (69) 392 – – – (12) 484 6 490 Share issue 514 – – – – – – 514 – 514 Increase in treasury shares (514) – – – – – – (514) – (514) Delivery of treasury shares 173 – (161) – – – (12) – – – Acquisition of subsidiaries with non-controlling interest – – – – – – – – 6 6 Employee share option schemes: – Value of employee services, net of tax – – 553 – – – – 553 – 553 Dividends paid to preference shareholders – (69) – – – – – (69) – (69) At end of the year 10 351 779 1 190 19 7 372 41 44 218 63 970 4 63 974 Year ended 30 June 2022 At beginning of the year 10 151 779 489 18 1 772 (344) 33 550 46 415 4 46 419 Total comprehensive income for the year – 56 – 17 1 051 309 5 422 6 855 1 6 856 Profit for the year – 56 – – – – 5 422 5 478 1 5 479 Other comprehensive income – – – 17 1 051 309 – 1 377 – 1 377 Transactions with owners 27 (56) 309 – – – – 280 – 280 Share issue 443 – – – – – – 443 – 443 Increase in treasury shares (443) – – – – – – (443) – (443) Delivery of treasury shares 27 – (17) – – – – 10 – 10 Employee share option schemes: – Value of employee services – – 326 – – – – 326 – 326 Dividends paid to preference shareholders – (56) – – – – – (56) – (56) At end of the year 10 178 779 798 35 2 823 (35) 38 972 53 550 5 53 555 1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income (FVOCI) and those debt instruments measured at FVOCI, in terms of IFRS 9 Financial Instruments. -- 23 of 217 -- 23 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 1. SEGMENT INFORMATION Discovery’s operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker (CODM). The CODM have been identified as the Chief Executive Officers of Discovery’s businesses, as identified in the segment information, who make strategic decisions regarding these businesses. An operating segment is a component of an entity: (a) That engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity); (b) Whose operating results are regularly reviewed by the entity’s CODM to make decisions about resources to be allocated to the segment and assess its performance; and (c) For which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. Discovery will report separately information about an operating segment that meets any of the following quantitative thresholds: (a) Its reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 percent or more of the combined revenue, internal and external, of all operating segments; (b) The absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount, of (i) the combined reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all operating segments that reported a loss; and (c) Its assets are 10 percent or more of the combined assets of all operating segments. Operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed, if management believes that information about the segment would be useful to users of the financial statements. Discovery may combine information about operating segments that do not meet the quantitative thresholds with information about other operating segments that do not meet the quantitative thresholds to produce a reportable segment only if the operating segments have similar economic characteristics. The Group has identified its reportable segments based on a combination of products and services offered to customers and the location of the markets served. The following summary describes the operations of each of the Group’s reportable segments: (i) Health South Africa: administers and provides managed care services to medical schemes and renders administration services to other business segments within the Group. (ii) Life South Africa: offers a range of insurance and financial solutions to the Group’s clients against the financial impact of lifestyle-changing events in South Africa. (iii) Invest South Africa: offers, through a range of investment fund choices, including Discovery managed unit trusts, a comprehensive and flexible range of investment choices. These products are sold through a number of investment wrappers including Discovery Life policies and are offered to individuals in South Africa. (iv) Vitality South Africa: offers health and lifestyle benefits with selected partners to the Group’s clients. (v) Insure South Africa: offers a range of personal line insurance (motor, building, household content and portable possessions) to the Group’s clients against the financial impact of loss or damage. The segment also includes Discovery’s interest in Cambridge Mobile Telematics (CMT). (vi) Bank South Africa: offers retail banking solutions, including deposits and loans and advances, to clients in the South African market. The Bank is still in a start-up phase. It also includes DiscoveryCard. (vii) Health United Kingdom: offers consumer-engaged private medical insurance products to employer groups and individuals in the UK. All contracts in this segment are short-term insurance contracts. (viii) Life United Kingdom: offers a risk-only life assurance product. All contracts in this segment are long-term assurance contracts offered to both employer groups and individuals in the UK. (ix) All other segments: includes those segments that do not meet the quantitative thresholds set out in IFRS 8 Operating Segments and cannot be aggregated with another reportable segment. It includes the following operating segments: – Insure South Africa commercial: provides commercial short-term risk insurance products to the South African market. – SA Distribution: provides sales and distribution services in respect of all SA products. – Vitality Group: provides a Vitality platform to international insurance businesses. – Other new business development costs: expenses incurred to investigate new products and markets. – UK, United States of America (USA), SA and Singapore head office costs, where not allocated to another segment. – Invest UK: includes investment products to individuals in the UK and is currently in wind-down. Notes to the Group annual financial statements for the year ended 30 June 2023 -- 24 of 217 -- 24 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 1. SEGMENT INFORMATION continued The Chief Executive Officers assess the performance of the reportable segments based on normalised profit/loss from operations. Items which are excluded from the normalised profit/loss from operations are separately disclosed in the segment information to reconcile back to the segment results. The segment information is presented on the same basis as reported to the CODM. The segment total is then adjusted for accounting reclassifications and entries required to produce IFRS compliant results. These adjustments include the following: (i) The VitalityLife results are reclassified to account for the contractual arrangement in respect of the business written on the Prudential Assurance Company (PAC) license, as an insurance contract which Discovery issues under IFRS 4 Insurance Contracts; (ii) Unit trusts which the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into Discovery’s results for IFRS purposes. The IFRS reporting adjustments include the effects of consolidating the unit trusts into Discovery’s results, effectively being the income and expenses relating to units held by third parties; (iii) The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments; and (iv) The effects of reclassifying items to align to IFRS results. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 25 of 217 -- DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 25 R million SA Health SA Life SA Invest SA Insure2 SA Vitality SA Bank UK Health UK Life All other segments Segment total IFRS reporting adjustments3 IFRS total 30 June 2023 Income statement Insurance premium revenue 245 16 620 15 104 5 177 – – 13 670 7 835 1 808 60 459 (788) 59 671 Reinsurance premiums (1) (3 852) – (414) – – (2 149) (4 277) (231) (10 924) 788 (10 136) Net insurance premium revenue 244 12 768 15 104 4 763 – – 11 521 3 558 1 577 49 535 – 49 535 Fee income from administration businesses 8 571 – 3 099 17 – – 46 – 3 024 14 757 – 14 757 Vitality income – – – – 2 573 – 462 238 618 3 891 – 3 891 Net banking fee and commission income – – – – – 943 – – 22 965 – 965 Banking fee and commission income – – – – – 1 292 – – – 1 292 – 1 292 Banking fee and commission expense – – – – – (349) – – 22 (327) – (327) Net bank interest and similar income – – – – – 574 – – – 574 – 574 Bank interest and similar income using the effective interest rate – – – – – 1 318 – – – 1 318 – 1 318 Bank interest and similar expense using the effective interest rate – – – – – (744) – – – (744) – (744) Investment income earned on assets backing policyholder liabilities – 8 – 159 – – 81 199 15 462 (462) – Net fair value gains on financial assets at fair value through profit or loss (6) 678 10 904 – (1) – – (1 213) 1 839 12 201 2 172 14 373 Other income 1 395 3 – – 1 – 48 – 97 1 544 – 1 544 Finance income/(charge) on negative reserve funding – – – – – – – 1 098 – 1 098 (1 098) – Intersegment funding 1 – (492) 492 – – – – – – – – – Net income 10 204 12 965 29 599 4 939 2 573 1 517 12 158 3 880 7 192 85 027 612 85 639 Net claims and policyholders’ benefits (74) (8 182) (13 304) (2 810) – – (5 370) (973) (9 422) (40 135) – (40 135) Claims and policyholders’ benefits (75) (11 452) (13 304) (3 153) – – (7 138) (2 514) (9 668) (47 304) 558 (46 746) Insurance claims recovered from reinsurers 1 3 270 – 343 – – 1 768 1 541 246 7 169 (558) 6 611 Acquisition costs (35) (1 833) (1 262) (784) (119) – (1 146) (2 449) 317 (7 311) 1 098 (6 213) Expected credit losses – – – – – (139) – – – (139) – (139) Marketing and administration expenses – depreciation and amortisation (140) (6) (12) (64) (9) (314) (420) (49) (794) (1 808) (169) (1 977) – derecognition of intangible assets and property and equipment (4) – – (3) – – (241) (19) (57) (324) – (324) – impairment of property and equipment – – – – – – (45) – – (45) – (45) – other expenses (6 097) (2 347) (1 267) (1 100) (2 429) (1 831) (4 998) (2 453) (3 937) (26 459) (100) (26 559) Recovery of expenses from reinsurers – – – – – – 1 320 2 272 1 3 593 – 3 593 Transfer from assets/liabilities under insurance contracts – change in assets arising from insurance contracts – 4 412 – – – – – 768 – 5 180 680 5 860 – change in assets arising from reinsurance contracts – 49 – – – – 61 18 10 138 (3) 135 – change in liabilities arising from insurance contracts – (230) (10 868) (100) – – (226) (31) 7 376 (4 079) 87 (3 992) – change in liabilities arising from reinsurance contracts – (18) – – – – – 73 – 55 (383) (328) Fair value adjustment to liabilities under investment contracts – (3) (1 326) – – – – – (1 264) (2 593) (2 979) (5 572) Share of net profits from equity-accounted investments – – – (16) – – 1 2 574 561 (46) 515 Normalised profit/(loss) from operations 3 854 4 807 1 560 62 16 (767) 1 094 1 039 (4) 11 661 (1 203) 10 458 Economic assumptions adjustments net of discretionary margins and interest rate derivatives – (2 811) – – – – – 147 – (2 664) 667 (1 997) Economic assumptions adjustments net of discretionary margins – (2 811) – – – – – 1 120 – (1 691) (306) (1 997) Fair value losses on VitalityLife interest rate derivatives – – – – – – – (973) – (973) 973 – Investment income earned on shareholder investments and cash 89 20 71 – 32 – 9 28 75 324 448 772 Intercompany investment income – – – – – – – – 1 184 1 184 (1 184) – Net fair value gains/(losses) on financial assets at fair value through profit or loss – 122 95 – – – – (204) (3) 10 (10) – Gains from dilution of equity-accounted investments – – – (5) – – – – – (5) – (5) Impairment of goodwill – – – – – – – – (9) (9) – (9) Expenses related to PAC book transfer – – – – – – – (177) – (177) 177 – Amortisation of intangibles from business combinations – – – (46) – – – – (56) (102) 46 (56) Market rentals related to Head Office building adjusted for finance costs and depreciation – – – – – – – – (134) (134) 134 – Finance costs (2) (1) – – – – (8) (216) (1 423) (1 650) (291) (1 941) Intercompany finance costs (362) – – – – – – (316) (520) (1 198) 1 198 – Foreign exchange (loss)/gains (4) 33 36 – – – 1 – 84 150 – 150 Profit/(loss) before tax 3 575 2 170 1 762 11 48 (767) 1 096 301 (806) 7 390 (18) 7 372 Income tax expense (972) (576) (573) (21) 4 226 (267) 53 56 (2 070) 18 (2 052) Profit/(loss) for the year 2 603 1 594 1 189 (10) 52 (541) 829 354 (750) 5 320 – 5 320 1 The intersegment funding of R492 million reflects a notional allocation of interest earned on the negative reserve backing policyholders’ funds of guaranteed investment products and hence is transferred to Discovery Invest. 2 This segment relates to SA Insure – Personal lines. . 1. SEGMENT INFORMATION continued Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 26 of 217 -- 26 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 R million SA Health SA Life SA Invest4 SA Insure2 SA Vitality SA Bank UK Health UK Life All other segments Segment total4 IFRS reporting adjustments IFRS total 4 30 June 2022 Restated 4 Income statement Insurance premium revenue 189 15 041 14 029 4 657 – – 11 299 6 750 7 035 59 000 (688) 58 312 Reinsurance premiums – (3 523) – (103) – – (1 556) (3 600) (168) (8 950) 688 (8 262) Net insurance premium revenue 189 11 518 14 029 4 554 – – 9 743 3 150 6 867 50 050 – 50 050 Fee income from administration businesses 7 910 – 2 834 15 – – 30 – 1 975 12 764 (12) 12 752 Vitality income – – – – 2 338 – 392 227 538 3 495 – 3 495 Net banking fee and commission income – – – – – 633 – – 12 645 – 645 Banking fee and commission income – – – – – 853 – – – 853 – 853 Banking fee and commission expense – – – – – (220) – – 12 (208) – (208) Net bank interest and similar income – – – – – 318 – – – 318 – 318 Bank interest and similar income using the effective interest rate – – – – – 811 – – – 811 – 811 Bank interest and similar expense using the effective interest rate – – – – – (493) – – – (493) – (493) Investment income earned on assets backing policyholder liabilities – 3 – 118 – – 9 27 7 164 (164) – Net fair value gains/(losses) on financial assets at fair value through profit or loss 10 485 913 1 1 – (52) (1 390) (1 195) (1 227) (598) (1 825) Other income 1 241 12 – – – – 32 – 56 1 341 – 1 341 Finance income/(charge) on negative reserve funding – – – – – – – 1 368 – 1 368 (1 368) – Intersegment funding 1 – (628) 628 – – – – – – – – – Net income 9 350 11 390 18 404 4 688 2 339 951 10 154 3 382 8 260 68 918 (2 142) 66 776 Net claims and policyholders’ benefits (49) (9 222) (12 075) (3 029) – – (4 331) (877) (1 132) (30 715) – (30 715) Claims and policyholders’ benefits (49) (14 013) (12 075) (3 151) – – (5 652) (2 231) (1 346) (38 517) 495 (38 022) Insurance claims recovered from reinsurers – 4 791 – 122 – – 1 321 1 265 214 7 713 (495) 7 218 Recapture of reinsurance – – – – – – – 89 – 89 – 89 Acquisition costs (27) (1 605) (1 128) (702) (111) – (963) (1 884) 294 (6 126) 1 368 (4 758) Expected credit losses – – – – – (67) – – – (67) – (67) Marketing and administration expenses – depreciation and amortisation (106) (7) (11) (60) (12) (277) (458) (63) (739) (1 733) (169) (1 902) – derecognition of intangible assets and property and equipment – – – (18) – – (1) (14) (17) (50) – (50) – other expenses (5 568) (2 147) (1 156) (988) (2 207) (1 597) (4 091) (2 047) (3 032) (22 833) (424) (23 257) Recovery of expenses from reinsurers – – – – – – 1 041 1 818 – 2 859 – 2 859 Transfer from assets/liabilities under insurance contracts – change in assets arising from insurance contracts – 5 299 – – – – – 3 606 (101) 8 804 (3 018) 5 786 – change in assets arising from reinsurance contracts – 11 – 1 – – 40 11 1 64 (1) 63 – change in liabilities arising from insurance contracts – 662 (3 050) (41) – – (65) (17) (4 488) (6 999) 261 (6 738) – change in liabilities arising from reinsurance contracts – (351) – – – – – (3 244) – (3 595) 3 018 (577) Fair value adjustment to liabilities under investment contracts – (2) 220 – – – – – 42 260 (228) 32 Share of net profits from equity-accounted investments – – – (13) – – 2 – 474 463 (41) 422 Reversal of impairment of equity-accounted investment – – – – – – – – 134 134 – 134 Normalised profit/(loss) from operations 3 600 4 028 1 204 (162) 9 (990) 1 328 671 (304) 9 384 (1 376) 8 008 Economic assumptions adjustments net of discretionary margins and interest rate derivatives – (651) – – – – – 567 – (84) 253 169 Economic assumptions adjustments net of discretionary margins – (651) – – – – – 820 – 169 – 169 Fair value losses on VitalityLife interest rate derivatives – – – – – – – (253) – (253) 253 – Investment income earned on shareholder investments and cash 37 11 38 – 28 – – 8 18 140 156 296 Intercompany investment income – – – – – – – 5 913 918 (918) – Net fair value gains/(losses) on financial assets at fair value through profit or loss – 51 27 – – – – (454) (1) (377) 377 – Loss on dilution of equity-accounted investments – – – 19 – – – – 14 33 – 33 Expenses related to PAC book transfer – – – – – – – (182) – (182) 182 – Covid-19 vaccination programme – – – – – – – – (157) (157) 157 – Amortisation of intangibles from business combinations – – – (41) – – – – (59) (100) 41 (59) Market rentals related to Head Office building adjusted for finance costs and depreciation – – – – – – – – (158) (158) 158 – Finance costs3 (1) 25 – – – – (6) (104) (1 290) (1 376) (282) (1 658) Intercompany finance costs (297) – – – – – (4) (230) (396) (927) 927 – Foreign exchange gains/(losses) 4 25 37 – – – – – 89 155 – 155 Profit/(loss) before tax 3 343 3 489 1 306 (184) 37 (990) 1 318 281 (1 331) 7 269 (325) 6 944 Income tax expense (951) (718) (438) 43 (30) 218 (285) 224 147 (1 790) 325 (1 465) Profit/(loss) for the year 2 392 2 771 868 (141) 7 (772) 1 033 505 (1 184) 5 479 – 5 479 1 The intersegment funding of R628 million reflects a notional allocation of interest earned on the negative reserve backing policyholders’ funds of guaranteed investment products and hence is transferred to Discovery Invest. 2 This segment relates to SA Insure – Personal lines. 3 Finance costs in Discovery Life includes a reversal of interest payable to the South African Revenue Services provided for in the prior year. 4 The comparative information has been restated. Refer to note 45 for detail. 1. SEGMENT INFORMATION continued -- 27 of 217 -- 27 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK Discovery’s accounting policy to recognise and measure insurance contracts can be viewed in Annexure B, accounting policy 13. Discovery issues both short-term and long-term contracts that transfer significant insurance risk. Such contracts may also transfer financial risk. An insurance contract is a contract in which Discovery as issuer and/or insurer accepts significant insurance risk from the policyholder by agreeing to compensate the policyholder if a specified uncertain future event (the insured event) adversely affects the policyholder. A significant insurance risk is the possibility of having to pay benefits, on the occurrence of an insured event, that are significantly more than the benefits payable if the insured event did not occur. There is uncertainty around the timing and/ or the value of the resulting claim. A large portfolio of independent but similar insurance contracts, allow for the use of probability theory to predict the number and value of claims over a defined period. Insurance risk, when considering a large portfolio of insurance contracts, is thus the probability that the actual number of claims over a defined period is different to those expected. This could in turn result in the value of insurance liabilities being over or underestimated. Experience shows that the larger the portfolio of similar insurance contracts, the smaller the relative variability of the expected outcome will be. Discovery reduces claims variability by underwriting policies and by using reinsurance to protect against single large claims or catastrophe reinsurance to mitigate concentration risks. Discovery classifies its insurance contracts into five main categories, depending on the duration of the risk and the type of risk insured. These are: Contracts which are long term in nature – Individual life insurance: These contracts insure against a comprehensive spectrum of risks, including life cover, severe illness, disability and income continuation cover. – Investment products with insurance risk: These contracts attract insurance risk arising from additional benefits offered which mostly insure against mortality or morbidity risks. Contracts which are short term in nature – Health insurance: These contracts insure policyholders against healthcare-related claims. – Short-term insurance: These monthly contracts insure policyholders against a comprehensive spectrum of short-term risks including, but not limited to, motor vehicle, household, business, property and liability cover. – Group life insurance: These contracts insure against a comprehensive spectrum of protection benefits on a group basis. Life cover, severe illness, disability and income continuation benefits are offered. Refer to note 1 segment information for premium revenue per segment. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 28 of 217 -- 28 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued Discovery manages its insurance risk in terms of its risk management framework and holds regulatory and economic capital for protection against adverse experience. The following summarises the insurance risk associated with the various contracts offered by Discovery, and how Discovery manages these risks. Insurance risk Description How Discovery manages the risk Risks significant to all insurance business lines Lapse and surrender risk Policyholders have the option to discontinue or reduce contributions at any time. Accordingly, there is a risk of financial loss due to the withdrawal rate, lapses or premium reductions (with associated reduced cover) being higher than expected. The risk is highest during the early duration of the policy since the acquisition costs and commission incurred at the inception of the policy would not yet have been recouped. Contracts that are long term in nature For individual life insurance products there is a risk: – of reduced profits arising from lower than expected withdrawals at later durations of certain policies in cases where the reserves have turned positive. This is since withdrawals on such policies allow the reserves to be released as profits in the absence of surrender values being offered; and – that withdrawals are selective from a claims experience point of view. For example, healthy lives may find it easier to obtain cover elsewhere compared to less healthy lives. Future earnings on individual life plans are dependent on the number of policies remaining in future years and thus future earnings are dependent on the lapse rate. The future expected earnings vary by the premium funding method chosen by the policyholder. In general, the higher the increases, the higher the withdrawal risk to future earnings. For investment products with insurance risk, there is a risk: – that the surrender value may exceed the policy value, net of expenses, at early durations; and – that withdrawals are higher than expected. Future earnings arising from Invest plans are dependent on the value of assets under management and thus future earnings are dependent on the withdrawal and surrender rate. Contracts that are short term in nature For Discovery Insure there is a risk of reduced profits arising from higher than expected withdrawals at early durations of policies, resulting in acquisition costs not being recovered. Lapse risk is managed as follows: Product design Products are designed to be sustainable in the long term. New product offerings are made available to existing policyholders as far as possible to prevent lapse and re-entry risk. Integration between different product offerings across Discovery enhances the value proposition of the overall package of products from Discovery. For example, Discovery provides unique rewards and benefits as well as integration to members which has proven to be a credible risk differentiator. Premium discounts or cover increases are available to policyholders who actively engage in a healthier lifestyle and utilise the Vitality benefits. Better terms are thus offered to healthy lives compared to less healthy lives. No surrender benefit is offered on risk benefits and thus the loss on withdrawal is reduced. Commission claw back Discovery predominantly distributes via independent brokers, intermediaries and tied agents. Commissions are clawed back from intermediaries where a policy lapses within a specified timeframe since inception. The amount of commission clawback depends on the duration of the policy in months and gradually reduces from 100% to 0% over a specified period, depending on product sold. Experience monitoring Lapse experience is monitored on a monthly basis and data is analysed to establish possible trends for which management action can be taken. Where there is insufficient historic data to provide credible results, for example within VitalityLife Whole of Life, reliance is placed on reinsurers’ advice, industry experience as well as experience from Discovery Life. Proactive conservation Targeted conservation campaigns are run pro- actively. For example, financial advisors are notified of clients that do not have certain features on their policies that are correlated with good persistency. Financial advisors are thus encouraged to add such features. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 29 of 217 -- 29 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued Insurance risk Description How Discovery manages the risk Modelling and data risk Actuarial liabilities are calculated using complex discounted cash flow models. There is a risk that the models do not accurately project the policy cash flows in the future. The models rely on data from the administration system and there is thus a further risk that the data does not accurately reflect the policies being valued. Contracts that are short term have simplified models reducing modelling risk. The risk is controlled using specialist actuarial software that is widely used and accepted in the life insurance industry throughout the world. This is tailored for Discovery. The original actuarial models were tested and verified using an independent but identical parallel model. Any changes made are externally and independently reviewed. Parallel models are developed to test any modelling changes. The data for the model is extracted from modern administration systems and subjected to detailed checks together with high-level reasonability checks. Data is checked at each valuation date. Capital adequacy requirements and protection against adverse experiences There is a risk that future premiums, investment returns and estimates used to calculate liabilities are insufficient to provide for variations in actual future experience. Insurance liabilities are calculated using best estimates plus the addition of various margins to avoid premature recognition of profits and to provide for a buffer against future adverse experience. In addition, Discovery maintains shareholder capital to meet substantial deviations in experience beyond those provided for in the liability calculations. For discussion on how Discovery manages its capital adequacy requirements, refer to note 2.1. Liquidity risk Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with insurance liabilities due to insufficient cash being available to meet commitments as and when they become due. This is exacerbated by timing mismatches between assets and liabilities. Discovery maintains sufficient liquid assets to meet short-term liabilities under base and stress assumptions. Sufficient liquid assets are held to allow for the initial cash flow strain when writing new business. Contracts that are long term in nature Currently, Discovery Life’s and VitalityLife’s expected outflows are mostly long term and the main liquidity requirement is to fund acquisition expenses on new business and unexpected fluctuations in benefit payments. As discussed in note 3.4.3, Discovery invests primarily in liquid financial assets. For Discovery Life, large sums assured above a defined retention level are reinsured, providing stability in claims experienced and further reducing liquidity risk. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 30 of 217 -- 30 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Insurance risk Description How Discovery manages the risk Liquidity risk continued There is a need to meet liquidity requirements arising from Discovery Invest’s Guaranteed Plan book. Liquidity requirements are managed to ensure a liquidity buffer is maintained to meet potential outflows if exit rates are higher than expected. The liquidity risk on the existing portfolio is thus relatively small. VitalityLife also receives partial financing for new business strain from financing reinsurance treaties with reinsurers. For discussion on managing liquidity risk, refer to note 2.2. Contracts that are short term in nature VitalityHealth mostly has expected outflows which are short term in nature as the vast majority of claims are expected to be settled within 12 months of reporting. The existing book is mature and is cash generative which covers liquidity required for the cash flow strain of writing consistent levels of new business. Discovery Insure holds the majority of working and solvency capital in cash or near cash instruments to minimise liquidity risk. Large sums assured above a defined retention level are reinsured, providing stability in claims experience and further reducing the liquidity risk. Catastrophe reinsurance further reduces this risk. Concentration risk Claims experience risk There is a risk that a concentration of risk can lead to worse than expected experience. The concentration risk is the highest in group business, since assured lives live in the same geographical location and generally work in the same industry or at the same location. Discovery has a well-diversified book of business by source of new business and spread across brokers and agents. Furthermore, the claims experience risk is mitigated through catastrophe reinsurance. For details of diversification refer to note 2.3. Withdrawal concentration risk There is a financial risk of the withdrawal of a block of policies written by a single independent intermediary. Operational and implementation risk Operational risk is defined as the risk of loss arising from inadequate or failed internal processes, people and systems or from external events. Discovery offers a wide product range, which grows over time due to further product enhancements and development. In order to mitigate operational risk, Discovery maintains and follows a set of documented processes and procedures which are reviewed internally and externally to be in line with industry best practice. Testing protocols are implemented prior to launching new systems/products or businesses. Embedded in Discovery’s processes is the concept of segregation of duties which ensures that there are multiple checks on outputs by different areas within the business and protects against operational and implementation risk. . Policy wording/ legal risk There is a risk that Discovery could be financially exposed to obligations that differ from expectations and are not adequately provided for. The risk could also arise from legal proceedings. The risk is managed when new products are developed and all policy wording is reviewed by legal advisors and external advice is obtained where necessary to ensure that terms and conditions are clearly defined and unambiguous. 2. MANAGEMENT OF INSURANCE RISK continued Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 31 of 217 -- 31 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Insurance risk Description How Discovery manages the risk Regulatory risk Discovery operates in a highly regulated environment which is continuously being scrutinised and questioned by both consumers and regulators. This has resulted in the constant review of the in-force regulations and the interpretation thereof. The regulatory risk can thus be defined as the potential detrimental impact unexpected changes in regulations, or the interpretation thereof, may have on Discovery. Although Discovery endeavours to design insurance and financial solutions which meet the requirements of the current regulations in force, the risk does exist that changes in the regulations or the interpretation of the regulations, over time may result in the current products not fully complying with the regulations in force in future. This risk is managed through constantly seeking legal advice on new product developments. Further, all insurance products issued by Discovery have to be approved, including approval from a market conduct perspective. Depending on the business line, these are approved either by the Head of the Actuarial Function or Actuarial Committee. Discovery is a member of industry-wide bodies that engage in discussions with policymakers and regulators. Discovery’s compliance department enhances regulatory compliance through audits and by monitoring developments in the regulatory environment. Tax risk Tax risk is the risk that the actual future tax liability is different to what is currently expected. This could be as a result of an incorrect interpretation or application of tax legislation or as a result of changes to tax legislation. Clear understanding and close monitoring of tax changes, with appropriate tax allowance in product design and pricing. VitalityLife specific Tax relief on expenses does not apply to protection business sold from January 2013 onwards. Expense risk Expense risk is the risk of actual expenses being higher than expected. Expenses could exceed expectations due to an increase in expense inflation or due to a reduction in the number of in-force policies. A reduction in the assets under management could be an expense risk due to the value of fixed costs. Expenses are monitored on a monthly basis against budgeted expenses. Any deviation from the budget is investigated, reported and where necessary, remedial action is taken. Reputational risk Reputational risk is the risk of negative market reaction towards Discovery. Discovery may thus not be able to apply management policies to reduce risk. Discovery Life offers policies that integrate with the product offerings within the Discovery Group. The reputational risk to Discovery Life is thus extended to the reputational risk of the entire Discovery Group. Reputational risk may also arise on investment products with insurance risk, if these products experience worse investment returns than competitors. This may lead to lower future new business and higher surrenders. Reputational risk is carefully monitored. Decisions to repudiate claims are reviewed by a review committee comprising of a senior underwriter and claims assessor, representatives of the legal department and the medical team, as well as a compliance officer. Marketing material and policy wording are reviewed and designed to be clear and unambiguous to avoid creating unreasonable policyholder expectations. All products are approved prior to launch, by either the Head of the Actuarial Function or Actuarial Committee, depending on the business line. Approval is obtained prior to launch from a market conduct perspective. For investment products with insurance risk, the risk on investment returns is mitigated through the use of reputable experienced fund managers and unique, innovative products covering specific risks. 2. MANAGEMENT OF INSURANCE RISK continued Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 32 of 217 -- 32 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Insurance risk Description How Discovery manages the risk Risks significant to long-term insurance Mismatching and market risk Mismatching is the risk that insurance- related cash outflows (e.g. benefit payments, administration expenses) do not match expected future cash inflows (predominately future premiums). Mismatching risk can also arise when movements in assets and liabilities are out of line given changes in market risk, i.e. equity price risk, interest rate risk or currency risk. The value of assets and liabilities arising from insurance contracts are subject to interest rate risk, thus a risk exists that a change in the discount rate could cause a change in the value of the assets and liabilities arising from insurance contracts. For assets arising from insurance contracts, Discovery covers the insurance related outflows by expected future cash inflows (predominately future premiums). For liabilities arising from insurance contracts, the insurance related cash outflows are matched with a combination of a release of policyholder assets (net of retained fees), investment return on these assets and cash inflows. For further discussion on how Discovery manages this risk, refer to note 2.4 more specifically: – For mismatching risk, refer note 2.4.1 and 2.4.2; – For interest rate risk, refer note 2.4.3; and – For currency risk, refer note 2.4.4 Underwriting experience risk – Individual life plans and investment products with insurance risk For individual life plans, there is a risk that actual mortality and morbidity experience is higher than expected. This could arise as a result of the number of claims or the value of claims being higher than expected. In addition, there is a risk that the emergence of a new disease or epidemic can increase the number of claims. On guaranteed annuities there is a risk that mortality experience is lower than expected and thus income payments continue for longer than expected. Investment products with insurance risk may also carry mortality and morbidity risks. The risks are managed through various mechanisms: Product design and pricing Products are carefully designed to minimise adverse selection. Rating factors are applied to standard premium rates to differentiate between different levels of risk. For example, premiums are differentiated by income, education level, smoker status, gender, medical history and age. – From January 2013 onwards, no differentiation of premiums or benefits on the basis of gender is allowed in the UK. – Discovery Life has the unique ability to take additional rating factors into account for example the current medical scheme claims and lifestyle factors. All new premium rates are reviewed and approved by either the Head of Actuarial Function or Actuarial Committee. Product integration between the different product offerings in Discovery helps to attract healthier lives than average in the market, leading to positive selection. The product integration incentivises engagement in the Vitality programme, which has a positive impact on risk experience. Selection risk is the risk that worse risks than expected are attracted and these risks are then charged inadequate premiums. Selection risk could also lead to higher than expected mortality and morbidity experience on individual life plans or lower mortality on guaranteed annuity policies. For certain of the product options offered under the individual life plans, Discovery has retained the option to review premium rates annually throughout the life of the contract because of uncertainties underlying the value of the benefits offered. Only premiums that can be predicted with confidence are guaranteed longer periods. The guarantee provided to the policyholder will, however, be strengthened based on the policyholder’s actual annual historic Vitality status. Discovery Life predominantly operates in the high end of the South African insurance market where the risk of HIV/ AIDS is lower than for the South African market as a whole. The impact of HIV/AIDS is considered and allowed for during the product development and pricing. 2. MANAGEMENT OF INSURANCE RISK continued Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 33 of 217 -- 33 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Insurance risk Description How Discovery manages the risk Underwriting experience risk – Individual life plans and investment products with insurance risk continued Underwriting Underwriting ensures that only insurable risks are accepted and that premiums reflect the unique circumstances of each risk. Financial underwriting is applied to ensure that the policyholder can justify the amount of cover applied for. Premium loadings and exclusions are applied where high risks are identified. For integrated policies, Discovery Life can dynamically adjust certain premiums using the information from the health claims experience of a policyholder who is also a member of the Discovery Health Medical Scheme and Vitality. This provides Discovery Life with an advantageous position in the market. Monthly internal quality assurance audits are performed on underwriting to minimise the risk of incorrect underwriting decisions. Reinsurance Reinsurance protects against volatility in claims experience and against an accumulation of risk. Reinsurance is further utilised on a facultative basis if uncertainty exists over the terms that should be offered to a particular risk. In addition, reinsurers provide specialist advice when designing new products. Discovery Life utilises surplus and facultative reinsurance to reinsure amounts in excess of defined retention levels. Discovery Life is thus protected against large individual claims. In addition, catastrophe reinsurance reduces the risk of an accumulation of risk due to a single event. Both individual life are covered by catastrophe reinsurance which covers man-made or natural catastrophe events. For VitalityLife, the life, serious illness, disability and income protection benefits are reinsured with a maximum retention of GBP150 000. The unemployment benefit offered as part of the VitalityLife product is fully reinsured. Experience monitoring Experience investigations are conducted and corrective action is taken where adverse experience is noted. Experience monitoring is done on at least a quarterly basis, and in some business lines monthly. Where there is insufficient historic data to provide credible results, such as VitalityLife, reliance is placed on reinsurers’ advice, industry experience as well as experience from Discovery Life. 2. MANAGEMENT OF INSURANCE RISK continued Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 34 of 217 -- 34 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Insurance risk Description How Discovery manages the risk Risks significant to short-term insurance Underwriting experience risk The risk that claims experience turns out to be worse than anticipated in the pricing of the product and that claims reserves are insufficient to meet insurance liabilities as they fall due. The principal risk is that the frequency and/ or severity of claims are greater than expected. Insurance events are, by their nature, random and the actual number and size of events during any one year may vary from those estimated and experienced in prior periods. Frequency of claims can vary depending on, for instance, the levels of engagement with the Vitality programme, and severity of claims can be influenced by new treatments or changes in medical inflation. Group Life Group Life business is reviewed on a contract by contract basis, with the review period never exceeding two years. HIV/AIDS risk is specifically allowed for in the pricing of individual groups. Group business is underwritten on an employer by employer basis and additional allowance is made for the impact of industry class, income and geographic location on expected claims experience. The free cover limit is the sum assured that will be given automatically to a specific life without further specific underwriting. The free cover limits are set separately for each scheme depending on the size and cover chosen by the specific scheme. In addition to renewal pricing changes, standard terms and conditions applicable to the company’s products mitigate the risk of late reporting of claims. VitalityHealth New business is written in accordance with approved pricing assumptions. Underwriting criteria is defined and aligned to the approved pricing assumptions. VitalityHealth’s overall premium levels are determined by its pricing and lapse experience, as well as the level of new business written. VitalityHealth can manage the risk of new business policies through the ability to underwrite policies at inception or at the point of claim. Aside from large corporate clients, all other lives covered were underwritten through either full medical underwriting, continuation of previous exclusions (if the policy is moving from another UK health insurer), or moratorium conditions which limit claims for a specified period relating to previous conditions. VitalityHealth is able to manage the insurance risk in existing business premiums through the annual repricing of policies at renewal on a risk-related basis; this is a key differentiator as to why the UK market is less susceptible to volatility from insurance risk than South Africa. Whilst policyholders can choose to cancel their contract mid-term between renewals, this is not experienced in the SME or corporate products as the terms and conditions of the contract do not permit cancellation mid-term unless the customer is going into administration. Individual contracts can and do cancel between renewals however retaining these policies is a key activity for the business. VitalityHealth is only obligated to continue to pay for any authorised treatment whilst premiums are being received from the policyholder. 2. MANAGEMENT OF INSURANCE RISK continued Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 35 of 217 -- 35 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Insurance risk Description How Discovery manages the risk Underwriting experience risk continued Discovery Insure Discovery Insure aims to manage risk through diversifying the pool of insured risks by establishing a balanced portfolio of insurance risks over a wide geographical area. Short-term insurance risks are priced on an individual basis, therefore a minimal cross subsidy exists between risks. Premiums are calculated using statistical regression techniques. Insurance risk factors identified would typically include past insurance history, type and value of asset covered, measures taken to protect the asset, primary use of covered item and various other pertinent factors. Discovery Insure’s quotation and administration system calculates risk on an individual basis based on information captured by brokers and agents for each risk. Individual risks are accepted automatically up to cut-off limits which vary by risk type. Insurance conditions and exclusions are also automatically set at an individual risk level. Individual risks greater than the limit are automatically referred and underwritten by the underwriting department. No risks are accepted which exceed the upper limits of the reinsurance contracts without the necessary facultative cover being arranged. Discovery Insure uses telematic devices to manage risks related to motor vehicle cover. The telemetry received in respect of vehicles in which the devices are installed, highlights speeding, harsh breaking, harsh cornering and other risk related incidents. By informing the driver of how they are driving and in turn rewarding them for driving well, the risk of an accident is reduced. The ’deep install’ device is also equipped with a stolen vehicle recovery transponder that increases the probability of recovering a vehicle should it be stolen. Reinsurance – VitalityHealth VitalityHealth currently utilises reinsurance to better match the high upfront costs of acquisition with the profit emergence across the lifetime of the policies written. VitalityHealth currently has quota share agreements in place with two reinsurers with an outstanding balance of GBP246.0 million (R5 902 million) at year end (2022: GBP198.5 million (R3 971 million)). 2. MANAGEMENT OF INSURANCE RISK continued Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 36 of 217 -- 36 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Insurance risk Description How Discovery manages the risk Underwriting experience risk continued Reinsurance – Discovery Insure Discovery Insure mitigates its insurance risk through its reinsurance programme which is structured to protect the company against material losses to either a single insured risk, or group of insured risks in the case of a catastrophe where there would tend to be a concentration of insured risks. Furthermore, Discovery Insure reinsures a portion of the risk it underwrites to protect the profitability and the capital of the company. A variety of treaties are entered into in order to limit losses resulting from individual and collective insurance risks. Additional facultative reinsurance is purchased for certain individual risks that are in excess of the relevant treaty limits. Discovery Insure only enters into reinsurance arrangements with reinsurers that have adequate credit ratings. Experience monitoring Across both premiums and claims, recent actual experience is compared against financial forecasts, with any deviations investigated. The results provide a feedback loop into the overall pricing approach, enabling Discovery to react quickly to any changes in behaviour. 2.1 Capital adequacy requirements and protection against adverse experience Refer to the Directors’ report for a breakdown of Statutory Capital Requirement cover ratios. Discovery manages its capital requirements in line with the statutory requirements of the relevant Prudential Authorities. During the period Discovery met the Statutory Capital Requirements. 2.1.1 Discovery Life Discovery Life is required to demonstrate solvency to the PA in South Africa in accordance with the Insurance Act 18 of 2017 (Insurance Act). Discovery Life thus needs to maintain sufficient shareholder assets (Own Funds), over and above the assets required to meet policyholder liabilities (best-estimate liabilities plus a prescribed risk margin), to support a multiple of the Solvency Capital Requirement (SCR). Discovery Life is required to undertake an internal assessment of its risks and capital needs, in addition to meeting the minimum capital requirements set by the PA. The SCR is calculated in accordance with the Prudential Standards as issued by the PA. The SCR calculation is intended to approximate a risk-based capital measure and covers the major areas of insurance risk. It explicitly covers the following key areas of risk to Discovery Life: – Lapse and withdrawal risk – Fluctuations in mortality and morbidity experience including catastrophe risk – Interest rate risk – Equity and property risk – Expense risk – Operational risk – Spread and counterparty default risk – Currency risk – Concentration risk. 2. MANAGEMENT OF INSURANCE RISK continued Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 37 of 217 -- 37 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued 2.1 Capital adequacy requirements and protection against adverse experience continued 2.1.1 Discovery Life continued Discovery Life regularly reviews the capital position and also considers various new business scenarios. Typically, a five-year new business projection horizon is allowed for and the capital position is assessed at each valuation date during the projection to ensure an acceptable capital cover is maintained. Discovery Life has calculated its solvency position in accordance with the Insurance Act and related Prudential Standards since 30 June 2013. A consistent level of solvency cover, comfortably in excess of the statutory minimum, was observed at all valuation dates. 2.1.2 VitalityLife The Vitality Life business comprises business underwritten directly by VitalityLife (from 1 January 2016) and business underwritten on behalf of VitalityLife on PAC’s life insurance license (up to 31 December 2015). Through a number of contractual and loan arrangements, Discovery retains 100% of the insurance risk associated with the VitalityLife policies underwritten on the PAC life insurance license. All policies are administered by VitalityLife, and they are managed as a single portfolio. The arrangement with the PAC is accounted for in substance under IFRS as an insurance contract that Discovery issues. Accordingly, all information for VitalityLife is presented on a combined basis comprising both the business underwritten by VitalityLife and underwritten on behalf of VitalityLife on the PAC life insurance license. The business that was underwritten on PAC life insurance license will, as per contractual agreement with PAC, still be valued under the Solvency I or old capital requirement rules described below until it is transferred to the Vitality Life Limited (VLL) license. After this date, this business would need to be fully Solvency II compliant. During the financial period ended 30 June 2022, Discovery and PAC have finalised a contractual agreement to a long-term deferral of the transfer to the VLL license (the Part VII transfer). The agreement is such that the Part VII transfer is now deferred for the long term with options to extend further and for all intents and purposes should be viewed as an indefinite deferral. The business written on its own life insurance license within VitalityLife needs to be fully Solvency II compliant. VitalityLife obtained its own life insurance license at the end of the calendar year 2015. This significant milestone, together with the implementation of Solvency II in the UK from 1 January 2016, required a change to the capital requirements of VitalityLife. SOLVENCY I The Financial Services Authority (FSA) was replaced by two distinct regulators in 2013 namely the Prudential Regulation Authority (PRA) and the Finance Conduct Authority (FCA). The PRA is a part of the Bank of England and responsible for the prudential regulation and supervision of insurers. It sets standards and supervises financial institutions. The FCA regulates the financial services industry in the UK. Their aim is to protect consumers, ensure the industry remains stable and promote healthy competition between financial services providers. The Prudential Sourcebook for Insurers (INSPRU) contains standards for capital management. Capital requirements are calculated based on the concept of two pillars: – Pillar 1, which covers public solvency information that appears within the regulatory returns on the basis of prescriptive rules. This includes the statutory valuation of liabilities together with a prescribed measure of additional capital, the Long-term Insurance Capital Requirement (LTICR); and – Pillar 2, the Individual Capital Assessment (ICA), which covers a confidential company-specific assessment of solvency. This assessment is done on a realistic basis with the aim to protect against risks up to the 99.5 percentile over a one-year period. The LTICR is a minimum required margin for solvency on the statutory valuation basis and covers the following basic risks: – Mortality risk; – Expense risk; – Market risk; and – Health risk. The amount of capital that ultimately needs to be held by a life insurance company in the UK is the larger of the Pillar 1 and Pillar 2 result. VitalityLife is required to provide capital to the PAC equal to one times the Pillar 1 capital requirement, increasing to one and a half times from the Pillar 1 capital requirements from March 2024 onwards. The cover requirements were observed at all valuation dates. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 38 of 217 -- 38 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued 2.1 Capital adequacy requirements and protection against adverse experience continued 2.1.2 VitalityLife continued SOLVENCY II Capital requirements under Solvency II are calculated using the regulations and guidance originally published by the European Insurance and Occupational Pensions Authority (EIOPA) and enforced by the PRA in the UK. A Solvency Cover ratio is calculated which has several components, the key ones are discussed below: – Best estimate liabilities (BEL): policyholder liabilities are calculated on a best estimate basis (excluding any margins) and discounted at the latest swap curve published by Bank of England; – SCR: 1-in-200 year stresses to the key assumptions are applied to the BEL and the impacts aggregated using specified correlation matrices; – Risk Margin (RM): 6% of the SCR run-off over time is discounted at the latest swap curve; – Technical Provisions (TP): the sum of the BEL and the RM; – Eligible Own Funds: the net assets of the company available to cover the SCR; negative TP can be included in the eligible Own Funds ; and – Solvency cover ratio: Eligible Own funds divided by SCR 2.1.3 VitalityHealth VitalityHealth maintains shareholder capital to meet substantial deviations in experience and to support business growth. The objective of VitalityHealth’s capital management policy is to define the principles and guiding philosophy for capital management that ensures capital and solvency levels are managed effectively in line with the defined risk appetites. The policy and objectives are reviewed at least annually. Alongside ensuring VitalityHealth complies with capital requirements imposed by its regulator (the PRA), the guiding principles for the policy are to: – Foster an environment of regulatory compliance within the Group’s culture, strategy and decision making; – Continually develop and enhance the Group’s regulatory compliance capability; – Actively communicate the effectiveness and benefits of compliance management to all stakeholders; and – To provide reasonable and independent assurance to the Group’s key management, board and regulator. VitalityHealth is required to hold sufficient capital (measured in accordance with PRA Rulebook) to meet the PRA capital requirements. The capital requirements were met at all valuation dates. With effect from 1 January 2016 the insurance regulatory regime Solvency II was implemented in the UK. Refer to 2.1.2 for discussion on Solvency II. Under this solvency regime, insurers have the opportunity to either follow the standard formula approach, or apply to the regulators to move away from this. VitalityHealth follows a standard formula, and as such has a SCR in line with that prescribed. Annually, the business publicly discloses a Solvency and Financial Condition Report (SFCR) alongside private disclosures to the regulators on its Own Risk and Solvency Assessment (ORSA). The standard formula approach is also annually reviewed to determine its appropriateness for the business and as at 30 June 2023 the standard formula review determined it was not an inappropriate assessment of the risks present in VitalityHealth. The actual and projected capital position of VitalityHealth is monitored on a regular basis through a number of forums and governance committees including the Board of Directors as well as through VitalityHealth’s ORSA. In the event that sufficient capital is not projected to be available, actions would be taken to obtain additional capital or to reduce the amount of risk accepted and therefore reduce the capital requirement through, for example, reinsurance or investment strategy. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 39 of 217 -- 39 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued 2.1 Capital adequacy requirements and protection against adverse experience continued 2.1.4 Discovery Insure Similar to Discovery Life, Discovery Insure is required to demonstrate solvency to the PA in accordance with the Insurance Act. Discovery Insure thus needs to maintain sufficient shareholder assets (Own Funds), over and above the assets required to meet policyholder liabilities (BEL plus a prescribed risk margin), to support a multiple of the SCR. In addition, Discovery Insure is required to undertake an internal assessment of its risks and capital needs, in addition to meeting the minimum capital requirements set by the PA. The SCR is calculated in accordance with the Prudential Standards as issued by the PA. The SCR calculation is intended to approximate a risk-based capital measure and covers the major areas of short-term insurance risk. It explicitly covers the following key areas of risk to Discovery Insure: – Catastrophe risk – Premium and reserve risk – Lapse risk – Interest rate risk – Equity and property risk – Expense risk – Operational risk – Spread and counterparty default risk – Currency risk – Concentration risk. The internal assessment of risks and capital needs usually considers, amongst others, the following risks: – Lapse risk not captured in the SCR – New business volume risk – Expense risk over and above allocated loss adjustment expense (ALAE) risk Discovery Insure regularly reviews the capital position and considers various new business scenarios. Typically, a five-year new business projection horizon is allowed for and the capital position is assessed at each financial year during the projection to ensure an acceptable capital cover is maintained. The solvency cover was observed at all valuation dates. 2.2 Liquidity risk 2.2.1 Contracts that are long term in nature DISCOVERY LIFE, DISCOVERY INVEST AND VITALITYLIFE For Discovery Life, Discovery Invest and VitalityLife, the discounted expected embedded value cash flows arising from in-force contracts after policyholder liabilities have been met, net of tax, as at 30 June were as follows: Gross of reinsurance R million Total Year 1 Years 2 to 5 Years 6 to 10 Years 11 to 20 Years 21+ 2023 Discovery Life 28 547 28 547 1 651 1 651 6 274 6 274 6 799 6 799 8 219 8 219 5 604 5 604 Discovery Invest 9 469 9 469 735 735 3 417 3 417 2 747 2 747 2 112 2 112 458 458 VitalityLife 17 698 17 698 3 304 3 304 7 971 7 971 5 607 5 607 2 133 2 133 (1 317) (1 317) 2022 Discovery Life 28 101 1 690 5 618 6 382 8 221 6 190 Discovery Invest 8 602 547 2 640 2 677 2 354 384 VitalityLife 12 830 2 436 6 194 4 597 1 581 (1 978) Net of reinsurance R million Total Year 1 Years 2 to 5 Years 6 to 10 Years 11 to 20 Years 21+ 2023 Discovery Life 23 834 1 072 4 566 5 463 7 454 5 279 VitalityLife 11 822 1 193 3 606 4 484 2 259 280 2022 Discovery Life 23 473 1 298 4 003 4 994 7 367 5 811 VitalityLife 8 818 743 2 292 3 723 1 705 355 Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 40 of 217 -- 40 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued 2.2 Liquidity risk continued 2.2.1 Contracts that are long term in nature continued The cash flows in the tables above differ from those disclosed in notes 2.4.1 and 2.4.2 since the cash flows in the tables above are based on best estimate free cash flows after meeting policyholder liabilities, are discounted at the risk discount rate and are capped at 40 years as per the Discovery Life and Discovery Invest embedded value methodology. Cash flows arising from investment management contracts are also included. No allowance has been made for new business and related expenses. 2.2.2 Contracts that are short term in nature VITALITYHEALTH VitalityHealth maintains sufficient liquid assets to meet short-term liabilities and to allow for the initial cash flow strain when writing new business. Currently, VitalityHealth’s expected liabilities are mostly short term and the main liquidity requirement is to fund acquisition expenses on new business, with the existing book mature enough to generate sufficient liquidity to cover cash flow strain of writing consistent levels of new business. DISCOVERY INSURE Discovery Insure holds the majority of working and solvency capital in cash or near cash instruments to minimise liquidity risk. Large sums assured above a defined retention level are reinsured, providing stability in claims experience and further reducing the liquidity risk. Catastrophe reinsurance further reduces this risk. 2.3 Concentration risk 2.3.1 Claims experience risk DISCOVERY LIFE Discovery Life maintains a well-diversified portfolio of policies. Reinsurance is further used to protect against the concentration of risk. Catastrophe reinsurance protects against the accumulation of claims from a single event, for example an airplane crash. The catastrophe reinsurance for Discovery Life covers single event disasters for up to R975 million where the net of reinsurance impact is greater than R52 million. For its biggest four group schemes, a further layer of catastrophe reinsurance cover of R3 750 million in excess of R1 027 million is in place. Reinsurance removes the exposure to large individual claims. The following graph demonstrates that the distribution of policies by sum assured is shifted towards lower sum assured due to the reinsurance cover. 0 – 0.5 Before reinsurance After reinsurance Number of Lives >5.0 4.5 – 5.0 4.0 – 4.5 3.5 – 4.0 3.0 – 3.5 2.5 – 3.0 2.0 – 2.5 1.5 – 2.0 1 – 1.5 0.5 – 1.0 2023 Distribution of Sums Retained: before and after reinsurance (Sum retained – Rm) 0 20 000 40 000 60 000 80 000 100 000 Reinsurance results in a reduction in exposure to large individual sums-at-risk, leading to this transfer from large to small case sizes Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 41 of 217 -- 41 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued 2.3 Concentration risk continued 2.3.1 Claims experience risk continued DISCOVERY LIFE CONTINUED 0 – 0.5 Before reinsurance After reinsurance Number of Lives >5.0 4.5 – 5.0 4.0 – 4.5 3.5 – 4.0 3.0 – 3.5 2.5 – 3.0 2.0 – 2.5 1.5 – 2.0 1 – 1.5 0.5 – 1.0 2022 Distribution of Sums Retained: before and after reinsurance (Sum retained – Rm) 0 20 000 40 000 60 000 80 000 100 000 Reinsurance results in a reduction in exposure to large individual sums-at-risk, leading to this transfer from large to small case sizes VITALITYLIFE VitalityLife maintains a well-diversified portfolio of policies. Reinsurance removes the exposure to large individual claims. The following graph demonstrates that the distribution of policies by sum assured is shifted towards lower sum assured due to the reinsurance cover. The profile is largely the same as the prior period, although a shift towards higher sums assured due to annual benefit increases and inflationary impacts on new business was observed as expected. 0 – 25 Before reinsurance After reinsurance >250 225 – 250 200 – 225 175 – 200 150 – 175 125 – 150 75 – 100 50 – 75 25 – 50 100 – 125 Number of Lives 2023 Distribution of Sums Retained: before and after reinsurance (Sum retained – GBP’000) 0 40 000 80 000 120 000 160 000 200 000 0 – 25 Before reinsurance After reinsurance >250 225 – 250 200 – 225 175 – 200 150 – 175 125 – 150 75 – 100 50 – 75 25 – 50 100 – 125 Number of Lives 2022 Distribution of Sums Retained: before and after reinsurance (Sum retained – GBP’000) 0 30 000 60 000 90 000 120 000 150 000 180 000 Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 42 of 217 -- 42 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued 2.3 Concentration risk continued 2.3.1 Claims experience risk continued VITALITYHEALTH VitalityHealth has the risk of single large medical expense claims arising abroad, or multiple small travel claims due to a single event which could cause losses. In order to manage these risks VitalityHealth holds a reinsurance policy specifically on travel benefits which can help to cover the concentration risks from these events. The threshold for a potential claim on the reinsurance for either of these reasons is GBP250 000. DISCOVERY INSURE There is a risk that a concentration of risk can lead to a worse than expected claims experience. In order to manage this concentration of insurance risk, Discovery has entered into a catastrophe excess of loss reinsurance treaty that would limit the loss of the Group to pre-determined levels following the occurrence of a localised catastrophe in that area. Discovery Insure has concentration of policyholders in the main metropolitan areas such as Johannesburg, Pretoria, Cape Town and Durban. A catastrophic flood, hail, fire or earthquake would result in disproportionate losses in these areas given the accumulation of risk. Catastrophe reinsurance is used to limit the size of such losses and their impact on the underwriting result. 2.3.2 Withdrawal concentration risk DISCOVERY LIFE AND VITALITYLIFE There is a financial risk of the withdrawal of a block of policies written by a single independent intermediary. In order to manage these risks, Discovery diversifies its book of business by source of new business and spread across its brokers and agents. Brokers and agents Maximum exposure to single intermediary % of total premium income 2023 2022 2023 2022 Long-term insurance – Discovery Life 7 800 7 500 1.2% 1.2% – VitalityLife 31 443 30 199 3.2% 2.9% Small concentration (0 – 99 policies) Medium concentration (100 – 999 policies) Large concentration (1 000+ policies) 21% 28% 51% 2023 API concentration by intermediary – Discovery Life Small concentration (0 – 99 policies) Medium concentration (100 – 999 policies) Large concentration (1 000+ policies) 21% 28% 51% 2022 API concentration by intermediary – Discovery Life Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 43 of 217 -- 43 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued 2.4 Mismatching and market risk 2.4.1 Assets arising from insurance contracts Assets arising from insurance contracts in the Statement of financial position include assets for Discovery Life and VitalityLife. The reconciliation of the assets arising from insurance contracts disclosed in the cash flows below, to the Statement of financial position (refer to note 5) is as follows: R million 2023 2022 Assets arising from insurance contracts relating to: – Discovery Life 41 263 39 661 – VitalityLife 22 602 16 984 Total 63 865 56 645 Cash flows are calculated in accordance with the accounting policies. Contractual premium and benefit increases are recognised in the cash flow projections. The expected discounted future cash flows utilised in the calculation of assets arising from insurance contracts are disclosed in the table below. Discounting is performed using: – the prevailing risk-free SA and US yield curve for Discovery Life; and – a modified passive rate for VitalityLife whereby the one-year average of the risk-free gilt yield is used. The assumption is only changed if the one-year average changes by more than a pre-determined range around the set passive rate. R million Total Year 1 Years 2 to 5 Years 6 to 10 Years 11 to 20 Years 21+ 2023 Discovery Life 41 263 2 787 10 210 9 464 10 773 8 029 VitalityLife 22 602 4 375 12 330 9 413 9 239 (12 755) 2022 Discovery Life 39 661 2 403 9 267 8 761 10 662 8 568 VitalityLife 16 984 3 746 10 523 7 587 7 012 (11 884) Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 44 of 217 -- 44 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued 2.4 Mismatching risk continued 2.4.2 Liabilities arising from insurance contracts continued Refer to page 52 for a breakdown of the assets backing these liabilities. The reconciliation of the liabilities arising from insurance contracts disclosed in the cash flows below, to the Statement of financial position (refer to note 18) is as follows: R million 2023 Restated1 2022 Long-term insurance contract liabilities with fixed and guaranteed terms (note 18) 22 087 21 273 Long-term insurance contract liabilities with fixed and guaranteed terms: VitalityInvest (34) (5) Long-term insurance contract liabilities with fixed and guaranteed terms 22 053 21 268 Negative insurance liability included in unit-linked insurance contracts (note 18) (5 770) (5 541) Discovery Invest value of liabilities arising from insurance contracts 16 283 15 727 The expected discounted future cash flows in the calculation of liabilities arising from insurance contracts are disclosed in the table below, allowing for compulsory and discretionary margins. Discounting is performed using the prevailing risk free SA gilt yield curve. R million Total Year 1 Years 2 to 5 Years 6 to 10 Years 11 to 20 Years 21+ 2023 Discovery Invest Long-term insurance contract liabilities with fixed and guarantee terms (22 053) (5 608) (14 655) (800) (682) (308) Negative insurance liability included in unit-linked insurance contracts 5 770 (41) 2 121 2 278 1 909 (497) 2022 Restated 1 Discovery Invest Long-term insurance contract liabilities with fixed and guarantee terms (21 268) (4 460) (15 450) (540) (554) (264) Negative insurance liability included in unit-linked insurance contracts 5 541 29 1 667 2 055 1 911 (121) 1 The comparative information has been restated. Refer to note 45 for detail. 2.4.3 Market risk – Interest rate risk DISCOVERY LIFE For Discovery Life, increased nominal or real interest rates would result in an adverse impact on the present value of future profits. Cash flows on a material segment of the book are linked to inflation. While this retains cash flows in real terms, this segment is exposed to real interest rate movements. The balance of the book is exposed to changes in the nominal rates. VITALITYLIFE As a long-term insurance provider in the UK, VitalityLife has significant exposure to long-term interest rate risk, given the impact on reserves of lower investment rate assumptions related to fixed future premium receipts to meet policy obligations. Accordingly, lower long-term interest rates and yield assumptions may negatively impact on the valuation of future policy obligations and result in a valuation loss. Interest rates in the UK have displayed significant volatility in recent years and after a period of decline have risen sharply in the last 12 months. In recent years, VitalityLife has implemented an interest rate risk mitigation strategy to protect itself against volatility in interest rates by entering into derivative contracts. This strategy ensures that the VitalityLife business operates well within its pre- determined risk appetite and removes a large amount of volatility from its earnings and cash flows. A number of the VitalityLife swaps were removed just before the end of the period under review. In addition, the swaption purchased in June 2022 was sold. VitalityLife continues to hold interest rate swaps to manage the interest rate risk on the legacy PAC book of business. At 30 June 2023 the derivative instruments comprised of interest rate swaps, with a nominal value of GBP226.8 million (R5 441 million). This interest rate swap derivative swaps exposure to variable interest rates in return for a fixed interest rate reference to the 50-year UK SONIA swap rate (VitalityLife receives the fixed rate and pays the variable rate). The weighted average (by nominal value) fixed interest rate is 2.248%. The interest rate swap derivative is in place for an extended period of time. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 45 of 217 -- 45 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued 2.4 Mismatching risk continued 2.4.3 Market risk – Interest rate risk continued VITALITYLIFE continued Due to the nature of the underlying exposures, the hedge accounting requirements of IFRS were not met. Therefore, these derivative instruments were classified at fair value with changes recognised in profit or loss throughout the term which may result in volatility in the reported IFRS earnings of VitalityLife. As at 30 June, the following mark-to-market positions were recorded: GBP/Rand million June 2023 June 2022 Line item in financial statements GBP R GBP R Statement of financial position (65.1) (1 562) 19.8 395 Interest rate swap valuation Financial liabilities: Derivative – financial instruments at fair value through profit or loss – – (3.9) (79) Other payables: VitalityLife working capital funding1 (65.1) (1 562) 12.9 258 Swaption valuation Financial assets: Derivative – financial instruments at fair value through profit or loss – – 10.8 216 Income statement (54.9) (1 177) (34.9) (707) Fair value remeasurement Net fair value losses on financial assets at fair value through profit or loss (54.9) (1 177) (47.8) (968) Marketing and administration expenses1 – – 12.9 261 1 The VitalityLife results are reclassified to account for the contractual arrangement in respect of the business written on the PAC license, as on insurance contract which Discovery issues under IFRS 4 Insurance Contracts. DISCOVERY LIFE AND DISCOVERY INVEST The outstanding claims and incurred but not reported claims are mostly short term in nature and have consequently been matched with cash. Reserves backing income contribution benefits in payment are backed by a combination of cash, money market, gilts and negative Rand reserves of appropriate duration. The risk arising from the global linkage benefit is fully reinsured and Discovery does not face any net direct market risk. For Discovery Invest, guaranteed return plan liabilities are backed by a combination of negative Rand reserves and bonds of appropriate duration. As maturity approaches, cash flows from negative reserves are invested in bonds and therefore a reinvestment risk exists. Furthermore, investment policy fee income is dependent on the underlying value of policyholders’ investments, which may be interest rate sensitive. 2.4.4 Market Risk – Currency risk All of VitalityLife’s insurance benefits and premiums are Pound Sterling denominated as all business is sold in the UK market. A significant part of operational expenses are Rand denominated as systems and administration are based in South Africa. This creates a potential mismatching risk. The Dollar Life Plan, offered by Discovery Life provides a sum insured in US Dollars. Premiums are paid in Rands but linked to the Rand/USD exchange rate. Certain versions of the Dollar Life Plan provide guarantees on the Rand/USD exchange rate for a specified period, thereby exposing Discovery Life to currency risk. Other insurance business lines do not have significant currency risk. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 46 of 217 -- 46 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued 2.5 Sensitivity analysis The financial impact of the key risks that Discovery is exposed to can be demonstrated by considering the sensitivity of the financial results to a hypothetical change in the underlying assumptions or prevailing market conditions. Although the sensitivities demonstrate the impact of a change in assumption, the results generally cannot be extrapolated to demonstrate the impact on future earnings and earnings forecasts. For each sensitivity illustrated, all other assumptions have been left unchanged. No allowance has been made for any management action, for example premium increases, to react to the worse-than-expected experience. The ranges of sensitivity were chosen for illustration purposes and do not represent the extremes of possible experience. The sensitivities shown under insurance risks consider a change in the long-term assumption used in the projection model. The following sensitivities are provided under insurance risk: Lapses: The lapse, surrender and withdrawal rates are increased or decreased across all policies and investment plans; Long-term investment return and inflation: A parallel shift is assumed in the yield curve. The investment return, inflation, renewal expense inflation and inflation-linked premium increases are adjusted consistently; Renewal expenses: Renewal expense per policy is increased or decreased across all policies and investment plans; and Mortality and morbidity: The mortality rate, disability rate and severe illness rates are increased and decreased across all policies and investment plans. Real rate returns: The assumed real rate curve is increased or decreased across all policies and investment plans. 2.5.1 Discovery Life Gross exposure Net of reinsurance Assets arising from insurance contracts R million Change from base assumption % Assets arising from insurance contracts R million Change from base assumption % Base: June 2023 assumptions 41 263 37 746 Lapses +10% (e.g. from x% to 1.1x%) 36 791 (10.8) 33 404 (11.5) Lapses –10% (e.g. from x% to 0.9x%) 46 603 12.9 42 951 13.8 Investment return and inflation –1% (e.g. from 5% to 4%) 42 574 3.2 39 003 3.3 Investment return and inflation +1% (e.g. from 5% to 6%) 40 002 (3.1) 36 533 (3.2) Expense assumption +10% 40 686 (1.4) 37 169 (1.5) Expense assumption –10% 41 840 1.4 38 323 1.5 Mortality and morbidity +10% 33 724 (18.3) 31 967 (15.3) Mortality and morbidity –10% 49 011 18.8 43 728 15.8 Real curve –1% and inflation +1% 44 414 7.6 40 664 7.7 Real curve +1% and inflation –1% 38 755 (6.1) 35 440 (6.1) Base: June 2022 assumptions 39 661 36 182 Lapses +10% (e.g. from x% to 1.1x%) 34 937 (11.9) 31 602 (12.7) Lapses –10% (e.g. from x% to 0.9x%) 45 366 14.4 41 735 15.3 Investment return and inflation –1% (e.g. from 5% to 4%) 40 928 3.2 37 388 3.3 Investment return and inflation +1% (e.g. from 5% to 6%) 38 434 (3.1) 35 006 (3.3) Expense assumption +10% 39 094 (1.4) 35 614 (1.6) Expense assumption –10% 40 230 1.4 36 750 1.6 Mortality and morbidity +10% 32 044 (19.2) 30 321 (16.2) Mortality and morbidity –10% 47 459 19.7 42 212 16.7 Real curve –1% and inflation +1% 42 977 8.4 39 251 8.5 Real curve +1% and inflation –1% 37 050 (6.6) 33 782 (6.6) The above sensitivities reflect the impact on profit or loss if there are no discretionary margins. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 47 of 217 -- 47 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued 2.5 Sensitivity analysis continued 2.5.1 Discovery Life continued Liabilities arising from insurance contracts consist of outstanding reported claims, Incurred But Not Reported (IBNR) claims and long-term liabilities relating to fixed and guaranteed contracts and unit-linked contracts. For outstanding reported claims and IBNR claims any deviation from the best estimate liabilities would have a direct impact on profit. For long-term insurance liabilities relating to fixed and guaranteed contracts and unit-linked contracts (refer to reconciliation on note 2.4.2), the sensitivities are detailed in the table below: Liabilities under insurance contracts R million Change from base assumption % Base: June 2023 assumptions 16 283 Lapses +10% (e.g. from x% to 1.1x%) 16 391 0.7 Lapses –10% (e.g. from x% to 0.9x%) 16 217 (0.4) Investment return and inflation –1% (e.g. from 5% to 4%) 16 824 3.3 Investment return and inflation +1% (e.g. from 5% to 6%) 15 778 (3.1) Expense assumption +10% 16 438 1.0 Expense assumption –10% 16 128 (1.0) Mortality and morbidity +10% 16 279 (0.0) Mortality and morbidity –10% 16 288 0.0 Real curve –1% and inflation +1% 16 647 2.2 Real curve +1% and inflation –1% 15 969 (1.9) Base: June 2022 assumptions Restated 1 15 727 Lapses +10% (e.g. from x% to 1.1x%) 15 749 0.1 Lapses –10% (e.g. from x% to 0.9x%) 15 784 0.4 Investment return and inflation –1% (e.g. from 5% to 4%) 16 276 3.5 Investment return and inflation +1% (e.g. from 5% to 6%) 15 212 (3.3) Expense assumption +10% 15 868 0.9 Expense assumption –10% 15 587 (0.9) Mortality and morbidity +10% 15 736 0.1 Mortality and morbidity –10% 15 719 (0.1) Real curve –1% and inflation +1% 15 945 1.4 Real curve +1% and inflation –1% 15 547 (1.1) 1 The comparative information has been restated. Refer to note 45 for detail. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 48 of 217 -- 48 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued 2.5 Sensitivity analysis continued 2.5.2 VitalityLife Gross exposure Net of reinsurance Assets arising from insurance contracts R million Change from base assumption % Assets arising from insurance contracts R million Change from base assumption % Base: June 2023 assumptions 22 602 14 014 Lapses +10% (e.g. from x% to 1.1x%) 21 951 (2.9) 13 363 (4.6) Lapses –10% (e.g. from x% to 0.9x%) 23 275 3.0 14 726 5.1 Investment return and inflation –1% (e.g. from 5% to 4%) 21 484 (4.9) 12 774 (8.8) Investment return and inflation +1% (e.g. from 5% to 6%) 23 260 2.9 14 800 5.6 Expense assumption +10% 22 116 (2.2) 13 528 (3.5) Expense assumption –10% 23 089 2.2 14 500 3.5 Mortality and morbidity +10% 18 217 (19.4) 12 154 (13.3) Mortality and morbidity –10% 27 039 19.6 15 872 13.3 Real curve -1% and inflation +1% 22 764 0.7 14 200 1.3 Real curve +1% and inflation –1% 22 356 (1.1) 13 749 (1.9) Base: June 2022 assumptions 16 984 9 853 Lapses +10% (e.g. from x% to 1.1x%) 16 525 (2.7) 9 413 (4.5) Lapses –10% (e.g. from x% to 0.9x%) 17 451 2.7 10 297 4.5 Investment return and inflation –1% (e.g. from 5% to 4%) 15 487 (8.8) 8 382 (14.9) Investment return and inflation +1% (e.g. from 5% to 6%) 17 919 5.5 10 809 9.7 Expense assumption +10% 16 595 (2.3) 9 465 (3.9) Expense assumption –10% 17 374 2.3 10 244 4.0 Mortality and morbidity +10% 13 646 (19.7) 8 397 (14.8) Mortality and morbidity –10% 20 361 19.9 11 302 14.7 Real curve -1% and inflation +1% 17 790 4.7 10 713 8.7 Real curve +1% and inflation –1% 15 466 (8.9) 8 348 (15.3) The above sensitivities reflect the impact on profit or loss if there are no discretionary margins. 2.5.3 VitalityHealth – IBNR Reserves VitalityHealth’s reserves are set based on the results of a frequency and severity model which looks at the expected cost of each claim which is authorised for treatment. Historical costs per type of claim and the expected shape of emergence of each claims costs are compared to the amounts already paid to help determine the appropriate reserve for the business. Within the monthly reserving process, adjustments to the model results are made where evidence arises that there are changes in development patterns. The Reserving Committee considers both the model results and other business indicators when setting the actual reserves and it is attended by colleagues from across the relevant business areas including operational, clinical and risk specialists. The IBNR is GBP53.5 million (R1 284 million) at 30 June 2023 (2022: GBP43.0 million (R860 million)), which approximates 1.7 months’ worth of claims – which is the expected delay in claims reporting discussed above. Claims provisions at 30 June 2023 include a supplier settlement. The total of such provisions is GBP2.3 million (R55 million) (2022: GBP2.9 million (R58 million)). VitalityHealth’s IBNR reserves are sensitive to changes in the business’s invoice processing speeds – which has seen significantly improved stability over recent years. Currently the IBNR is set using the average expected cost of each claim (in the prior period the IBNR was set as an 80th percentile reserve in recognition of the volatility in the reserving environment). A 50th and 95th percentile reserve would result in the following: Million 2023 Rand 2022 Rand 2023 GBP 2022 GBP Base case 1 265.2 846.5 52.7 42.3 50th percentile 1 222.5 775.4 50.9 38.8 95th percentile 1 395.5 933.1 58.2 46.6 Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 49 of 217 -- 49 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. MANAGEMENT OF INSURANCE RISK continued 2.5 Sensitivity analysis continued 2.5.4 Discovery Insure – IBNR Reserves Discovery Insure’s IBNR reserves are set based on the Bornhuetter-Ferguson model – a reserving model widely used in the short-term insurance industry. As with other traditional chain ladder models, the model assumes stability in the reporting and settlement delays and an expected loss ratio to arrive at a view of ultimate claims. In contrast, the outstanding claims reserve (OCR) is set predominantly by claims assessors. The claims reserve for the personal lines business, made up of both the IBNR and OCR reserves, is R428 million at 30 June 2023 (2022: R480 million). Sensitivity tests were performed with the results as outlined below (in the prior period the IBNR reserve was set at the 71st percentile level). Given the OCR is not probabilistic in nature, the sensitivity tests are performed purely on the IBNR reserve. R million 2023 2022 Base case 428.2 479.8 50th percentile 426.8 469.0 95th percentile 444.4 505.5 3. MANAGEMENT OF FINANCIAL RISK Discovery’s activities expose it to a variety of financial risks. Financial risks include market risk, credit risk and liquidity risk. Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices and investment return. Market risk that could impact on future cash flows and hence the value of a financial instrument arises from: Equity price risk: The impact of changes in equity prices and dividend income. Interest rate risk: The impact of changes in market interest rates. Currency risk: The impact of changes in foreign exchange rates. Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. Liquidity risk is the risk that Discovery will encounter difficulty in meeting obligations associated with financial liabilities due to insufficient cash or other financial asset being available to meet commitments as and when they become due. Financial risks are managed by Discovery as follows: Discovery has appointed reputable external asset managers to manage its investments. The Actuarial Committee reviews the overall matching of shareholder and policyholder assets to their respective liabilities. The Capital, Currency, and Investment Committee (CCIC) is a sub-committee of the Group Executive Committee and meets quarterly to focus on shareholder assets and the performance of asset managers responsible for managing these assets. The CCIC also sets exposure limits for exposures to individual counterparties. Discovery periodically engages external consultants to review past investment decisions. The Investment Committee is a sub-committee of the CCIC and meets monthly to make operational decisions regarding Discovery’s liquidity and foreign currency exposure. Discovery’s approach in monitoring credit risk Discovery’s credit risk rating systems and processes differentiate and quantify credit risk across counterparties and asset classes. Discovery uses different credit rating approaches to monitor credit risk dependent on the financial assets. For financial assets with externally rated ratings, e.g. Moody’s, the external rating is always used. For non-Moody’s rated instruments, the following approaches will apply: RATING SCALES FOR FUNDS A credit rating, being a ranking of creditworthiness, is allocated to the obligor. Where external ratings are unavailable, internal rating assessments are conducted through analysis of the latest financial and other relevant information, in a consistent and systematic manner. Where external ratings are available, the standard rating classifications used by the external rating agencies have been applied and is mapped to the internal categories per the Group’s internal rating scale. The internal rating scale is based on internal definitions and influenced by definitions published by the external ratings agency, Moody’s. Where applicable, internal ratings are mapped to equivalent external Moody’s rating scales. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 50 of 217 -- 50 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued Discovery’s approach in monitoring credit risk continued The Group’s Internal Rating Scale categories for disclosure purposes are defined below: Group internal grading for disclosures Moody’s Investors Service equivalent of internal rating S&P Global Ratings equivalent of internal rating Discovery internal risk weighting (RW) grading for internal credit risk assessment1 Investment grade Grade Aaa Aaa AAA RW1 Grades Aa1, Aa2, Aa3 Aa1, Aa2, Aa3 AA+, AA, AA- RW2-RW4 Grades A1, A2, A3 A1, A2, A3 A+,A,A- RW5-RW7 Grades Baa1, Baa2, Baa3 Baa, Baa1, Baa2, Baa3 BBB+,BBB,BBB- RW8-RW10 Sub-investment grade Grades Ba1, Ba2, Ba3 Ba1, Ba2, Ba3 BB+, BB, BB- RW11-RW14 Grades B1, B2, B3 B1, B2, B3 B+, B, B- RW16-RW19 Grades Caa1, Caa2, Caa3 Caa1, Caa2, Caa3 CCC+, CCC, CCC- RW22-RW23 Grades Ca1, Ca2, Ca3 Ca1, Ca2, Ca3 CC RW24 Default Grade C C RD RW25 1 Discovery utilises an internal risk weighting (RW) scale, calibrated to external rating agencies to develop internal credit ratings for financial guarantee contracts and its internal borrowings amongst Discovery Group entities. It is a 25 point rating scale. The ratings are mapped to their probability of default, which is then calibrated to a similar range of S&P Global Ratings and Moody’s Investors Service ratings. Where a short-term rating is available, e.g. short-term cash deposits, Discovery includes for the purposes of credit risk disclosures the financial instrument as per the respective entity’s long-term credit rating. Discovery’s internal grading for disclosures aligns to Moody’s Investors Service definitions of their respective ratings as follows: Investment grade Aaa Obligations rated Aaa are judged to be of the highest quality, subject to the lowest level of credit risk Aa Obligations rated Aa are judged to be of the highest quality, subject to the lowest level of credit risk A Obligations rated A are judged to be upper-medium grade and are subject to low credit risk Baa Obligations rated Baa are judged to be medium-grade and subject to moderate credit risk and as such may possess certain speculative characteristics Sub-investment grade Ba Obligations rated Ba are judged to be speculative and are subject to substantial credit risk B Obligations rated B are considered speculative and are subject to high credit risk Caa Obligations rated Caa are judged to be speculative of poor standing and are subject to very high credit risk Ca Obligations rated Ca are highly speculative and are likely in, or very near, default, with some prospect of recovery of principal and interest Default C Obligations rated C are the lowest rated and are typically in default, with little prospect for recovery of principal or interest A numerical modifier may be added to each generic rating classification. Each modifier indicates the following: the modifier 1 indicates that the obligation ranks in the higher end of its generic rating category the modifier 2 indicates a mid-range ranking; and the modifier 3 indicates a ranking in the lower end of that generic rating category. POOLED FUNDS The Group invests in funds through which it is also exposed to credit risk of the underlying assets in which the funds are invested. The Group’s exposure to risk is classified at fund level and not at the underlying asset level. Although funds are not rated, fund managers are required to invest in credit assets within the defined parameters stipulated in the fund’s mandate. These rules limit the extent to which fund managers can invest in unlisted and/or unrated credit assets and generally restrict funds to the acquisition of local currency investment grade assets. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 51 of 217 -- 51 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued Discovery’s approach in monitoring credit risk continued DISCOVERY BANK Loans and advances to customers are categorised with Discovery Bank’s own internally developed credit models. The Discovery Bank model uses a 10-point Discovery Risk Grade classification, with each point being in two decrements to further distinguish risk. The following table summarises how Discovery Bank classifies its loans: Discovery Risk Category Discovery Risk Grades Risk of default assessment Exceptional low risk DRG1 – DRG2 Less than 0.4% Low risk DRG3 – DRG5 Less than 1.5% Medium risk DRG5 – DRG8 Less than 6% High risk DRG8 – DRG9 Less than 24% Very high risk DRG10 More than 24% Categorisation of business in the analysis of financial risk To assist in the analysis of the financial risks that Discovery and its policyholders are exposed to, the Statement of financial position has been divided into five categories, based on the nature of the products provided by Discovery and the nature of the financial assets held to back the policyholder liabilities. Unit-linked investment contracts: this category relates to contracts issued by Discovery where there is a direct relationship between the returns earned on the underlying portfolio and the returns credited to the contract. Discovery holds the assets on which the unit prices are based and as a result there is no mismatch. The market risk (including equity price, interest rate and currency risk) as well as the credit risk for these contracts is therefore borne by the policyholder and not the Discovery shareholders. Unit-linked insurance contracts: this category relates to insurance contracts issued by Discovery which have a component that is linked to the units of an underlying portfolio. For this component, Discovery holds the assets on which the unit prices are based. However, the gross unit liabilities are reduced by the present value of future charges less the present value of future expenses and risk claims. Under IFRS, the unit-linked component is not accounted for separately from the host insurance contract. These contracts expose both Discovery shareholders and policyholders to financial risks. Insurance contracts: this category relates to insurance contracts issued by Discovery which Discovery funds with a portfolio of matching assets, exposing the Discovery shareholders to financial risk. The financial assets in this category include those financial assets held within specific portfolios matched to specific liabilities, for example claims reserves and IBNR. Shareholder financial assets and liabilities: this category includes the financial assets and financial liabilities that expose the Discovery shareholders to financial risks, including financial assets and cash backing insurance reserves and statutory capital. This category includes those financial assets that are not held in specific portfolios matched to insurance related liabilities. Shareholder non-financial assets and liabilities: No financial risk disclosures are required for these items. The financial assets at fair value in each of these categories are sub-categorised into a second tier of classification, namely: Equity portfolios Debt portfolios Money market portfolios Multi-asset portfolios In applying the definitions below, reliance is placed on the classifications by asset managers. Equity portfolios The following have been defined as equity portfolios: Portfolios that invest a minimum of circa 75% of the market value of the portfolio in equities and generally seek maximum capital appreciation as their primary goal. These portfolios invest in selected shares across the range of large, mid, and smaller cap shares. While the managers of these portfolios may subscribe to different investment styles or approaches, their intent is to produce a risk/return profile that is comparable with the risk/return profile of the overall equities market. The portfolios in this category offer medium to long-term capital growth as their primary investment objective. Investments or portfolios of equity linked notes. Debt (interest-bearing) portfolios Interest-bearing portfolios are portfolios that invest exclusively in bond, money market investments and other interest earning securities. These portfolios may not include equity securities, real estate securities or cumulative preference shares. In addition to the above the inflation-linked bonds have been defined as Debt portfolios. Inflation-linked bonds are essentially loans where the principal and interest payments are contractually linked to an inflation measure. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 52 of 217 -- 52 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued Money market portfolios Money market portfolios are portfolios that seek to maximise interest income, preserve the portfolio’s capital, and provide immediate liquidity. This is achieved by investing in money market instruments with a maturity of less than 13 months while the average duration of the underlying assets may not exceed 90 days and a weighted average legal maturity of 120 days. The portfolios are typically characterised as short term, highly liquid vehicles. Multi-asset portfolios Multi-asset portfolios are portfolios that invest in a wide spread of investments in the equity, bond, money, and property markets to maximise total returns, comprising capital and income growth over the long term. These portfolios do not fall within the thresholds that have been determined for the Equity portfolios or the Debt portfolios. The following tables reconcile the Group Statement of financial position to the classes of risks and the categories listed on the previous pages. Group R million Total Unit–linked investment contracts Unit–linked insurance contracts Insurance contracts Shareholder Financial assets and liabilities Other assets and liabilities 30 June 2023 Assets arising from insurance contracts 63 865 – – 63 865 – – Loans and advances to customers at amortised cost 4 702 – – – 4 702 – Investments at amortised cost Unlisted: – Debt 6 856 – – – 6 856 – – Fixed deposits 3 054 – – – 3 054 – Financial instruments mandatorily at fair value through profit or loss: Listed: – Equity portfolios 50 204 22 218 27 425 361 200 – – Debt portfolios 42 172 8 960 18 303 13 521 1 388 – – Money market portfolios 11 721 1 685 2 884 3 677 3 475 – – Multi-asset portfolios 33 535 12 946 20 247 246 96 – Unlisted: – Equity portfolios 6 321 387 5 884 – 50 – – Debt portfolios 401 1 262 – 138 – – Money market portfolios 10 935 1 034 1 908 6 382 1 611 – – Multi-asset portfolios 137 – 137 – – – Derivative financial instruments at fair value: – used as cash flow hedges 59 – – – 59 – – not designated as hedging instruments 60 – – – 60 – Receivables: – Insurance receivables 10 316 – – – 10 316 – – Contract receivables 1 268 – – – 1 268 – – Other receivables 4 475 200 920 28 1 916 1 411 Reinsurance contracts 709 – – 709 – – Cash and cash equivalents 20 370 1 158 4 202 639 14 371 – Other non-financial assets 30 767 – 979 – – 29 788 Total assets 301 927 48 589 83 151 89 428 49 560 31 199 Liabilities arising from insurance contracts 114 807 – 75 257 39 550 – – Liabilities arising from reinsurance contracts 14 669 – – 14 669 – – Deposits from customers 14 333 – – – 14 333 – Borrowings at amortised cost 20 586 11 21 1 20 553 – Other payables 14 780 533 1 122 651 12 113 361 Investment contracts at fair value through profit or loss 48 044 48 044 – – – – Derivative financial instruments at fair value: – used as cash flow hedges 1 – – – 1 – – not designated as hedging instruments 19 1 2 – 16 – Other non-financial liabilities 10 714 – – – – 10 714 Total liabilities 237 953 48 589 76 402 54 871 47 016 11 075 Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 53 of 217 -- 53 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued Group R million Restated 1 Total Restated1 Unit-linked investment contracts Restated 1 Unit-linked insurance contracts Insurance contracts Shareholder Financial assets and liabilities Other assets and liabilities 30 June 2022 Assets arising from insurance contracts 56 645 – – 56 645 – – Loans and advances to customers at amortised cost 3 944 – – – 3 944 – Investments at amortised cost: Unlisted: – Debt 5 205 – – – 5 205 – – Fixed deposits 1 956 – – – 1 956 – Financial instruments mandatorily at fair value through profit or loss: Listed: – Equity portfolios 53 947 16 270 37 265 252 160 – – Debt portfolios 47 012 8 594 18 953 18 714 751 – – Money market portfolios 8 052 415 830 327 6 480 – – Multi-asset portfolios 21 179 11 330 9 689 93 67 – Unlisted: – Equity portfolios 4 001 171 3 784 – 46 – – Debt portfolios 580 80 485 – 15 – – Money market portfolios 6 628 1 180 2 121 2 131 1 196 – – Multi-asset portfolios 95 – 87 – 8 – Derivative financial instruments at fair value: – used as cash flow hedges 17 – – – 17 – – not designated as hedging instruments 259 9 12 – 238 – Non-current asset held for sale 171 – – – – 171 Receivables: – Insurance receivables 7 887 – – – 7 887 – – Contract receivables 1 209 – – – 1 209 – – Other receivables 4 017 370 890 13 1 369 1 375 Reinsurance contracts 511 – – 511 – – Cash and cash equivalents 19 775 1 142 3 533 333 14 767 – Other non-financial assets 28 277 – 834 – – 27 443 Total assets 271 367 39 561 78 483 79 019 45 315 28 989 Liabilities arising from insurance contracts 108 067 – 70 869 37 198 – – Liabilities arising from reinsurance contracts 13 192 – – 13 192 – – Deposits from customers 10 881 – – – 10 881 – Borrowings at amortised cost 20 584 22 132 – 20 430 – Other payables 15 123 902 1 107 438 12 264 412 Investment contracts at fair value through profit or loss 38 637 38 637 – – – – Derivative financial instruments at fair value: – used as cash flow hedges 56 – – – 56 – – not designated as hedging instruments 146 – – – 146 – Other non-financial liabilities 11 126 – – – – 11 126 Total liabilities 217 812 39 561 72 108 50 828 43 777 11 538 1 The comparative information has been restated. Refer to note 45 for detail. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 54 of 217 -- 54 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued The financial risks associated with each category are discussed below. 3.1 Unit-linked investment contracts Unit-linked investment contracts relate to contracts where there is a direct relationship between the returns earned on the underlying portfolio and the returns credited to the contract. Investments held at risk of policyholders R million Group 2023 Restated1 Group 2022 Financial instruments mandatorily at fair value through profit or loss: Listed: – Equity portfolios 22 218 16 270 – Debt portfolios 8 960 8 594 – Money market portfolios 1 685 415 – Multi-asset portfolios 12 946 11 330 Unlisted: – Equity portfolios 387 171 – Debt portfolios 1 80 – Money market portfolios 1 034 1 180 Derivative financial instruments at fair value: – not designated as hedging instruments – 9 Receivables: Other receivables at amortised cost 200 370 Cash and cash equivalents 1 158 1 142 Total assets 48 589 39 561 Borrowings at amortised cost 11 22 Other payables 533 902 Investment contracts at fair value through profit or loss 48 044 38 637 Derivative financial instruments at fair value: – not designated as hedging instruments 1 – Total liabilities 48 589 39 561 1 The comparative information has been restated. Refer to note 45 for detail. 3.1.1 Market risk EQUITY AND INTEREST RATE RISK Discovery’s primary exposure to market risk from these contracts is the volatility in asset management fees earned by Discovery, due to the impact of interest rate, equity price and currency movements on the fair value of the assets held in the linked funds, on which the investment management fees are based. An increase of 10% in the value of the assets would increase the asset management fees by R78 million per annum (2022: R60 million). A decrease of 10% in the value of the assets would reduce the asset management fees by R78 million per annum (2022: R60 million). In respect of IFRS-defined investment management contracts there may be an associated asset for the costs of obtaining contracts. There is a risk that in the event of adverse market movements, future expected management fees may reduce and consequently this asset may not be realised and therefore necessitate impairment. There were no impairments necessary in the current or previous financial year. CURRENCY RISK The Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the US dollar and the UK pound. Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities. The currency risk is borne by the policyholder. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 55 of 217 -- 55 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.1 Unit-linked investment contracts continued 3.1.2 Credit risk Credit risk is borne by the policyholder. For the majority of the unit-linked investments, Discovery has invested in mutual funds in order to provide for obligations under unit-linked investment contract liabilities. Each mutual fund has its own legal constitution and operates within a mandate that is delegated to the appointed fund manager. Credit risks assumed within the assets held are controlled by various protection mechanisms within the mandate and in law. Each fund’s trustees or board appoints administrators who are responsible to ensure that the fund’s mandate and any internal and legislated control procedures are adhered to. In the event of breach, they are obligated to bring it immediately to the attention of the fund’s trustees or board and management of the administrators for remedial action. In the case where unit-linked investment contracts are linked to structured products, Discovery’s policy dictates that these obligations are matched exactly. At inception of these contracts, assets which have proceeds that exactly match the pay-out under the policy, with the exception of credit risk, are purchased. Credit risk on these products is therefore also borne by the policyholder. 3.1.3 Liquidity risk Certain contracts can be surrendered before maturity for a cash surrender value specified in the contractual terms and conditions. This surrender value is equal to or less than the carrying amount of the contract liabilities. If all the contracts with this option were surrendered at the financial year-end, a loss of R1 034 million (2022: R935 million) would have been recorded in profit or loss. This loss would result from an impairment to the asset raised for costs of obtaining contracts, but the impact is reduced by the surrender penalties receivable. A maturity analysis based on the earliest contractual repayment date would present 100% (2022: 100%) of the policyholder liabilities due within one year. The assets held to match these policyholder liabilities are realisable in the short term. 3.2 Unit-linked insurance contracts A unit-linked insurance contract is an IFRS-defined insurance contract with a component that is linked to the units of an underlying portfolio. Investments held at risk of policyholders R million Group 2023 Restated 1 Group 2022 Financial instruments mandatorily at fair value through profit or loss: Listed: – Equity portfolios 27 425 37 265 – Debt portfolios 18 303 18 953 – Money market portfolios 2 884 830 – Multi-asset portfolios 20 247 9 689 Unlisted: – Equity portfolios 5 884 3 784 – Debt portfolios 262 485 – Money market portfolios 1 908 2 121 – Multi-asset portfolios 137 87 Derivative financial instruments at fair value: – not designated as hedging instruments – 12 Receivables: – Other receivables 920 890 Cash and cash equivalents 4 202 3 533 Other assets 979 834 Total assets 83 151 78 483 Liabilities arising from insurance contracts 75 257 70 869 Borrowings at amortised cost 21 132 Other payables 1 122 1 107 Derivative financial instruments at fair value: – not designated as hedging instruments 2 – Total liabilities 76 402 72 108 1 The comparative information has been restated. Refer to note 45 for detail. The assets are greater than the liabilities as a result of the Negative insurance liability of R5 770 million (2022: R5 541 million) included in unit-linked insurance contracts (refer to note 18) and the deferred tax asset of R979 million (2022: R834 million) in relation to the Individual Policyholder Fund. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 56 of 217 -- 56 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.2 Unit-linked insurance contracts continued 3.2.1 Market risk Discovery’s primary exposure to market risk from these contracts is the volatility in asset management fees due to the impact of interest rate, equity price and currency movements on the fair value of the assets held in the linked funds, on which the investment management fees are based. An increase of 10% in the value of the assets would increase the asset management fees by R183 million per annum (2022: R147 million). A decrease of 10% in the value of the assets would reduce the asset management fees by R183 million per annum (2022: R148 million). 3.2.2 Credit risk The credit risk for the unit-linked insurance contracts is similar to the credit risk for the unit-linked investment contracts. Refer to section 3.1.2 on the detail for the exposure to the credit risk. 3.2.3 Liquidity risk All contracts can be surrendered before maturity for a cash surrender value specified in the contractual terms and conditions. This surrender value is equal to or less than the carrying amount of the contract liabilities. If all the contracts with this option were surrendered at the financial year-end, a loss of R6 234 million (2022: R5 805 million) would have been recorded in profit or loss. This loss results from the impairment of assets arising from insurance contracts relating to these contracts, but the impact is reduced by the surrender penalties receivable. The assets held to match these policyholder liabilities are highly liquid and are realisable in the short term. A maturity analysis based on the earliest contractual repayment date is as follows: Group R million Total Restated 1 <1 Year 1 – 2 Years 3 – 5 Years 30 June 2023 Unit-linked insurance contracts 81 031 80 624 177 230 30 June 2022 Unit-linked insurance contracts 76 448 76 231 98 119 1 The comparative information has been restated. Refer to note 45 for detail. 3.3 Insurance contracts For insurance contracts, Discovery funds the insurance liabilities with a portfolio of matching assets. R million Group 2023 Group 2022 Assets arising from insurance contracts 63 865 56 645 Financial instruments mandatorily at fair value through profit or loss: Listed: – Equity portfolios 361 252 – Debt portfolios 13 521 18 714 – Money market portfolios 3 677 327 – Multi-asset portfolios 246 93 Unlisted: – Money market portfolios 6 382 2 131 Receivables: – Other receivables 28 13 Reinsurance contracts 709 511 Cash and cash equivalents 639 333 Total assets 89 428 79 019 Liabilities arising from insurance contracts 39 550 37 198 Liabilities arising from reinsurance contracts 14 669 13 192 Borrowings at amortised cost 1 – Other payables 651 438 Total liabilities 54 871 50 828 3.3.1 Market risk When calculating the liabilities arising from insurance contracts, an increase/decrease in the investments would result in an increase/decrease in the liability but it may not be an equal Rand value movement, resulting in the difference being accrued to the shareholders. Discovery aims to closely match liabilities with appropriate assets and maintains sufficient assets to protect against residual mismatches between assets and liabilities at a 99.5% confidence interval over a one-year time horizon. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 57 of 217 -- 57 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.3 Insurance contracts continued 3.3.2 Credit risk Discovery is exposed to credit risk through financial investments comprising of money market portfolios and debt portfolios entered into to match policyholders’ insurance contract liabilities. Discovery is exposed to the issuer’s credit standing on these instruments which is monitored by the CCIC by setting a minimum credit rating. Discovery has appointed reputable asset managers to manage these instruments. Group R million Total Aaa1 Aaa2 Aaa3 Aa1 Aa2 Aa3 A1 A2 A3 Ba1 Ba2 Ba3 Govt 1 Pooled funds 30 June 2023 Financial instruments mandatorily at fair value through profit or loss: Listed: – Debt portfolios 13 521 – 28 2 753 12 727 11 – Money market portfolios 3 677 – – – 3 677 – – Unlisted: – Money market portfolios 6 382 – 372 199 5 811 – – Reinsurance contracts 709 – 370 339 – – – Cash and cash equivalents 639 – 6 10 623 – – Total 24 928 – 776 550 10 864 12 727 11 30 June 2022 Financial instruments mandatorily at fair value through profit or loss: Listed: – Debt portfolios2 18 714 1 2 – 588 18 085 38 – Money market portfolios 327 – – – 325 – 2 Unlisted: – Money market portfolios 2 131 – 146 – 1 967 18 – Reinsurance contracts 511 – 321 166 24 – – Cash and cash equivalents 333 – – 1 332 – – Total 22 016 1 469 167 3 236 18 103 40 1 These instruments are issued by the South African government. 2 In the prior period, SA Government bonds of R11 619 million were disclosed under Ba rating. The correct classification should have been Govt. The classification has been corrected in the table above. . 3.3.3 Liquidity risk The liquidity risk for assets and liabilities arising from insurance contracts are discussed in insurance risks in note 2 Management of Insurance Risk. The financial investments held at fair value through profit or loss are realisable in the short term. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 58 of 217 -- 58 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.4 Shareholder financial assets and liabilities The shareholders are exposed to financial risk through the following financial assets and liabilities: Investments held at risk of shareholders R million Group 2023 Group 2022 Loans and advances to customers at amortised cost 4 702 3 944 Investments at amortised cost: Unlisted: – Debt 6 856 5 205 – Fixed deposits 3 054 1 956 Financial instruments mandatorily at fair value through profit or loss: Listed: – Equity portfolios 200 160 – Debt portfolios 1 388 751 – Money market portfolios 3 475 6 480 – Multi-asset portfolios 96 67 Unlisted: – Equity portfolios 50 46 – Debt portfolios 138 15 – Money market portfolios 1 611 1 196 – Multi-asset portfolios – 8 Derivative financial instruments at fair value: – used as cash flow hedges 59 17 – not designated as hedging instruments 60 238 Receivables: – Insurance receivables 10 316 7 887 – Contract receivables 1 268 1 209 – Other receivables at amortised cost 1 916 1 369 Cash and cash equivalents 14 371 14 767 Total assets 49 560 45 315 Deposits from customers 14 333 10 881 Borrowings at amortised cost 20 553 20 430 Other payables 12 113 12 264 Derivative financial instruments at fair value: – used as cash flow hedges 1 56 – not designated as hedging instruments 16 146 Total liabilities 47 016 43 777 -- 59 of 217 -- 59 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.4 Shareholder financial assets and liabilities continued 3.4.1 Market risk EQUITY PRICE RISK Investments Discovery is exposed to equity price risk through its equity investments held that have been classified as investments at fair value through profit or loss (FVTPL), on the Statement of financial position. To manage its equity risk arising from investments in Equity portfolios of R250 million (2022: R206 million), the Group diversifies its portfolio and uses experienced asset managers. For shareholder investments, a reasonable increase of 10% in the equity markets would result in a profit of R20 million before tax (2022: R16 million). A reasonable decrease of 10% in the equity markets would result in a loss of R20 million before tax (2022: R16 million). This impact would be recognised in profit or loss and equity. The sensitivity assumes that the equity markets had increased/decreased by 10% with all other variables held constant. Discovery is also exposed to equity price risk through its cash-settled share incentive schemes, namely the Phantom share scheme and the Acquisition share scheme, the details of which are described in note 32. This liability has been included in Other payables at amortised cost in the Statement of financial position. To manage this risk, Discovery has purchased total return equity swaps (TRS) from Ba2 and Ba3 (2022: Ba1) South African banks to hedge a portion of its exposure to changes in the Discovery share price. With effect from 1 July 2022 the hedges became ineffective. Accordingly, Discovery discontinued hedge accounting under IFRS on these TRSs. Previously accumulated balances in the hedge reserve will be reclassified to profit or loss during the future service period. INTEREST RATE RISK Sensitivity to changes in interest rates is relevant to financial assets and financial liabilities bearing floating interest rates due to the risk that future cash flows will fluctuate. However, sensitivity will also be relevant to fixed-rate financial assets and financial liabilities that are remeasured to fair value. The table below details the specific interest rate risk that the Group is exposed to: Group R million Carrying amount Fixed Floating Non-interest bearing 30 June 2023 Loans and advances to customers at amortised cost 4 702 – 4 702 – Investments at amortised cost: Unlisted: – Debt 6 856 6 856 – – – Fixed deposits 3 054 2 783 271 – Financial instruments mandatorily at fair value through profit or loss: Listed: – Debt portfolios 1 388 1 012 376 – – Money market portfolios 3 475 2 497 978 – – Multi-asset portfolios 96 – – 96 Unlisted: – Debt portfolios 138 116 22 – – Money market portfolios 1 611 703 908 – Derivative financial instruments at fair value: – used as cash flow hedges 59 59 – – – not designated as hedging instruments 60 – 31 29 Receivables: – Insurance receivables 10 316 – – 10 316 – Contract receivables 1 268 – – 1 268 – Other receivables at amortised cost 1 916 130 385 1 401 Cash and cash equivalents 14 371 224 13 387 760 Total financial assets 49 310 14 380 21 060 13 870 Deposits from customers 14 333 3 434 10 505 394 Borrowings at amortised cost 20 553 9 052 11 501 – Other payables at amortised cost 12 113 8 3 105 9 000 Derivative financial instruments at fair value: – used as cash flow hedges 1 1 – – – not designated as hedging instruments 16 – – 16 Total financial liabilities 47 016 12 495 25 111 9 410 Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 60 of 217 -- 60 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.4 Shareholder financial assets and liabilities continued 3.4.1 Market risk continued Group R million Carrying amount Fixed Floating Non-interest bearing 30 June 2022 Loans and advances to customers at amortised cost 3 944 – 3 944 – Investments at amortised cost: Unlisted: – Debt 5 205 5 2051 – – – Fixed deposits 1 956 1 610 346 – Financial instruments mandatorily at fair value through profit or loss: Listed: – Debt portfolios 751 620 131 – – Money market portfolios 6 480 2 470 3 993 17 – Multi-asset portfolios 67 1 – 66 Unlisted: – Debt portfolios 15 3 12 – – Money market portfolios 1 196 26 1 170 – – Multi-asset portfolios 8 – – 8 Derivative financial instruments at fair value: – used as cash flow hedges 17 17 – – – not designated as hedging instruments 238 – 216 22 Receivables: – Insurance receivables 7 887 – – 7 887 – Contract receivables 1 209 – – 1 209 – Other receivables at amortised cost 1 369 259 10 1 100 Cash and cash equivalents 14 767 122 14 580 65 Total financial assets 45 109 10 333 24 402 10 374 Deposits from customers 10 881 3 372 7 360 149 Borrowings at amortised cost 20 430 9 859 10 571 – Other payables at amortised cost 12 264 7 381 26 4 857 Derivative financial instruments at fair value: – used as cash flow hedges 56 56 – – – not designated as hedging instruments 146 – 79 67 Total financial liabilities 43 777 20 668 18 036 5 073 1 In the prior period unlisted debt was incorrectly disclosed under Floating, instead of Fixed. This has been corrected in the table above. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 61 of 217 -- 61 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.4 Shareholder financial assets and liabilities continued 3.4.1 Market risk continued Investments For shareholder investments with a floating rate at amortised cost a 1% increase/decrease in the local interest rate would result in an impact on profit or loss (investment income) and equity before tax of R2 million (2022: R67 million). The sensitivity assumes that the interest rate had increased/decreased by 1% with all other variables held constant. Borrowings at amortised cost and related hedges For the floating interest rate borrowings at amortised cost, a 1% increase/decrease in the local interest rate would result in an impact on profit or loss (finance costs) and equity before tax of R67 million (2022: R65 million). The sensitivity assumes that the interest rate had increased/decreased by 1% with all other variables held constant. Discovery is exposed to interest rate risk through long-term borrowings held with various financial institutions. Refer to note 20 Borrowings at amortised costs for a breakdown of the borrowings, including details of fixed rate and floating rate facilities. 2023 2022 Group R million Ref Carrying value Facility value Carrying value Facility value Interest rate risk from borrowings from banks Fixed interest rate loan facilities 4 827 4 999 5 737 5 850 Floating interest rate facilities with floating-to-fixed interest rate swap i 4 569 4 518 5 038 5 000 Floating interest rate facilities 3 250 5 341 2 411 5 109 Foreign floating interest rate facilities 3 682 3 080 3 122 4 281 Total bank borrowings (refer to note 20) 16 328 17 938 16 308 20 240 i. During prior years and in the current financial year, Discovery entered into long-term borrowing facilities at floating interest rates, which expose Discovery to cash flow interest rate risk. This risk has been managed by using floating-to-fixed interest rate swaps. These interest rate swaps have the economic effect of converting the borrowings from floating to fixed rates. Interest is payable quarterly in arrears, with capital repayable on maturity. The hedge ratio is 1:1. The Group enters into interest rate swaps that have similar critical terms as the hedged item, such as reference rate, reset dates, payment dates, maturities, and notional amount. As all critical terms matched during the year, there is an economic relationship. Under the Group’s policy, the critical terms of the hedging instrument, such as the settlement dates, maturity dates and notional amount, are matched with the interest rate risk of the hedged item. Hedge ineffectiveness for interest rate swaps can arise from: – day one fair value of the swap; – events leading to mismatch in terms; and – the credit value/debit value adjustment on the interest rate swaps which is not matched by the loan. The fair value movement of the notional cash flow interest rate hedge accumulated in equity is as follows: Group R million 2023 2022 Balance at beginning of the year 39 335 Unrealised gains accumulated in equity (76) (296) Recycled to profit or loss during the current year1 (4) – Balance at end of the year (41) 39 The cash flow hedge will be recycled to profit or loss as follows: Recycled to profit or loss within one year (9) 20 Recycled to profit or loss within two to five years (32) 19 (41) 39 1 Disclosed as finance costs in profit or loss. -- 62 of 217 -- 62 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.4 Shareholder financial assets and liabilities continued 3.4.1 Market risk continued The interest rate swaps held by the Group at 30 June were: Group R million 2023 2022 Nominal value Fair value asset Nominal value Fair value liability Maturity date: 21 November 2022 – – 500 (7) 2 March 2023 – – 1 000 (14) 21 August 2023 500 5 500 13 21 November 2024 800 1 800 1 21 November 2024 1 200 21 1 200 (19) 21 August 2026 300 7 300 3 21 August 2026 700 (1) 700 (16) 21 May 2027 509 9 – – 21 May 2027 509 16 – – 4 518 58 5 000 (39) Deposits from customers For the floating interest rate deposits measured at amortised cost a 1% increase/decrease in the local interest rate would result in an impact on profit or loss (finance cost) and equity before tax of R14.3 million (2022: R10.5 million). The sensitivity assumes that the interest rate had increased/decreased by 1% with all other variables held constant. Group R million 2023 Carrying value 2022 Carrying value Term deposits from customers – fixed rate 3 434 3 372 Term deposits from customers – variable rates 3 232 1 807 On demand deposits from customers – non-rate sensitive 394 149 On demand deposits from customers – variable rate 7 273 5 249 Wholesale Negotiable Certificates of Deposit (NCDs) – variable rate – 304 Total customer deposits Discovery Bank 14 333 10 881 Non-hedge derivative financial instruments i. Interest rate swap VitalityLife has significant exposure to long-term interest rate risk, given the impact on reserves of lower investment rate assumptions related to fixed future premium receipts to meet policy obligations. Accordingly, lower long-term interest rates and yield assumptions may negatively impact on the valuation of future policy obligations and result in a valuation loss. Refer to note 2.4.3 for details of the interest rate mitigation strategy implemented. In addition to the above, VitalityLife has an exposure to the ’FTSE’ Actuaries UK Conventional Gilts over 15 Year Index (‘the index’) because of products underwritten by the PAC on behalf of VitalityLife. To economically hedge the Vitality UK group’s exposure to the index, Discovery Holdings Europe Limited (DHEL) has previously been party to a number of over-the-counter total return interest rate swap derivatives. These derivatives provided DHEL with the capital depreciation/appreciation and coupon payments on a basket of gilts designed to closely match that of the index in return for a payment of fixed interest to the counterparty. By 30 June 2022 these derivatives had been exited in DHEL and the associated index risk is now managed directly on the balance sheet of the PAC. As at 30 June 2023 the mark-to-market position recorded on the PAC balance sheet was a liability of GBP 12.6 million (R302 million) (2022: asset of GBP 9 million (R180 million)). These derivatives have been presented in Other payables, VitalityLife working capital funding. Although the derivative instruments held during the year reduce the exposure to the volatility of the index, they do not qualify for hedge accounting. Accordingly, these derivatives were classified as financial assets or liabilities carried at fair value through profit or loss. Fair value adjustments of GBP 56.6 million (net loss) (R1 213 million) have been recognised in Net fair value gains on financial assets at fair value through profit or loss (2022: GBP 77.6 million (net loss) (R1 572 million)). Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 63 of 217 -- 63 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.4 Shareholder financial assets and liabilities continued 3.4.1 Market risk continued Non-hedge derivative financial instruments continued ii. Derivative instruments used by Discovery’s asset managers Discovery also has interest rate swap agreements and the value of exposure towards these parties was calculated by taking into consideration the International Swaps and Derivatives Association (ISDA) agreements in place which allow for netting off between positive and negative exposures. The table below details Discovery’s derivative exposure: Group R million Notional amount Fair value asset Fair value liability June 2023 Interest rate contracts: – floating for fixed swaps 4 518 59 (1) 4 518 59 (1) June 2022 Interest rate contracts: – floating for fixed swaps 5 000 17 (56) 5 000 17 (56) CURRENCY RISK The Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the US dollar and the UK pound. Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities. The following table segregates the currency exposure by major currency: Group R million Total Rand GBP in UK subsidiary GBP other USD in US subsidiary USD other Other currencies 30 June 2023 Loans and advances to customers at amortised cost 4 702 4 702 – – – – – Investments at amortised cost: Unlisted: – Debt 6 856 6 856 – – – – – – Fixed deposits 3 054 1 744 1 205 – – 105 – Financial instruments mandatorily at fair value through profit or loss: Listed: – Equity portfolios 200 118 8 1 – 63 10 – Debt portfolios 1 388 786 583 – – 16 3 – Money market portfolios 3 475 829 2 640 – – 6 – – Multi-asset portfolios 96 23 – – – 73 – Unlisted: – Equity portfolios 50 50 – – – – – – Debt portfolios 138 138 – – – – – – Money market portfolios 1 611 1 339 272 – – – – Derivative financial instruments at fair value: – used as cash flow hedges 59 59 – – – – – – not designated as hedging instruments 60 57 – – – 3 – Receivables: – Insurance receivables 10 316 3 110 7 118 – 47 41 – – Contract receivables 1 268 913 – – 348 – 7 – Other Receivables 1 916 1 272 332 3 217 90 2 Cash and cash equivalents 14 371 6 213 5 806 438 380 1 371 163 Total financial assets 49 560 28 209 17 964 442 992 1 768 185 Deposits from customers 14 333 13 939 – 88 – 203 103 Borrowings at amortised cost 20 553 16 383 3 958 – 212 – – Other payables 12 113 4 370 7 391 7 161 141 43 Derivative financial instruments at fair value: – used as cash flow hedges 1 1 – – – – – – not designated as hedging instrument 16 16 – – – – – Total financial liabilities 47 016 34 709 11 349 95 373 344 146 Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 64 of 217 -- 64 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.4 Shareholder financial assets and liabilities continued 3.4.1 Market risk continued CURRENCY RISK continued Group R million Total Rand GBP in UK subsidiary GBP other USD in US subsidiary USD other Other currencies 30 June 2022 Loans and advances to customers at amortised cost 3 944 3 944 – – – – – Investments at amortised cost: Unlisted: – Debt 5 205 5 205 – – – – – – Fixed deposits 1 956 1 747 209 – – – – Financial instruments mandatorily at fair value through profit or loss: Listed: – Equity portfolios 160 66 12 1 – 65 16 – Debt portfolios 751 130 613 – – 3 5 – Money market portfolios 6 480 2 665 3 815 – – – – – Multi-asset portfolios 67 15 1 – – 51 – Unlisted: – Equity portfolios 46 46 – – – – – – Debt portfolios 15 15 – – – – – – Money market portfolios 1 196 1 196 – – – – – – Money market portfolios 8 – 8 – – – – Derivative financial instruments at fair value: – used as cash flow hedges 17 17 – – – – – – not designated as hedging instruments 238 22 216 – – – – Receivables: – Insurance receivables 7 887 3 095 4 755 – 3 34 – – Contract receivables 1 209 886 – – 322 – 1 – Other Receivables 1 369 936 320 – 58 53 2 Cash and cash equivalents 14 767 5 721 7 659 164 295 822 106 Total financial assets 45 315 25 706 17 608 165 678 1 028 130 Deposits from customers 10 881 10 732 – 32 – 72 45 Borrowings at amortised cost 20 430 17 027 3 272 – 131 – – Other payables 12 264 5 289 6 661 – 85 123 106 Derivative financial instruments at fair value: – used as cash flow hedges 56 56 – – – – – – not designated as hedging instrument 146 68 78 – – – – Total financial liabilities 43 777 33 172 10 011 32 216 195 151 Financial assets and financial liabilities in respect of the Group’s US and UK subsidiaries are accounted for in their functional currency. Foreign currency movements will be recognised in the foreign currency translation reserve. The exchange rates at year-end are detailed in the table below (quoted as Rand per foreign currency): USD GBP 30 June 2023 18.87 23.99 30 June 2022 16.47 20.00 Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 65 of 217 -- 65 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.4 Shareholder financial assets and liabilities continued 3.4.1 Market risk continued CURRENCY RISK continued Sensitivity analysis The Group determined that a 10% change is a reasonable expected strengthening/(weakening) of the US dollar and the UK Pound against the other functional currencies, most notably South African Rand, US Dollar and Pound Sterling. The impact on profit or loss and equity at 30 June is shown below. For the purpose of the analysis, the foreign exchange impact of intergroup balances which eliminate on consolidation has been excluded. The effect of translation differences which are recognised separately in other comprehensive income has also been excluded. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases. Profit or loss Equity R million Strengthening Weakening Strengthening Weakening 30 June 2023 USD 194 (194) 194 (194) GBP 28 (28) 28 (28) 30 June 2022 USD 278 (278) 278 (278) GBP 14 (14) 14 (14) Investments Discovery has offshore assets in its investment portfolios. These offshore investments are made for the purpose of seeking international diversification. There is a risk to future earnings that the value of these assets reduces due to a strengthening in the Rand. Performance of foreign currency assets is benchmarked against the MSCI World Index, an international index that represents large and mid-capitalisation companies across 23 developed market countries. Refer to www.msci.com for further detail. Currency derivative contracts To manage its foreign exchange risk arising from future commercial transactions, Discovery enters into various currency derivative contracts. Discovery entered into these contracts with third party banks which have short-term rated risks of P-2 and P-1, as rated by Moody’s. The fair value of these contracts have been included in financial assets and liabilities. (Refer to note 13). Discovery entered into these contracts as an economic hedge against foreign currency risk for expenses to be paid in the future. These transactions are not designated as hedges and as a result gains and losses are recognised in profit or loss. The amount recognised in profit or loss for the current year was a gain of R11 million (2022: R78 million), with a corresponding derivative asset of R3 million (2022: Derivative asset and liability of R2 million and R1 million respectively). The notional value of these contracts are USD2 million (2022: USD5.3 million). Currency risk for foreign exchange contracts (FECs) are determined with reference to the designated pricing (settlement) currency of each respective contract. The pricing currency is usually the functional currency of the entity taking out the contract. For the purposes of currency risk, Discovery discloses FEC contracts using the pricing currency. Borrowings Discovery has long-term borrowings in the UK, which exposes the Group to currency risks. These risks are managed by aligning the currency exposure to the underlying operational assets for which these borrowings have been raised. The currency risk is mitigated as the cash flows emerging from the underlying assets are in the same currency (GBP) as the interest and capital payments. Deposits from customers Discovery Bank offers its customers the option to hold deposits in foreign currency of GBP, USD and EUR. These risks are managed by aligning the currency exposure to the underlying assets. Discovery Bank does so by holding deposits in foreign currency of GBP, USD and EUR. The currency risk is therefore matched in a 1:1 ratio to not transfer foreign currency risk to the Group. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 66 of 217 -- 66 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.4 Shareholder financial assets and liabilities continued 3.4.2 Credit risk Key areas where Discovery is exposed to credit risk are: Financial investments comprising money market and debt instruments entered into to invest surplus shareholder funds: Discovery is exposed to the issuer’s credit standing on these instruments which is monitored by the CCIC by setting a minimum credit rating and maximum exposures per issuer. Discovery has appointed reputable asset managers to manage these instruments. Information regarding the aggregated credit risk exposure for debt and money market instruments categorised by credit ratings is provided below. Cash and cash equivalents: This risk is managed by monitoring exposure to external financial institutions against approved limits per institution. Credit ratings are provided below. Certain accounts within the Statement of financial position category of ’Insurance receivables, contract receivables and other non-financial receivables’. Reinsurance assets comprising receivables raised for expected recoveries on projected claims (Discovery’s liability as primary insurer is not discharged) and amounts due from reinsurers in respect of claims already paid: This risk is limited as risk premiums are paid monthly to reinsurers and claims can be offset against risk premiums. Further, it is expected that there will be little build-up of actuarial liability on the reinsurers’ side. The risk thus mainly arises following a period of higher than expected claims. Credit ratings of reinsurers are considered in reinsurance placement decisions. Credit exposure to reinsurers is also limited through the use of several reinsurers. Reinsurance is placed with reputable international companies directly or through their national offices. The reinsurance companies used by Discovery are rated A or higher by A.M. Best, a rating agency with an exclusive insurance industry focus. Refer to www.ambest.com for further detail. VitalityHealth makes use of cashless financial reinsurance as a financing tool for new business acquisition costs. The credit ratings of these reinsurers are Aa3. Loans and advances to customers at amortised cost, which arises from credit extended to Discovery Bank customers. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 67 of 217 -- 67 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.4 Shareholder financial assets and liabilities continued 3.4.2 Credit risk continued The following table details the aggregated credit risk exposure that the Group is exposed to, categorised by the rating scale noted in section 3 ’Discovery’s approach in monitoring credit risk’. Group R million Total Aaa Aa1 Aa2 Aa3 A1 A2 A3 Baa1 Baa2 Baa3 Ba1 Ba2 Ba3 Govt 1 Inter- nally rated Pooled funds 30 June 2023 Loans and advances to customers at amortised cost 4 702 – – – – – – 4 702 – Investments at amortised cost: Unlisted: – Debt 6 856 – – – – – 6 856 – – – Fixed deposits 3 054 – – 1 300 – 1 744 – – 10 Financial instruments mandatorily at fair value through profit or loss: Listed: – Debt portfolios 1 388 – 30 313 243 517 239 – 46 – Money market portfolios 3 475 700 11 94 1 940 459 70 – 201 Unlisted: – Debt portfolios 138 – – – – 138 – – – – Money market portfolios 1 611 25 – 247 – 1 322 17 – – Derivative financial instruments at fair value: – used as cash flow hedges 59 – – – – 59 – – – – not designated as hedging instruments 60 – – – – 60 – – – Cash and cash equivalents 14 371 – 1 123 5 848 464 3 856 3 078 2 – 35 714 725 1 164 7 802 2 647 8 155 10 260 4 704 257 30 June 2022 Loans and advances to customers at amortised cost 3 944 – – – – – – 3 944 – Investments at amortised cost: Unlisted: – Debt 5 205 – – – – – 5 205 – – – Fixed deposits 1 956 – 91 574 208 1 083 – – – Financial instruments mandatorily at fair value through profit or loss: Listed: – Debt portfolios 751 2 42 224 366 116 1 – – – Money market portfolios 6 480 745 1 348 1 752 64 2 447 124 – – Unlisted: – Debt portfolios 15 – – – – 13 2 – – – Money market portfolios 1 196 – – – – 1 184 12 – – Derivative financial instruments at fair value: – used as cash flow hedges 17 – – – 17 – – – – – not designated as hedging instruments 238 – – 216 2 20 – – – Cash and cash equivalents 14 767 – 7 852 1 800 1 011 1 575 2 529 – – 34 569 747 9 333 4 566 1 668 6 438 7 873 3 944 – 1 These instruments are issued by the South African government. Financial instruments included in cash and cash equivalents, fixed deposits and treasury bills have high credit quality based on the rating of counterparties and/or have relatively short-term maturities. Impairment based on the expected credit loss approach was assessed and considered immaterial. There are no amounts within these balances which are credit impaired or where there has been a significant increase in credit risk since initial recognition. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 68 of 217 -- 68 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.4 Shareholder financial assets and liabilities continued 3.4.2 Credit risk continued CREDIT RISK RELATING TO RECEIVABLES The table below summarises Discovery’s shareholder insurance receivables, contract receivables and other receivables, at 30 June. This table only relates to shareholder’s credit exposure and will therefore not agree to note 14. R million Group 2023 Group 2022 Receivables arising from insurance and reinsurance contracts: – Premium debtors 1 070 801 – Less provision for impairment of premium debtors (97) (81) – Reinsurance debtors 9 343 7 167 Contract receivables: – Closed scheme debtors 120 107 – Discovery Health Medical Scheme 775 724 – Other contract receivables 377 382 – Less allowance for expected credit losses (4) (4) Other loans and receivables: – Agents and brokers 521 439 – Cash-in-transit debtors 8 7 – Consolidated unit trust debtors 2 2 – Loans to BEE initiatives 309 256 – Security deposit on derivatives1 27 72 – Vitality partner debtors 171 148 – Other financial receivables 1 288 837 – Less allowance for expected credit losses (410) (392) 13 500 10 465 1 Refer to note 3.7 for an explanation of the nature of the security deposit (cash collateral). Credit risk relating to receivables is managed as follows: i. Premium debtors are not rated by Discovery as exposure to any single customer is insignificant. The premium debtors comprise amounts receivable from individuals and corporates. In addition, Discovery suspends benefits when contributions are not received. Premium debtors that are past due are handled by a specialist area in business. Where amounts remain uncollected for more than six months, the debtors are then handed to specialist debt collection agencies. ii. VitalityHealth makes use of financial reinsurance as a financing tool for new business acquisition costs. The receipt from the reinsurer is recognised in profit or loss upfront in the year received. GBP246 million (R5 902 million) (2022: GBP199 million (R3 981 million)) is outstanding in respect of cashless reinsurance treaties. The credit ratings of these reinsurers are Aa3. Refer to introduction to note 3.4.2 for detail regarding the management of risk in respect of reinsurance receivables raised for expected recoveries on projected claims and amounts due from reinsurers in respect of claims already paid. Discovery’s liability as primary insurer is not discharged. iii. The Discovery Health Medical Scheme (DHMS) has been rated AAA(za) by Global Credit Ratings. The closed schemes have not been rated. Payments by DHMS and the other closed schemes are managed by Discovery and are paid by the seventh of the following month. iv. Agents and brokers are subject to a comprehensive relationship management programme including credit assessment. Agents and brokers are not rated by Discovery as exposure to any single intermediary is insignificant. The widespread nature of the individual amounts combined with this close management relationship reduces credit risk. Most commission claw backs are offset against future payments and hence the risk of outstanding commission clawbacks is reduced. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 69 of 217 -- 69 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.4 Shareholder financial assets and liabilities continued 3.4.2 Credit risk continued Discovery ages and pursues unpaid accounts on a monthly basis. The ageing of the components of receivables at 30 June was: Group R million Gross 2023 Impairment 2023 Gross 2022 Impairment 2022 Not past due (current) 11 760 (121) 9 294 (111) 30 days 447 (33) 267 (38) 60 days 211 (13) 179 (23) 90 days 365 (8) 131 (10) 120 days 155 (29) 95 (20) 150 days 189 (13) 91 (10) >150 days 884 (294) 885 (265) 14 011 (511) 10 942 (477) Discovery establishes an allowance for expected credit losses that represents its estimate of expected losses in respect of receivables that are financial assets. The allowance comprises of a specific loss component that relates to individually significant exposures, and a collective loss component, established for groups of similar assets. The loss allowance is determined based on historical data of payment statistics for similar financial assets, and where available without undue cost or effort, incorporates forward-looking information. For an analysis of the movement in the allowance for expected credit losses as well as provision for impairment of premium debtors during the year, refer to note 12 Financial assets and note 14 Insurance receivables, contract receivables and other financial receivables. 3.4.3 Liquidity risk Cash flow forecasting is performed in the operating entities of the Group and aggregated by Group finance. Group finance monitors rolling forecasts of the Group’s liquidity requirements to ensure it has sufficient cash to meet operational needs at all times so that the Group does not breach borrowing limits or covenants (where applicable) on any of its borrowing facilities (refer to note 20). Such forecasting takes into consideration the Group’s debt financing plans, covenant compliance and, if applicable, external regulatory or legal requirements – such as capital requirements. Cash held by the operating entities is managed by Group treasury. Group treasury invests it in interest-bearing accounts, time deposits and money market deposits, choosing instruments with appropriate maturities or sufficient liquidity to provide sufficient headroom as determined by the above-mentioned forecasts. For information on the liquidity risk management of contracts with insurance risk, refer to note 2.2 Liquidity risk. Discovery Bank manages its liquidity risk by comparing the credit utilisation and expected future utilisation of committed facilities on its loans and advances against the deposits it holds. Discovery Bank performs normal stresses as well as additional stresses to ensure that it can meet its obligations continuously. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 70 of 217 -- 70 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.4 Shareholder financial assets and liabilities continued 3.4.3 Liquidity risk continued The table below analyses the Group’s financial assets and liabilities and net-settled interest rate swap derivative financial liabilities into relevant maturity groupings based on the remaining period at the reporting date to the contractual maturity date. The amounts are the undiscounted contractual payments and will therefore not agree to the Statement of financial position. Group R million Total <1 year 1 – 2 years 3 – 5 years 6 – 10 years >10 years 30 June 2023 Loans and advances to customers at amortised cost 6 794 4 076 2 718 – – – Investments at amortised cost 10 168 6 497 679 1 916 1 076 – Investments at fair value through profit or loss 6 958 5 743 614 382 75 144 Derivative financial instruments at fair value: – not designated as hedging instruments 60 26 24 10 – – Receivables 13 505 8 950 930 2 612 971 42 Cash and cash equivalents 14 371 14 371 – – – – Total financial assets 51 856 39 663 4 965 4 920 2 122 186 Deposits from customers 14 718 13 233 605 880 – – Borrowings net of interest rate swap – Borrowings 16 723 3 403 5 752 7 320 248 – – Interest rate swap (58) (5) (22) (31) – – Lease liabilities 6 761 666 662 1 990 3 351 92 Other payables at amortised cost 12 113 11 729 77 295 12 – Derivative financial instruments at fair value: – not designated as hedging instruments 16 16 – – – – Total financial liabilities 50 273 29 042 7 074 10 454 3 611 92 30 June 2022 Loans and advances to customers at amortised cost 3 944 2 367 1 577 – – – Investments at amortised cost 7 161 6 927 234 – – – Investments at fair value through profit or loss 8 723 7 651 149 393 114 416 Derivative financial instruments at fair value: – not designated as hedging instruments 238 14 224 – – – Receivables 10 465 6 338 1 412 2 006 668 41 Cash and cash equivalents 14 767 14 767 – – – – Total financial assets 45 298 38 064 3 596 2 399 782 457 Deposits from customers 10 881 9 381 1 133 367 – – Borrowings net of interest rate swap – Borrowings 15 695 4 445 3 883 7 110 257 – – Interest rate swap 311 117 90 104 – – Lease liabilities 6 723 190 1 709 1 866 2 487 471 Other payables at amortised cost 12 264 11 970 117 44 7 126 Derivative financial instruments at fair value: – not designated as hedging instruments 146 41 26 – – 79 Total financial liabilities 46 020 26 144 6 958 9 491 2 751 676 Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 71 of 217 -- 71 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.5 Capital management The Group’s capital is defined as capital and reserves attributable as presented on the consolidated statement of financial position. The Group’s objectives when managing capital are: To comply with the statutory capital requirements required by the regulators of the insurance markets where the Group operates; refer to Capital section of the directors’ report for the statutory capital requirements. To maintain a capital buffer in excess of the statutory capital requirements in order to reduce the risk of breaching the statutory requirement in the event of deviations from the main assumptions affecting the Group’s insurance businesses. To ensure that sufficient capital is available to fund the Group’s working capital and strategic capital requirements. To achieve an optimal and efficient capital funding profile; and To consider capital management needs both in the short term and over a five-year planning horizon. Discovery has a Finance and Capital Committee that ensures alignment in strategic financial management between the centre and subsidiaries within SA, UK and US. The committee is the governance body for all capital allocation activities across the Group. A range of capital raising options are available to manage the capital structure of the Group, which includes the issue of new shares, debt, reinsurance arrangements and other hybrid instruments. FINANCIAL LEVERAGE RATIO As part of the capital management process, the Group monitors its capital structure utilising the Financial Leverage Ratio (FLR). This ratio is calculated as total debt 1 divided by total debt plus total equity. The Group’s strategy is to maintain a prudent FLR of 28% per the Group Risk Appetite statement. However, the 28% is merely a risk appetite indicator, and not a hard line to indicate any form of a breach in terms of regulatory or covenant restrictions. The table below summarises the FLR as at 30 June. R million Group 2023 Group 2022 – Borrowings at amortised cost (refer to note 20)1 16 361 16 464 – Guaranteed deposit facilities – 300 Total debt and guarantees1 16 361 16 764 Total equity 63 974 53 555 Financial Leverage Ratio (%) 20.4% 23.8% 1 Excluding all IFRS 16 lease liabilities of R4 225 million (2022: R4 120 million). The FLR at 30 June 2023 is in line with Discovery’s risk appetite. Minimum capital requirements For Group subsidiaries that operate in the insurance and financial services sectors, the regulator specifies the minimum amount and type of capital that must be held by each of the subsidiaries in addition to their insurance liabilities. The minimum required capital must be maintained at all times throughout the period. With effect from 1 July 2018, the Insurance Act 18 of 2017 and the related Prudential Standards were implemented in South Africa. Discovery Life and Discovery Insure are regulated under the Insurance Act, while VitalityHealth and VitalityLife are regulated under the European Solvency II regulatory regime, which was implemented from 1 January 2016. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 72 of 217 -- 72 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.5 Capital management continued Debt covenants The following are the key debt covenant ratios and their proximity to breaching the covenant triggers: Debt covenant and explanation Minimum requirement Group 2023 Group 2022 Group Debt to EBITDA Ratio: – Group debt is contractually defined and means the aggregate consolidated financial indebtedness of the Group and excludes items such as the 1 Discovery Place (’1 DP’) lease and includes guarantees issued to third parties. – EBITDA is contractually defined and specifically includes items such as dividends from associates, rental paid on 1 DP and excludes such items deemed extraordinary, such as economic assumption adjustments, and specified FinRe arrangements. Less than 2.5 times 1.30 1.83 Group financial indebtedness to embedded value – Group financial indebtedness is as per Group Debt in the calculation. Less than 30% of Group embedded value 17.6% 20.3% Discovery Life SCR Cover SCR cover must be more than 1.1 1.88 times 1.74 times Group embedded value Greater than R30 billion R98 176 million R86 258 million New business embedded value must not be negative Positive value of new business for 3 consecutive 6-month periods June 2023: R463 million Dec 2022: R940 million June 2022: R1 124 million June 2022: R1 124 million Dec 2021: R937 million June 2021: R946 million Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 73 of 217 -- 73 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.6 Fair value hierarchy of financial instruments The Group’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has three levels that reflect the significance of the inputs used in measuring fair value. These are as follows: Level 1: includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical financial instruments. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency and those prices represent actual and regularly occurring market transactions on an arm’s length basis. Level 2: includes financial instruments that are valued using techniques based significantly on observable market data. Instruments in this category are valued using: (a) quoted prices for similar instruments or identical instruments in markets which are not considered to be active; or (b) valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on observable market data. Level 3: includes financial instruments that are valued using valuation techniques that incorporate information other than observable market data and where at least one input (which could have a significant effect on instruments’ valuation) cannot be based on observable market data. R million Level 1 Level 2 Level 3 Total 30 June 2023 Financial assets Financial instruments mandatorily at fair value through profit or loss: – Equity portfolios 50 204 6 321 – 56 525 – Debt portfolios 40 852 1 721 – 42 573 – Money market portfolios – 22 656 – 22 656 – Multi-asset portfolios – 33 672 – 33 672 Derivative financial instruments at fair value: – used as cash flow hedges – 59 – 59 – not designated as hedging instruments – 60 – 60 Total financial assets 91 056 64 489 – 155 545 Financial liabilities Investment contracts at fair value through profit or loss – 48 044 – 48 044 Derivative financial instruments at fair value: – used as cash flow hedges – 1 – 1 – not designated as hedging instruments – 19 – 19 Total financial liabilities – 48 064 – 48 064 There where no transfers between level 1 and level 2 during the current financial period. -- 74 of 217 -- 74 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.6 Fair value hierarchy of financial instruments continued R million Level 1 Restated 1 Level 2 Level 3 Restated1 Total 30 June 2022 Financial assets Financial instruments mandatorily at fair value through profit or loss: – Equity portfolios 54 271 3 677 – 57 948 – Debt portfolios 46 672 920 – 47 592 – Money market portfolios – 14 680 – 14 680 – Multi-asset portfolios – 21 274 – 21 274 Derivative financial instruments at fair value: – used as cash flow hedges – 17 – 17 – not designated as hedging instruments – 259 – 259 Total financial assets 100 943 40 827 – 141 770 Non-financial assets – – 171 171 Non-current assets held for sale – – 171 171 Financial liabilities Investment contracts at fair value through profit or loss – 38 637 – 38 637 Derivative financial instruments at fair value: – used as cash flow hedges – 56 – 56 – not designated as hedging instruments – 146 – 146 Total financial liabilities – 38 839 – 38 839 1 The comparative information has been restated. Refer to note 45 for detail. There were no transfers between level 1 and 2 during the current financial year. During the year under review, management reassessed the observability of significant inputs into fair value determination of money markets and multi-asset portfolios from level 1 to level 2. The prior period was restated accordingly. Non-financial assets measured at fair value During the prior financial period there was a non-recurring fair value measurement for the investment in an associate that has been categorised as a level 3 fair value. Refer to note 11.2.1 for details on the fair value. Specific valuation techniques used to value financial instruments in level 2 If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange traded financial instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques including the use of recent arm’s length market transactions, reference to the current fair value of another instrument that is substantially the same, discounted cash flow techniques, option pricing models or other valuation techniques that provide a reliable estimate of prices obtained in actual market transactions. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 75 of 217 -- 75 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.6 Fair value hierarchy of financial instruments continued Valuation techniques used in determining the fair value of assets and liabilities: Instruments Valuation technique Main inputs and assumptions Within equity portfolios, Equity-linked notes The calculation of the daily value of the equity linked investments is made by the provider of the note. Discovery has procedures in place to ensure that these prices are correct. Aside from the daily reasonableness checks versus similar funds and movement since the prior day’s price, the fund values are calculated with reference to a specific formula or index, disclosed to the policyholders, which is recalculated by Discovery in order to check if the price provided by the provider is correct. For level 2 fair value hierarchy items: – discount rate – spot prices of the underlying Multi-assets The fair values of third-party financial liabilities arising on the consolidation of mutual funds are determined using the quoted put (exit) price provided by the fund manager and discounted for the applicable notice period. The fair value of a financial liability with a demand feature is not less than the amount payable on demand, discounted from the first date on which the amount could be required to be paid. For level 2 fair value hierarchy items: – discount rate Debt portfolios and Money market instruments Discounted cash flow techniques are most commonly used for the valuation of debt securities (included in the debt portfolios) and money market instruments. The future cash flows are discounted using a risk-adjusted rate. For level 2 fair value hierarchy items: – discount rate, credit spread Investment contracts at fair value through profit or loss Unit-linked policies: assets which are linked to the investment contract liabilities are owned by the Group. The investment contract obliges the Group to use these assets to settle these liabilities. Therefore, the fair value of investment contract liabilities is determined with reference to the fair value of the underlying assets (i.e., amount payable on surrender of the policies). Annuity: certain discounted cash flow models are used to determine the fair value of the stream of future payments. For level 2 fair value hierarchy items: – discount rate – spot price of underlying Derivatives Standard derivative contracts are valued using market accepted models and quoted parameter inputs. More complex derivative contracts are modelled using more sophisticated modelling techniques applicable to the instrument. Techniques include: – Discounted cash flow model – Black-Scholes model – Combination technique models For level 2 fair value hierarchy items: – discount rate – spot prices of the underlying – correlation factors – volatilities – earnings yield – valuation multiples -- 76 of 217 -- 76 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 3. MANAGEMENT OF FINANCIAL RISK continued 3.7 Offsetting financial assets and financial liabilities continued Financial assets The following financial assets are subject to offsetting: Group R million Gross financial assets Gross offsetting financial liabilities Net amount presented 30 June 2023 Cash and cash equivalents 20 827 (457) 20 370 30 June 2022 Cash and cash equivalents 19 807 (32) 19 775 Offsetting of cash and cash equivalents takes place as a result of sweeping arrangements that Discovery has in force with various financial institutions. No other amounts presented on the financial statements are subject to netting arrangements. Cash collateral To reduce the credit risk exposure from derivative instruments purchased (refer to note 3.4.1), Discovery has entered into collateral agreements with the relevant financial institutions to post cash collateral periodically, equal to the fair value of the derivatives. A total of R27 million (2022: R72 million) cash collateral was being held by the various financial institutions and R39 million (2022: R245 million) was held by Discovery at 30 June 2023. The posting of the collateral does not result in legal settlement of the outstanding derivative balance. The collateral will only be used to settle the derivative upon default or bankruptcy of either party. The offsetting requirements of IAS 32 Financial Instruments: Presentation are therefore not met. -- 77 of 217 -- 77 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 4. SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS IN APPLYING ACCOUNTING POLICIES In preparing the Annual Financial Statements, estimates, assumptions and judgements are made that could materially affect the reported amounts of assets and liabilities within the next financial year. Accounting estimates and judgements are regularly reviewed and are based on historical experience, current best estimates and expectations of future outcomes as well as anticipated changes in the environment. The following represents the most material key management assumptions applied by management in preparing these Annual Financial Statements. 4.1 Policyholder liabilities assumptions and estimates, including assets arising from insurance contracts Discovery Life and VitalityLife Discovery values its insurance policies issued by Discovery Life and VitalityLife using various methodologies and assumptions. Accounting policy 13.1 sets out the methodology used in its valuation of the policyholder liabilities, including the use of available discretionary margins in accounting policy 13.1.1. The assumptions used are best estimate assumptions, with the addition of explicit compulsory margins required by: SAP 104 of the Actuarial Society of South Africa for Discovery Life; and INSPRU of the PRA, SAP 104 and Benchmarking information in the UK Per the accounting policy, the best estimate assumptions and margins are reset at every valuation date to reflect the underlying profitability of the portfolio. The most recent valuation date is 30 June 2023. MORTALITY AND MORBIDITY Assumptions of future mortality and morbidity experience are derived from reinsurers and industry data and compared to actual past experience. Where appropriate, the assumptions are adjusted to reflect actual past experience or for expected changes in future experience. The assumptions are modified for each policy based on actual data from underwriting performed on the policy and compared against standard industry tables for reasonability. The key mortality and morbidity assumptions are reviewed and benchmarked against the industry by independent actuarial consultants to ensure that the assumptions are reasonable upon implementing significant new products for Discovery Life. An adjustment to the standard mortality and morbidity assumptions is made to reflect the expected impact of engagement in the Vitality programme. It has been observed that higher rates of engagement result in lower mortality and morbidity claims. An allowance is made for the impact of AIDS on South African mortality rates. For individual life South African business, a fixed loading is applied to the expected best estimate mortality rates to allow for the expected effect of AIDS. The loading varies based on socio-economic class. Discovery Life further operates in the high end of the market, where the AIDS risk is lower than the full market. The additional loading for AIDS is set in consultation with external independent actuaries and reinsurers. For Group Life policies, a loading is applied at the underwriting stage to allow for the expected effect of AIDS. The loading varies based on the industry and geographic area and composition of the group and is derived from advice received from the reinsurers. The loading then forms the AIDS assumption for Group policies. The sensitivity of the policyholder liabilities due to changes in mortality and morbidity assumptions are set out in note 2.5.1 for Discovery Life and note 2.5.2 for VitalityLife. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 78 of 217 -- 78 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 4. SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS IN APPLYING ACCOUNTING POLICIES continued 4.1 Policyholder liabilities assumptions and estimates, including assets arising from insurance contracts continued Discovery Life and VitalityLife continued SURRENDER AND LAPSE RATES Lapse rates are based on actual past experience where available. The lapse analysis is done by considering the in–force duration of policies. For durations longer than actual data, lapse rates are set based on expectations of future experience based on internal and external expert advice as well as available industry benchmarking. The lapse experience investigation covers at least the last two years of lapse experience to identify trends. Lapse assumptions are varied between different types of policies where the lapse experience is expected to differ significantly. Allowance is made for the estimated impact of the economic environment. For Discovery Life and VitalityLife, an adjustment is made to the lapse assumptions to reflect the expected impact of engagement in the Vitality programme because it has been observed that higher rates of engagement result in lower lapses. For Discovery Life, the surrender rates are also based on actual past experience where available. The sensitivity of the policyholder liabilities due to changes in lapse rate assumptions are set out in note 2.5.1 for Discovery Life and note 2.5.2 for VitalityLife. ECONOMIC ASSUMPTIONS/INVESTMENT RETURNS Discovery Life The discount rate for Discovery Life and Discovery Invest is based on the risk-free rates at 30 June 2023. The real rate assumption is based on the average of the real rate curves for the preceding twelve months. This real rate assumption will remain unchanged over time unless the equivalent single rate, derived based on the weighted duration of the cash flows, moves by more than 25 basis points since the preceding valuation. The inflation assumption is set as the differential between the assumed nominal and real interest rates. For comparison purposes, it is noted that the single risk-free rate at 30 June 2023 would have increased to 13.2% (2022: increased to 12.3%). The implied single real interest rate has also increased to 4.7% in June 2023 (2022: decreased to 4.2%). Other investment returns and economic assumptions are set relative to this yield curve. The assumptions for Discovery Life are as follows: Cash: Risk-free – 1.5% Fixed interest: Risk-free Equity: Risk-free + 3.5% Property: Risk-free +1% The sensitivity of the policyholder liabilities due to changes in real curve assumptions are set out in note 2.5.1. VitalityLife For the PAC book the nominal investment return is set as the active market rate on UK long-term swap rates plus a fixed adjustment (based on long-term averages) for liquidity premium, the gilt/swap spread and cash flow weighting. For the VitalityLife book, the nominal investment return is set with reference to the UK gilt yield curve plus a fixed adjustment (based on long-term averages) for liquidity premium. The best estimate inflation assumption is set in line with long-term UK inflation expectations and observed real yields consistent with the term of the liabilities. The risk-free rate at 30 June 2023 was set at 4.4% (2022: 2.3%). The investment fees and tax rates are taken into account in setting the economic assumptions. The sensitivity of the policyholder liabilities due to changes in real curve assumptions are set out in note 2.5.2. EXPENSE ASSUMPTIONS Renewal expense assumptions are based on the results of the latest expense and budget information. Expenses are considered non-recurring when they relate to the start-up of a new business area or when they are material and are specific to an event that is not expected to occur in the future. The allocation of expenses between initial and renewal is based on the latest expense analysis, where expenses are directly allocated based on the function performed. Where an expense could relate to both initial and renewal functions, the expenses are allocated proportionately based on estimates of the functions performed. Per Discovery’s policy, expenses are projected to increase in line with consumer price inflation. Non-recurring expenses are excluded from the expense analysis used to derive the assumption. The sensitivity of the policyholder liabilities due to changes in expense assumptions are set out in note 2.5.1 for Discovery Life and note 2.5.2 for VitalityLife. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 79 of 217 -- 79 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 4. SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS IN APPLYING ACCOUNTING POLICIES continued 4.1 Policyholder liabilities assumptions and estimates, including assets arising from insurance contracts continued Discovery Life and VitalityLife continued POLICY ALTERATIONS AND AUTOMATIC PREMIUM INCREASES In calculating policyholder liabilities, allowance is made for overall negative policy alterations over time. Automatic premium increases could include both contractual and voluntary increases. No allowance is made for voluntary premium increases when calculating liabilities under insurance contracts. Contractual premium increases are defined as increases that the policyholder cannot cancel without altering the terms of the benefits provided under the policy. Contractual increases are included in the calculation of policyholder liabilities. CHANGES IN ASSUMPTIONS Expected profits regarding future options on products are not recognised, but expected losses in respect of such options are allowed for, in line with actuarial guidance. Modelling and assumptions changes were made to the valuation at 30 June 2023 to ensure that assumptions are in line with the best estimate of future experience. For Discovery Life, the total effect of these changes on the Assets arising from insurance contracts was a decrease in the assets on the Financial Soundness Valuation basis of R3 464 million (2022: R1 760 million decrease). For VitalityLife, the total effect of these changes was an increase in the assets of R745 million (2022: R596 million increase). In addition to this, for Discovery Life, discretionary margins were reset to reflect the underlying profitability of the overall portfolio. The reset of margins increased the assets on the Financial Soundness Valuation basis by R194 million (2022: R377 million increase). Refer to note 5 for an analysis of these changes. TAXATION Future tax is allowed according to the current tax legislation and current tax rates. It is assumed that future tax on statutory profits will be payable at the prevailing company tax rate of 27% (2022: 28%) in South Africa. South Africa’s National Treasury announced that the corporate tax rate should reduce to 27% for tax years commencing ending on or after 31 March 2023. The rate is deemed substantively enacted, and deferred tax has been appropriately adjusted. The prevailing tax rate in the UK is 25% (2022: 19%). The UK has enacted an increase in the tax rate to 25% effective from 1 April 2023. Tax amendments for Life Insurance companies introduced a Risk Policy Fund for all new risk business written after 1 July 2016. In terms of this legislation, Discovery Life elected to move existing risk business to this Fund. As a result of these changes, the assessed loss in the Individual Policyholder Fund is expected to stop increasing and be utilised over time. Therefore, in terms of IAS 12 Income Taxes, a value of R979 million (2022: R834 million), which was previously implicit in the valuation of insurance contract liabilities, was recognised explicitly as a deferred tax asset. The value is net of deferred capital gains tax liabilities. To calculate this value, Discovery Life performed a probability-weighted cash flow forecast of the annual cash flows expected to arise from the utilisation of the assessed loss. The primary factors that management has considered when arriving at the probability are the expected market growth and withdrawal rate of the Linked Asset and Guaranteed Endowment book. For Linked Assets, given the uncertainty inherent in market growth assumptions and the fact that discounting of cash flows is not permitted by IAS 12, future market growth was assumed to be 0% to calculate the deferred tax asset. The expected income on the debt portfolio held to match policyholder liabilities has been fully allowed for at current rates. For both the linked and debt portfolio, cash flows arising from the tax asset were further reduced to account for the uncertainty of future lapse rates and product mix as well as the broader economic and legislative environment. REINSURANCE All prospective liabilities are valued gross of reinsurance and then adjusted for the expected effect of reinsurance. For outstanding reported claims and IBNR, a specific allowance is made for reinsurance recoveries. The Global Linkage Benefit is fully reinsured. The cost of the future reinsurance is dependent on the cost at which the reinsurer can buy assets to match the liability under this benefit. Assumptions are made around the cost at which the reinsurer can purchase these benefits based on the current and historical costs of these assets. FINANCIAL SOUNDNESS VALUATION The sensitivity of the policyholder liabilities on the Financial Soundness Valuation basis is set out in note 2.5.1. The sensitivity of the policyholder liabilities on the INSPRU basis is set out in note 2.5.2. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 80 of 217 -- 80 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 4. SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS IN APPLYING ACCOUNTING POLICIES continued 4.2 Annual assessment of goodwill impairment Refer to note 10 Goodwill for a breakdown of business acquisitions resulting in goodwill. Discovery annually assesses goodwill allocated to the respective businesses as set out in note 10. Based on the work performed for the financial years ended 30 June 2023 and 30 June 2022, management considered that there is a very low risk of material adjustment to the carrying amount of goodwill allocated to VitalityHealth and VitalityLife within the next financial year. Accordingly, no further information is included within this note, as this no longer meets the requirement of significant estimation uncertainty under IAS 1 Presentation of Financial Statements. Discovery Bank The Discovery Bank Cash Generating Unit (CGU) comprise the various assets that collectively produce independent cash flows for Discovery Bank. Discovery Bank’s income streams comprise interest earned on loans to customers, interest on excess cash invested, fees (e.g. banking fees, interchange fees and transaction fees) from banking. For the financial years ended 30 June 2023 and 30 June 2022, the recoverable amount of the Discovery Bank CGU was determined based on fair value less costs to sell. Inherent in the determination of fair value less costs to sell is estimation uncertainty. The recoverable amount is the fair value less costs to sell using the income approach. In determining the assets to attribute to the Discovery Bank CGU, Discovery considered the assets required to perform banking operations, including the banking license costs, the internally developed software in use, and the goodwill associated with the DiscoveryCard business acquisition and related assets and liabilities. Therefore, the valuation also supports the recoverability of goodwill, intangible assets and deferred tax. Management has reviewed its business forecast, which comprises: – A detailed 10-year business plan. The 10-year plan considers regulatory capital requirements, macro-economic forecasts and customer behaviour assumptions when forecasting a Statement of financial position, income statement and resultant equity cash flows to/from shareholders. The 10-year period used to assess the impairment is longer than the standard 5-year forecast model generally applied in Discovery’s impairment testing. The business is still in the start-up phase, resulting in a 5-year forecast not adequately reflecting the business plan. Management can project beyond the 5 years due to the insights from the DiscoveryCard business it acquired. – The terminal value was calculated using an extended cash flow forecasting method until the growth in earnings has stabilised in year 20 and a final value considering perpetual terminal growth. This terminal value was discounted to year 10. – As a reasonability check, Discovery Bank translates the value of the business at year 10 into a Price-Earnings (PE) multiple, which it benchmarks against Discovery’s PE ratio and other emerging banks within the South African environment. The ratio was determined to be within range. The key assumptions used by Discovery in the estimation are as follows: – Conservative customer growth, targeting an achievable level of customers in year 10. After that, the customer base is treated as stable. From the point of stability in year 20, the projected growth in profits is estimated at a conservative 5.65% (2022: 5.55%) considering long-term inflation and long-term nominal GDP estimations. The increase in growth projections is based on the growth over the past financial year. System-build costs and intangible assets acquired in the business combination have been amortised over 10 years (2022: 10 years). The useful lives of these assets are determined as 10 years. – The discount rate applied to the cashflows comprises the following: Group 2023 Group 2022 Risk-free rate based on 10-year SA bond curve 11.59% 10.60% Beta factor: The beta factor is a weighted average of large SA banks and Discovery 0.86 1.07 Discount rate applied 17.80% 17.97% For the year ended 30 June 2023, management has engaged independent external valuation experts to benchmark the key assumptions and ratios within the South African market. This exercise determined that the assumptions are within acceptable ranges. Management has further performed stress tests by increasing the discount rate to 21% while simultaneously decreasing the terminal growth rate to 4.5%. Again, no impairment was triggered with these stressed scenarios. Based on management’s assessment, Discovery did not identify any impairments in respect of the Discovery Bank CGU. -- 81 of 217 -- 81 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 5. ASSETS ARISING FROM INSURANCE CONTRACTS Group R million 2023 2022 Restated 2 Gross Reinsurance Net Gross Reinsurance Net Movement in assets arising from insurance contracts Balance at beginning of the year 56 645 (10 610) 46 035 50 483 (10 143) 40 340 Expected movement in policyholder liabilities (5 196) 2 311 (2 885) (2 659) 1 297 (1 362) Unwinding of discount rate 5 032 (859) 4 173 3 748 (640) 3 108 New business written 6 064 (2 567) 3 497 5 389 (2 019) 3 370 Experience variances 990 275 1 265 1 200 150 1 350 – Economic 1 086 (64) 1 022 332 (147) 185 – Operational (96) 339 243 868 297 1 165 Modelling and method changes 2 (20) (18) (202) 23 (179) Changes in assumptions (3 495) 794 (2 701) (1 914) 828 (1 086) – Economic (2 265) 277 (1 988) 88 81 169 – Operational (1 230) 517 (713) (2 002) 747 (1 255) Changes in margins1 198 (4) 194 394 (17) 377 Translation differences 3 625 (1 425) 2 200 206 (89) 117 Balance at end of the year 63 865 (12 105) 51 760 56 645 (10 610) 46 035 Current 7 891 (2 572) 5 319 7 178 (2 051) 5 127 Non-current 55 974 (9 533) 46 441 49 467 (8 559) 40 908 Total assets arising from insurance contracts 63 865 (12 105) 51 760 56 645 (10 610) 46 035 1 In line with accounting policy 13.1.1, the best estimate assumptions and margins are reset at every valuation date to reflect the underlying profitability of the overall portfolio. Assumptions and margins are not set on new business in isolation but on a portfolio level. 2 The comparative period has been restated to present the assets arising from insurance contracts on a gross basis. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 82 of 217 -- 82 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 6. PROPERTY AND EQUIPMENT Group R million Land and buildings Furniture, fittings and equipment Computer equipment and operating systems Leasehold improve- ments Motor Vehicles Telematics devices1 Total Year ended 30 June 2023 Opening carrying amount 2 741 35 368 556 11 100 3 811 Additions 219 42 325 155 12 61 814 Disposals – Cost (76) – – – (7) (21) (104) – Accumulated depreciation 76 – – – 4 14 94 Derecognition – Cost (59) (78) (67) (93) – (48) (345) – Accumulated depreciation 59 77 67 91 – 17 311 Impairment – Accumulated depreciation (45) – – – – – (45) Acquisition of subsidiary – Cost – 1 – – – – 1 Depreciation charge (293) (19) (194) (103) (8) (41) (658) Lease termination (81) – – – – – (81) Translation differences 74 4 16 17 – 1 112 Closing carrying amount 2 615 62 515 623 12 83 3 910 Year ended 30 June 2023 Cost 4 076 154 1 191 1 112 69 260 6 862 Accumulated depreciation (1 461) (92) (676) (489) (57) (177) (2 952) Carrying amount 2 615 62 515 623 12 83 3 910 Year ended 30 June 2022 Opening carrying amount 3 071 45 324 638 18 92 4 188 Additions 95 5 211 39 4 59 413 Disposals – Cost (24) – – (10) (12) (3) (49) – Accumulated depreciation 9 – – 1 9 2 21 Derecognition – Cost (12) (10) (302) (38) (11) (60) (433) – Accumulated depreciation 10 10 302 37 11 51 421 Depreciation charge (299) (15) (171) (116) (8) (41) (650) Lease modification (125) – – – – – (125) Translation differences 16 – 4 5 – – 25 Closing carrying amount 2 741 35 368 556 11 100 3 811 Year ended 30 June 2022 Cost 3 969 168 875 1 018 63 269 6 362 Accumulated depreciation (1 228) (133) (507) (462) (52) (169) (2 551) Carrying amount 2 741 35 368 556 11 100 3 811 1 In Discovery Insure, when policies relating to motor vehicle insurance lapse, the telematics devices installed in those vehicles are not always recovered. The value of these unrecovered units are derecognised. Impairment The R45 million impairment pertains to a property in the UK Composite. UK commercial property values have come under pressure during the last year as interest rates have increased. Rent levels in certain areas have also been under pressure, with several buildings having significant vacant space. Consequently, rent levels have not experienced the growth needed to offset the impact of interest rates on yields. An external valuation ascertained that the recoverable amount, being fair value less cost to sell, was R45 million lower than the carrying value of the building. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 83 of 217 -- 83 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 6. PROPERTY AND EQUIPMENT continued LEASED ASSETS Property and equipment includes the following assets which are leased under a finance lease: R million Group 2023 Group 2022 Land and buildings 2 372 2 480 Computer equipment and operating systems 45 11 Leasehold improvements 71 23 Motor vehicles 1 2 Total leased assets 2 489 2 516 7. INTANGIBLE ASSETS Group R million Software development Business acquisitions: Identifiable intangibles Banking license Total Year ended 30 June 2023 Opening carrying amount 6 133 377 29 6 539 Additions 1 760 – – 1 760 Amortisation charge (1 319) (56) – (1 375) Derecognition – Cost (1 873) (37) – (1 910) – Accumulated amortisation 1 583 37 – 1 620 Translation differences 298 50 – 348 Closing carrying amount 6 582 371 29 6 982 Year ended 30 June 2023 Cost 11 207 2 548 29 13 784 Accumulated amortisation (4 625) (2 177) – (6 802) Carrying amount 6 582 371 29 6 982 Business acquisitions Intangibles identified in the acquisition of business combinations are amortised over their remaining useful lives and only tested for impairment if an indication of impairment arises. There was no indication of impairment for the current reporting period. Included in the value of business acquisitions are: Customer contracts represented by value of in-force business acquired in the Standard Life Healthcare and PrimeMed business combinations. The carrying amount as at 30 June 2023 is R286 million (2022: R277 million); and Client relationships and Core Deposit Funding Benefit acquired in the DiscoveryCard business combination. The carrying amounts as at 30 June 2023 are R74 million and R11 million respectively (2022: R87 million and R13 million). Banking license During the 2018 financial year, Discovery incurred costs of R29 million in respect of the application for a banking license. Discovery has capitalised these costs in terms of IAS 38 Intangible Assets. This asset has an indefinite useful life. -- 84 of 217 -- 84 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 7. INTANGIBLE ASSETS continued Group R million Software development Business acquisitions: Identifiable intangibles Banking license Total Year ended 30 June 2022 Opening carrying amount 5 911 431 29 6 371 Additions 1 567 – – 1 567 Amortisation charge (1 252) (59) – (1 311) Impairment – Cost (49) – – (49) – Accumulated amortisation 49 – – 49 Derecognition 1 – Cost (546) – – (546) – Accumulated amortisation 344 – – 344 Translation differences 109 5 – 114 Closing carrying amount 6 133 377 29 6 539 Year ended 30 June 2022 Cost 10 663 1 872 29 12 564 Accumulated amortisation (4 530) (1 495) – (6 025) Carrying amount 6 133 377 29 6 539 1 Included in derecognition for the year is an amount of R164 million resulting from the IFRIC interpretation on capitalisation of costs associated with configuration or customisation costs in a cloud arrangement. R75 million has been recognised in profit and loss and presented in salaries, wages and allowances (refer to note 31) and R89 million was recognised in prepayments (refer to note 14) of which R45 million has been expensed at 30 June 2022. Accordingly, the headline earnings per share has not been adjusted to reflect the derecognition as a result of this interpretation. -- 85 of 217 -- 85 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 8. DEFERRED ACQUISITION COSTS R million Group 2023 Group 2022 Balance at beginning of the year 640 585 Additions 2 297 1 524 Deferred acquisition costs amortised (2 255) (1 475) Translation differences 117 6 Balance at the end of the year 799 640 9A. ASSETS ARISING FROM CONTRACTS WITH CUSTOMERS AND CONTRACT LIABILITIES TO CUSTOMERS Where either party to a contract has performed, Discovery presents either a contract asset or contract liability, depending on the relationship between Discovery’s performance and the customer’s payment. Unconditional rights to consideration is presented separately as a receivable. Group R million Assets arising from contracts with customers 1 Costs of obtaining contracts 1 Contract liabilities Contract receivables2 Year ended 30 June 2023 Balance at beginning of the year 256 1 436 (944) 1 209 Accrued income recognised during the year 313 – – – Payments received (57) – – (13 614) Costs of obtaining new contracts – 550 – – Amortised during the year – (341) – – Contract liabilities recognised in the current year – – (426) – Revenue recognised in the year – – 747 13 629 Provision of impairment of contract receivables – – – (4) Foreign exchange revaluations (21) 13 – – Translation differences 51 1 (33) 48 Balance at end of the year 542 1 659 (656) 1 268 Year ended 30 June 2022 Restated 3 Balance at beginning of the year 162 1 213 (776) 1 217 Accrued income recognised during the year 111 – – – Payments received (45) – – (12 100) Costs of obtaining new contracts – 465 – – Amortised during the year – (253) – – Contract liabilities recognised in the current year – – (534) – Revenue recognised in the year – – 404 12 016 Provision of impairment of contract receivables – – – 24 Foreign exchange revaluations – 8 – 7 Translation differences 28 3 (38) 45 Balance at end of the year 256 1 436 (944) 1 209 1 Presented as Assets arising from contracts with customers. 2 Presented as part of insurance receivables, contract receivables and other receivables. 3 The comparative information has been restated. Refer to note 45 for detail. -- 86 of 217 -- 86 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 9A. ASSETS ARISING FROM CONTRACTS WITH CUSTOMERS AND CONTRACT LIABILITIES TO CUSTOMERS continued The contract liability primarily relates to the advance consideration received from customers for the initial advisor fees, for which revenue will be recognised over the expected terms of the arrangement. It further includes the Discovery Miles liability on the Vitality programme. Discovery has unsatisfied performance obligations relating to providing intellectual property services for the VitalityOne System. The transaction price relating to unsatisfied performance obligations is expected to be recognised as revenue as follows: R million Group 2023 Group 2022 Provision of stand-ready Intellectual Property services – <1 year 519 439 – 2 – 3 years 1 042 910 – 4 – 5 years 584 675 – >5 years 1 004 1 124 Total contract amount for future services 3 149 3 148 Where performance obligations are discharged within 12 months or where contracts are cancellable giving 12 months or less notice, without the payment of a significant penalty, a practical expedient has been applied. Discovery has excluded these contracts from the disclosures above. Contracts that include variable considerations have also not been included in the table above. 9B. REVENUE Discovery Group’s Revenue includes ’Fee income from administration business’, ’Vitality income’ and ’Banking fee and commission income’. Also refer to accounting policy 20 Revenue recognition. The split of revenue per geographical region and reportable segment can be viewed in note 1 Segment information. The split of revenue according to the timing of satisfaction of performance obligation, i.e. ’over time’ or a ’point-in-time’ is as follows: R million Group 2023 Group 2022 Fee income from administration business: Health income 11 959 10 971 – Over time 11 932 10 548 – Point-in-time 27 423 Fee income from administration business: Intellectual Property fees 2 798 1 781 – Over time 2 798 1 781 Vitality income 3 891 3 495 – Over time 2 660 2 348 – Point-in-time 1 231 1 147 Banking fee and commission income 1 292 853 – Over time 687 389 – Point-in-time 605 464 -- 87 of 217 -- 87 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 10. GOODWILL Goodwill is not amortised, but is tested on an annual basis for impairment. Any impairment is recognised immediately in profit or loss and is not subsequently reversed. The table below sets out the goodwill allocated to the respective CGUs which is expected to benefit from the synergies of the combination. Impairment of goodwill is assessed at this CGU level. R million Goodwill per CGU Value in functional currency on date of acquisition Group 2023 Group 2022 Goodwill – VitalityHealth1, 2, 5, 6 GBP100.3 million 2 407 2 007 – VitalityLife 1, 5, 7 GBP23.4 million 562 468 – Discovery Bank3 R2 417 million 2 417 2 417 – Discovery Administration Services4 R20 million 20 20 – Nanolabs8 R9 million - – Total 5 406 4 912 1 GBP96.7 million and GBP23.4 million of the goodwill was allocated to VitalityHealth and VitalityLife respectively as at 31 July 2010. The goodwill arose from the acquisition of Standard Life Healthcare and related capital restructure of the PAC joint venture. 2 GBP2.5 million goodwill from the acquisition of Insure Your Health (25 March 2013) and GBP1.1 million of goodwill from the acquisition of KYS Paid Limited (30 April 2014) were allocated to the VitalityHealth CGU. 3 R2 417 million goodwill from the acquisition of the DiscoveryCard business on 1 March 2019 was allocated to the Discovery Bank CGU. 4 In October 2020, Discovery acquired Liberty Health Administration, a wholly owned subsidiary, which performs medical aid administration for specified medical aids. Liberty Health Administration has been renamed to Discovery Administration Services Proprietary Limited as of 11 August 2021. 5 As part of the annual assessment of impairment, Discovery has done significant stresses on the goodwill of VitalityHealth and VitalityLIfe. The value-in-use considers the value of in-force business as well as new business. The value-in-use is calculated as the present value of the best-estimate pre-tax cash flows of the CGU for the in-force policies at the valuation date and 10 years of new business. The outcome of the working indicated that the recoverable amount significantly exceeds the carrying amount of the CGUs, with little risk of impairment. 6 Net exchange rate differences of R400 million (2022: R27 million) were recognised in the financial year ended 30 June 2023. 7 Net exchange rate differences of R94 million (2022: R6 million) were recognised in the financial year ended 30 June 2023. 8 At the beginning of July 2022 Discovery acquired a controlling stake in Nanolabs Health Solutions Proprietary Limited (Nanolabs) with Point of Care Testing technology. Subsequent to the acquisition this goodwill was fully impaired. -- 88 of 217 -- 88 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 11. INVESTMENT IN EQUITY-ACCOUNTED INVESTEES R million Group 2023 Group 2022 Carrying value of material interest in associates and joint ventures – Ping An Health Insurance 5 380 4 499 Carrying value of material interest in associates and joint ventures – CMT 1 400 1 263 Carrying value of individually immaterial interest in associates 148 112 Carrying value of individually immaterial interest in joint ventures 96 134 Investment in equity-accounted investees 7 024 6 008 11.1 Material interests in associates and joint ventures The table below provides summarised financial information for the Group’s material joint ventures and associates. The information disclosed reflects the amounts presented in the financial statements of the relevant associates and joint ventures and not Discovery’s share of those amounts. Ping An Health Insurance Company of China, Limited (PAHI) Ping An Health Insurance offers policyholders in China cover for a range of private healthcare-related claims. PAHI is a strategic partnership for the Group, providing access to new clients and markets in China. Cambridge Mobile Telematics Inc. (CMT) A United States of America based leading telematics technology provider. This partnership provides the Group with expertise in the telematics environment that Discovery Insure harnesses to manage its insurance risk. Ping an Health Insurance CMT Ownership structure Equity-accounted associate Equity-accounted associate Nature Insurance Telematics technology Place of business China USA R million 2023 2022 2023 2022 % of ownership interest at end of the year 24.99% 24.99% 8.76% 8.85% Summarised statement of comprehensive income Revenue 36 300 29 540 3 292 2 285 Net profit/(loss) for the year 2 604 1 637 (461) (521) Other comprehensive (loss)/income (62) 69 – – Total comprehensive income/(loss) 2 542 1 706 (461) (521) Summarised statement of financial position Current assets 19 971 19 048 4 264 3 852 Non-current assets 53 046 39 144 12 929 11 686 Current liabilities (9 169) (6 526) (1 204) (1 054) Non-current liabilities (43 543) (34 833) (460) (604) Net assets 20 305 16 833 15 529 13 880 Reconciliation to carrying amounts: Opening net assets 16 833 7 725 13 880 12 270 Net profit/(loss) for the year 2 604 1 637 (461) (521) Other comprehensive (loss)/income (62) 69 – – Increase in share capital and share premium – 5 950 110 267 Foreign exchange gains 930 1 452 2 000 1 864 Closing net assets 20 305 16 833 15 529 13 880 Group’s share of net assets 5 074 4 207 1 360 1 228 Goodwill 306 292 40 35 Carrying value at 30 June 5 380 4 499 1 400 1 263 -- 89 of 217 -- 89 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 11. INVESTMENT IN EQUITY-ACCOUNTED INVESTEES continued 11.2 Individually immaterial associates and joint ventures 11.2.1 Individually material transactions DISPOSAL OF INVESTMENT IN AIAV During the financial year ended 30 June 2022, the investment in AIA Vitality Proprietary Limited (AIAV) was reclassified from equity- accounted investments to non-current assets held for sale in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations. At date of reclassification, there were no additional impairment losses or reversals due to reclassification. At 30 June 2022, the disposal group was stated at fair value less costs to sell. The disposal group comprised of: – Investment in AIAV equity-accounted investment AUD15 million (R171 million) The non-recurring fair value measurement for the investment in AIAV of AUD15 million (R171 million) was categorised as a level 3 fair value due to the binding offer being subject to significant unobservable inputs. Discovery used the binding offer without adjustment as the fair value and therefore there are no quantitative unobservable inputs developed when measuring the fair value. The investment was sold effective 1 February 2023 at AUD15 million (R184 million). 11.2.2 Summary of financial information The table below provides summarised information of the aggregate amounts of the Group’s share of total income: Group R million Associates Joint ventures 2023 2022 2023 2022 Aggregate amount of the Group’s share of (loss)/profit (165) (21) 69 137 Reversal of Impairment of equity-accounted investment – 134 – – Aggregate amount of the Group’s share of other comprehensive income/(loss) 8 8 6 (5) Aggregate amount of the Group’s share of total comprehensive (loss)/income (157) 121 75 132 -- 90 of 217 -- 90 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 12. FINANCIAL ASSETS The Group’s investment in financial assets are summarised by measurement category in the table below: R million Notes Group 2023 Group 2022 Financial assets at fair value through profit or loss – mandatorily: 155 426 141 494 – Equity portfolios 56 525 57 948 – Debt portfolios 42 573 47 592 – Money market portfolios 22 656 14 680 – Multi-asset portfolios 33 672 21 274 Financial assets at amortised cost 1 14 612 11 105 Investments at amortised cost 9 910 7 161 – South African Treasury Bills 6 856 5 205 – Deposits 3 054 1 956 Loans and advances to customers at amortised cost 12.1 4 702 3 944 Total investments 170 038 152 599 Listed 137 632 130 192 Unlisted 32 406 22 407 170 038 152 599 Shareholder investments: 21 570 19 828 – Investments at amortised cost 3 14 612 11 105 – Investments at fair value through profit and loss – mandatorily 6 958 8 723 Policyholder investments: 148 468 132 771 – Investments at fair value through profit and loss – mandatorily 148 468 132 771 Total investments 170 038 152 599 1 The fair value of instruments at amortised cost approximates the carrying amount due to the relatively short-term nature of the instrument. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 91 of 217 -- 91 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 12. FINANCIAL ASSETS continued 12.1 Loans and advances to customers at amortised cost R million Notes Group 2023 Group 2022 Gross loans and advances (unsecured) 5 113 4 308 Accrued interest 58 39 Total gross loans and advances 5 171 4 347 Less: IFRS9 Expected credit losses (ECL) 12.1.2 (469) (403) Total net loans and advances 4 702 3 944 12.1.1 Loans and advances per credit risk rating Group R million DRG 1 – 4 DRG 5 – 7 DRG 8 – 10 Not rated Total As at 30 June 2023 Stage 1 2 617 1 468 352 – 4 437 Stage 2: SICR1 3 12 323 – 338 Stage 2: Arrears 2 11 69 – 82 Stage 3 1 8 247 – 256 Gross loans and advances 2 623 1 499 991 – 5 113 As at 30 June 2022 Stage 1 2 166 1 272 309 – 3 747 Stage 2: SICR1 4 24 271 5 304 Stage 2: Arrears – 1 2 62 65 Stage 3 2 4 10 176 192 Gross loans and advances 2 172 1 301 592 243 4 308 1 Significant increase in credit risk. Discovery risk grade (DRG), is an internal client rate allocated on the basis of their risk profile. An adjusted DRG is allocated for the purposes of calculating the expected credit losses. In the prior year, Loans and advances classified as ‘not rated’ pertained to loans and advances migrated from DiscoveryCard which had not been through Discovery Bank credit assessment, and assigned a DRG. To determine the ECL on these customers in the prior year, information from the DiscoveryCard back book was used. In the current financial year, these loans and advances have now been through Discovery Bank credit assessment and assigned a DRG. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 92 of 217 -- 92 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 12. FINANCIAL ASSETS continued 12.1.2 Reconciliation of the expected credit losses (ECL) Group R million Stage 1 (12-month ECL) Stage 2 (Lifetime ECL, but not missed payments) Stage 2 (Lifetime ECL, and missed payments) Stage 3 (Lifetime ECL, and credit impaired, default) Total 30 June 2023 Balance at beginning of the year 167 37 35 164 403 Total changes in ECL due to changes in balances of advances (8) 7 5 (90) (86) – New loans originated and acquired 1 4 – – – 4 – Repayments and other movements (10) 7 5 21 23 – Change in ECL due to derecognition other than write-off (2) – – (3) (5) – Change in ECL due to write-off3 – – – (108) (108) 159 44 40 74 317 Transfers between stages 1 (3) 10 6 139 152 – Transfer (to)/from stage 1 – 12 18 85 115 – Transfer (to)/from stage 2: SICR 1 – 1 22 24 – Transfer (to)/from stage 2: Arrears (1) – – 32 31 – Transfer (to)/from stage 3 (3) (2) (13) – (18) Balance at end of the year 156 54 46 213 469 30 June 2022 Balance at beginning of the year 192 41 24 208 465 Total changes in ECL due to changes in balances of advances (16) 2 10 (134) (138) – New loans originated and acquired 3 1 – – 4 – Repayments and other movements 2 (16) 2 10 30 26 – Change in ECL due to derecognition other than write-off (3) (1) – (6) (10) – Change in ECL due to write-off3 – – – (158) (158) 176 43 34 74 327 Transfers between stages 1 (9) (6) 1 90 76 – Transfer (to)/from stage 1 – (4) 11 51 58 – Transfer (to)/from stage 2: SICR (3) – 1 10 8 – Transfer (to)/from stage 2: Arrears (2) – – 29 27 – Transfer (to)/from stage 3 (4) (2) (11) – (17) Balance at end of the year 167 37 35 164 403 1 Discovery Bank’s policy is to transfer accounts between stages based on the ECL stage at the end of the reporting period. Therefore, exposures can be transferred directly from stage 3 to stage 1 as the curing requirements would have been satisfied during the reporting period. The expected credit loss recognised on new exposures originated during the reporting period (which are not included in opening balances) are recognised in new loans originated and acquired based on the exposures’ ECL stage as at the end of the month the account comes on book. Any change in status will be reflected in the transfers between stages as described above. 2 For the year ended 30 June 2022, management had increased the ECL by R28.6 million for the effects of COVID-19 in considering forward looking macroeconomic factors. These factors are no longer applicable and therefore no adjustment is required for June 2023. 3 The contractual amount outstanding on financial assets that were written off during the year ended 30 June 2023 and that are still subject to enforcement activity is R113 million (2022: R158 million). Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 93 of 217 -- 93 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 13. DERIVATIVE FINANCIAL INSTRUMENTS R million Group 2023 Assets Group 2023 Liabilities Group 2022 Assets Group 2022 Liabilities Derivatives used as cash flow hedges: Interest rate derivatives1 59 (1) 17 (56) Derivatives not designated as hedging instruments: Equity price risk derivatives 26 (16) 19 (66) Interest rate swaps 31 – – (79) Swaptions – – 216 – Currency derivative contracts 3 (3) 24 (1) Total derivative financial instruments 119 (20) 276 (202) Current 31 (19) 36 (62) Non-current 88 (1) 240 (140) Total derivative financial instruments 119 (20) 276 (202) 1 The interest rate derivative portfolio consists of both interest rate swaps and interest rate caps. The effects of the derivatives used in cash flow hedges on the Group’s financial position and performance are as follows: Year ended 30 June 2023 Group R million Notional amount of the hedging instrument Carrying amount of the hedging instrument Line item in the Statement of financial position where the hedging instrument is presented Changes in value of hedging instrument used for calculating hedge ineffective- ness Ineffective- ness recognised in profit or loss Line item in which hedge ineffectiveness is presented in profit or loss Assets Liabilities Interest rate risk 4 518 59 (1) (76) – Interest rate derivatives 4 518 59 (1) Financial Asset- Derivative/ Financial Liability- Derivative (76) – Net fair value gains on financial assets at fair value through profit and loss Refer to note 3.4.1 for a detailed description of the derivative financial instruments listed above. Group R million Changes in the value of the hedging instrument recognised in other comprehen- sive income Amount reclassified from the cash flow hedge reserve to profit or loss Line item in which the recycled amount is presented in profit or loss Carrying amount of the hedged item Changes in value of hedged item used for calculating hedge ineffective- ness Cash flow hedge reserve Assets Liabilities Interest rate risk 1 76 4 – (4 569) 63 41 Interest rate derivatives 76 4 Cash flow hedges-gains recycled to profit or loss – (4 569) 63 41 1 The interest rate risk derivatives have been recycled to the ’Cash flow hedges – gains recycled to profit or loss’ line item in the Statement of other comprehensive income (SOCI). Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 94 of 217 -- 94 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 13. DERIVATIVE FINANCIAL INSTRUMENTS continued Year ended 30 June 2022 Group R million Notional amount of the hedging instrument Carrying amount of the hedging instrument Line item in the Statement of financial position where the hedging instrument is presented Changes in value of hedging instrument used for calculating hedge ineffective- ness Ineffective- ness recognised in profit or loss Line item in which hedge ineffectiveness is presented in profit or loss Assets Liabilities Interest rate risk 5 000 17 (56) (295) – Interest rate derivatives 5 000 17 (56) Financial Asset- Derivative/ Financial Liability- Derivative (295) – Net fair value gains on financial assets at fair value through profit or loss Refer to note 3.4.1 for a detailed description of the derivative financial instruments listed above. Group R million Changes in the value of the hedging instrument recognised in other comprehen- sive income Amount reclassified from the cash flow hedge reserve to profit or loss Line item in which the recycled amount is presented in profit or loss Carrying amount of the hedged item Changes in value of hedged item used for calculating hedge ineffective- ness Cash flow hedge reserve Assets Liabilities Interest rate risk 1 295 – – – (5 038) (185) (40) Interest rate derivatives 295 – – – (5 038) (185) (40) 1 The interest rate risk derivatives have been recycled to the Cash flow hedges – gains recycled to profit or loss’ line item in the SOCI. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 95 of 217 -- 95 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 14. INSURANCE RECEIVABLES, CONTRACT RECEIVABLES AND OTHER RECEIVABLES R million Group 2023 Group 2022 Receivables arising from insurance and reinsurance contracts: 10 316 7 887 – Premium debtors 1 070 801 – Less provision for impairment of premium debtors 14.1 (97) (81) – Reinsurance debtors 9 343 7 167 Contract receivables: 9A 1 268 1 209 – Closed scheme debtors 120 107 – Discovery Health Medical Scheme 775 724 – Other contract receivables 377 382 – Less allowance for expected credit losses 14.2 (4) (4) Other financial receivables: 3 064 2 642 – Agents and brokers 534 439 – Cash-in-transit debtors 544 443 – Consolidated unit trust debtors 628 770 – Loans to BEE initiatives 309 256 – Security deposit on derivatives 2 27 72 – Vitality partner debtors 171 148 – Other debtors 1 261 906 – Less allowance for expected credit losses 14.2 (410) (392) Other non-financial receivables1 1 411 1 375 – Prepayments 1 204 1 022 – Value-added tax asset 48 158 – Other debtors 159 195 Total insurance receivables, contract receivables and other receivables 16 059 13 113 Current 11 404 8 822 Non-current 4 655 4 291 Total insurance receivables, contract receivables and other receivables 16 059 13 113 1 These non-financial assets have been excluded from the risk disclosures presented in note 3. 2 To reduce the credit risk exposure from the hedge derivative instruments purchased, Discovery has entered into collateral agreements with the relevant financial institutions to post cash collateral periodically, equal to the fair value of the derivatives. The posting of the collateral does not result in legal settlement of the outstanding derivative balance. The collateral will only be used to settle the derivative upon default or bankruptcy of either party. The fair value of short-term receivables approximates the carrying value. Long-term receivables are interest bearing at market rates and fully secured. -- 96 of 217 -- 96 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 14. INSURANCE RECEIVABLES, CONTRACT RECEIVABLES AND OTHER RECEIVABLES continued 14.1 Provision for impairment of premium debtors Group R million <30 days 30 – 60 days 60 – 120 days more than 120 days Total Year ended 30 June 2023 Balance at beginning of the year 25 22 26 7 80 Increase in provision 14 10 17 2 43 Amount utilised during the period (3) (10) (19) – (32) Translation differences 1 2 3 – 6 Balance at end of the year 37 24 27 9 97 Year ended 30 June 2022 Balance at beginning of the year 26 16 16 6 64 Increase in provision 2 25 22 7 56 Amount utilised during the period (3) (19) (11) (6) (39) Translation differences * * (1) * (1) Balance at end of the year 25 22 26 7 80 * Amount is less than R500 000. 14.2 Reconciliation of expected credit losses (ECL) Group R million General model Simplified model Stage 1 (12-month ECL) Stage 2 (Lifetime ECL) Stage 3 (Lifetime ECL/credit impaired) Not Credit impaired 90 days past due/ credit impaired Total Year ended 30 June 2023 Balance at beginning of the year 8 10 228 107 43 396 Increase in provision (1) (7) 29 8 5 34 Amount utilised during the period – – – (12) (10) (22) Translation differences – – – 5 1 6 Balance at end of the year 7 3 257 108 39 414 Year ended 30 June 2022 Balance at beginning of the year 11 8 230 98 143 490 Increase in provision 1 2 2 33 39 77 Amount utilised during the period (4) – (4) (26) (140) (174) Translation differences * * * 2 1 3 Balance at end of the year 8 10 228 107 43 396 * Amount is less than R500 000. 15. REINSURANCE CONTRACTS R million Group 2023 Group 2022 Reinsurers’ share of insurance contract liabilities 709 511 Current 709 511 Amounts due from reinsurers in respect of claims paid and reported by the Group on the contracts that are reinsured are included in Insurance receivables, contract receivables and other receivables (refer to note 14). -- 97 of 217 -- 97 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 16. CASH AND CASH EQUIVALENTS R million Group 2023 Group 2022 Cash at bank and in hand 19 113 17 625 Short-term deposits 1 257 2 150 Total cash and cash equivalents 20 370 19 775 The fair value of cash and cash equivalents approximates the carrying amount due to the relatively short-term nature of the instrument. 17. SHARE CAPITAL AND SHARE PREMIUM 17.1 Ordinary share capital and share premium Issued Treasury shares Group R million Share capital Share premium Discovery Health BEE share trust LTIP Total outstanding At 1 July 2021 1 11 121 (14) (50) (907) 10 151 Share movements: – new issue – 443 – – – 443 – treasury shares delivered – 24 – 3 – 27 – treasury shares purchased – – – – (443) (443) At 30 June 2022 1 11 588 (14) (47) (1 350) 10 178 Share movements: – new issue – 514 – – – 514 – treasury shares delivered – – – 3 170 173 – treasury shares purchased – – – – (514) (514) At 30 June 2023 1 12 102 (14) (44) (1 694) 10 351 Treasury shares Number of shares Company Discovery Health BEE share trust LTIP Total outstanding At 1 July 2021 665 768 601 (680 268) (805 961) (7 477 865) 656 804 507 Share movements: – new issue 3 194 870 – – – 3 194 870 – treasury shares delivered – – 152 104 – 152 104 – treasury shares purchased – – – (3 194 870) (3 194 870) At 30 June 2022 668 963 471 (680 268) (653 857) (10 672 735) 656 956 611 Share movements: – new issue 4 182 946 – – – 4 182 946 – treasury shares delivered – – 64 714 1 402 275 1 466 989 – treasury shares purchased – – – (4 182 946) (4 182 946) At 30 June 2023 673 146 417 (680 268) (589 143) (13 453 406) 658 423 600 The total authorised number of ordinary shares is 1 billion (2022: 1 billion), with a par value of 0.1 cent per share. Share issue in 2023 financial reporting period Discovery issued 4 182 946 shares for a cash consideration of R514 189 249. This was a specific issuance, to the Discovery Long-term Incentive Plan Trust. As approved at the AGM of 28 November 2019, Discovery is authorised pursuant to section 41 of the Companies Act, as amended, and the requirements of the memorandum of incorporation to allot and issue, and representing cumulatively the maximum allotment over the multiple year duration of the Discovery Long Term Incentive Plan (LTIP) (also see note 32 Share-based payments and long-term incentives), a maximum of 32 914 537 ordinary shares in the authorised share capital of the Discovery. -- 98 of 217 -- 98 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 17. SHARE CAPITAL AND SHARE PREMIUM continued 17.2 Preference share capital R million Group 2023 Group 2022 Authorised 40 000 000 A no par value preference shares – – 20 000 000 B preference shares of R100 each 2 000 2 000 20 000 000 C no par value preference shares – – 2 000 2 000 Issued 8 000 000 B preference shares of R100 each 800 800 Share issue costs (21) (21) At 30 June 779 779 The B preference shares are non-compulsory, non-cumulative, non-participating, non-convertible, voluntarily redeemable (at option of Discovery) preference shares and were issued at a coupon rate of 85% of prime rate. With the introduction of dividend withholding tax on 1 April 2012, the coupon rate on the preference shares was increased to 100% of the prime rate. 18. LIABILITIES ARISING FROM INSURANCE CONTRACTS R million Group 2023 Restated2 Group 2022 Gross – claims reported and loss adjustment expenses 13 559 12 662 – claims incurred but not reported 2 938 2 118 – IFA liability 129 100 – unearned premiums 833 1 007 – unit-linked insurance contracts 75 261 70 907 – with fixed and guaranteed terms 22 087 21 273 Total liabilities arising from insurance contracts, gross 114 807 108 067 Recoverable from reinsurers – claims incurred but not reported (699) (501) – unearned premiums (10) (10) Total reinsurers’ share of liabilities arising from insurance contracts (refer to note 15) (709) (511) Net – claims reported and loss adjustment expenses 13 559 12 662 – claims incurred but not reported 2 239 1 617 – IFA liability 129 100 – unearned premiums 823 997 – unit-linked insurance contracts 75 261 70 907 – with fixed and guaranteed terms 22 087 21 273 Total liabilities arising from insurance contracts, net 114 098 107 556 Current1 98 513 91 784 Non-current 15 585 15 772 114 098 107 556 1 Includes R81 031 million (2022: R76 448 million) which is repayable to policyholders on demand. For contractual maturity refer to note 3.2.3. 2 The comparative information has been restated. Refer to note 45 for detail. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 99 of 217 -- 99 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 18. LIABILITIES ARISING FROM INSURANCE CONTRACTS continued Movements in the liabilities are as follows: Group R million 2023 2022 Gross Reinsurance Net Gross Reinsurance Net Claims reported and loss adjustment expenses and IBNR Notified claims 12 662 – 12 662 11 234 – 11 234 Incurred but not reported 2 118 (501) 1 617 2 074 (439) 1 635 Balance at beginning of the year 14 780 (501) 14 279 13 308 (439) 12 869 Cash paid for claims settled in the year (15 438) 76 (15 362) (13 601) 73 (13 528) Increase/(decrease) in liabilities: – arising from current year claims 18 919 (316) 18 603 16 545 (183) 16 362 – arising from prior year claims (2 050) 104 (1 946) (1 500) 50 (1 450) Economic assumptions movement1 (306) – (306) – – – Translation differences 592 (62) 530 28 (2) 26 Balance at end of the year 16 497 (699) 15 798 14 780 (501) 14 279 Notified claims 13 559 – 13 559 12 662 – 12 662 Incurred but not reported 2 938 (699) 2 239 2 118 (501) 1 617 Balance at end of the year 16 497 (699) 15 798 14 780 (501) 14 279 IFA liability Balance at beginning of the year 100 – 100 82 – 82 Increase in the year 64 – 64 42 – 42 Cash paid (35) – (35) (24) – (24) Balance at end of the year 129 – 129 100 – 100 Provisions for unearned premiums Balance at beginning of the year 1 007 (10) 997 1 091 (6) 1 085 Increase in the year 2 008 (10) 1 998 1 625 (10) 1 615 Release in the year (2 313) 10 (2 303) (1 725) 6 (1 719) Translation differences 131 – 131 16 – 16 Balance at end of the year 833 (10) 823 1 007 (10) 997 Additional unexpired risk reserve Balance at beginning of the year – – – 300 – 300 Decrease in the year – – – (300) – (300) Balance at end of the year – – – – – – 1 Presented as Claims and policyholders’ benefits in the Income statement. R million Group 2023 Restated 1 Group 2022 Unit-linked insurance contracts Balance at beginning of the year 70 907 63 496 Premiums received 12 059 17 256 Fair value adjustment 8 833 (536) Withdrawals (16 797) (7 440) Fees (1 534) (1 400) Movement in negative insurance liability (229) (551) Translation differences 2 022 82 Balance at end of the year 75 261 70 907 Balance is made up as follows: Unit-linked liabilities 81 031 76 448 Negative insurance liability (5 770) (5 541) 75 261 70 907 With fixed and guaranteed terms Balance at beginning of the year 21 273 21 764 Expected movement in policyholder liabilities (4 226) (4 324) Unwinding of discount rate 1 297 968 New business written 3 993 3 187 Experience variances (263) (322) Economic assumptions movement 9 – Translation differences 4 – Balance at end of the year 22 087 21 273 1 The comparative information has been restated. Refer to note 45 for detail. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 100 of 217 -- 100 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 19. LIABILITIES ARISING FROM REINSURANCE CONTRACTS R million Group 2023 Group 2022 Financial reinsurance 2 564 2 582 Reinsurance recoveries relating to assets arising from insurance contracts (refer to note 5) 12 105 10 610 14 669 13 192 Balance at beginning of the year 13 192 12 525 Increase in liability1 53 577 – gross increase/(decrease) in liability 700 (458) – receipt arising from reinsurance contracts 3 272 2 597 – reinsurance premiums paid (3 919) (1 562) Translation differences 1 424 90 Balance at end of the year 14 669 13 192 Current 2 927 2 131 Non-current 11 742 11 061 14 669 13 192 1 The increase in liability of R53 million for the current year includes economic assumptions gains of R277 million, which has been presented in Economic assumptions adjustments net of discretionary margins in the Income statement. The liabilities arising from reinsurance contracts releases with the associated underlying insurance contracts. 20. BORROWINGS AT AMORTISED COST R million Group 2023 Group 2022 Borrowings from banks 20.1 16 328 16 308 Lease liabilities 20.2 4 225 4 120 Bank overdraft 33 156 Balance at end of the year 20 586 20 584 Current 2 490 3 940 Non-current 18 096 16 644 Balance at end of the year 20 586 20 584 For variable rate loans, the fair value approximates the carrying amount because the variable rate is set on market related terms. For fixed rate loans, the fair value is R4 806 million (2022: R6 122 million) relative to the carrying value of R4 827 million (2022: R 5 737 million). 20.1 Borrowings from banks Movement analysis of borrowings R million Group 2023 Group 2022 Balance at beginning of the year 16 308 15 230 Loans raised 7 450 3 261 Loans repaid (8 038) (2 087) Interest accrued 1 335 1 037 Interest paid (1 335) (1 188) Raising fees capitalised (8) (3) Translation differences 616 58 Balance at end of the year 16 328 16 308 Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 101 of 217 -- 101 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 20. BORROWINGS AT AMORTISED COST continued 20.1 Borrowings from banks continued SA borrowing facilities DISCOVERY LIMITED Carrying value R million Facility amount R million Variable rate Interest per annum Capital repayment and maturity date Group 2023 Group 2022 Listed DMTN 4 500 3-month Jibar + 161bps 8.10%1,3 At maturity – 21 November 2022 – 503 500 3-month Jibar + 205bps 4.25%1,3 At maturity – 21 August 2023 505 503 200 – 10.46%2 At maturity – 21 November 2024 202 202 800 3-month Jibar + 191bps 8.40%1,3 At maturity – 21 November 2024 808 805 1 200 3-month Jibar + 191bps 7.30%1,3 At maturity – 21 November 2024 1 218 1 217 700 3-month Jibar + 180bps 8.49%1,3 At maturity – 21 August 2026 707 704 300 3-month Jibar + 180bps 7.60%1,3 At maturity – 21 August 2026 304 303 792 3-month Jibar + 173bps 7.98%1,3 At maturity – 21 May 2027 799 792 226 3-month Jibar + 180bps 7.98%1,3 At maturity – 21 May 2029 228 226 Unlisted DMTN5 1 100 – 8.92%3 At maturity – 10 March 2023 – 1 104 2 500 – 9.62%3 At maturity – 22 February 2025 2 522 2 520 1 650 – 9.55%3 At maturity – 10 March 2026 1 658 – Other 1 400 3-month Jibar + 125bps – At maturity – 12 October 2022 – 702 1 000 3-month Jibar + 245bps 7.83%1,3 At maturity – 02 March 2023 – 1 003 1 000 3-month Jibar + 190bps3 – At maturity – 02 March 2028 997 – 9 948 10 584 1 The interest rate has been fixed through interest rate swaps. 2 Interest is payable semi-annually in arrears. 3 Interest payable quarterly in arrears. 4 DMTN refers to the R10 billion Discovery Domestic Medium Term Note (DMTN) program registered in 2017. 5 During the financial year ended 30 June 2020, Discovery Limited refinanced R3.6 billion bank syndicated loans through the issue of unlisted DMTN notes. The notes, although underwritten by a bank until maturity, are structured to enable short-term issuances into the commercial paper market on an ongoing basis. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 102 of 217 -- 102 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 20. BORROWINGS AT AMORTISED COST continued 20.1 Borrowings from banks continued SA borrowing facilities DISCOVERY CENTRAL SERVICES Carrying value R million Facility amount R million Interest rate per annum Capital repayment and maturity date Group 2023 Group 2022 1 400 3-month Jibar + 2.05%1,2 Instalments – 29 October 2027 1 408 1 417 650 11.56%3 At maturity – 29 October 2027 445 494 691 3-month Jibar + 1.9% At maturity – 30 June 2027 694 691 1 500 3-month Jibar + 1.45% At maturity – 8 June 2024 151 – 2 698 2 602 1 Interest payable quarterly in arrears. 2 During the financial year, the rate was renegotiated from a fixed rate of 10.60%, to a floating interest rate. 3 Instalments of interest and capital is monthly. UK borrowing facilities UK BORROWINGS Carrying value GBP (Rand) million Facility amount GBP million Variable rate Capital repayment and maturity date Group 2023 Group 2022 GBP R GBP R 25 SONIA + 2.75%1 At maturity – 23 December 20252 25 597 – – 75 SONIA + 3.00%1 At maturity – 21 December 20242,3 75 1 793 – – 55 SONIA + 2.85%1 At maturity – 12 December 20254 54 1 292 – – 100 SONIA + 2.38%1 At maturity – 31 July 20232 – – 100 1 999 80 SONIA + 2.73%1 Instalments – 31 July 20234 – – 42 847 34 SONIA + 1.31%1 At maturity – 19 October 20224 – – 14 276 154 3 682 156 3 122 1 Interest payable quarterly in arrears. 2 The GBP100 million facility drawn down at 30 June 2022, was refinanced in December 2022. 3 One year extension option available at discretion of lender. 4 The GBP80 million and GBP30 million facilities, of which GBP56 million was drawn down at 30 June 2022 in total, was refinanced in December 2022. 20.2 Leases R million Group 2023 Group 2022 Balance at beginning of the year 4 120 4 263 New leases entered into 260 138 Lease incentive payment received 58 – Interest accrued 432 426 Repayments (627) (600) Modifications (81) (126) Translation differences 63 19 Balance at end of the year 4 225 4 120 Total payments for leases for the year is R924 million (2022: R825 million). During the 2018 financial year Discovery took occupation of a new head office building under a finance lease. A lease liability and related asset (refer to note 6) of R3 155 million was raised. At year end, R3 326 million (2022: R3 373 million) remained outstanding. Finance charges of R361 million (2022: R366 million) have been recognised in profit or loss and repayments of R408 million (2022: R381 million) have been made. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 103 of 217 -- 103 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 21. INVESTMENT CONTRACTS AT FAIR VALUE THROUGH PROFIT OR LOSS R million Group 2023 Restated2 Group 2022 The movements during the year were as follows: Balance at beginning of the year 38 637 33 354 Deposits received 10 719 12 239 Account balances paid on withdrawal and other terminations in the year (6 884) (6 924) Fair value adjustment 5 572 (32) Balance at end of the year 48 044 38 637 Current1 48 044 38 637 1 There is no maturity profile for these liabilities as this will depend on policyholder behaviour. Contractually, policyholders may disinvest on demand. 2 The comparative information has been restated. Refer to note 45 for detail. The benefits offered under the Group’s unit-linked investment contracts are based on the return of selected equities, debt securities and money market securities. The Group communicates the actual performance of these contracts to its contract holders. Investment contracts at fair value through profit or loss are exactly matched with related assets and managed collectively as a pool. Discovery’s credit risk is not reflected in the measurement of the assets or consequently the liability, which is measured with reference to the underlying assets. Own credit risk has been assessed and determined to be immaterial. 22. OTHER PAYABLES R million Group 2023 Group 2022 Commissions payable 322 251 Consolidated unit trust payables 482 512 Due to reinsurers 1 100 651 Expired hedge payables 3 6 Intermediary payables 192 130 Payables and accrued liabilities 4 335 3 672 Payroll creditors 1 097 987 Policyholder unallocated funds 1 531 1 180 Security deposits on derivatives 39 245 Unsettled trades 190 580 VitalityLife working capital funding1 4 097 5 477 Other financial payables 1 031 1 020 Other non-financial payables2 361 412 – Value-added tax liability 189 258 – Premiums and fees received in advance 172 154 Balance at end of the year 14 780 15 123 Current 14 396 14 827 Non-current 384 296 Total other payables 14 780 15 123 1 Includes the ’deposit back’ of GBP108.9 million (R2 612 million) (2022: GBP236 million (R4 780 million)) related to the level premium reinsurance treaty in respect of business written on PAC’s life license, payable to the reinsurer. 2 Value-added tax liabilities and premiums received in advance are non-financial liabilities and have been excluded from the risk disclosures presented in note 3. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 104 of 217 -- 104 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 23. DEPOSITS FROM CUSTOMERS R million Group 2023 Group 2022 Term deposits from customers – fixed rate 3 434 3 372 Term deposits from customers – variable rates 3 232 1 807 On demand deposits from customers – non-rate sensitive 394 149 On demand deposits from customers – variable rate 7 273 5 249 Wholesale NCDs – variable rate – 304 Total customer deposits 14 333 10 881 24. DEFERRED TAX R million Group 2023 Group 2022 Deferred tax asset – non-current 4 404 4 455 Deferred tax liability – non-current (9 559) (9 335) Total deferred tax (5 155) (4 880) Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 105 of 217 -- 105 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 24. DEFERRED TAX continued Deferred tax comprises: Charge for the year Group R million Balance at beginning of the year Recognised in profit or loss Recognised in other comprehensive income Recognised in equity Translation differences Balance at end of the year Year ended 30 June 2023 Assessed loss in Company Policyholders’ Fund 160 (5) – – – 155 Assessed loss in Individual Policyholders’ Fund 834 145 – – – 979 Assessed loss in subsidiaries 2 700 98 – – 218 3 016 Financial Instruments and share-based payments (15) (28) 1 8 6 (28) Deferred acquisition costs (206) (3) – – 2 (207) Contract liability 89 166 – – 20 275 Difference between wear and tear and depreciation/amortisation and leases (299) 86 – – (22) (235) Intangible asset recognised on acquisition of business (2) (11) – – 3 (10) Prepayments (3) (6) – – – (9) Provisions 386 96 – – 2 484 Difference between accounting and tax balances arising from insurance contracts (8 480) (615) – – – (9 095) Unrealised gains on revaluation of investments1 (282) (36) – – 17 (301) Other1 238 (389) – – (28) (179) Total (4 880) (502) 1 8 218 (5 155) Charge for the year Group R million Balance at beginning of the year Recognised in profit or loss Recognised in other comprehensive income Recognised in equity Translation differences Balance at end of the year Year ended 30 June 2022 Assessed loss in Company Policyholders’ Fund 185 (25) – – – 160 Assessed loss in Individual Policyholders’ Fund 1 134 (300) – – – 834 Assessed loss in subsidiaries 2 439 158 – – 103 2 700 Financial Instruments and share-based payments 169 (181) (3) – – (15) Deferred acquisition costs (227) 19 – – 2 (206) Contract liability 70 10 – – 9 89 Difference between wear and tear and depreciation and leases (276) (11) – – (12) (299) Intangible asset recognised on acquisition of business (57) 53 – – 2 (2) Prepayments (14) 11 – – – (3) Provisions 340 26 – 17 3 386 Difference between accounting and tax balances arising from insurance contracts (8 929) 449 – – – (8 480) Other 300 (141) – – (203) (44) Total (4 866) 68 (3) 17 (96) (4 880) 1 The value of ‘unrealised gains on revaluations of investments’ has been separated out from ‘other’ during the year ended 30 June 2023 in order to provide better disclosure and disaggregate the ‘other’ category which, without this change, would have had a material closing value as at 30 June 2023. -- 106 of 217 -- 106 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 24. DEFERRED TAX continued Assessed losses Discovery did not recognise deferred tax assets in respect of the following assessed losses: R million Group 2023 Group 2022 Better Health Insurance Advice Limited 40 37 Cogence Proprietary Limited 33 2 Discovery Central Services Proprietary Limited 4 806 4 062 Discovery Group Europe Limited 1 52 Discovery Life Limited – Individual Policyholders’ Fund 5 194 7 907 Discovery Partner Market Services Private Limited – 33 Discovery Vitality Australia Proprietary Limited 306 47 Grove Nursing Services Proprietary Limited 43 43 Medical Services Organisation International Proprietary Limited 10 3 Southern Rx Proprietary Limited 96 109 Vitality Healthy Workplace Limited – 17 10 529 12 312 A deferred tax asset has been partly recognised on assessed losses in the Discovery Life Limited – Individual Policyholders’ Fund. Refer to note 4.1. The Group recognises deferred tax assets on carried forward losses to the extent that there are sufficient estimated future taxable profits and/or taxable temporary differences against which the tax losses can be utilised. 25. EMPLOYEE BENEFITS R million Group 2023 Group 2022 Leave pay Balance at beginning of the year 320 315 Additional provisions raised 325 299 Used during the year (282) (262) Paid to terminated employees (33) (32) Translation differences 4 – Balance at end of the year 334 320 Current 280 269 Non-current 54 51 Total employee benefits 334 320 Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 107 of 217 -- 107 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 26. NET INSURANCE PREMIUM REVENUE R million Group 2023 Restated2 Group 2022 Health 11 527 9 744 Recurring premiums 13 667 11 299 Reinsurance premiums (2 140) (1 555) Individual life and invest 29 767 32 955 Recurring premiums 26 719 29 832 Single premiums 10 109 9 335 Reinsurance premiums1 (7 061) (6 212) Group life 2 885 2 411 Recurring premiums 3 164 2 634 Reinsurance premiums (279) (223) Short-term insurance 5 356 4 940 Recurring premiums 6 012 5 212 Reinsurance premiums1 (656) (272) 49 535 50 050 Insurance premium revenue 59 671 58 312 Outward reinsurance premiums (10 136) (8 262) Net insurance premium revenue 49 535 50 050 1 For June 2022, R230 million has been reclassified from Individual life and Invest reinsurance premiums to Short-term insurance reinsurance premiums, to better reflect the nature of these reinsurance premiums. 2 The comparative information has been restated. Refer to note 45 for detail. 27. INVESTMENT INCOME R million Group 2023 Group 2022 At amortised cost interest income using the effective interest rate method 151 17 Cash and cash equivalents interest income using the effective interest rate method 621 279 772 296 Attributable to: – Shareholders 310 164 – Policyholders 462 132 Total investment income 772 296 Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 108 of 217 -- 108 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 28. NET FAIR VALUE GAINS/(LOSSES) ON FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS R million Group 2023 Group 2022 Investment income 3 815 3 128 – Interest 3 087 2 528 – Dividends 728 600 Mutual fund distributions 2 124 1 371 Net fair value gains/(losses) 8 434 (6 324) 14 373 (1 825) 29. NET CLAIMS AND POLICYHOLDERS’ BENEFITS R million Group 2023 Restated 3 Group 2022 Health insurance claims 5 364 4 322 Gross claims 7 134 5 644 Less: Reinsurance recoveries (1 770) (1 322) Individual life insurance claims 6 897 7 502 Death 4 274 6 499 Disability 4 544 4 484 Payback benefits 2 145 1 930 Less: Recapture of reinsurance – (89) Less: Reinsurance recoveries (4 066) (5 322) Group life insurance claims 2 256 2 594 Death 996 1 747 Disability 1 425 1 076 Payback benefits 20 10 Less: Reinsurance recoveries (185) (239) Individual investment benefits 22 532 13 099 Surrenders1 21 784 12 405 Guaranteed payments 117 65 Annuity payments 631 629 Short-term insurance claims 3 086 3 198 Gross claims 3 676 3 533 Less: Reinsurance recoveries (590) (335) 40 135 30 715 Claims and policyholders’ benefits2 46 746 38 022 Insurance claims recovered from reinsurers (6 611) (7 218) Recapture of reinsurance – (89) Net claims and policyholders’ benefits 40 135 30 715 1 Includes surrenders in respect of the wind down of VitalityInvest following the decision to exit the UK investment market. 2 Includes R306 million of economic assumption movements in respect of Discovery Life. 3 The comparative information has been restated. Refer to note 45 for detail. 30. ACQUISITION COSTS R million Group 2023 Restated 1 Group 2022 Commission and other costs of obtaining contracts 6 255 4 807 Movement in deferred acquisition costs (refer to note 8) (42) (49) Total acquisition costs 6 213 4 758 1 The comparative information has been restated. Refer to note 45 for detail. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 109 of 217 -- 109 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 31. MARKETING AND ADMINISTRATION EXPENSES R million Group 2023 Group 2022 Auditors remuneration Audit fees 130 113 Fees for other services 4 1 Prior year 13 (8) 147 106 Lease charges Short-term leases 80 69 Low-value item leases 217 156 297 225 Staff costs including executive directors1 Salaries, wages and allowances 9 319 8 456 Medical aid fund contributions 529 482 Defined contribution provident fund contributions 444 401 Social security levies 397 304 Share-based payment expenses – equity-settled 545 326 – cash-settled 95 93 – (gains)/losses on cash flow hedge (1) 22 Staff training 89 69 Recruitment fees 64 51 Temporary staff 694 537 Provision for leave pay 43 37 Other 233 168 12 451 10 946 Other operating costs Amortisation of software2 (note 7) 1 319 1 252 Building related and office costs 530 518 Depreciation of property and equipment (note 6) 307 229 Depreciation of right of use assets (note 6) 351 421 Loss on derecognition of property and equipment and intangible assets 324 50 Loss on disposal of property and equipment 8 3 Gain on disposal of intangible assets – (131) Impairment of property and equipment (note 6) 45 – Allowance for expected credit losses on receivables 77 (79) Insurance 75 51 IT systems and consumables 2 663 2 183 Marketing and distribution costs 2 101 1 743 Non-executive directors fees 47 37 Professional fees 964 895 Vitality benefit expenses 4 340 3 694 Other operating expenses 2 859 3 066 16 010 13 932 Total marketing and administration expenses 28 905 25 209 1 Executive directors’ and prescribed officers’ remuneration is included in employee costs. Refer to Annexure C - Directorate for detailed disclosure. 2 The transactions relating to business combinations are not included in marketing and administration expenses as it is disclosed separately in the Income statement. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 110 of 217 -- 110 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 32. SHARE-BASED PAYMENTS AND LONG-TERM INCENTIVES Incentive schemes Discovery operates various share-based payment and long-term incentive arrangements. The details of these arrangements are described below: 1. BEE STAFF SHARE TRUST In 2005, 5 290 000 shares in Discovery Limited’s shares were issued to the BEE staff share trust for current and future employees. These shares had all been allocated during prior years. Additional shares have been purchased in prior years, for future allocation to employees. The trusts consist of two components; the allocation scheme and the option scheme as described below. ALLOCATION SCHEME Shares have been allocated to senior black employees based on level of seniority and length of past service. The shares vest to employees two, three, four and five years after allocation at a rate of 25% per annum. On each vesting date, the trustees shall distribute to the employees the allocated shares to which the employees may be entitled. OPTION SCHEME Options granted to black employees may be exercised two, three, four and five years after the option is granted at a rate of 25% per annum. Any options not exercised by the end of the fifth year from the grant date shall lapse. On exercise of the option, the employee pays cash to the trust for the full purchase price of the option. 2. DISCOVERY’S PHANTOM SCHEME Participants earn a cash bonus based on allocation of bonus scheme units which in turn are linked to the performance of the Discovery Limited share price. The bonus is earned if the participant is employed on each vesting date, with the vesting dates ranging between one and five years after allocation of the bonus units. The bonus may not be carried forward. 3. DISCOVERY’S LONG-TERM INCENTIVE PLANS (EQUITY SETTLED) DISCOVERY LONG-TERM INCENTIVE PLAN (LTIP) The LTIP was introduced in the financial year ended 30 June 2020 and replaced the cash-settled Discovery Phantom scheme (see point 2 above) with an equity-settled LTIP. Participants will receive Discovery Limited shares subject to performance criteria and if the participant is employed on each vesting date. For LTIP awards granted prior to the introduction of the Single Incentive Plan (SIP), the performance conditions are aligned to the organic growth methodology of the Group and will vest from between the third and fifth anniversary of these awards. SINGLE INCENTIVE PLAN During the financial year ended 30 June 2022, Discovery replaced its management short-term incentive scheme and long-term incentive schemes with a single incentive scheme called SIP, consisting of a cash incentive (short-term incentive) and deferred share awards (long-term incentive). The SIP is based on the annual award of a single total incentive relating to the performance of the Group, business unit and the individual, and is assessed against financial and non-financial measures as outlined by the Group scorecard as well as business unit and individual scorecards. The first deferred share awards were granted in November 2022. These shares will vest between one and three years after allocation of the shares for senior management and between three and five years for executive directors and prescribed officers. 4. ACQUISITION SCHEMES There are various schemes offered to franchise directors, agents and employees where participants are allocated share units which replicate the economics of a Discovery Limited share. The share units are settled as a cash bonus on vesting. The bonus is earned if the participant is employed by Discovery or Discovery’s contracted affiliates on the vesting date. The vesting periods on the schemes vary from two to five years. The bonus may not be carried forward. 5. DISCOVERY BANK SCHEME Participants will receive Discovery Limited shares subject to the ’Value Created’, which references the growth in the value of Discovery Bank business after capital invested and interest. These awards vests from between the 3rd and 7th anniversary of the market launch date of Discovery Bank, and each vesting is settled in three equal instalments over three years, if the participant is employed on each vesting date. Other long-term incentive schemes The following schemes are long-term staff incentives where the value is determined with reference to something other than the Discovery Limited share price. These schemes are accounted for in terms of IAS 19: Employee benefits. 6. THE VITALITYHEALTH AND VITALITYLIFE PHANTOM SHARE SCHEME Participants earn a cash bonus based on allocation of bonus scheme units which in turn are linked to the performance of VitalityLife and VitalityHealth, and more specifically the value of in-force (ViF) of VitalityLife and the Embedded Value (EV) of VitalityHealth. The bonus is earned if the participant is employed on each vesting date. For units issued, the vesting of the units is two, three and four years after allocation of the bonus units. The bonus may not be carried forward. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 111 of 217 -- 111 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 32. SHARE-BASED PAYMENTS AND LONG-TERM INCENTIVES continued 7. OTHER DEVELOPMENT SEGMENT SCHEMES Various other long-term incentive schemes exist in the Discovery Group in the development segments. These schemes are individually and in aggregate immaterial and as a result no further information is disclosed. The share/option schemes mentioned in bullet 1, 3 and 5 have been classified as equity-settled schemes and therefore a share- based payment reserve has been recognised. The schemes mentioned in bullets 2 and 4 have been classified as cash-settled schemes and a liability is raised in terms of IFRS 2 Share-based Payment. The other long-term incentive schemes, have been accounted for in terms of IAS 19 Employee Benefits. The following is a summary of the terms and conditions of the units granted: Date granted Share/ Option price Final vesting date Shares under option at beginning of year Share/ Options granted during year Share/ Options vested during year Share/ Options cancelled or adjusted during year Shares under option at end of year 1. BEE staff share trust 01/07/2016 – 30/06/2017 R122.5 30/09/2021 1 722 – – – 1 722 01/07/2016 – 30/06/2017 R0.00 30/09/2021 287 – – – 287 01/07/2016 – 30/06/2017 R0.00 22/05/2023 4 655 – (4 655) – – 01/07/2018 – 30/06/2019 R0.00 31/03/2024 5 954 – (2 976) (967) 2 011 01/07/2019 – 30/06/2020 R0.00 30/09/2025 47 194 – (22 423) (1 961) 22 810 01/07/2020 – 30/06/2021 R0.00 31/03/2026 21 596 – (5 339) (1 174) 15 083 01/07/2021 – 30/06/2022 R0.00 30/09/2027 115 628 – (18 112) (27 308) 70 208 01/07/2022 – 30/06/2023 R0.00 30/04/2028 – 14 604 – – 14 604 2. The Discovery Limited phantom scheme 01/07/2016 – 30/06/2017 R0.00 30/09/2022 58 897 – (52 782) (6 115) – 01/07/2017 – 30/06/2018 R141.65 30/09/2022 163 558 – (163 346) (212) – 01/07/2017 – 30/06/2018 R0.00 31/03/2023 640 818 – (610 489) (28 990) 1 339 01/07/2018 – 30/06/2019 R0.00 31/03/2024 887 316 – (429 076) (44 064) 414 176 01/07/2022 – 30/06/2023 R0.00 30/09/2027 – 333 737 – (6 447) 327 290 3. Discovery LTIP and SIP 01/07/2019 – 30/06/2020 R0.00 30/09/2024 3 049 840 – (1 402 275) (138 010) 1 509 555 01/07/2020 – 30/06/2021 R0.00 30/09/2025 3 656 145 – – (107 536) 3 548 609 01/07/2021 – 30/06/2022 R0.00 30/09/2026 3 352 235 – – (118 790) 3 233 445 01/07/2022 – 30/06/2023 R0.00 30/09/2027 – 5 050 816 – (94 065) 4 956 751 4. Acquisition schemes 01/07/2017 – 30/06/2018 R0.00 30/06/2023 24 903 – (23 791) (1 112) – 01/07/2018 – 30/06/2019 R0.00 30/06/2024 63 728 – (35 133) (1 587) 27 008 01/07/2019 – 30/06/2020 R0.00 30/06/2025 658 068 – (557 635) (12 033) 88 400 01/07/2020 – 30/06/2021 R0.00 30/06/2026 767 414 – (40 870) (19 695) 706 849 01/07/2021 – 30/06/2022 R0.00 30/06/2027 717 351 – (6 979) (7 007) 703 365 Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 112 of 217 -- 112 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 32. SHARE-BASED PAYMENTS AND LONG-TERM INCENTIVES continued The VitalityHealth and VitalityLife phantom share scheme is cash-settled and thus repriced at each reporting date. The value of the shares and options allocated are dependent on the performance of VitalityLife and VitalityHealth, more specifically the ViF of VitalityLife and the EV of VitalityHealth. The Discovery Limited phantom scheme and Acquisition schemes are cash-settled and are thus repriced at each reporting date. The closing share price at 30 June 2023 was R145.85. Discovery determines the grant date fair value of its equity-settled schemes at the date of allocating the grant to the employee. The grant date fair value is then recognised over the vesting period. The significant assumptions in determining the grant date fair value were as follows: Spot price Risk free interest rate Vesting period Dividend yield Discovery LTIP and SIP 01/07/2019 – 30/06/2020 R113.81 6.68% – 7.01% 3 – 5 years 2.21% – 2.52% 01/07/2020 – 30/06/2021 R125.52 – R153.54 3.90% – 5.02% 3 – 5 years 2.26% – 2.57% 01/07/2021 – 30/06/2022 R135.94 5.76% – 6.57% 3 – 5 years 2.29% – 2.46% 01/07/2022 – 30/06/2023 R127.58 – R149.05 5.96% – 8.01% 1 – 5 years 0.00% – 1.08% BEE Staff share trust 01/07/2018 – 30/06/2019 R139.49 – R170.16 7.32% – 7.98% 2 – 5 years 1.46% – 2.01% 01/07/2019 – 30/06/2020 R86.00 – R133.76 4.85% – 7.54% 2 – 5 years 2.01% – 3.54% 01/07/2020 – 30/06/2021 R127.60 – R148.89 3.85% – 5.96% 3 – 5 years 2.34% – 2.78% 01/07/2021 – 30/06/2022 R136.00 – R181.49 4.91% – 7.49% 2 – 5 years 0.81% – 2.70% 01/07/2022 – 30/06/2023 R120.00 – R143.77 7.63% – 8.53% 2 – 5 years 0.85% – 1.47% 33. FINANCE COSTS R million Group 2023 Group 2022 Interest expense on: – Borrowings measured at amortised cost using the effective interest method 1 437 1 037 – Release from other comprehensive income 4 – – Lease liabilities (IFRS 16) 432 426 – Interest on other payables using the effective interest method 49 195 – Other 19 – Total 1 941 1 658 34. FOREIGN EXCHANGE GAINS R million Group 2023 Group 2022 Net foreign exchange gains 150 155 The net foreign exchange gains and losses arised primarily from foreign denominated loans, some which are internal. The total amount of foreign exchange gains recognised in profit or loss is R292 million (2022: R221 million) presented within various lines associated with the underlying transaction. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 113 of 217 -- 113 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 35. TAXATION R million Group 2023 Group 2022 Charge for the year: Current taxation 1 550 1 533 Normal taxation – prior year over provision – (22) – current year charge 1 524 1 550 Capital gains taxation 26 5 Deferred taxation 502 (68) Total income tax expense recognised in profit or loss 2 052 1 465 % % Taxation rate reconciliation Statutory rate 27.0 28.0 Non-taxable income: Equity-accounted profit or loss and dividend income (2.5) (2.7) Non-taxable income: Other individually immaterial (0.1) (0.3) Non-deductible expenditure: Including items of a capital nature and non-deductible provisions 0.6 4.0 Non-deductible expenditure: Other individually immaterial * * Subsidiary current period losses for which no deferred tax asset was recognised, net of deferred tax assets on losses recognised for prior period losses 3.5 3.1 PAC arrangement 0.1 (7.4) Insurance policyholder funds I-E taxes and related DTA recognitions (0.1) 2.0 Accounting gains and losses taxable at CGT rates (0.2) 0.1 CFC imputations and WHT not recovered 0.9 0.7 Additional tax allowances (0.1) (0.3) Prior year under provision * 0.1 Tax rate changes (0.5) (4.6) Tax rate differences (0.8) (1.6) Effective taxation rate 27.8 21.1 * Amount is less than 0.1%. The current tax rate for South African entities in a tax paying position is 27%. Discovery, a holding company listed on the JSE, uses the South African tax rate for its tax rate reconciliation since it is based in South Africa and the most significant operations are in South Africa. The South African life insurance operations tax rate is determined based on the rates and basis applicable to section 29A of the Income Tax Act 58 of 1962 at the reporting date. Vitality Group International Inc, a subsidiary of Discovery Limited in the US, is subject to taxation under section 11(b) of the Internal Revenue Code 1986. The applicable current tax rate for all of Vitality Group International Inc’s taxable profit is 21%. Discovery Group Europe Limited, incorporated and operating in the UK, is governed by the Corporation Tax Act 2010 Chapter 2, which sets the main corporation tax rate on taxable profit at 25%. As of 23 May 2023, the UK has enacted the Finance (No.2) Act 2023. This new legislation establishes a minimum global effective tax rate of 15%. It also enforces a top-up tax for domestic and multinational entities, which will apply for accounting periods beginning on or after 1 January 2023. Discovery has utilised the IAS 12 amendment exception to recognise and disclose deferred tax assets and liabilities for top-up income taxes. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 114 of 217 -- 114 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 36. EARNINGS, HEADLINE EARNINGS AND NORMALISED HEADLINE EARNINGS Basic earnings per share is the profit or loss attributable to the ordinary shareholders of the Company for the period, divided by the weighted-average number of ordinary shares outstanding during the period. To calculate diluted earnings per share, the Group adjusts the profit or loss attributable to the ordinary shareholders of the Company for the period and the weighted-average number of shares outstanding during the period for the effects of all dilutive potential ordinary shares. Note Group 2023 Group 2022 Number of shares used in calculation 36.1 Weighted average number of shares in issue (’000) 658 045 656 901 Diluted weighted average number of shares (’000) 661 328 663 082 Earnings per share (cents): 36.2 – basic 785.4 825.5 – diluted 781.5 817.8 Headline earnings per share (cents): 36.3 – basic 834.3 792.4 – diluted 830.1 785.0 Normalised headline earnings per share (cents): 36.4 – basic 1 166.7 885.5 – diluted 1 160.9 877.3 36.1 Weighted average number of ordinary shares ‘000 Group 2023 Group 2022 Issued ordinary shares at 1 July 656 957 656 805 Effect of treasury shares vested 1 052 – Effect of share options exercised and vesting of share awards 36 96 Weighted average number of ordinary shares at 30 June (basic) 658 045 656 901 Effect of share options exercised and vesting of share awards 3 283 6 181 Weighted average number of ordinary shares at 30 June (diluted) 661 328 663 082 36.2 Earnings reconciliation R million Group 2023 Group 2022 Profit attributable to the ordinary shareholders 5 258 5 422 Adjusted for: – Profit attributable to non-forfeitable dividend share plan (90) – Profit attributable to ordinary shareholders of the Company (basic and diluted) 5 168 5 422 Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 115 of 217 -- 115 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 36. EARNINGS, HEADLINE EARNINGS AND NORMALISED HEADLINE EARNINGS continued 36.3 Headline earnings reconciliation Headline earnings per share is disclosed per the JSE Limited’s Listings Requirements and is calculated in accordance with the circular titled Headline Earnings issued by SAICA, as amended from time to time. Headline earnings per share is based on the net profit after tax attributable to ordinary shareholders adjusted for items of a capital nature and the weighted average number of ordinary shares in issue. Group 2023 Group 2022 R million Gross Tax Net Gross Tax Net Profit attributable to the ordinary shareholders 5 168 5 422 Adjusted for: – IAS 38 Intangible assets: Gain on disposal of intangible assets – – – (131) 29 (102) – IAS 38 Intangible assets: Loss on derecognition of intangible assets 290 (60) 230 37 (5) 32 – IAS 16 Property, plant and equipment: Loss on derecognition of property and equipment 34 (7) 27 13 (1) 12 – IAS 16 Property, plant and equipment: Loss on disposal of property and equipment 8 (1) 7 3 – 3 – IFRS 3 Business Combinations: Impairment of goodwill 9 – 9 – – – – IAS 36 Impairment of Assets: Impairment of property and equipment 45 – 45 – – – Adjustments attributable to equity-accounted investments: – IAS 28 Investments in Associates and Joint Ventures: Loss/(gain) on dilution and disposal of equity-accounted investments 5 (1) 4 (33) 4 (29) – IAS 28 Investments in Associates and Joint Ventures: Reversal of impairment of equity- accounted investments1 – – – (134) – (134) Headline earnings (basic and diluted) 5 490 5 204 1 Impairment reversal was supported by a firm offer to purchase the equity accounted investment. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 116 of 217 -- 116 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 36. EARNINGS PER SHARE continued Earnings, Headline earnings and Normalised Headline Earnings 36.4 Normalised headline earnings reconciliation Normalised headline earnings is calculated per Discovery’s policy as set out in the Accounting Policy 29. Group 2023 Group 2022 R million Gross Tax Net Gross Tax Net Headline earnings 5 490 5 204 Adjusted for: – Economic assumption adjustments net of discretionary margins and interest rate derivatives 2 664 (728) 1 936 84 (74) 10 – Loss/(gain) on economic assumption adjustments net of discretionary margins 1 691 (529) 1 162 (169) (26) (195) – Loss on fair value changes on VitalityLife interest rate derivative 973 (199) 774 253 (48) 205 – Loss on fair value changes in the time value of swaption contract in VitalityLife 204 (42) 162 454 (87) 367 – Other 102 (12) 90 233 2 235 – Amortisation of intangible assets arising from business combinations 56 (12) 44 59 (13) 46 – Gain on disposal of intangible assets – – – 131 (29) 102 – Recognition of deferred tax assets on assessed losses not recognised in previous periods – – – – (14) (14) – Loss on fair value changes on foreign exchange contracts not designated as hedges – – – 2 (1) 1 – Increase or decrease in deferred tax balances resulting from use of different tax rates on items that were excluded from normalised headline earnings – – – – 59 59 Adjustments attributable to equity-accounted investments: – Amortisation of intangible assets arising from business combinations 46 – 46 41 – 41 Normalised headline earnings (basic and diluted) 7 678 5 816 Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 117 of 217 -- 117 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 37. CASH FLOW INFORMATION 37.1 Cash generated by operations R million Group 2023 Restated 1 Group 2022 Cash generated by operations Profit before taxation 7 372 6 944 Adjusted for: Investment income (4 587) (4 795) Realised (gains)/losses on financial assets (604) 3 574 Finance costs 1 941 1 658 Premiums, claims and investment charges for liabilities under investment contracts 3 836 5 315 Non-cash items: Allowance for expected credit losses 146 96 Allowance for expected credit losses on receivables 77 (79) Amortisation of intangibles from business combinations 56 59 Amortisation of software 1 319 1 252 Assets arising from contracts with customers 28 125 Cash flow hedge gains recycled to profit or loss (1) – Contract liabilities movement (321) 130 Deferred acquisition costs (42) (49) Depreciation 658 650 Derecognition and impairment of intangible assets 290 170 Derecognition and impairment of property and equipment 79 12 Finance (income)/charge on negative reserve funding (1 098) (1 368) Gain on disposal of intangible assets – (131) Impairment of goodwill 9 – Losses/(gains) from derivatives – (89) Losses/(gains) on dilution and disposal of equity-accounted investments 5 (33) Losses on disposal of property and equipment 8 3 Provision for employee benefits 43 37 Reversal of impairment of equity-accounted investment – (134) Share-based payment expenses – cash settled 95 93 Share-based payment expenses – equity settled 545 326 Share of profits from equity-accounted investments (515) (422) Transfer to assets under insurance contracts (5 860) (5 786) Transfer to assets under reinsurance contracts (135) (63) Transfer to liabilities under insurance contracts 3 992 6 738 Transfer to liabilities under reinsurance contracts 328 577 Economic assumptions adjustments net of discretionary margins 1 997 (169) Fair value adjustment to liabilities under investment contracts 5 572 (32) Translation differences (142) (166) Unearned premiums (305) (100) Unrealised (gains)/losses on investments at fair value through profit or loss (4 073) 2 860 Working capital changes2: Deposits from customers 3 451 1 897 Loans and advances to customers (897) (679) Loans and receivables including insurance receivables (2 297) (2 457) Trade and other payables (2 662) 4 979 Cash generated by operations 8 308 20 943 1 The comparative information has been restated. Refer to note 45 for detail. 2 The comparatives for Working capital changes have been restated to separately present R96 million of Allowance for expected credit losses and R1 368 million of Finance (income)/charge on negative reserve funding, in line with the current year presentation. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 118 of 217 -- 118 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 37. CASH FLOW INFORMATION continued 37.2 Taxation paid R million Group 2023 Group 2022 Balance at beginning of the year (307) 22 Taxation charged for the year in the income statement (2 052) (1 465) Adjustment for movement in deferred taxation 502 (68) Reallocation to separately disclosable items (115) 20 Translation differences 9 3 Balance at end of the year 124 307 Taxation paid (1 839) (1 181) 37.3 Movement in borrowings R million Group 2023 Group 2022 Balance at beginning of the year excluding bank overdraft 20 428 19 493 Leased assets acquired 260 138 Increase in borrowings 7 450 3 261 Raising fees capitalised (8) (3) Interest accrued on borrowings 1 767 1 463 Interest paid on borrowings (1 335) (1 188) Repayment of borrowings (8 607) (2 687) Modification to lease assets (81) (126) Translation differences 679 77 Balance at end of the year excluding bank overdraft 20 553 20 428 37.4 Interest paid R million Group 2023 Group 2022 Finance cost per the income statement 1 941 1 658 Adjusted for: – Lease liabilities interest accrual not paid (432) (426) – Other payables or interest accrual (8) 180 Interest paid 1 501 1 412 38. COMMITMENTS Capital commitments R million Group 2023 Group 2022 Capital expenditure approved but not contracted for at the reporting date as follows: – Property and equipment 106 41 – Intangible assets 397 120 – Developments costs for Discovery Bank 328 394 831 555 Also refer to Capital section of Directors’ report. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 119 of 217 -- 119 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 39. DIVIDENDS PER SHARE 39.1 Dividends per ordinary share Due to the uncertain and potentially volatile environment caused by the COVID-19 pandemic, Discovery did not pay out any ordinary dividends for the year ended 30 June 2023. 39.2 Dividends per preference share The dividends paid in 2023 totalled R69 million and comprised a final dividend of 382.26027 cents (305.80822 cents net of dividend withholding tax) per share paid on 26 September 2022 and an interim dividend of 476.91781 cents (381.53425 cents net of dividend withholding tax) per share paid on 13 March 2023. The dividends paid in 2022 totalled R56 million and comprised a final dividend of 347.12329 (277.69863 net of withholding tax) cents per share paid on 27 September 2021 and an interim dividend of 355.75342 (284.60274 net of withholding tax) cents per share paid on 14 March 2022. 40. CONTINGENCIES The Group is not exposed to material contingencies at 30 June 2023. 41. RELATED PARTIES 41.1 List of related parties as defined Subsidiaries, associates and joint ventures Details of subsidiaries directly and indirectly owned by Discovery Limited are contained in Company note 2. Details of the Discovery Group’s material associates and joint ventures are contained in note 11. Annexure A sets out details of all subsidiaries, associates and joint ventures held within the Discovery Group. Key management personnel Key management personnel have been defined as directors of Discovery Limited, Discovery Health Proprietary Limited and Discovery Life Limited, as these businesses constitute the majority of the Discovery Group. A list of the directors and prescribed officers of Discovery Limited can be found in the Directors’ report. Also refer to Annexure C for Directorate remuneration. To the extent specific transactions have occurred between Discovery and key management personnel, including close family members of key management, (as defined in IAS 24 Related Party Disclosures) the details are included in the aggregate disclosure contained below under key management and where significant, full details of all relationships and terms of the transactions are provided. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 120 of 217 -- 120 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 41. RELATED PARTIES continued 41.2 Transactions with related parties Cambridge Mobile Telematics Inc. (CMT) Discovery Insure paid fees monthly to CMT for the collation and interpretation of data and the translating of driving behaviour into scorable events. Fees paid for the year totalled R17 million (2022: R16 million). Key management personnel of Discovery Limited, families of key management (as defined in IAS 24) and entities significantly influenced or controlled by key management INSURANCE CONTRACTS Aggregated insured cover Premiums received Claims paid R’000 2023 2022 2023 2022 2023 2022 Life insurance 1 259 392 1 098 794 9 673 8 419 – – Short-term insurance 692 874 882 273 2 639 3 327 1 034 1 300 Short-term health insurance – – 16 12 – 7 INVESTMENT CONTRACTS Investment values Premiums received Withdrawal benefits Investment returns R’000 2023 2022 2023 2022 2023 2022 2023 2022 Investment contracts 81 237 86 526 7 359 13 461 2 959 11 902 9 344 6 778 VITALITY PROGRAMME Premiums received Amounts paid R’000 2023 2022 2023 2022 Vitality benefits 190 272 2 789 4 460 Key management personnel, their families (as defined in IAS 24) and entities significantly influenced or controlled by key management accrued 360 431 Discovery miles as part of the Vitality Programme for the year ended 30 June 2023 (2022: 444 903). DISCOVERY BANK Loans Savings Fees R’000 2023 2022 2023 2022 2023 2022 Discovery Bank 2 347 2 259 38 915 26 399 219 287 AGGREGATE SHAREHOLDING Aggregate shareholdings of key management personnel, their families (as defined in IAS 24) and entities significantly influenced or controlled by key management, in Discovery Limited as at 30 June 2023 was 77 576 400 ordinary shares (2022: 78 169 727 ordinary shares). ENTITIES SIGNIFICANTLY INFLUENCED OR CONTROLLED BY KEY MANAGEMENT In the prior year, sponsorship and enterprise development grants to the value of R0.7 million were made to organisations where members of key management personnel have significant influence. No transactions occurred in the current year. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 121 of 217 -- 121 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 41. RELATED PARTIES continued 41.3 Major customers and other Discovery entities not part of Discovery Group Discovery Health Medical Scheme Discovery Health administers Discovery Health Medical Scheme (DHMS) and provides managed care services for which it charges an administration fee and a managed healthcare fee respectively. These fees are determined on an annual basis and approved by the trustees of DHMS. The fees totalled R7 414 million (2022: R6 804 million). Discovery Health and its subsidiaries also provides wellness services to DHMS. The fees received for these services totalled R69 million (2022: R28 million). Discovery Third Party Recovery Services (DTPRS) paid DHMS R20 million (2022: R15 million) to purchase all the risks and rewards of ownership to the claims due from the Road Accident Fund up to 7 February 2023 (2022: 14 January 2022). DTPRS also provides a service to DHMS to recover all claims that are due from the Compensation for Occupational Injuries and Diseases. DTPRS received R16 million (2022: R20 million) for this service. DTPRS owes DHMS R2 million (2022: R6 million) at year-end. The Discovery Group offers the members of DHMS access to the Vitality programme. Discovery Vitality receives monthly contributions from DHMS members that have activated this benefit through various product integrations. The membership fees totalled R1 840 million for the year ended 30 June 2023 (2022: R1 686 million). DHMS owes the Discovery Group R775 million (2022: R724 million) at year-end. Discovery Central Services received rental income of R7 million (2022: R9 million) from DHMS for office space at 1 Discovery Place. Closed schemes Discovery Health administers the following restricted membership medical schemes: – Anglo Medical Scheme – Malcor Medical Scheme – Anglovaal Group Medical Scheme – Multichoice Medical Aid Scheme – Bankmed Medical Scheme – Netcare Medical Scheme – BMW Employees Medical Aid Society – Remedi Medical Scheme – Engen Medical Benefit Fund – Retail Medical Scheme – Glencore Medical Scheme – SAB Medical Aid Scheme (terminated effective 31 December 2023) – LA Health Medical Scheme – TFG Medical Scheme – Libcare Medical Scheme – Tsogo Sun Group Medical Scheme – Lonmin Medical Scheme – UKZN Medical Scheme Discovery Health charges these schemes administration fees which are determined on an annual basis and approved by the trustees of the respective closed schemes. The fees totalled R1 285 million (2022: R1 212 million). Discovery Health and its subsidiaries also provide wellness services to these schemes. The fees received for these services totalled R5 million (2022: R1 million). DTPRS did not purchase any risks and rewards of ownership for the claims due from the Road Accident Fund during the current financial year from any of the closed schemes. During the prior financial year DTPRS paid Bankmed R2 million. DTPRS also provides a service to some of the closed schemes to recover all claims that are due from the Compensation for Occupational Injuries and Diseases. DTPRS received R0.3 million (2022: R0.5 million) for this service. Discovery Vitality receives monthly contributions from the closed scheme members that have activated the Vitality Wellness programme through various product integrations. The membership fees totalled R95 million (2022: R86 million). Amounts due to the Discovery Group at year-end totalled R120 million (2022: R107 million). Discovery Franchises Discovery has established a network of 29 franchises in order to establish a national footprint for its products. Discovery has paid R254 million (2022: R229 million) in fees to the franchises. The franchises participate in the Acquisition Scheme (refer to note 32 for further details). During the year, R21 million (2022: R15 million) was accrued for in terms of this scheme. The Discovery Foundation The Discovery Foundation, which is an independent shareholder of Discovery, received contributions of R12 million (2022: R3 million) from Discovery in the current year. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 122 of 217 -- 122 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 41. RELATED PARTIES continued 41.3 Major customers and other Discovery entities not part of Discovery Group continued The Discovery Fund The Discovery Fund is a fund for sustainable non-governmental healthcare projects, especially in primary healthcare. These projects complement the delivery of primary and preventative care in the public sector and help to relieve the burden on state facilities. The Discovery Fund received contributions from Discovery of R23 million during the year (2022: R24 million). Discovery also paid a management fee of R2 million (2022: R2 million). Discovery Retirement Funds The Discovery Life Pension Umbrella Fund and the Discovery Life Provident Umbrella Fund (the Funds) are underwritten and administered by Discovery Life and are the retirement funds used by all the Discovery staff employed by the Group in South Africa. Contributions to the Funds by Discovery staff during the year amounted to R569 million (2022: R520 million). The Funds have R5 167 million (2022: R4 334 million) of assets under administration on behalf of Discovery staff – R4 974 million is invested in unit-linked insurance policies issued by Discovery Life (2022: R4 159 million) of which, R4 417 million (R3 732 million) of the unit- linked insurance policies are in turn linked to unit trusts managed by Discovery Life Collective Investments. 42. ACCELERATED REINSURANCE PREMIUMS – VITALITYHEALTH VitalityHealth uses quota share reinsurance treaties as one of the mechanisms to manage initial acquisition cost strain and underwriting experience risk. During the 2021 financial year, VitalityHealth modified certain of its existing quota share reinsurance treaties to adjust the repayment profile thereof. The modification resulted in VitalityHealth making additional repayments of GBP39.7 million (R823 million) in 2021, with GBP19.8 million of reduced repayments in the financial year ended 30 June 2022 and 2023 respectively. The net impact in profit or loss over the three-year period to 30 June 2023, is nil. 43. DIVIDENDS PAID DURING THE CURRENT AND PRIOR FINANCIAL YEAR B preference shares Payment date Nature and financial period Dividend declared per share 13 March 2023 Interim dividend Financial year 2023 476.91781 cents (381.53425 cents net of dividend withholding tax) 26 September 2022 Final dividend Financial year 2022 382.26027 cents (305.80822 cents net of dividend withholding tax) 14 March 2022 Interim dividend Financial year 2022 355.75342 (284.60274 cents net of dividend withholding tax) 27 September 2021 Final dividend Financial year 2021 347.12329 cents (277.69863 cents net of dividend withholding tax) Ordinary shares In the current and prior financial years, no ordinary dividends were paid as a result of the considerable uncertainty arising from the COVID-19 pandemic and macro-economic risks. The Group followed a conservative approach to capital management – the dividend was suspended, a strategy of reducing financial leverage was pursued, and further structures were implemented to ensure that the Group remained protected from movements in interest rates. Importantly, the pursuit of growth was not curtailed most notably on the build of Discovery Bank. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 123 of 217 -- 123 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 44. EVENTS AFTER REPORTING DATE B preference share cash dividend declaration The directors declared a final gross cash dividend of 548.49315 cents (438.79452 cents net of dividend withholding tax) per B preference share for the period 1 January 2023 to 30 June 2023, payable from the income reserves of the Company. A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt. The issued preference share capital at the declaration date is 8 million B preference shares. The salient dates for the dividend will be as follows Last day of trade to receive a dividend Tuesday, 19 September 2023 Shares commence trading “ex” dividend Wednesday, 20 September 2023 Record date Friday, 22 September 2023 Payment date Tuesday, 26 September 2023 B Preference share certificates may not be dematerialised or rematerialised between Wednesday, 20 September 2023 and Friday, 22 September 2023, both days inclusive. Ordinary share cash dividend declaration: The Board of Directors declared a final gross cash dividend of 110 cents (88 cents net of dividend withholding tax) per ordinary share, out of the income reserves of Discovery Limited. A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt. The number of ordinary shares in issue at the date of declaration is 673 146 417. The salient dates for the dividend will be as follows Last day of trade to receive a dividend Tuesday, 10 October 2023 Shares commence trading “ex” dividend Wednesday, 11 October 2023 Record date Friday, 13 October 2023 Payment date Monday, 16 October 2023 Share certificates may not be dematerialised or rematerialised between Wednesday, 11 October 2023 and Friday 13 October 2023, both days inclusive. VitalityHealth termination of reinsurance based financing quota share treaty VitalityHealth terminated all reinsurance based financing quota share treaties on 1 July 2023, after the end of the reporting period. The termination was in response to the impact of IFRS 17 on the Company’s strategy to utilise reinsurance based financing to offset the total strain of writing new business. VitalityHealth holds the following reinsurance related balances under IFRS 4 which would have a net impact of £245.96m on the assets position as at 30 June 2023: Debtors arising out of reinsurance operations amounting to a GBP246 million asset (ZAR5 901.5 million). Reinsurers share of insurance contract liabilities, including UPR, amounting to a GBP94 million asset (ZAR2 255 million); and Creditors arising out of reinsurance operations amounting to a GBP 94 million liability (ZAR2 255 million). The transition to IFRS 17 sees these assets and liabilities retrospectively revalued to nil upon implementation of IFRS 17 for the financial year commencing 1 July 2023. The termination on 1 July 2023, following the retrospective revaluation under IFRS 17, is expected to have a nil impact in the financial year commencing 1 July 2023. Notes to the Group annual financial statements continued for the year ended 30 June 2023 -- 124 of 217 -- 124 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Group annual financial statements continued for the year ended 30 June 2023 45. RESTATEMENT AS A RESULT OF PRIOR PERIOD ERROR – RECLASSIFICATION OF UNIT-LINKED INSURANCE CONTRACTS TO UNIT-LINKED INVESTMENT CONTRACTS During its IFRS 17 project, Discovery performed a full reassessment of all its insurance contracts to ensure the products were correctly included in the scope of the IFRS 17 project. This full assessment and evaluation was necessary to determine whether the contracts transfer significant insurance risk, a prerequisite for the contract to be recognised under IFRS 17. During the year, Discovery identified that certain offshore unit-linked policies do not transfer significant insurance risk as required under IFRS 17. Instead of being classified as unit-linked insurance contracts, these policies should have been accounted for as unit- linked investment contracts under IFRS 9 Financial Instruments. Discovery noted that the definition of significant insurance risk under IFRS 17 and IFRS 4 is the same. Accordingly, the change in treatment did not constitute a change because of the transition to IFRS 17. Instead, a correction would be required under IFRS 4 of the previously published information. The error was rectified as a reclassification from IFRS 4 to IFRS 9. Accordingly, these policies were reclassified from unit-linked insurance contracts as disclosed in note 18 Liabilities arising from insurance contracts to note 21 Investment contracts at fair value through profit or loss which includes unit-linked investment products. The unit priced component of the fair value measurement of the policyholder liability remained unchanged. The negative rand reserve that was previously recognised under IFRS 4 was derecognised. The incremental costs to obtain the contracts have also been recognised accordingly in note 9A Assets arising from contracts with customers and contract liabilities. The change in presentation of the unit-linked policies also affected the Income statement but did not affect the previously reported earnings. The tables below summarise the restatement’s impact on the Statement of financial position and the Income statement. STATEMENT OF FINANCIAL POSITION R million Group 30 June 2021 (previously reported) Correction Group 1 July 2021 (as restated) Assets arising from contracts with customers 1 248 127 1 375 Liabilities arising from insurance contracts (100 977) 936 (100 041) Investment contracts at fair value through profit or loss (32 291) (1 063) (33 354) STATEMENT OF FINANCIAL POSITION R million Group 30 June 2022 (previously reported) Correction Group 30 June 2022 (as restated) Assets arising from contracts with customers 1 549 143 1 692 Liabilities arising from insurance contracts (109 200) 1 133 (108 067) Investment contracts at fair value through profit or loss (37 361) (1 276) (38 637) INCOME STATEMENT R million Group 30 June 2022 (previously reported) Correction Group 30 June 2022 (as restated) Insurance premium revenue 58 782 (470) 58 312 Claims and policyholders’ benefits (38 207) 185 (38 022) Acquisition cost (4 774) 16 (4 758) Net transfer to/from assets and liabilities under insurance contracts (6 935) 197 (6 738) Fair value adjustment to liabilities under investment contracts (40) 72 32 Profit from operations 7 858 – 7 858 The restatement has had no change to operating, investing, and financing cash flows and no changes to the Statement of changes in equity. There is no impact on Discovery’s Profit from operations; consequently, basic or diluted earnings per share remain unchanged. -- 125 of 217 -- DISCOVERY COMPANY ANNUAL FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2023 -- 126 of 217 -- 126 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 R million Notes Company 2023 Company 2022 Assets Deferred tax asset 12 5 82 Investments in subsidiaries 2 30 579 29 027 Investment in associate 3 2 584 2 584 Financial assets – Loans to subsidiaries 5 9 614 8 397 – Loans to BEE partners 6 219 186 – Other receivables 7 229 185 – Derivatives at fair value through profit or loss 4 59 18 Cash and cash equivalents 19.5 282 607 Total assets 43 571 41 086 Equity Capital and reserves Ordinary share capital and share premium 8.1 10 467 10 293 Perpetual preference share capital 8.2 779 779 Other reserves 1 601 1 129 Retained earnings 11 315 8 003 Total equity 24 162 20 204 Liabilities Financial liabilities – Borrowings at amortised cost 9 9 948 10 584 – Financial guarantee contracts 20 12 25 – Trade and other payables 11 9 403 10 216 – Derivatives at fair value through profit or loss 10 1 56 Current tax liability 19.2 45 1 Total liabilities 19 409 20 882 Total liabilities and equity 43 571 41 086 Company statement of financial position at 30 June 2023 -- 127 of 217 -- 127 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 R million Notes Company 2023 Company 2022 Investment income 13 4 056 1 049 At amortised cost interest income, using the effective interest rate 863 688 Dividends received from subsidiaries 3 193 361 Other income 14 36 57 Net fair value losses on financial instruments at fair value through profit or loss 15 (2) (2) Marketing and administration expenses 16 (16) (19) Movement in allowance for expected credit losses 17 8 * Profit from operations 4 082 1 085 Finance costs (943) (937) Foreign exchange gains 386 16 Profit before tax 3 525 164 Taxation 18 (124) (31) Profit for the year 3 401 133 Attributable to: – Ordinary shareholders 3 332 77 – Preference shareholders 69 56 3 401 133 * Amount is less than R500 000. Company Income statement for the year ended 30 June 2023 R million Company 2023 Company 2022 Profit for the year 3 401 133 Items that are or may be reclassified subsequently to profit or loss: Cash flow hedges 80 295 – Unrealised gains 76 295 – Tax on unrealised gains – – – Losses recycled to profit or loss 4 – – Tax on recycled losses – – Other comprehensive income for the year, net of tax 80 295 Total comprehensive income for the year 3 481 428 Attributable to: – Ordinary shareholders 3 412 372 – Preference shareholders 69 56 3 481 428 Company statement of other comprehensive income for the year ended 30 June 2023 -- 128 of 217 -- 128 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 R million Notes Company 2023 Company 2022 Cash flow from operating activities 1 600 492 Cash generated by operations 19.1 1 864 1 067 Dividends received 425 237 Interest received 19.6 231 102 Interest paid (917) (914) Taxation paid 19.2 (3) * Cash flow from investing activities (1 713) (2 078) Increase investment in subsidiaries 19.3 (1 493) (1 559) Increase investment in associate – (1 487) Increase in loans granted to subsidiaries 5 (4 686) (1 789) Proceeds from settlement of subsidiary loans 5 4 466 2 757 Cash flow from financing activities (230) 2 106 Proceeds from treasury shares * 9 Proceeds from issuance of ordinary shares 514 443 Proceeds from long-term borrowings 19.4 2 650 2 410 Repayment of long-term borrowings 19.4 (3 304) (700) Premium paid on interest rate swap (21) – Dividends paid to preference shareholders (69) (56) Net (decrease)/increase in cash and cash equivalents (343) 520 Cash and cash equivalents at beginning of the year 607 93 Exchange gains/(losses) on cash and cash equivalents 18 (6) Cash and cash equivalents at end of the year 19.5 282 607 * Amount is less than R500 000. Company statement of cash flows for the year ended 30 June 2023 -- 129 of 217 -- 129 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Company R million Share capital and share premium Preference share capital Hedging reserve Share- based payment reserve Retained earnings Total Year ended 30 June 2022 At beginning of the year 10 281 779 (334) 844 7 926 19 496 Total comprehensive income for the year – 56 295 – 77 428 Profit for the year – 56 – – 77 133 Other comprehensive income – – 295 – – 295 Transactions with owners 12 (56) – 324 – 280 Issue of shares 443 – – – – 443 Increase in treasury shares (443) – – – – (443) Delivery of treasury shares 3 – – (3) – – Proceeds from treasury shares 9 – – – – 9 Employee share option schemes: – Value of employee services – – – 327 – 327 Dividends paid to preference shareholders – (56) – – – (56) Balance at 30 June 2022 10 293 779 (39) 1 168 8 003 20 204 Year ended 30 June 2023 At beginning of the year 10 293 779 (39) 1 168 8 003 20 204 Total comprehensive income for the year – 69 80 – 3 332 3 481 Profit for the year – 69 – – 3 332 3 401 Other comprehensive income – – 80 – – 80 Transactions with owners 174 (69) – 392 (20) 477 Issue of shares 514 – – – – 514 Increase in treasury shares (514) – – – – (514) Delivery of treasury shares 171 – – (171) – – Proceeds from treasury shares 3 – – (3) – – Employee share option schemes: – Value of employee services – – – 546 – 546 Transfer of vested shares – – – 20 (20) – Dividends paid to preference shareholders – (69) – – – (69) Balance at 30 June 2023 10 467 779 41 1 560 11 315 24 162 Company statement of changes in equity for the year ended 30 June 2023 -- 130 of 217 -- 130 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The principal accounting policies applied in the preparation of these separate financial statements are consistent with those set out in Annexure B. In addition to those policies, the following policies apply specifically to these separate financial statements. 1. Investment in subsidiaries and associates The company is directly and indirectly the holding company of subsidiaries and investments as set out in Annexure A. Investments in subsidiaries and associates are accounted for at cost less impairment. Cost includes the fair value of any asset or liability resulting from a contingent consideration arrangement on initial recognition. Discovery assesses at each reporting date whether there is objective evidence that the investment in subsidiaries and associates are impaired. If such evidence of impairment exists, Discovery calculates the amount of impairment as the difference between the recoverable amount of the investment and its carrying value. 1.1 Common control transactions Common control transactions refer to business combinations in which all the combining entities or businesses are ultimately controlled by the same party (or parties) before and after the combination. This includes businesses which are associates and joint ventures. Discovery Limited applies book value accounting to account for common control transactions. Discovery Limited will dispose of its investment at the carrying amount. Any difference between the consideration received and the carrying amount of the investment disposed of is recognised as an equity transaction with shareholders in equity. No gain or loss is recognised in profit or loss on disposal. 2. Financial guarantee contracts The Company accounts for financial guarantee contracts (FGCs) in accordance with IFRS 9 Financial Instruments (IFRS 9). The Company issues FGCs to assist in securing funding for its subsidiaries. FGCs are contracts which require the Company, as the issuer of the contract, to make specified payments to reimburse the holder for a loss that the holder incurs because the specified debtor fails to make payment when it is due under the original or modified terms of the debt instrument. The Company measures the FGC: Initially at fair value; and Subsequently at the higher of: – The amount of expected credit losses determined under IFRS 9 (calculation 1); and – The amount initially recognised less, when appropriate, the cumulative amount of income recognised under the principles of IFRS 15 Revenue from Contracts with Customers (calculation 2). 2.1 Initial recognition In instances where the Company issues FGCs for the debt of a related entity in the Discovery Group, the Company determines the fair value. These FGCs are seen as transactions in a capacity as shareholder and are treated as capital contributions. In some instances, the other Discovery Group entity can also pay a premium to the issuer of the FGCs. The Company then determines if the price represents the fair value, or whether there is still an additional cost of the FGC that the Company should recognise. In the instance where the Company does not receive all the premiums upfront, it recognises the FGC using a net approach. The net approach requires that the Company presents the financial guarantee as its fair value less all future premiums. COMPANY ACCOUNTING POLICIES for the year ended 30 June 2023 -- 131 of 217 -- 131 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 COMPANY ACCOUNTING POLICIES continued for the year ended 30 June 2023 2. Financial guarantee contracts continued 2.2 Subsequent measurement The Company recognises financial guarantee fee income as follows: Amortises the fair value recognised on initial recognition over the period that the FGC is outstanding, being generally the period of the underlying debt; Recognises any premiums received for issuing the FGC as financial guarantee fee income; and Where the Company has applied the net approach, the Company adjusts for the premiums subsequently received to ensure it takes into account all premiums in using calculation 2. The Company calculates the lifetime expected credit losses for purposes of calculation 1. Where the outcome is such that calculation 1 is more than calculation 2, differences are recognised and presented as part of expected credit losses. Where the outcome is such that calculation 2 is more than calculation 1, no adjustments are required. Any previously recognised expected credit losses can be reversed, but limited to the total value previously recognised. 2.3 Derecognition The Company derecognises FGCs when the FGC is extinguished, expires or the underlying debt is extinguished. At the date of derecognition: Where the FGC is extinguished in exchange for a new FGC to the same holder and in respect of the same guaranteed entity, the FGC derecognised is seen as compensation for the new FGC; or In all other instances, the FGC is derecognised with an associated gain or loss in profit or loss. 3. Share based payments Also refer to Accounting Policies 17 Employee benefits set out in Annexure B and Group note 32 Share-based payments and long- term incentives. Two of the schemes that Discovery operates, namely the BEE staff share trust and Discovery long-term incentive plan (LTIP) (equity settled), are both equity-settled share-based payment arrangements in accordance with the requirements of IFRS 2 Share-based Payment. In these schemes, Discovery Limited grants the awards to the employees within the Discovery Group of entities. Discovery classifies the share-based payment transaction according to whether the entity has the obligation to settle. As it is Discovery Limited’s shares being awarded to employees, Discovery classifies the transaction as equity-settled. Under IFRS, Discovery does not consider any repayment or recharge arrangements in determining the classification of these group share-based payments. Any recharge payments Discovery receives from its subsidiaries is treated as a return on capital from the subsidiary. Any excess of recharge above the carrying amount of investment in subsidiary is recognised immediately as dividend income. Discovery manages two share trusts. Discovery treats the share trusts set up to facilitate the share-based payment arrangements as an agent, i.e., an extension of Discovery Limited. In other words, shares held by the trust is treated as treasury shares of Discovery Limited. BEE Staff Share Trust: Shares and option to acquire shares have been allocated to senior black employees based on level of seniority and length of past service. The trust will hold shares until the date of vesting of the shares to the employee or exercise date of the option. Discovery LTIP Trust: Participants will receive Discovery Limited shares subject to performance criteria and if the participant is employed on each vesting date. The trust will hold shares until the date of vesting of the shares to the employee. Per the LTIP Trust deed, the LTIP Trust recharges the costs of the shares acquired for the employees to the relevant subsidiary whose employees are awarded the shares. The recharge is upfront. -- 132 of 217 -- 132 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Company annual financial statements for the year ended 30 June 2023 1. MANAGEMENT OF FINANCIAL RISK The Company’s activities expose it to a variety of financial risks. Financial risks include market risk, credit risk and liquidity risk. Refer to Group note 3 Management of financial risk for a detailed explanation of financial risks and how they are managed. 1.1 Interest rate risk Sensitivity to changes in interest rates is relevant to financial assets or liabilities bearing floating interest rates due to the risk that future cash flows fluctuate. However, sensitivity will also be relevant to fixed-rated financial assets and financial liabilities that are re-measured to fair value. The table below details the specific interest rate risk that the Company is exposed to: Company R million Carrying amount Fixed Floating Non-interest bearing At 30 June 2023 Derivative financial instruments at fair value: – Used as cash flow hedges1 59 59 – – Loans to subsidiaries 9 614 2 453 7 161 – Loans to BEE partners 219 – 193 26 Other receivables 226 – – 226 Cash and cash equivalents 282 – 282 – Total financial assets 10 400 2 512 7 636 252 Borrowings at amortised cost 9 948 4 382 5 566 – Derivative financial instruments at fair value: – Used as cash flow hedges 1 1 1 – – Financial guarantee contracts 12 – – 12 Trade and other payables 9 403 – – 9 403 Total financial liabilities 19 364 4 383 5 566 9 415 At 30 June 2022 Derivative financial instruments at fair value: – Not designated as hedging instruments 1 – – 1 – Used as cash flow hedges 1 17 17 – – Loans to subsidiaries 8 397 2 216 6 181 – Loans to BEE partners 186 – 184 2 Other receivables 176 – – 176 Cash and cash equivalents 607 – 607 – Total financial assets 9 384 2 233 6 972 179 Borrowings at amortised cost 10 584 3 826 6 758 – Derivative financial instruments at fair value: – Used as cash flow hedges 1 56 56 – – Financial guarantee contracts 25 – – 25 Trade and other payables 10 216 – – 10 216 Total financial liabilities 20 881 3 882 6 758 10 241 1 For further information on the use of interest rate swaps to manage the interest rate risk of Discovery Limited, refer to the following notes in the Group financials, which equally apply to Discovery Limited: – Note 3.4 Shareholder financial assets and liabilities, "Borrowings at amortised cost and related hedges", page 61. For those financial assets at amortised cost, a change of 1% in the interest rate would result in an increase/decrease of R80 million (2022: R69 million) in interest income. The sensitivity is based on the assumption that the interest rate has increased/decreased by 1% with all other variables held constant. Borrowings at amortised cost include facilities at floating interest rates, which expose Discovery Limited to cash flow interest rate risk. This risk has been managed by using floating-to-fixed interest rate swaps. These interest rate swaps have the economic effect of converting the borrowings from floating to fixed rates. Interest is payable quarterly in arrears, with capital repayable on maturity. The hedge ratio is 1:1. For borrowings at floating interest rates that have not been hedged, a change of 1% in the interest rate would result in an increase of R4 million (2022: R6 million) in finance costs. The sensitivity is based on the assumption that the interest rate has increased/decreased by 1% with all other variables held constant. -- 133 of 217 -- 133 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Company annual financial statements continued for the year ended 30 June 2023 1. MANAGEMENT OF FINANCIAL RISK continued 1.2 Currency risk The Company operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the US dollar and the UK pound. Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities. The following table segregates the currency exposure by major currency: Company R million Total Rand GBP USD At 30 June 2023 Derivative financial instruments at fair value: – Used as cash flow hedges 59 59 – – Loans to subsidiaries 9 614 7 456 2 158 – Loans to BEE partners 219 219 – – Other receivables 226 191 35 – Cash and cash equivalents 282 39 243 * Total financial assets 10 400 7 964 2 436 * Borrowings at amortised cost 9 948 9 948 – – Derivative financial instruments at fair value: – Used as cash flow hedges 1 1 – – Financial guarantee contracts 12 12 – – Other payables 9 403 9 400 3 – Total financial liabilities 19 364 19 361 3 – At 30 June 2022 Derivative financial instruments at fair value: – Not designated as hedging instruments 1 1 – – – Used as cash flow hedges 17 17 – – Loans to subsidiaries 8 397 6 621 1 776 – Loans to BEE partners 186 186 – – Other receivables 176 143 33 – Cash and cash equivalents 607 526 59 22 Total financial assets 9 384 7 494 1 868 22 Borrowings at amortised cost 10 584 10 584 – – Derivative financial instruments at fair value: – Used as cash flow hedges 56 56 – – Financial guarantee contracts 25 17 8 – Other payables 10 216 10 216 * – Total financial liabilities 20 881 20 873 8 – * Amount is less than R500 000. A 10% increase on respective foreign exchange rates of GBP: ZAR would result in additional gains of R226 million (2022: R186 million), or in the case of decrease, a loss of R226 million (R186 million), recognised in profit or loss. 1.3 Credit risk Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The credit risk associated with Cash and cash equivalents is managed by monitoring exposure to external financial institutions against limits set by the CCIC. -- 134 of 217 -- 134 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Company annual financial statements continued for the year ended 30 June 2023 1. MANAGEMENT OF FINANCIAL RISK continued 1.3 Credit risk continued Credit exposure for debt instruments, money market instruments and cash and cash equivalents The following table provides information regarding the credit risk exposure categorised as set out in the Group note 3 Management of financial risk. These assets are all in stage 1 for purposes of determining expected credit losses. Company R million Total Aa1-3 Baa1-3 Ba1-3 B1-3 Internally rated/ assessed At 30 June 2023 Derivative financial instruments at fair value: – Used as cash flow hedges 59 – – 59 – – Loans to subsidiaries 9 614 – 3 756 5 858 – – Loans to BEE partners 219 – – – – 219 Other receivables 226 – 178 48 – – Cash and cash equivalents 282 1 – 281 – – Total financial assets 10 400 1 3 934 6 246 – 219 Financial guarantee contracts 1 12 – – 12 – – At 30 June 2022 Derivative financial instruments at fair value: – Not designated as hedging instruments 1 – – 1 – – – Used as cash flow hedges 17 – – 17 – – Loans to subsidiaries 8 397 – – 8 397 – – Loans to BEE partners 186 – – – – 186 Other receivables 176 – – 158 18 – Cash and cash equivalents 607 – – 607 – – Total financial assets 9 384 – – 9 180 18 186 Financial guarantee contracts 1 25 – – 25 – – 1 Financial guarantee contracts have been included and comparative information has been restated. Long-term credit ratings were used in the credit risk analysis above. Refer to Group note 3 Management of financial risk, ’Discovery’s approach in monitoring credit risk’ for a summary of how credit ratings are aligned to external credit ratings. Loans to BEE partners are not assigned formal credit ratings externally or internally. These loans are structured considering creditworthiness of the individual partners, and the purpose of the BEE relationship. These loans are managed and monitored on an individual basis, and ECL is accordingly recognised on an individual basis using management’s best estimate. Discovery Limited has issued financial guarantees as security for loans incurred by subsidiaries in the group. The maximum credit risk that Discovery Limited is exposed to on these contracts is the carrying amount, which amounted to R3 940 million (2022: R6 917 million). For majority of the issued financial guarantees, Discovery Limited is co-guarantor with Discovery Health (Pty) Ltd and Discovery Vitality (Pty) Ltd. Loans to subsidiaries and financial guarantee contracts do not have external credit ratings. Credit ratings are internally assigned using the RW rating scale. Prior period Loans to subsidiaries have been restated to align to the new RW ratings. -- 135 of 217 -- 135 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Company annual financial statements continued for the year ended 30 June 2023 1. MANAGEMENT OF FINANCIAL RISK continued 1.4 Liquidity risk Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities due to insufficient cash available to meet commitments as and when due. Liquidity is managed through the Group Treasury Management function, which considers the liquidity position at the respective Company level as well as the overall Group position. As part of this assessment, the liquidity position in each entity is optimised and takes account of available credit facilities to the Group within the Board approved maximum financial leverage ratio. The Company is in the process of refinancing short-term borrowings as part of its ongoing debt capital management activities. The group structure is conducive for the Company to receive dividends and other forms of funding from underlying subsidiaries to enable it to meet its obligations. Cash flow forecasting is performed by the Company and liquidity requirements are monitored to ensure it has sufficient cash to meet operational needs. Such forecasting takes into consideration the Company’s debt financing plans and covenant compliance. Cash held by the Company is invested in interest-bearing accounts, term deposits and money market deposits with appropriate maturities or sufficient liquidity to provide headroom as determined by the above-mentioned forecasts. At the reporting date, the Company had money market funds and cash and cash equivalents of R282 million (2022: R607 million). The table below analyses Discovery Limited’s financial liabilities into relevant maturity groupings based on the remaining period at the reporting date to the contractual maturity date. These amounts do not agree to the Statement of financial position as these are the undiscounted contractual payments. Company R million Total <1 year 1 – 2 years 3 – 5 years 6 – 10 years At 30 June 2023 Borrowings 12 187 1 425 5 429 5 085 248 Derivative financial instruments: – Used as cash flow hedges 59 5 22 32 – Trade and other payables 9 403 9 403 – – – 21 649 10 833 5 451 5 117 248 Financial guarantees 3 940 3 940 – – – 25 589 14 773 5 451 5 117 248 At 30 June 2022 Borrowings 12 416 4 013 1 036 7 110 257 Derivative financial instruments: – Used as cash flow hedges 311 117 90 104 – Trade and other payables 10 216 10 216 – – – 22 943 14 346 1 126 7 214 257 Financial guarantees 6 917 6 917 – – – 29 860 21 263 1 126 7 214 257 1.5 Fair value estimation Discovery Limited’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has three levels that reflect the significance of the inputs used in measuring fair value. Refer to Group note 3.6 Fair value estimation for more details on the valuation techniques. These are as follows: Level 1: includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical financial instruments. An active market is a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide information on an ongoing basis. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency and those prices represent actual and regularly occurring market transactions on an arm’s length basis. Level 2: includes financial instruments that are valued using techniques based significantly on observable market data. Instruments in this category are valued using: (a) Quoted prices for similar instruments or identical instruments in markets which are not considered to be active; or (b) Valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on observable market data. Level 3: includes financial instruments that are valued using valuation techniques that incorporate information other than observable market data and where at least one input (which could have a significant effect on instrument’s valuation) cannot be based on observable market data. -- 136 of 217 -- 136 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Company annual financial statements continued for the year ended 30 June 2023 1. MANAGEMENT OF FINANCIAL RISK continued 1.5 Fair value estimation continued Company R million Total Level 1 Level 2 Level 3 At 30 June 2023 Derivative financial instruments at fair value: – Used as cash flow hedges 59 – 59 – Total financial assets 59 – 59 – Derivative financial instruments at fair value: – Used as cash flow hedges 1 – 1 – Total financial liabilities 1 – 1 – At 30 June 2022 Derivative financial instruments at fair value: – not designated as hedging instruments 1 – 1 – – Used as cash flow hedges 17 – 17 – Total financial assets 18 – 18 – Derivative financial instruments at fair value: – Used as cash flow hedges 56 – 56 – Total financial liabilities 56 – 56 – 2. INVESTMENTS IN SUBSIDIARIES Issued ordinary capital R million Effective percentage holding % Investment in subsidiaries3 R million 2023 2022 2023 2022 2023 2022 Cogence Proprietary Limited * * 100 100 * * Discovery Bank Holdings Limited 9 699 8 771 100 100 9 963 8 996 Discovery Connect Distribution Services Proprietary Limited 555 555 100 100 546 551 Discovery Central Services Proprietary Limited * * 100 100 34 34 Discovery Finance Company Europe Limited1 393 393 100 100 394 394 Discovery Group Europe Limited 1 14 172 14 080 100 100 14 159 14 063 Discovery Health Proprietary Limited 271 271 100 100 253 216 Discovery Insure Limited 2 552 2 402 100 100 1 588 1 442 Discovery Life Limited 1 416 1 416 100 100 1 502 1 486 Discovery Life Collective Investments Proprietary Limited 15 15 100 100 15 15 Discovery Life Investment Services Proprietary Limited 203 203 100 100 204 203 Discovery Mauritius Asset Management 1 1 100 100 1 1 Discovery Vitality Proprietary Limited * * 100 100 – – Discovery Partner Markets Asia Private Limited 2 211 211 100 100 113 113 Vitality Group International Incorporated 4 3 643 3 319 100 100 1 807 1 513 Balance at the end of the year 30 579 29 027 * Amount is less than R500 000. 1 Incorporated in England and Wales. 2 Incorporated in Singapore. 3 Investments in subsidiaries include cost less impairments plus the value of share options issued to subsidiary staff. 4 Incorporated in the United States of America. Refer to Company note 19.3 for a detailed movement analysis. -- 137 of 217 -- 137 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Company annual financial statements continued for the year ended 30 June 2023 3. INVESTMENT IN ASSOCIATE R million % ownership interest Company 2023 Company 2022 2023 2022 Investment at cost: – Ping An Health Insurance Company in China, Limited 24.99% 24.99% 2 584 2 584 Refer to Group note 11 for disclosure of the investment in associate. 4. DERIVATIVES AT FAIR VALUE THROUGH PROFIT OR LOSS R million Company 2023 Company 2022 Interest rate derivatives – used as cash flow hedges1 59 17 Derivatives not designated as hedging instrument – 1 Total 59 18 Current 5 1 Non-current 54 17 Total 59 18 1 The interest rate derivative portfolio consists of both interest rate swaps and interest rate caps. Refer to the Group note 3.4.1 for a detailed description of the derivative financial instruments listed above. 5. LOANS TO SUBSIDIARIES 1 R million Company 2023 Company 2022 Discovery Group Europe Limited 2 639 2 270 Discovery Health Proprietary Limited 3 758 3 410 Discovery Central Services Proprietary Limited 3 225 2 725 Total gross loans 9 622 8 405 Less: IFRS9 Expected credit losses (ECL)2 (8) (8) Total net loans 9 614 8 397 Current 3 225 3 214 Non-current 6 389 5 183 9 614 8 397 Balance at beginning of the year 8 397 8 758 Additional loan granted 4 686 1 789 Repayment of loans – capital portion (4 466) (2 757) – interest portion (198) (93) Interest receivable 836 676 Movement in allowance for expected credit losses – 1 Exchange differences 359 23 Balance at end of the year 9 614 8 397 1 All loans to subsidiaries are measured at amortised cost, which approximates to fair value, as the loans bear interest at market related terms 2 The information is separately disclosed in the current period, and the comparative information has been restated accordingly. -- 138 of 217 -- 138 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Company annual financial statements continued for the year ended 30 June 2023 5. LOANS TO SUBSIDIARIES continued GBP denominated Discovery Limited has granted GBP denominated loans to Discovery Group Europe Limited, the terms are as follows: Carrying value Original loan value GBP million Variable rate Capital repayment and maturity date Company 2023 Company 2022 R million GBP million R million GBP million 11.9 Bank of England base rate + 400bps At maturity – 31 July 2025 411 17.2 319 16.0 24.7 Bank of England base rate + 600bps At maturity – 1 April 2027 591 24.6 493 24.6 6.0 Bank of England base rate + 600bps At maturity – 1 November 2027 144 6.0 120 6.0 10.5 Bank of England base rate + 600bps At maturity – 1 June 2028 252 10.5 210 10.5 9.0 Bank of England base rate + 600bps At maturity – 21 August 2028 216 9.0 180 9.0 6.5 Bank of England base rate + 600bps At maturity – 24 November 2028 156 6.5 130 6.5 2.8 Bank of England base rate + 615bps At maturity – 1 March 2029 67 2.8 56 2.8 7.1 Bank of England base rate + 615bps At maturity – 1 June 2029 170 7.1 142 7.1 6.5 Bank of England base rate + 615bps At maturity – 31 July 2029 156 6.5 130 6.5 2 163 90.2 1 780 89.0 ZAR denominated Discovery Limited has granted ZAR denominated loans to subsidiaries, the terms are as follows: Carrying value Rand million Subsidiary the loan was granted to Original loan value R million Variable rate Capital repayment and maturity date Company 2023 Company 2022 Discovery Group Europe Limited 268 3-month Jibar + 200bps At maturity – 31 July 2030 476 489 Discovery Health Proprietary Limited1 727 3-month Jibar + 240bps At maturity – 30 June 2026 1 304 1 194 Discovery Health Proprietary Limited1,2 93 At maturity – 30 September 2026 185 167 Discovery Health Proprietary Limited1,2 282 At maturity – 30 September 2026 561 507 Discovery Health Proprietary Limited1,2 235 At maturity – 15 December 2026 458 414 Discovery Health Proprietary Limited1,2 173 At maturity – 28 March 2027 328 296 Discovery Health Proprietary Limited1,2 288 At maturity – 30 June 2027 531 480 Discovery Health Proprietary Limited1,2 212 At maturity – 3 July 2027 391 353 Discovery Central Services Proprietary Limited 2 932 South African prime lending rate On demand 3 225 2 725 7 459 6 625 1 Interest payable quarterly in arrears, with the option available for Discovery Health to capitalise the interest to the value of the loan. 2 Interest accrues at a fixed rate of 10.2% per annum. For the loans to Discovery Group Europe Limited, interest of R208 million was earned in respect of these loans in the current financial year (2022: R136 million) and R359 million foreign exchange gain was recognised in profit and loss (2022: R23 million gain). -- 139 of 217 -- 139 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Company annual financial statements continued for the year ended 30 June 2023 6. LOANS TO BEE PARTNERS 1 R million Company 2023 Company 2022 Balance at the beginning of the year 186 149 Interest receivable 15 9 Additional loan granted 39 35 Repayment of loans (21) (7) Balance at the end of the year 219 186 Current 219 186 Balance at the end of the year 219 186 1 All loans to BEE partners are measured at amortised cost, which approximates to fair value. These loans are due from Mohau Equity Partners. R193 million (2022: R184 million) is a bridge loan that accrues interest at prime rate less 2%. R26 million (2022: R2 million) is an interest-free loan to provide empowerment financing towards a newly formed brokerage. There are no repayment terms for these loans. 7. OTHER RECEIVABLES R million Company 2023 Company 2022 Intercompany receivables 226 176 Prepayments 3 9 Less allowance for credit losses * * Balance at the end of the year 229 185 Intercompany receivables include: Cogence Proprietary Limited 7 4 Discovery Bank Limited – 29 Discovery Connect Distribution Services Proprietary Limited – 6 Discovery Finance Company Europe Limited 32 14 Discovery Group Europe Limited – 3 Discovery Holdings Europe Limited 3 19 Discovery Insure Limited – 43 Discovery Life Investment Services Proprietary Limited 93 – Discovery Vitality Proprietary Limited 85 58 Vitality Corporate Services Limited 6 – Balance at the end of the year 226 176 * Amount is less than R500 000. 8. SHARE CAPITAL AND SHARE PREMIUM 8.1 Ordinary share capital and share premium Issued Treasury Shares R million Share capital Share premium BEE Share Trust Long-term incentive plan Total Outstanding Issued At 1 July 2021 1 11 237 (51) (906) 10 281 Share movements: – shares issued * 443 – – 443 – treasury shares delivered – 8 4 – 12 – treasury shares purchased – – – (443) (443) At 30 June 2022 1 11 688 (47) (1 349) 10 293 Share movements: – shares issued * 514 – – 514 – treasury shares delivered – 171 3 – 174 – treasury shares purchased – – – (514) (514) At 30 June 2023 1 12 373 (44) (1 863) 10 467 * Amount is less than R500 000. -- 140 of 217 -- 140 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Company annual financial statements continued for the year ended 30 June 2023 8. SHARE CAPITAL AND SHARE PREMIUM continued 8.1 Ordinary share capital and share premium continued Treasury Shares Number of shares Company BEE Share Trust Long-term incentive plan Total Outstanding Issued At 1 July 2021 665 768 601 (805 961) (7 477 865) 657 484 775 Share movements: – shares issued 3 194 870 – – 3 194 870 – treasury shares delivered – 152 104 – 152 104 – treasury shares purchased – – (3 194 870) (3 194 870) At 30 June 2022 668 963 471 (653 857) (10 672 735) 657 636 879 Share movements: – shares issued 4 182 946 – – 4 182 946 – treasury shares delivered – 64 714 1 402 275 1 466 989 – treasury shares purchased – – (4 182 946) (4 182 946) At 30 June 2023 673 146 417 (589 143) (13 453 406) 659 103 868 The total authorised number of ordinary shares is 1 billion (2022: 1 billion), with a par value of 0.1 cent per share. 8.2 Preference share capital R million Company 2023 Company 2022 Authorised 40 000 000 A no par value preference shares – – 20 000 000 B preference shares of R100 each 2 000 2 000 20 000 000 C no par value preference shares – – 2 000 2 000 Issued 8 000 000 B preference shares of R100 each 800 800 Share issue costs (21) (21) 779 779 The preference shares are non-compulsory, non-cumulative, non-participating, non-convertible, voluntarily redeemable (at option of Discovery Limited) preference shares and were issued at a coupon rate of 85% of prime rate. With the introduction of dividend withholding tax on 1 April 2012, the coupon rate on the preference shares was increased to 100% of the prime rate. 9. BORROWINGS AT AMORTISED COST R million Company 2023 Company 2022 Borrowings from banks1 9 948 10 584 Current 587 3 312 Non-current 9 361 7 272 Balance at the end of the year 9 948 10 584 1 Financial guarantees were provide by Discovery Health Proprietary Limited, Discovery Vitality Proprietary Limited and Discovery Central Services Proprietary Limited has been given to secure these borrowings. The borrowings were acquired for general corporate purposes in order to fund the various growth initiatives within the Group. Credit rating In January 2023 Moody’s Investors Service (“Moody’s”) reaffirmed Discovery Limited’s Global scale long-term issuer rating of Ba3 and the national scale long-term issuer rating at A1.za. The outlook was unchanged as stable, aligned to the outlook of the country. -- 141 of 217 -- 141 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Company annual financial statements continued for the year ended 30 June 2023 9. BORROWINGS AT AMORTISED COST continued Carrying value R million Facility amount R million Variable rate Interest per annum Capital repayment and maturity date Company 2023 Company 2022 Listed DMTN4 500 3-month Jibar + 161bps 8.095%1, 3 At maturity – 21 November 2022 – 503 500 3-month Jibar + 205bps 4.253%1, 3 At maturity – 21 August 2023 505 503 200 – 10.46%2 At maturity – 21 November 2024 202 202 800 3-month Jibar + 191bps 8.4% 1, 3 At maturity – 21 November 2024 808 805 1 200 3-month Jibar + 191bps 7.295%1, 3 At maturity – 21 November 2024 1 218 1 217 700 3-month Jibar + 180bps 8.49% 1, 3 At maturity – 21 August 2026 707 704 300 3-month Jibar + 180bps 7.60% 1, 3 At maturity – 21 August 2026 304 303 792 3-month Jibar + 173bps 7.98% 1, 3 At maturity – 21 May 2027 799 792 226 3-month Jibar + 180bps 7.98% 1, 3 At maturity – 21 May 2029 228 226 Unlisted DMTN5 1 100 – 8.915%3 At maturity – 10 March 2023 – 1 104 2 500 – 9.615%3 At maturity – 22 February 2025 2 522 2 520 1 650 – 9.55%3 At maturity – 10 March 2026 1 658 – Other 1 400 3-month JIBAR + 125bps At maturity – 12 October 2022 – 702 1 000 3-month JIBAR + 245bps 7.83%1,3 At maturity – 02 March 2023 – 1 003 1 000 3-month JIBAR + 190bps At maturity – 02 March 2028 997 – 9 948 10 584 1 The interest rate has been fixed through interest rate swaps. 2 Interest is payable semi-annually in arrears. 3 Interest payable quarterly in arrears. 4 DMTN refers to the R10 billion Discovery Domestic Medium Term Note (DMTN) program registered in 2017. 5 During the financial year ended 30 June 2020, Discovery Limited refinanced R3.6 billion bank syndicated loans through the issue of unlisted DMTN notes. The notes, although underwritten by a bank until maturity, are structured to enable short-term issuances into the commercial paper market on an ongoing basis. The borrowings are unsecured senior debt and are not callable or convertible. Interest is payable quarterly in arrears other than footnote 2 in the table above. Refer to company note 19.4 for movement analysis and Group note 20. 10. DERIVATIVES AT FAIR VALUE THROUGH PROFIT OR LOSS R million Company 2023 Company 2022 Interest rate swaps – used as cash flow hedges1 1 56 Total 1 56 Current – 21 Non-current 1 35 Total 1 56 1 For further information, refer to Group note 13, which sets out information on the ’Interest Rate Swaps’ which equally apply to the Company. -- 142 of 217 -- 142 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Company annual financial statements continued for the year ended 30 June 2023 11. TRADE AND OTHER PAYABLES R million Company 2023 Company 2022 Accrued expenditure 10 11 Dividends due to shareholders 9 10 Intercompany payables 9 384 10 195 9 403 10 216 Intercompany payables include: Discovery Bank Limited * – Discovery Health Proprietary Limited 4 615 5 430 Discovery Insure Limited 1 – Discovery Life Limited 4 768 4 765 9 384 10 195 * Amount is less than R500 000. Discovery Limited receives funds from its subsidiaries through intercompany loan accounts, to assist with operational requirements. The loans are interest free and are settled as and when sufficient cash becomes available. The amortised cost of the trade and other payables approximate the fair value due to the short-term nature of these payables. 12. DEFERRED TAX ASSET R million Company 2023 Company 2022 Deferred tax asset – non-current 5 82 Movement summary: Balance at beginning of the year 82 113 Income statement charge (77) (31) Balance at end of the year 5 82 Deferred taxation comprises: Assessed losses – 67 Section 6 quat credits 3 15 Unrealised gains on financial instruments – (1) Realised capital losses 2 1 5 82 -- 143 of 217 -- 143 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Company annual financial statements continued for the year ended 30 June 2023 13. INVESTMENT INCOME1 R million Company 2023 Company 2022 At amortised cost interest income, using the effective interest rate 863 688 Dividends received from subsidiaries 3 193 361 4 056 1 049 Dividends received from subsidiaries include: – Discovery Central Services Proprietary Limited 23 117 – Discovery Health Proprietary Limited2 2 740 – – Discovery Insure Limited – 30 – Discovery Life Collective Investments Proprietary Limited 408 – – Discovery Mauritius Asset Management 17 7 – Discovery Vitality Proprietary Limited 1 207 – Vitality Corporate Services Limited 4 – 3 193 361 1 Investment income for Discovery Limited is seen as Revenue. 2 The dividend received settled the loan due to Discovery Health Proprietary Limited and was not received in cash. . 14. OTHER INCOME R million Company 2023 Company 2022 Guarantee fees i 31 53 Amortisation of financial guarantee contracts ii 5 3 Other income – 1 36 57 i Discovery Limited issued guarantees in respect of Discovery Finance Company Europe Limited and Discovery Holdings Europe Limited obligations. A guarantee fee is charged by Discovery Limited to Discovery Finance Company Europe Limited of R13 million (2022: R25 million) and Discovery Holdings Europe Limited of R18 million (2022: R28 million). ii Amortisation of initial financial guarantee contracts over the term of the loan. Refer to Company note 20 for a list of all the guarantees that Discovery Limited has issued. 15. NET FAIR VALUE LOSSES ON FINANCIAL INSTRUMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS R million Company 2023 Company 2022 Net fair value losses/(gains) on non-hedge derivatives 2 2 2 2 16. MARKETING AND ADMINISTRATION EXPENSES R million Company 2023 Company 2022 Marketing and administration expenses comprises: – Audit fees 6 6 – Professional fees 7 11 – Other 3 2 16 19 -- 144 of 217 -- 144 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Notes to the Company annual financial statements continued for the year ended 30 June 2023 17. MOVEMENT IN ALLOWANCE FOR EXPECTED CREDIT LOSSES1 R million Company 2023 Company 2022 Financial guarantee contracts: – Discovery Bank Limited 1 (*) – Discovery Central Services Proprietary Limited * (*) – Discovery Finance Company Europe Limited 7 – 8 (*) * Amount is less than R500 000. 1 In determining the expected credit loss, credit ratings are internally assigned using the RW rating scale. Refer to note 1.3 Credit risk, for more information. 12 month credit losses Lifetime credit losses Total 30 June 2023 Balance at beginning of the year (16) – (16) Decrease in allowance 8 – 8 Balance at end of the year (8) – (8) 30 June 2022 Balance at beginning of the year (16) – (16) Increase in allowance (*) – (*) Balance at end of the year (16) – (16) * Amount is less than R500 000. 18. TAXATION R million Company 2023 Company 2022 Charge for the year: Current taxation 47 * Normal taxation – prior year under/(over) provision * (*) – current year charge 47 * Deferred taxation 77 31 – prior year under/(over) provision * (*) – current year charge 77 31 Total income tax expense recognised in profit or loss 124 31 * Amount is less than R500 000. % % Taxation rate reconciliation Effective taxation rate 3.5 18.8 Capital profits and dividend income 24.2 61.0 Exempt income 0.2 – Disallowed expenditure: Capital in nature (0.6) (44.1) Prior year over provision – 0.5 Taxable Income: International tax adjustments (0.3) (6.5) Change in tax rate – (1.5) Difference in tax rate * (0.2) Standard rate of taxation 27.0 28.0 The current tax rate for South African entities in a tax paying position is 27% (2022: 28%). Discovery, a holding company listed on the JSE, uses the South African tax rate for its tax rate reconciliation since it is based in South Africa and the most significant operations are in South Africa. -- 145 of 217 -- 145 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 19. CASH FLOW INFORMATION 19.1 Cash generated by operations R million Company 2023 Company 2022 Profit before taxation 3 525 164 Adjusted for: Interest received (863) (688) Dividends received (3 193) (361) Finance costs 943 937 Non-cash items: Movement in expected credit losses (8) * Amortisation of financial guarantee contracts (5) (3) Fair value losses/(gains) on derivatives not designated as hedging instruments 2 (73) Unrealised foreign exchange gain (386) (16) Working capital changes: Loans and receivables (78) 1 105 Trade and other payables and loans from subsidiaries 1 927 2 1 864 1 067 19.2 Taxation paid R million Company 2023 Company 2022 Balance at beginning of the year (1) * Current taxation charged for the year in the income statement (47) * Balance at end of the year 45 1 (3) * 19.3 Increase in investments in subsidiaries R million Company 2023 Company 2022 Balance at beginning of the year 29 027 27 458 Value of share options issued to subsidiary staff 546 327 Financial guarantee contracts raised – 1 Deemed dividends 27 125 Long-term incentive plan share recharges (514) (443) Balance at end of the year (30 579) (29 027) Increase in investment in subsidiary (1 493) (1 559) 19.4 Long-term borrowings R million Company 2023 Company 2022 Balance at beginning of the year 10 584 8 858 Interest accrued 860 686 Interest paid (840) (683) Increase in borrowings 2 650 2 418 Raising fees capitalised (9) (8) Raising fees amortised 7 13 Repayment of borrowings (3 304) (700) Balance at end of the year 9 948 10 584 19.5 Cash and cash equivalents R million Company 2023 Company 2022 Cash at bank and in hand 256 93 Short-term deposits 26 514 282 607 * Amount is less than R500 000. Notes to the Company annual financial statements continued for the year ended 30 June 2023 -- 146 of 217 -- 146 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 19. CASH FLOW INFORMATION continued 19.6 Interest received R million Company 2023 Company 2022 At amortised cost interest income, using the effective interest rate 863 688 Interest received from Loans to subsidiaries (note 5) (638) (583) – accrued (836) (676) – received 198 93 Interest received from Loans to BEE partners (note 6) 6 (3) – accrued (15) (9) – received 21 6 231 102 20. FINANCIAL GUARANTEE CONTRACTS R million Company 2023 Company 2022 Discovery Limited has provided guarantees for the following subsidiaries: Discovery Finance Company Europe Limited i – 3 Discovery Central Services Proprietary Limited ii 12 16 Discovery Holdings Europe Limited iii – 5 Discovery Bank Limited iv – 1 Total 12 25 i Discovery Limited has issued guarantees for 2 facilities in respect of the obligations of Discovery Finance Company Europe Limited for the amounts of GBP80 million and GBP34 million. Both these facilities were repaid during the current financial year. In December 2022, a new facility of GBP56 million was entered into and Discovery Limited has guaranteed this loan. As at 30 June 2023, Discovery Finance Company Europe Limited owed GBP54 million (2022: GBP56 million) in respect of these borrowing facilities. ii Discovery Limited has guaranteed the following borrowing facilities of Discovery Central Services Proprietary Limited: – R650 million facility to fund the systems build of Discovery Bank. The full amount has been drawn down and the balance outstanding at 30 June 2023 is R445 million (2022: R494 million). – a 5-year borrowing facility for an amount of R1.4 billion. These funds were acquired for general corporate purposes and the full amount has been drawn down and the balance outstanding at 30 June 2023 is R1 408 million (2022: R1 417 million). – a R1.5 billion Financial Credit Facility. The balance outstanding at 30 June 2023 is R151 million (2022: Rnil). – a R691 million facility and the full amount has been drawn down. The balance outstanding at 30 June 2023 is R694 million (2022: R691 million). – a R750 million facility, undrawn at 30 June 2023. This facility expired subsequent to year end on 31 July 2023 and was renewed for a further 12 months to 31 July 2024. iii During 2020, Discovery Holdings Europe Limited entered into borrowing facilities for an amount of GBP100 million to fund its operations. In December 2022, GBP25 million was refinanced. This facility has been guaranteed by Discovery Limited. iv In the prior year, Discovery Limited issued a guarantee for a facility in respect of the obligations of Discovery Bank Limited for the amount of R300 million. This facility was settled during the current financial year. 21. EVENTS AFTER REPORTING DATE Refer to Group note 44 for a list of the events after reporting date. Notes to the Company annual financial statements continued for the year ended 30 June 2023 -- 147 of 217 -- DISCOVERY ANNEXURES -- 148 of 217 -- 148 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure A – Group structure for the year ended 30 June 2023 Discovery is directly and indirectly the holding company of: Audited information Classification Percentage Holding at 30 June 2023 Country Discovery Limited which holds the interest in: Cogence Proprietary Limited Subsidiary 100% South Africa Discovery Bank Holdings Limited which holds the interest in: Subsidiary 100% South Africa – Discovery Bank Limited Subsidiary 100% South Africa Discovery Central Services Proprietary Limited which holds the interest in: Subsidiary 100% South Africa – Glucode Proprietary Limited Associate 25% South Africa Discovery Connect Distribution Services Proprietary Limited Subsidiary 100% South Africa Discovery Finance Company Europe Limited Subsidiary 100% United Kingdom Discovery Group Europe Limited which holds the interest in: Subsidiary 100% United Kingdom – Discovery Holdings Europe Limited which holds the interest in: Subsidiary 100% United Kingdom ○ Better Health Insurance Advice Limited Subsidiary 100% United Kingdom ○ Healthcode Limited Associate 20% United Kingdom ○ Vitality Corporate Services Limited which holds an interest in: Subsidiary 100% United Kingdom – Healthcare Purchasing Alliance Limited Joint venture 50% United Kingdom – Vitality Healthy Workplace Limited Subsidiary 100% United Kingdom ○ Vitality Invest Trustee Company Limited Subsidiary 100% United Kingdom ○ Vitality Life Limited which holds the interest in: Subsidiary 100% United Kingdom – Vitality Health Insurance Limited which holds the interest in: Subsidiary 100% United Kingdom ○ Vitality Health Limited Subsidiary 100% United Kingdom – Discovery Offshore Holdings No.2 Limited Subsidiary 100% United Kingdom Discovery Health Proprietary Limited , which holds the interest in: Subsidiary 100% South Africa – Discovery Administration Services Proprietary Limited Subsidiary 100% South Africa – Discovery Third Party Recovery Services Proprietary Limited Subsidiary 100% South Africa – Discovery Healthcare Service Proprietary Limited which holds the interest in: Subsidiary 100% South Africa ○ Discovery Medical Suppliers Proprietary Limited Subsidiary 100% South Africa ○ Grove Nursing Services Proprietary Limited Subsidiary 100% South Africa ○ Southern Rx Distributors Proprietary Limited Subsidiary 100% South Africa – Medical Services Organisation International Proprietary Limited which holds an interest in: Subsidiary 70% South Africa ○ Mediguide Africa Proprietary Limited Associate 25% South Africa ○ Medical Services Organisation Proprietary Limited Subsidiary 51% Swaziland – Medical Services Organisation International Limited which holds an interest in: Subsidiary 70% Isle of Man ○ Medical Services Organisation S.A (previously Global Access Health Network SARL) Subsidiary 80% Democratic Republic of Congo ○ MSOI Health Risk Managers Limited Subsidiary 85% Nigeria – Quantium Health SA Proprietary Limited Joint venture 50% South Africa – Nanolabs Health Solutions Proprietary Limited Subsidiary 52% South Africa Discovery Insure Limited which holds an interest in: Subsidiary 100% South Africa – Discovery Telematics Services Proprietary Limited which holds an interest in: Subsidiary 100% South Africa ○ Bi-Me Proprietary Limited Associate 33% South Africa ○ ZeroG Network Proprietary Limited Associate 19% South Africa Discovery Life Limited Subsidiary 100% South Africa Discovery Life Collective Investments Proprietary Limited Subsidiary 100% South Africa Discovery Life Investment Services Proprietary Limited which holds an interest in: Subsidiary 100% South Africa – Discovery Life Nominees Proprietary Limited Subsidiary 100% South Africa Discovery Mauritius Asset Management which holds an interest in: Subsidiary 100% Mauritius – Discovery International Collective Investments PLC Subsidiary 100% Mauritius Discovery Partner Markets Asia Private Limited which holds an interest in: Subsidiary 100% Singapore – Discovery Partner Market Services Private Limited which holds an interest in: Subsidiary 100% Singapore ○ Vitality (Shangai) Business Consulting Services Company Limited Subsidiary 100% China Discovery Vitality Proprietary Limited Subsidiary 100% South Africa Ping An Health Insurance Company of China Limited Associate 25% China Vitality Group International Incorporated which holds an interest in: Subsidiary 100% United States – AIA Vitality (Hong Kong) Limited Joint venture 44% Hong Kong – Amplify Health Asia Private Limited Associate 25% Singapore – Cambridge Mobile Telematics Incorporated Associate 9% United States – Discovery Vitality Australia Proprietary Limited which holds an interest in: Subsidiary 100% Australia ○ Quantium Health Proprietary Limited which holds an interest in: Joint venture 50% Australia – Health Outcomes Australia Proprietary Limited Joint venture 100% Australia – Quantium Health Hong Kong Proprietary Limited Joint venture 100% Hong Kong ○ Quantium Health Limited UK Joint venture 50% United Kingdom – The Vitality Group Incorporated which holds an interest in: Subsidiary 100% United States ○ The Vitality Group Limited Liability Company Subsidiary 100% United States – Vitality International Health Insurance Company Limited Subsidiary 100% Isle of Man – Vitality Management Company Limited Liability Company Subsidiary 100% United States Vitality Green Proprietary Limited was registered in South Africa in 2023. No shares have been issued yet. -- 149 of 217 -- 149 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure A – Group structure continued for the year ended 30 June 2023 In addition to the above subsidiaries, Discovery consolidates unit trusts which are deemed to be under the Group’s control in terms of IFRS 10 Consolidated Financial Statements. The consolidated unit trusts include: Discovery Aggressive Dynamic Asset Optimiser Fund of Funds Discovery Balanced Fund Discovery Cautious Balanced Fund Discovery Conservative Dynamic Asset Optimiser Fund of Funds Discovery Diversified Income Fund Discovery Equity Fund Discovery Flexible Property Fund Discovery Global Equity Feeder Fund Discovery Global Real Estate Securities Feeder Fund Discovery Global Value Equity Feeder Fund Discovery Moderate Balanced Fund Discovery Moderate Dynamic Asset Optimiser Fund of Funds Discovery Money Market Fund Discovery Target Retirement 2015 Fund Discovery Target Retirement 2020 Fund Discovery Target Retirement 2025 Fund Discovery Target Retirement 2030 Fund Discovery Target Retirement 2035 Fund Discovery Target Retirement 2040 Fund Discovery Target Retirement 2045 Fund Discovery Target Retirement 2050 Fund Discovery Target Retirement 2055 Fund Discovery Target Retirement 2060 Fund Discovery Global Multi Asset Fund (previously named Discovery Worldwide Best Ideas Fund) Discovery Strategic Bond Fund Discovery Global Conservative Fund (Mauritius) Discovery Global Moderate Fund (Mauritius) Discovery Global Growth Portfolio Fund (Mauritius) -- 150 of 217 -- 150 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies for the year ended 30 June 2023 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The principal accounting policies applied in the preparation of these consolidated and separate financial statements are set out below. These policies have been consistently applied to all the years presented. Other interpretations, amendments and annual improvements effective for the first time in the current year have been considered and have no impact on the current reporting period. 1. Basis of presentation The consolidated and separate Annual Financial Statements have been prepared in accordance with IFRS Accounting Standards, IFRIC Interpretations, the South African Institute of Chartered Accountants (SAICA), Financial Reporting Guides as issued by the Accounting Practices Committee, the JSE Limited Listings and Debt Listings Requirements as well as the South African Companies Act. They have been prepared in accordance with the going concern principle using the historical cost basis except where otherwise stated in the accounting policies below. The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying Discovery’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements, are outlined in Group note 4 to the Annual Financial Statements. All monetary information and figures presented in these financial statements are stated in millions of Rand (R million), unless otherwise indicated. New standards and amendments which became effective during the financial year Discovery has elected to early adopt the requirements of IFRS 9 general hedge accounting. Refer to accounting policy 10 Derivative financial instruments. There were no other new standards, amendments, and interpretations which became effective during the year that had a material impact on recognised amounts. New standards and amendments to published standards not yet effective Discovery has not early adopted any accounting standards, amendments or annual improvements issued but not yet effective. The accounting standards, amendments and annual improvements described below are those that are expected to have an impact on Discovery’s results and/or disclosures. Accounting standards, amendments and annual improvements not mentioned below are not expected to have a significant impact on recognised amounts. For IFRS 17, please refer to accounting policy note 30. 2. Consolidation The consolidated financial statements include the assets, liabilities and results of the operations of the holding company and its subsidiaries, joint ventures and associates. 2.1 Business combinations The acquisition method of accounting is used to account for business combinations by the Group. The consideration transferred for the acquisition of a business is the fair values of the assets transferred, the liabilities incurred and the equity interests issued by the Group. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. Acquisition-related costs are expensed as incurred. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. On an acquisition-by-acquisition basis, Discovery recognises any non-controlling interest in the acquiree either at fair value or at the non-controlling interest’s proportionate share of the acquiree’s net assets. The excess of the consideration transferred, being the amount of any non-controlling interest in the acquiree and the acquisition-date fair value of any previous equity interest in the acquiree over the fair value of the identifiable net assets acquired, is recorded as goodwill. If this is less than the fair value of the net assets of the subsidiary acquired in the case of a bargain purchase, the difference is recognised directly in profit or loss. -- 151 of 217 -- 151 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 2. Consolidation continued 2.2 Consolidation of entities in which the Group holds less than 50% Discovery analysed its relationships with the Discovery Unit Trusts and has determined that it has significant power to direct the relevant activities of the funds, has sufficient exposure to the variable returns of the funds and has the ability to use its power over the investee to affect its returns. This analysis concluded that Discovery has control of the Discovery Unit Trusts even if the economic interest is less than 50% and is therefore required to consolidate these funds. Discovery controls these unit trusts as it has the right to the variable returns in the form of fund management fees that it receives from its involvement with the funds. Furthermore, Discovery exercises control over these unit trusts through the setting of the mandates as well as the appointment of the independent trustees. Discovery can, within the regulatory framework, also amend the mandates and change the independent trustees. Of the 27 (2022: 27) Discovery Unit Trusts consolidated at 30 June 2023, Discovery holds less than a 50% economic interest in 1 (2022: 1) of these funds. Refer to Annexure A for a list of consolidated unit trustees. 2.3 Subsidiaries Subsidiaries are all entities (including structured entities) over which Discovery has control. Discovery controls an entity when it has power over the investee, is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to Discovery. Consolidation is discontinued from the date on which control ceases. Intra-group transactions, balances and unrealised gains or losses on intra-group transactions are eliminated. Subsidiaries’ accounting policies have been changed where necessary to ensure consistency with the policies adopted by Discovery. Intra-group foreign exchange gains or losses arising on intra-group balances do not eliminate. 2.4 Associates and joint arrangements ASSOCIATES AND JOINT VENTURES Associates are entities over which Discovery has the ability to exercise significant influence but not control over the financial and operational policies. Significant influence is determined based primarily on the percentage of voting rights, generally between 20% and 50%, together with other factors such as board participation and participation in the policy-making process. In certain instances, Discovery holds less than 20% equity interests, but holds rights that still give it significant influence. These rights include activities such as board representation and material transactions. These are equity accounted. A joint venture is a joint arrangement whereby the parties have joint control of an arrangement and have rights to the net assets of the arrangement. Discovery recognises its interest in an associate or a joint venture as an investment and accounts for that investment using the equity method. Under the equity method, on initial recognition, the investment in an associate or a joint venture is recognised at cost. The carrying amount is adjusted to recognise Discovery’s share of the post-acquisition profit or loss of the investee and is recognised in profit or loss. Distributions received from an investee reduce the carrying amount of the investment. Dividends received from the investee are presented as part of investing activities in the Statement of cash flows. Adjustments to the carrying amount may also be necessary for changes in Discovery’s proportionate interest in the investee arising from changes in the investee’s other comprehensive income. Such changes include those arising from foreign exchange translation differences. Discovery’s share of those changes is recognised in other comprehensive income. Discovery will discontinue the use of the equity method from the date when its investment ceases to be an associate or a joint venture. Discovery discontinues equity accounting when the carrying amount of the investment in an associate or a joint venture reaches zero, unless it has incurred obligations, guaranteed obligations or made payments on behalf of the associate or the joint venture. Discovery resumes equity accounting only after its share of the profits equals the share of losses not recognised. Discovery increases the carrying amount of investments with its share of the associate’s or joint venture’s income when equity accounting is resumed. Discovery’s investment in an associate or a joint venture includes goodwill identified on acquisition. Discovery assesses at each reporting date whether there is objective evidence that an associate or a joint venture is impaired. If such evidence of impairment exists, Discovery calculates the amount of impairment as the difference between the recoverable amount of the investment and its carrying value. Unrealised gains or losses on transactions between Discovery and its associates or joint ventures are eliminated to the extent of the Group’s interest in these entities unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of associates and joint ventures have been changed where necessary to ensure consistency with the policies adopted by the Group. The carrying amounts of the equity-accounted investments are tested for impairment. Annexure B – Group accounting policies continued for the year ended 30 June 2023 -- 152 of 217 -- 152 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 2. CONSOLIDATION continued FINANCIAL GUARANTEE CONTRACTS (FGCs) ISSUED OVER THE DEBT OF AN EQUITY ACCOUNTED INVESTMENT Discovery accounts for financial guarantee contracts (FGCs) under IFRS 9 Financial Instruments (IFRS 9) when Discovery becomes a party to the contract. FGCs are contracts which require Discovery, as the issuer of the contract, to make specified payments to reimburse the holder for a loss that the holder incurs because the specified debtor fails to make payment when it is due under the original or modified terms of the debt instrument. Discovery may issue FGCs over the debt of an equity accounted investment. Discovery measures the FGC: Initially at fair value, and Subsequently, at the higher of: – The amount of expected credit losses determined under IFRS 9 (calculation 1), and – The amount initially recognised less, when appropriate, the cumulative amount of income recognised under the principles of IFRS 15 Revenue from Contracts with Customers (calculation 2). In instances where Discovery issues FGCs over the debt of a related entity that is equity accounted in accordance with the provisions of IAS 28 Investments in Associates and Joint Ventures, Discovery determines the fair value of the FGCs. These FGCs issued over the debt of an associate entity are seen as transactions in the capacity as shareholder and are treated as capital contributions. In some instances, the other associate entity can also pay a premium to the issuer of the FGCs. Discovery then determines if the price represents the fair value or whether there is still an additional cost of the FGC that Discovery should recognise. In the instance where Discovery does not receive all the premiums upfront, it recognises the FGC using a net approach. The net approach requires that Discovery presents the financial guarantee as its fair value less all future premiums. Discovery subsequently recognises financial guarantee fee income as follows: Amortises the fair value recognised on initial recognition over the period that the FGC is outstanding, being generally the period of the underlying debt. Recognises any premiums received for issuing the FGC as financial guarantee fee income, and Where Discovery has applied the net approach, Discovery adjusts for the premiums subsequently received to ensure it takes into account all premiums in using calculation 2. Discovery calculates the lifetime expected credit losses for purposes of calculation 1. Where the outcome is such that calculation 1 is more than calculation 2, differences are recognised and presented as part of expected credit losses. Where the outcome is such that calculation 2 is more than calculation 1, no adjustments are required. Any previously recognised expected credit losses can be reversed but limited to the total value previously recognised. Discovery derecognises FGCs when the FGC is extinguished, expires, or the underlying debt is extinguished. At the date of derecognition: Where the FGC is extinguished in exchange for a new FGC to the same holder and in respect of the same guaranteed entity, the FGC derecognised is seen as compensation for the new FGC, or In all other instances, the FGC is derecognised with an associated gain or loss in profit or loss. -- 153 of 217 -- 153 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 2. Consolidation continued 2.4 Associates and joint arrangements continued ASSOCIATES AND JOINT VENTURES continued A decrease in interest while an investment continues to be classified as an associate can also result from a dilution. The gain or loss on the dilution of an equity-accounted investee is calculated as the difference between: the entity’s ownership interest in the new assets received by the investee for the subscription of the new shares (e.g. the cash paid by the other party); and the reduction in ownership interest in the previous carrying amount JOINT OPERATIONS A joint operation is a joint arrangement whereby the parties have joint control of an arrangement and rights to the assets and obligations for the liabilities relating to the arrangement. Discovery recognises its share of those assets, liabilities, revenues and expenses that the operators incur jointly. 3. Foreign currency translation 3.1 Functional and presentation currency Items included in the financial statements of each of Discovery’s entities are measured using the currency of the primary economic environment in which the entity operates (the functional currency). The consolidated financial statements are presented in Rand, which is the presentation currency of Discovery Limited. 3.2 Transactions and balances Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from: The settlement of trading transactions is included in the results of operating activities in profit or loss, The settlement of financing transactions and the translation at year-end exchange rates of assets and liabilities denominated in foreign currencies are recognised in profit or loss as foreign exchange gains and losses, and Qualifying cash flow hedges are deferred in the Statement of other comprehensive income and are recycled to profit or loss in the periods in which the hedged item affects profit or loss. 3.3 Group companies The results and financial position of all Discovery entities (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows: Assets and liabilities for each Statement of financial position presented are translated at the closing rate at the date of that statement of financial position. Income and expenses for each Income statement are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at rates at the date of the transactions); and All resulting exchange differences are recognised as a separate component of equity, namely the foreign currency translation reserve. On consolidation, exchange differences arising from the translation of the net investment in foreign entities are recognised in the foreign currency translation reserve in the Statement of other comprehensive income. When a foreign operation is partially disposed of or sold, such exchange differences are recognised in profit or loss as part of the gain or loss on sale. Goodwill and fair value adjustments arising on the acquisition of a foreign entity are treated as assets and liabilities of the foreign entity and translated at the closing rate. -- 154 of 217 -- 154 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 4. Property and equipment Items of property and equipment are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation and any accumulated impairment losses. Subsequent costs are included in the asset’s carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to Discovery and the cost of the item can be measured reliably. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred. If significant parts of an item of property and equipment have different useful lives, then they are accounted for as separate items (major components) of property and equipment. Property and equipment are depreciated using the straight-line method to allocate their cost to their residual values over their estimated useful lives, as follows: Owner occupied property 40 years Leasehold improvements Shorter of estimated life or period of lease Leased asset 3 – 15 years Computer equipment 3 – 7 years Furniture, fittings and building fit out 5 – 15 years Motor vehicles 4 years Telematics devices 2 – 5 years The assets’ residual values and useful lives are reviewed at each reporting period and adjusted if appropriate. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount. The recoverable amount is the higher of the asset’s fair value less costs to sell and value-in-use. Gains or losses on disposals are determined by comparing the proceeds with the carrying amount. These are recorded in profit or loss. 5. Intangible assets 5.1 Computer software development costs Items of computer software development costs are measured at cost, less accumulated amortisation and any accumulated impairment losses. Costs associated with maintaining computer software programmes are recognised as an expense as incurred. Development costs that are directly attributable to the design and testing of identifiable software products controlled by Discovery are recognised as intangible assets when the following criteria are met: It is technically feasible to complete the software product so that it will be available for use. Management intends to complete the software product and use or sell it. There is an ability to use or sell the software product. It can be demonstrated how the software product will generate probable future economic benefits. Adequate technical, financial and other resources to complete the development and to use or sell the software product are available, and The expenditure attributable to the software product during its development can be reliably measured. Directly attributable costs that are capitalised as part of the software product include the software development employee costs and an appropriate portion of directly attributable overheads. For cloud computing arrangements, implementation costs that do not meet the requirements to be capitalised as an asset are expensed as incurred. Other development expenditures that do not meet these criteria are recognised as an expense as incurred. Development costs previously recognised as an expense are not recognised as an asset in a subsequent period. Computer software development costs are recognised as assets from the point where the recognition criteria above are satisfied and are amortised once the asset is ready for use over their useful lives. The amortisation is reflected under marketing and administration expenses in profit or loss. If significant parts of computer software development costs have different useful lives, then they are accounted for as separate items (major components) of computer software development costs. Computer software development costs recognised as assets are amortised over their useful lives. Software applications 3 – 7 years Core Systems 16 years (2022: 15 years) An intangible asset is derecognised: On disposal, or When no future economic benefits are expected from its use or disposal. The gain or loss arising from the derecognition of an intangible asset is determined as the difference between the net disposal proceeds, if any, and the carrying amount of the asset. Discovery recognises such gains or losses in profit or loss when the intangible asset is derecognised. -- 155 of 217 -- 155 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 5. Intangible assets continued 5.2 Other intangible assets Discovery does not recognise costs incurred to internally develop trademarks, patents and similar rights and assets, including franchises and management contracts. These costs are recognised in profit or loss in the period in which they are incurred. Purchased intangible assets, which represent rights to receive future profits, are capitalised at their fair values, represented by the estimated net present value of future cash flows relating to existing business, or at a value as determined by an independent valuer. These intangible assets are amortised into profit or loss as profits are expected to emerge and are only tested for impairment if an indication of impairment arises. Intangible assets acquired as part of business combinations are capitalised at their fair value, represented by the estimated net present value of future cash flows relating to existing business, or at a value as determined by an independent valuer. These intangible assets are amortised over their useful lives and only tested for impairment if an indication of impairment arises. 6. Deferred acquisition costs The direct costs of acquiring new business, which are expected to be recovered out of future revenue margins, are deferred over the period in which the related performance obligations are satisfied and recognised as an asset in the Statement of financial position. The accounting policies relating specifically to deferred acquisition costs for insurance contracts are detailed in accounting policies 13. 7. Goodwill Goodwill arises on the acquisition of businesses and represents the excess of the consideration transferred, the amount of any non-controlling interest in the acquiree and the acquisition-date fair value of any previous equity interest in the acquiree over the fair value of the identifiable net assets acquired. Goodwill is reviewed for impairment annually or more frequently if events or changes in circumstances indicate a potential impairment. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash generating units (CGUs) or groups of CGUs that are expected to benefit from the synergies of the combination. Each unit or group of units to which the goodwill is allocated represents the lowest level within the entity at which the goodwill is monitored for internal management purposes. Goodwill is monitored at the operating segment level. The carrying value of the CGU containing the goodwill is compared to the recoverable amount, which is the higher of value-in-use and the fair value less costs to sell. Any impairment is recognised immediately as an expense and is not subsequently reversed. 8. Impairment of non-financial assets Goodwill is tested annually for impairment or more frequently if events or changes in circumstances indicate that goodwill may be impaired. Other assets, including equity-accounted investments, intangible assets and costs of obtaining contracts other than those relating to insurance contracts (see accounting policy 13), are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Such indicators include continued losses, changes in technology, market, economic, legal and operating environments. An impairment loss is recognised for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is measured using the higher of the fair value less costs to sell and the value-in-use. Value-in-use is the present value of projected cash flows covering the remaining useful life of the asset. An impairment loss is recognised in profit or loss immediately. Other assets, other than goodwill, that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period. 9. Financial instruments Discovery initially recognises financial instruments when it becomes a party to the contract. Financial instruments are measured at initial recognition at fair value net of directly attributable transaction costs, unless the financial instrument is classified as fair value through profit or loss. For instruments classified at fair value through profit or loss attributable transaction costs are immediately expensed. -- 156 of 217 -- 156 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 9. Financial instruments continued 9.1 Financial assets 9.1.1 RECOGNITION, CLASSIFICATION, MEASUREMENT AND DERECOGNITION At initial recognition, the Group considers the appropriate classification as at Amortised cost (AC), Fair value through profit or loss (FVTPL) or Fair value through other comprehensive income (FVOCI) for debt instruments. Discovery considers: Whether the contractual cash flows of the financial asset are solely payments of principal and interest (SPPI). Such contractual cash flows are consistent with a basic lending arrangement and compensate Discovery for the elements of time value of money, credit risk and other basic lending risks and a profit margin. Examples of such instruments include Treasury Bills, Government Bonds, cash and fixed-term deposits. It excludes instruments such as equity-linked financial assets or puttable investments in unit trusts, and The business model for holding the financial assets. Based on the criteria above, Discovery will classify a debt instrument as: Amortised cost, if the financial asset meets the SPPI criterion and is held for the purpose to collect the contractual cash flows. Examples of this include loans and advances to customers (e.g. credit card advances) and fixed-term deposits; Fair value with changes in other comprehensive income (debt instruments), if the financial asset meets the SPPI criterion and is held either to collect contractual cash flows or for sale. Discovery currently does not hold financial assets in this category. However, specified associates do have certain of their debt instruments in the category. Fair value through profit or loss, for all other financial assets that do not meet the criteria above (mandatorily). In addition, Discovery can irrevocably designate financial assets into this category if this will reduce measurement inconsistencies (i.e. ’accounting mismatch’) (designated). Discovery’s business includes, amongst others, providing unit-linked insurance, unit-linked investment and non-linked insurance products to customers. Financial assets and liabilities in these portfolios are managed to achieve the objectives of the portfolio and to ensure that liabilities are appropriately matched with assets. In considering whether the objective of a portfolio is to collect contractual cash flows or to trade in financial instruments, Discovery considers the purpose for which instruments are held, the methods of risk management in a portfolio, the manner of performance reporting on a portfolio and the basis for determining compensation to managers for asset performance. For those financial assets backing insurance contracts, Discovery measures these financial assets at fair value through profit or loss. Unit-linked investment contracts are also mandatorily classified at fair value through profit or loss. For equity instruments Discovery is permitted to make the irrevocable election to present changes in fair value in other comprehensive income. However cumulative gains or losses recognised cannot be reclassified to profit or loss on disposal. This election is available on an instrument-by-instrument basis. This election has only been made in the accounting records of specified associates. All other equity instruments are measured at FVTPL. Subsequent measurement Amortised cost (AC) These instruments are measured at amortised cost using the effective interest method. Movements in the balance of the instrument relate to expected credit losses, interest income and foreign exchange gains and losses, which are recognised on profit or loss. Fair value through profit or loss (FVTPL) These instruments are measured at fair value with gains and losses recognised in profit or loss. Movements in this balance are due to fair value gains or losses, interest or dividends, and foreign exchange gains or losses. Dividends are recognised in profit or loss. Fair value through other comprehensive income (FVOCI) – equity These instruments are measured at fair value with gains and losses recognised in other comprehensive income. On derecognition, gains and losses accumulated in OCI are not reclassified to profit or loss. Dividends are recognised in profit or loss. Fair value through other comprehensive income (FVOCI) – debt These instruments are measured at fair value with changes in fair value recognised in other comprehensive income. Discovery recognises interest using effective interest method, movements in the balance related to expected credit losses, interest income and foreign exchange gains and losses in profit or loss. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss. There are no financial assets that have been designated at fair value through profit or loss. The business model for managing a group of financial instruments is expected to remain stable. In rare instances where the business model changes, there can be a reclassification of the business model. Any reclassifications are applied prospectively from the first day of the first reporting period after the change in business model, with no restatement of any previously recognised gains, losses or interest. Discovery has not had any changes in business models in the current reporting period and consequently there have been no reclassifications. Financial assets are derecognised when the rights to receive cash flows from them have expired or where they have been transferred and Discovery has also transferred substantially all risks and rewards of ownership with no retention of control of the financial asset. -- 157 of 217 -- 157 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 9. Financial instruments continued 9.1 Financial assets continued 9.1.2 EXPECTED CREDIT LOSSES Expected credit losses are recognised on the following items: Debt instruments at amortised cost or fair value with changes in other comprehensive income (FVOCI), which includes treasury bills, banking loans and advances and fixed deposits. This also includes loan commitment for undrawn credit facilities, Lease receivables Financial guarantee contracts Other receivables which are financial assets at amortised cost, and Contract receivables and contracts assets with non-insurance customers and cash and cash equivalents. Discovery has a multitude of different debtors and loans included in other receivables as financial assets, which do not represent a homogeneous group of assets. The approach to determining credit losses varies according to the asset type, past bad debt experience and the potential to incorporate forward-looking information. In certain instances, financial assets have been grouped based on shared characteristics (i.e. debt payment pattern similarities, financial instruments with collateral, debtor type) and expected credit losses determined on a collective basis. The general expected credit loss approach requires that Discovery assesses the credit risk of the instrument and determine whether there has been a significant increase in credit risk since initial recognition. Where there has not been a significant increase in credit risk since initial recognition expected credit losses are measured as the 12-month expected credit losses. These are referred to as Stage 1 financial assets. Where there has been a significant increase in credit risk, expected credit losses are recognised as the lifetime credit losses. These are referred to as Stage 2 or Stage 3 financial assets. Discovery measures expected credit losses on: Financial assets that are not credit-impaired after the reporting date: as the present value of all cash shortfalls (i.e. the difference between the cash flows due to the entity in accordance with the contract and the cash flows that Discovery expects to receive) Financial assets that are credit-impaired at the reporting date: as the difference between the gross carrying amount and the present value of estimated future cash flows, and Undrawn loan commitments: as the present value of the difference between the contractual cash flows that are due to Discovery if the commitment is drawn down and the cash flows that Discovery expects to receive (adjusted using a credit conversion factor). Discovery measures assets that are trade receivables, contract assets, and lease receivables using the simplified approach when there is no significant financing component. The simplified approach does not require Discovery to track the changes in credit risk, but instead requires it to recognise a loss allowance based on lifetime expected credit loss at each reporting date. Discovery does not recognise expected credit losses on Treasury Bills issued by the South African Reserve Bank as well as cash and cash equivalents receivable on demand due to the assessment that it is immaterial. SIGNIFICANT INCREASE IN CREDIT RISK At each reporting date, Discovery assesses whether the credit risk on a financial asset has increased significantly since initial recognition. When making the assessment, an entity uses the change in the risk of a default occurring over the expected life of the financial instrument instead of the change in the amount of expected credit losses. Qualitative Quantitative When contractual payments are more than 30 days past due, the presumption is applied in conjunction with Discovery Risk Grade (DRG). The eligibility rules used in the credit underwriting and account management strategies are considered as triggers of a significant increase in credit risk, since they provide a view in terms of how the client performs on their other credit facilities outside Discovery Bank. The rules comprise of a list of statuses at the bureau such as: judgements, adverse, deceased, and debt counselling statuses. Performing (up-to-date and current) accounts that have shown deterioration with respect to Discovery Bank risk grades will also be regarded as a significant increase in credit risk. Currently Discovery Bank is not considering the quantitative triggers of a significant increase in credit risk due to lack of origination data on the back book (i.e. DiscoveryCard joint venture data). As the book in Discovery Bank matures, it will be in a position to perform the assessment. -- 158 of 217 -- 158 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 9. Financial instruments continued 9.1 Financial assets continued CREDIT IMPAIRED AND DEFAULT Discovery considers a financial instrument to be credit-impaired where current circumstances and economic conditions indicate that the expected future cash flows from a financial instrument may not be recoverable. These circumstances include but are not limited to evidence of financial or operational challenges for the debtor and missed contractual payments. Default is defined on a facility level and considers both quantitative and qualitative factors as provided in the Basel capital framework. The qualitative criterion requires banks to identify credit deterioration before the exposure becomes delinquent “unlikeliness to pay” events, while the quantitative criterion requires banks to look at the material delinquency status. The following factors are what constitutes default from a qualitative and quantitative perspective, and it is in line with the South African Reserve Bank definition. Qualitative Quantitative The borrower is placed in debt counselling/debt review. The borrower is deceased. The facility has undergone a distressed restructure/special arrangement. The facility has been transferred to charge-off/legal status. The client is under debt review. The client is insolvent, or The facility is written off. A material amount on the facility is 90 days or more in arrears, whereby material is set to avoid technical defaults. WRITE-OFF Discovery Bank will reduce the gross carrying amount of a financial asset when it has no reasonable expectation of recovering a financial asset in its entirety or a portion thereof. Currently the write-off point is based on time in default and is set as 12 months in default. To ensure the appropriateness of the write-off point, the proposed write-off point will be assessed on an annual basis and both time in default and recency of repayments will be considered. Where Discovery has no reasonable expectation of recovery of a debt, the amount is written off. This is considered to occur when all avenues of legal recourse to recover the debt have been unsuccessful. 9.2 Financial liabilities At initial recognition, the Group considers the appropriate classification as at Amortised costs (AC) or Fair value through profit or loss (FVTPL). Financial liabilities are measured at FVTPL if: It is held for trading, or The financial liabilities are part of a group of financial assets and financial liabilities, which are managed and performance evaluated on a fair value basis. These include financial liabilities held within the portfolios of unit-linked insurance and unit- linked investments. All other financial liabilities in Discovery, which are in the scope of IFRS 9, are measured at amortised cost. Qualitative Subsequent measurement Amortised cost (AC) These instruments are measured at amortised cost using the effective interest method. Interest and foreign exchange gains and losses are recognised in profit or loss. Fair value through profit or loss (FVTPL) These instruments are measured at fair value with gains and losses and any interest recognised in profit or loss. Discovery has investment contracts which have financial risk and are consequently recognised and measured in terms of IFRS 9 rather than IFRS 4 Insurance Contracts. These contracts are classified at fair value through profit or loss. The policies are linked to the return on underlying financial assets and are directly matched. The movement on Discovery’s own credit risk is considered immaterial. The remaining financial liabilities are carried at amortised cost. Financial liabilities are derecognised when the obligation is extinguished. -- 159 of 217 -- 159 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 9. Financial instruments continued 9.3 Offset Financial assets and liabilities are offset, and the net amount reported in the Statement of financial position when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of Discovery or the counterparty. 9.4 Modifications Where an existing financial asset or liability is replaced by another with the same counterparty on substantially different terms, or the terms of an existing financial asset or liability are substantially modified, such an exchange or modification is treated as a derecognition of the original asset or liability and the recognition of a new asset or liability at fair value, including calculating a new effective interest rate, with the difference in the respective carrying amounts being recognised in other gains and losses on financial instruments within non-interest revenue. The date of recognition of a new asset is consequently considered to be the date of initial recognition for impairment calculation purposes. If the terms are not substantially different for financial assets or financial liabilities, the group recalculates the new gross carrying amount by discounting the modified cash flows of the financial asset or financial liability using the original effective interest rate. The difference between the new gross carrying amount and the original gross carrying amount is recognised as a modification gain or loss within credit impairments (for distressed financial asset modifications) or in other gains and losses on financial instruments within non-interest revenue (for all other modifications). In assessing whether a financial asset was substantially modified, Discovery performs a qualitative assessment to determine if the terms were substantially modified. In assessing whether a financial liability has been substantially modified, Discovery performs both a qualitative and quantitative (10% threshold) assessment to determine if the terms were substantially modified. For discussion on modifications as a result of the interbank offered rates (IBOR) reforms, refer to accounting policy 10.5. 10. Derivative financial instruments Derivative financial instruments are classified as held for trading unless they are designated as effective hedging instruments. Discovery initially recognises derivative financial instruments in the Statement of financial position at fair value on the date on which a derivative contract is entered into (the best evidence of fair value on day one is the transaction price). Discovery subsequently remeasures these instruments to fair value. The method of recognising the resulting fair value gain or loss depends on whether the derivative is designated as a hedging instrument, and if so, the nature of the item being hedged. Fair values are obtained from quoted prices in active markets, including recent market transactions, and valuation techniques, including discounted cash flow models and options pricing models, as appropriate. All derivatives are carried as assets when the fair value is positive and as liabilities when the fair value is negative. 10.1 Hedge accounting HEDGE ACCOUNTING PRIOR TO 1 JULY 2022 Discovery applied IAS 39 for its hedging relationships that met IAS 39 hedging accounting requirements for the financial year ended 30 June 2022 and prior periods. Where Discovery held derivatives for risk management purposes, and the transactions met the IAS 39 required criteria for documentation and hedge effectiveness, Discovery applied cash flow hedge accounting to the risks being hedged. Discovery assessed on an ongoing basis whether the hedge(s) had been highly effective. A hedge under IAS 39 is regarded as highly effective only when offsetting changes in fair value or cash flows attributable to the hedged risk during the period are within a range of between 80% and 125%. Discovery duly documented the following as required in IFRS under IAS 39 Financial Instruments: Recognition and Measurement for hedge accounting purposes: Relationship between hedging instruments and hedged items Risk management objective and strategy for undertaking various hedge transactions, and Assessments, both at hedge inception and on an ongoing basis, of whether the derivatives that are used in hedging transactions are expected to be and have been highly effective in offsetting changes in fair values or cash flows of hedged items. -- 160 of 217 -- 160 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 10. Derivative financial instruments continued 10.1 Hedge accounting continued HEDGE ACCOUNTING AFTER 1 JULY 2022 Discovery has elected to adopt and transition to IFRS 9 general hedge accounting prospectively from 1 July 2022. The revised general hedge accounting requirements closer aligned with Discovery’s risk management activities. Discovery currently applies hedge accounting to certain cash flow hedges of interest rate risk. The total hedge reserve remains unchanged on transition to IFRS 9 general hedge accounting. The impact on the Group financial results, disclosures or comparative information as a result of these amendments is immaterial. Under general hedge accounting, Discovery has ensured that derivatives that qualify for cash flow hedge accounting are those derivatives designated as hedges of highly probable future cash flows attributable to a recognised asset or liability, or a forecasted transaction. Discovery applies hedge accounting when the hedging relationship meets the following requirements: There is an economic relationship between the hedged item and the hedging instrument. The effect of credit risk does not dominate the value changes that result from that economic relationship, and The hedge ratio of the hedging relationship is the same as that resulting from the quantity of the hedged item that the entity actually hedges and the quantity of the hedging instrument that the entity actually uses to hedge that quantity of hedged item. Discovery documents at inception of the transaction, the relationship between hedged items and hedging instruments, as well as its risk management objective and strategy for undertaking various hedging relationships. Discovery also documents its assessment, both at the inception of the hedge and on an ongoing basis, of whether the derivatives that are used in hedging transactions are expected to be and have been highly effective in offsetting changes in fair values or cash flows of hedged items. As of 1 July 2022, the hedge documentation for all Discovery interest rate micro hedges has been updated to comply with the requirements of IFRS 9 general hedge accounting. 10.2 Cash flow hedge Discovery recognises the effective portion of fair value changes of derivatives that are designated as cash flow hedges in the cash flow hedging reserve in the Statement of other comprehensive income. The gain or loss relating to the ineffective portion is recognised immediately in profit or loss, within Net fair value gains on financial assets at fair value through profit or loss in the Income statement. Amounts accumulated in the Statement of other comprehensive income are recycled to profit or loss in the period in which the hedged item will affect profit or loss. Where the forecast transaction or a foreign currency firm commitment results in the recognition of a non-financial asset or liability, the gains and losses previously deferred are transferred from the Statement of other comprehensive income and included in the initial measurement of the cost of the non-financial asset or liability. Where the forecast transaction subsequently results in the recognition of a financial asset or liability, gains or losses deferred in equity are transferred from the Statement of other comprehensive income to profit or loss when the financial asset or liability is sold or impaired. When a hedging instrument expires or is sold, or when a hedge no longer meets the criteria for hedge accounting, any cumulative gain or loss existing in equity at that time remains in equity and is recognised when the forecast transaction is ultimately recognised in profit or loss. When a forecast transaction is no longer expected to occur, the cumulative gain or loss that was reported in equity is immediately transferred to profit or loss. 10.3 Derivatives that do not qualify for hedge accounting Certain derivative instruments do not qualify for hedge accounting. Changes in the fair value of all such derivative instruments are recognised immediately in profit or loss, within Net fair value gains on financial assets at fair value through profit or loss in the Income statement. 10.4 Hedging reserve The hedging reserve includes the cash flow hedge reserve. The cash flow hedge reserve is used to recognise the effective portion of gains or losses on derivatives that are designated and qualify as cash flow hedges. Amounts are subsequently recycled to profit or loss as follows: For the effective portion recycled for hedges relating to share-based payments, as part of marketing and administration expenses (staff costs), and For the effective portion recycled for hedges relating to interest rate risk, as part of finance costs. -- 161 of 217 -- 161 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 10. Derivative financial instruments continued 10.5 Interbank offered rates (IBOR) reforms A fundamental reform of major interest rate benchmarks is being undertaken globally, including the replacement of some IBORs with alternative nearly risk-free rates (referred to as ’IBOR reform’). The Group has exposures to IBORs on its financial instruments, which have been or will be replaced or reformed as part of these market-wide initiatives, such as Libor and Jibar. The United Kingdom has seen a change from the GBP Libor to the Reformed Sterling Overnight Index Average (SONIA). The South African Reserve Bank has indicated its intention to move away from Jibar and to create an alternative reference rate for South Africa. However, there is currently no indication when the designated successor rate will be made available. The IBOR reforms will generally result in changes in the basis for determining the contractual cash flows of financial assets and financial liabilities, including derivatives. For financial assets and liabilities measured at amortised cost, an entity will update the effective interest rate only if: The change is necessary as a direct consequence of reform, and The new basis for determining the contractual cash flows is economically equivalent to the previous basis. For the purpose of cash flow hedges (see accounting policy 10.2), in determining whether a forecast transaction is highly probable, an entity will assume that the interest rate benchmark on which the hedged cash flows are based is not altered as a result of IBOR reforms. The Group anticipates that IBOR reform will impact some of its Jibar risk management and hedge accounting relationships in the longer term. However, as noted, there is no indication of a designated successor rate for Jibar. 11. Cash and cash equivalents Cash and cash equivalents comprise: Cash in hand Deposits held at call and short notice, and Balances with banks. Cash and cash equivalents only include items held for the purpose of meeting short-term cash commitments rather than for investing or other purposes. Cash and cash equivalents have a maturity of less than three months from the date of acquisition. Cash and cash equivalents are carried at amortised cost (or in specified instances at fair value through profit or loss) which, due to their short-term nature, approximates fair value. Due to Discovery’s sweeping arrangements in force with various financial institutions, positive and negative cash balances are presented on a net basis for the purpose of presenting cash and cash equivalents in the statement of cash flows. 12. Share capital Shares are classified as equity when there is no contractual obligation to transfer cash or other financial assets to the holder. Incremental costs directly related to the issue of new shares or options are shown in equity as a deduction from the proceeds, net of tax. Where any Group company purchases Discovery Limited equity share capital (treasury shares), the consideration paid, including any directly attributable incremental costs (net of income taxes), is deducted from equity attributable to Discovery Limited equity holders. Where such shares are subsequently sold, reissued or otherwise disposed of, any consideration received is included in equity attributable to Discovery Limited equity holders, net of any directly attributable incremental transaction costs and the related income tax effects. 13. Insurance contracts Insurance contracts are those contracts that transfer significant insurance risk. Such contracts may also transfer financial risk. Discovery defines significant insurance risk as the possibility of having to pay benefits, on the occurrence of an insured event, that are significantly more than the benefits payable if the insured event did not occur. Discovery developed its accounting policies for insurance contracts before the adoption of IFRS 4. As provided for in IFRS 4, Discovery continues to apply these same accounting policies for the recognition and measurement of obligations arising from insurance contracts that it issues and reinsurance contracts that it holds. -- 162 of 217 -- 162 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 13. Insurance contracts continued 13.1 Recognition and measurement Insurance contracts are classified into four main categories, depending on the duration of the risk and the type of risk insured. 13.1.1 INDIVIDUAL LIFE INSURANCE These contracts insure against a comprehensive spectrum of risks, including life, disability, severe illness and income continuation cover. These contracts are long term in nature. VALUATION OF POLICYHOLDER LIABILITIES The actuarial value of policyholder liabilities is determined based on a prospective discounted cash flow valuation basis calculated as the difference between the present value of future benefit payments plus expenses and the present value of future premiums. Best estimate assumptions regarding the future expected claims experience, premium income, expenses and commission are used. Where the same policy includes both insurance and investment components and where the policy is classified as an insurance policy, the liability for the insurance benefits and investment benefits are separately calculated. These components of the liability are not unbundled for reporting purposes. (Refer to accounting policy 14 for the recognition and measurement of investment benefit liabilities). Where the value of policyholder liabilities is negative in aggregate, this is shown as Assets arising from insurance contracts. Applying the valuation basis using the best estimate assumptions described above, would result in a gain at initial recognition. Compulsory and discretionary margins are therefore added to the best estimate assumption to avoid the premature recognition of future profits. At initial recognition, profits are recognised to the extent of the actual acquisition costs incurred but considering the premium loadings available on the total portfolio to recoup acquisition costs. Discretionary and compulsory margins are therefore added to the best estimate assumptions within the following framework. All margins are at least equal to the compulsory margins prescribed by regulations. For the discount rate and lapse rate margins, the direction of the margins may vary based on policy type and duration to ensure that the margin is in the conservative direction, overall. Given the level of uncertainty in the best estimate assumptions for lapse, mortality and morbidity, margins are added to protect against future possible adverse experience. Additional margins are added to allow for the release of profit over the term of the policy. Margins are released over the term of a policy in line with the risk borne. The best estimate assumptions and margins are reset at every valuation date to reflect the underlying profitability of the portfolio. Changes to assumptions, models and benefits are therefore offset at the portfolio level through an increase in discretionary margin (or release if sufficient discretionary margin exists). The impact of experience variances (with the exception of lapse and mortality experience) on the end-of-period prospective liability recognised in respect of in-force policies is offset at the portfolio level against an increase in discretionary margin (or release if sufficient discretionary margin exists). The impact of experience variances on the in-period cash flows is accounted for in profit or loss for the period and not offset through changes in discretionary margins. Where insurance contracts are backed by assets, other than negative reserves, changes in economic assumptions are recognised directly in profit or loss. Discovery has established a procedure to utilise the available discretionary margin in a specified order. First, Discovery will utilise available discretionary margins to absorb all experience items on in-force policies. This is after in-period experience variances which are recognised immediately in profit or loss as noted above. Secondly, Discovery utilises available discretionary margins to offset non-economic assumption variances, model, and benefit changes. Lastly, the discretionary margins are utilised to offset economic assumption changes. Where there are insufficient discretionary margins to offset losses arising from negative changes in non-economic assumptions, models and benefit and or negative changes in economic assumptions, those losses in excess of the discretionary margin are recognised immediately in profit or loss; and In subsequent periods, positive changes in economic assumptions and positive variance in non-economic assumptions, models and benefits are first recognised separately in profit or loss to extent that it reverses related losses previously recognised in profit or loss. This is in the reversed sequence in which the negative variances were utilised against discretionary margin and any excess previously recognised in profit or loss. -- 163 of 217 -- 163 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 13. Insurance contracts continued 13.1 Recognition and measurement continued 13.1.1 INDIVIDUAL LIFE INSURANCE continued Contractual premium and benefit increases are included in the valuation of the policyholder liability. It is further assumed that no voluntary benefits are taken up where a future take-up of these benefits would reduce the liability. This is in line with South African actuarial guidance which requires that expected profits in respect of future options that may be taken up by policyholders should not be recognised in the policyholder liability. The actuarial liabilities are calculated gross of reinsurance. The expected impact of reinsurance is valued separately. The valuation basis meets the requirement of the liability adequacy test as required by IFRS 4 for individual life insurance and no additional tests are performed. The liability estimates are reviewed at every reporting period and any changes in estimates to the liability are reflected in profit or loss as they occur. PREMIUM REVENUE For individual life insurance contracts, premiums are recognised as revenue when due. Premiums are shown net of premium discounts received, premiums provided for as bad debts and before the deduction of commission. Premiums exclude taxes and levies. INSURANCE BENEFITS AND CLAIMS Insurance benefits and claims relating to individual life insurance contracts are recognised in profit or loss based on the estimated liability for benefits owed to the contract holders. Death, disability and severe illness and surrender claims are accounted for when notified. These claims include claims reported but not yet validated. The estimate is determined taking into account the likelihood of the claim being valid and the expected severity of the claim given that the claim is valid. The proportion to be included is estimated separately for each benefit type. An estimate of the expected claim amount is charged to profit or loss and included in liabilities under insurance contracts. Maturity and income disability are recorded as incurred. Liabilities are held to reflect incurred but not yet reported (IBNR) claims. The IBNR liabilities are modified to reflect actual current operating conditions. The liabilities are calculated gross of reinsurance. An asset is then raised to allow for the expected recoveries from reinsurers. ACQUISITION COSTS Acquisition costs for these contracts represent commission and other costs that relate to the securing of new contracts and the renewing of existing contracts. The valuation basis for valuing insurance contracts makes implicit allowance for the deferral of acquisition costs and, hence, no explicit deferred acquisition cost asset is recognised in the Statement of financial position. These are expensed in profit or loss. 13.1.2 GROUP LIFE INSURANCE These contracts insure against a comprehensive spectrum of protection benefits on a group basis. Life cover, severe illness, disability and income continuation benefits are offered. These contracts are short term in nature. PREMIUM REVENUE For group life insurance contracts, premiums are recognised as revenue when due. Premiums are shown net of premiums provided for as bad debts, before the deduction of commission and exclude taxes and levies. INSURANCE BENEFITS AND CLAIMS Insurance benefits and claims relating to group life insurance contracts are recognised in profit or loss based on the estimated liability for benefits owed to the contract holder. Death, disability and severe illness claims are accounted for when notified. These claims include claims reported but not yet validated. The estimate is determined taking into account the likelihood of the claim being valid and the expected severity of the claim given that the claim is valid. The proportion to be included is estimated separately for each benefit type. An estimate of the expected claim amount is charged to profit or loss and included in liabilities under insurance contracts. Income disability is recorded as incurred. Liabilities are held to reflect IBNR claims. The IBNR is modified to reflect actual current operating conditions. The liabilities are calculated gross of reinsurance. An asset is then raised to allow for the expected recoveries from reinsurers. ACQUISITION COSTS Acquisition costs for group life insurance contracts comprise all direct costs arising from the sale of insurance contracts. Commission expenses are expensed. -- 164 of 217 -- 164 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 13. Insurance contracts continued 13.1 Recognition and measurement continued 13.1.3 HEALTH INSURANCE These contracts insure policyholders against healthcare-related claims. PREMIUM REVENUE Health insurance premiums received in respect of annual contracts are recognised proportionally over the period of the coverage. The portion of the premium received on in-force contracts that relates to unexpired risks at the reporting period is reported as unearned premiums within Liabilities arising from insurance contracts. The unearned premium income is amortised on a straight- line basis. INSURANCE BENEFITS AND CLAIMS Benefits payable under health insurance contracts are accounted for as incurred. Liabilities are held to reflect IBNR claims. The IBNR calculation is performed using the chain ladder approach. This allows for the historic patterns of claims payment in determining the likely future emergence of claims. The IBNR is further modified to reflect current operational conditions or known events. The liabilities are calculated gross of reinsurance. An asset is then raised to allow for the expected recovery from reinsurers. DEFERRED ACQUISITION COSTS The direct costs (commissions) of acquiring short-term health insurance business which are incurred during the year, but which are expected to be recoverable out of future revenue margins, are deferred and disclosed as an asset in the Statement of financial position (gross of tax). The costs are deferred over the period of the contract and amortised on a straight-line basis in line with unearned premiums. FINANCIAL REINSURANCE Where a financial reinsurance contract is taken out to protect against lapses, all acquisition costs related to the policy are effectively deferred over the period of the reinsurance contract. 13.1.4 SHORT-TERM INSURANCE These contracts insure policyholders against a comprehensive spectrum of short-term risks including, but not limited to, motor vehicle and household cover. PREMIUM REVENUE Short-term insurance premiums received in respect of contracts are recognised as revenue when due. Premiums are shown before the deduction of commission, less the fuel cash back rewards described below, and exclude value-added tax. UNEARNED PREMIUM PROVISION An unearned premium provision (UPP) is created at the commencement of each insurance contract and is released as the risk covered by the contract expires. The UPP represents a proportion of premiums underwritten in the current year, which relate to risks which have not expired by the end of the financial year. This is calculated on a time-proportionate basis for even risks. Therefore, the unearned premium is released over the period of insurance using a method which approximates the time period of the risk covered. The unearned premium provision is calculated on a gross basis. REINSURANCE COMMISSION INCOME Reinsurance commission income is recognised in profit or loss over the period of the related direct insurance business assumed. INSURANCE BENEFITS AND CLAIMS Claims are accounted for as incurred and consist of claims paid, movement in the provision for outstanding claims and related claims handling expenses. The provision for outstanding claims is based on estimates of the cost of settling all claims incurred but unpaid at the reporting date, whether reported or not. Related anticipated reinsurance recoveries are disclosed separately as assets in the Statement of financial position and are included in recoveries from reinsurers in profit or loss. SALVAGE AND SUBROGATION RECOVERIES Certain short-term insurance contracts allow Discovery to sell property acquired as a result of a claim (salvage). Discovery may also have the legal right to pursue third parties for payment of some or all of the costs (subrogation). The estimated salvage and subrogation reimbursements are treated as a reduction in the measurement of claims liability. ACQUISITION COSTS Acquisition costs for these contracts comprise all direct costs arising from the sale of insurance contracts and are recognised in profit or loss for monthly policies. For the remainder of the policies, the acquisitions costs are deferred and amortised over the term of the contract. -- 165 of 217 -- 165 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 13. Insurance contracts continued 13.1 Recognition and measurement continued 13.1.4 SHORT-TERM INSURANCE continued INSURE FUNDER ACCOUNT (IFA) This relates to a benefit on a short-term insurance product. A fuel cash back can be used to either reduce the premium that the policyholder is required to pay for the month in question or can be doubled and paid into an IFA. Where the policyholder has used the fuel cash back to reduce the monthly premium, the reduction has been shown in insurance premium revenue in profit or loss as incurred. If the policyholder has elected to double the fuel cash back and paid it into an IFA, an IFA liability is raised. The IFA liability is calculated using a discounted cash flow approach and is disclosed in liabilities arising from insurance contracts in the Statement of financial position, and the movement is disclosed in the transfer to liabilities under insurance contracts. When the member uses funds in the IFA to pay for his excess or other costs, the excess is paid by Discovery, and an expense is included in claims in the income statement. Where the member withdraws the funds after three years, the member is paid out in cash, and an expense is disclosed against insurance premium revenue in the income statement. 13.2 Embedded derivatives arising from insurance contracts A unit-linked insurance contract is an insurance contract with an embedded derivative linking payments on the contract to units of an investment fund purchased with the consideration received from the contract holders. This embedded derivative meets the definition of an insurance contract and is therefore not accounted for separately from the host insurance contract. The liability for such contracts is adjusted for all changes in the fair value of the underlying assets. Discovery does not separately measure embedded derivatives that meet the definition of an insurance contract or options to surrender insurance contracts for a fixed amount (or amount based on a fixed amount and an interest rate). All other embedded derivatives are separated and carried at fair value if they are not closely related to the host insurance contract and meet the definition of a derivative. Embedded derivatives that are separated from the host contract are fair valued through profit or loss. 13.3 Liability adequacy test At the reporting date, liability adequacy tests are performed to ensure the adequacy of the contract liabilities net of related deferred acquisition costs. In performing these tests, current best estimates of future contractual cash flows and claims handling and administration expenses are used. Any deficiency is immediately charged to profit or loss initially by writing off deferred acquisition costs and by subsequently establishing a provision for losses arising from the liability adequacy test. 13.4 Reinsurance contracts Contracts entered into by Discovery with reinsurers under which Discovery is compensated for insured events on one or more contracts that meet the classification requirements for insurance contracts are classified as reinsurance contracts. Contracts that do not meet these classification requirements are classified as financial assets. Amounts recoverable from or due to reinsurers are measured consistently with the amounts associated with the reinsured insurance contracts and in accordance with the terms of each reinsurance contract. The amounts Discovery is required to pay under its reinsurance contracts held are recognised as reinsurance liabilities (liabilities arising from reinsurance contracts). Outward reinsurance premiums are recognised as an expense and are accounted for when due under the reinsurance contract. The amounts due to Discovery under its reinsurance contracts are recognised as reinsurance assets (classified within insurance receivables). Discovery assesses its reinsurance assets for impairment on an annual basis. In certain cases there is a net gain or loss at inception of a reinsurance contract: Where these amounts relate directly to a reimbursement of expenses, the gain is disclosed as a recovery of expenses from reinsurers, or Other gains or losses are amortised over the life of the reinsurance contract on a consistent basis as the profit is expected to emerge on the underlying policies but considering the contractual terms and intent of the specific reinsurance contract. A reinsurance asset is impaired if, and only if: there is objective evidence, as a result of an event that occurred after initial recognition of the reinsurance asset, that the cedant may not receive all amounts due to it under the terms of the contract, and that event has a reliably measurable impact on the amounts that the cedant will receive from the reinsurer. In certain cases there is a net gain or loss upon early termination of a reinsurance contract. Where these amounts result directly from the termination, they are recognised as at the termination date and disclosed as recapture of reinsurance in profit or loss. -- 166 of 217 -- 166 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 13. Insurance contracts continued 13.5 Receivables and payables related to insurance contracts Receivables and payables are recognised when due. These include amounts due to and from agents, brokers and insurance contract holders. Amounts due are measured consistently and where applicable, provisions for impairments are recognised. 13.6 Derecognition of insurance contracts An insurance liability, or a part of such a liability, can be removed from the statement of financial position (derecognised) when, and only when, it lapses or is extinguished i.e., when the obligation specified in the contract is discharged, cancelled or expires. 14. Investment contracts Investment contracts are those contracts that transfer financial risk without significant insurance risk. Financial risk refers to the risk of a possible future change in the value of an asset or financial instrument due to a change in interest rate, commodity price, index of prices, foreign exchange rate or other measurable variables. Discovery issues investment contracts without fixed benefits (e.g. unit-linked and structured products) and investment contracts with fixed and guaranteed benefits (e.g. term certain annuity). Valuation of policyholder liabilities Investment contracts without fixed benefits are financial liabilities whose fair value is dependent on the fair value of the underlying financial assets and derivatives (unit-linked) which are classified at fair value through profit or loss. Discovery designates these investment contracts to be measured at fair value through profit or loss because it eliminates or significantly reduces a measurement or recognition inconsistency that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases. See accounting policy 9 for the accounting treatment of the financial assets backing these liabilities. Discovery’s main valuation techniques incorporate all factors that market participants would consider and are based on observable market data. The fair value of a unit-linked financial liability is determined using the current unit price that reflects the fair values of the financial assets contained within Discovery’s unitised investment funds linked to the financial liability. The fair value of the financial liabilities is obtained by multiplying the number of units attributed to each policyholder at the reporting date by the unit price for the same date. For investment contracts with fixed and guaranteed terms, valuation techniques are used to establish the fair value at inception and at each reporting date. Valuation techniques include discounted cash flow analysis using current market rates of interest and reference to other instruments that are substantially the same. Premium revenue All premiums received under investment contracts are recorded as deposits to investment contract liabilities and claims incurred on investment contracts are recorded as deductions from investment contract liabilities. Fees on investment contracts Service fee income on investment management contracts is recognised over time as and when the related performance obligation is satisfied. Refer to accounting policy note 20 Fees on investment contracts are included in fee income from administration business. A deferred revenue liability (DRL) is recognised as a contract liability to contracts with customers in respect of upfront fees for financial advice, investment management and other services which are directly attributable to a contract that is charged for securing the investment management service contract. The DRL is then released to revenue when the performance obligations are satisfied, which corresponds to the underlying expected profit signature of the contract. Regular fees are charged to the customer monthly, either directly or by making a deduction from invested funds. Costs of obtaining contracts Deferred acquisition costs on investment contracts represent the contractual customer relationship and the right to receive future investment management fees. Incremental costs directly attributable to securing rights to receive policy fees for services sold with investment contracts are recognised as an asset where they can be identified separately and measured reliably and it is probable that they will be recovered. An incremental cost is one that would not have been incurred if the Group had not secured the investment contract. The asset represents the Group’s contractual right to benefit from providing asset management services and is amortised over the expected life of the contract as the entity recognises the related revenue. 15. Borrowings Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortised cost. Any difference between the proceeds and the redemption value is recognised in profit or loss over the period of the borrowings using the effective interest method. Fees paid on the establishment of loan facilities are recognised as transaction costs against the loan to the extent that it is probable that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw-down occurs. To the extent there is no evidence that it is probable that some or all of the facility will be drawn down, the fee is capitalised as a prepayment and amortised over the period of the facility to which it relates. -- 167 of 217 -- 167 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 16. Income Tax 16.1 Current tax Discovery calculates and measures current tax at the amount expected to be paid to or recovered from the taxation authorities. Discovery uses the tax rates and tax laws that have been enacted or substantively enacted at the end of the reporting period. 16.2 Deferred tax Discovery calculates deferred tax on all temporary differences using the Statement of financial position approach. Deferred tax liabilities or assets are calculated by applying corporate tax rates that have been substantively enacted to the temporary differences between the tax values of assets and liabilities and their carrying amount, where such temporary differences are expected to result in taxable or deductible amounts in determining taxable income for future periods when the carrying amount of the assets or liabilities are recovered or settled. Discovery recognises deferred tax assets if the management of Discovery consider it probable that future taxable income will be available against which the tax losses can be utilised. Temporary differences arise primarily from the difference between accounting and tax balances arising from insurance contracts, depreciation of property and equipment, effect of accounting for leases, revaluation of certain financial assets and liabilities, provisions for leave pay, provisions for share-based payments and tax losses carried forward. For leases, Discovery assesses the lease asset and lease liability together as a single transaction and assesses the temporary difference on a net basis. Deferred tax is not accounted for if it arises from initial recognition of goodwill, or initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable income at the time of the transaction, does not give rise to equal taxable and deductible temporary differences. Deferred tax related to cash flow hedges, which are charged or credited directly to the statement of other comprehensive income, is also credited or charged directly to the statement of other comprehensive income and is subsequently recognised in profit or loss when the gain or loss is realised. Deferred tax assets and liabilities are offset when: There is a legally enforceable right to offset current tax assets against current tax liabilities, and When the deferred tax assets and liabilities relate to income taxes levied by the same taxation authority on either the taxable entity or different taxable entities where there is an intention to settle the balances on a net basis. If offsetting does not apply, Discovery separately discloses the deferred tax asset and deferred tax liability. 17. Employee benefits 17.1 Short-term employee benefits Short-term employee benefits are expensed as the related service is provided. A liability is recognised for the amount expected to be paid if Discovery has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably. 17.2 Post-employment benefits Discovery operates defined contribution schemes, the assets of which are held in separate private trustee-administered funds. Discovery pays contributions to these funds on a mandatory basis. These funds are registered in terms of the Pension Funds Act, 1956, and membership is compulsory for all Discovery employees. Qualified actuaries perform annual valuations. Discovery has no further payment obligations once the contributions have been paid. The contributions are recognised as an employee benefit expense when they are due. 17.3 Share-based compensation Discovery operates equity-settled and cash-settled share-based compensation plans. EQUITY-SETTLED SHARE-BASED COMPENSATION PLANS Discovery expenses the fair value of the employee services received in exchange for the grant of the options, over the vesting period of the awards, as employee costs in profit or loss, with a corresponding credit to a share-based payment reserve in the Statement of changes in equity. The total value of the services received is calculated with reference to the fair value of the options on grant date. The fair values of the options are determined excluding non-market vesting conditions. These vesting conditions are included in the assumptions of the number of options expected to vest. At each reporting date, Discovery revises its estimate of the number of options expected to vest. Any changes to the estimated number of options are recognised in profit or loss immediately. CASH-SETTLED SHARE-BASED COMPENSATION PLANS Discovery recognises employee services received in exchange for cash-settled share-based payments at the fair value of the liability incurred and expenses these services over the vesting period of the benefits, as employee costs in profit or loss. The liability is re-measured at each reporting period to its fair value, with all changes recognised immediately in profit or loss. -- 168 of 217 -- 168 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 17. Employee benefits continued 17.4 Leave pay Discovery accrues in full the employees’ rights to annual leave entitlement in respect of past service. This is expensed over the period the services are rendered. 17.5 Profit share and bonus plan Discovery operates several other profit-sharing and bonus compensation arrangements and recognises these when a constructive obligation has been created by past practice. These are calculated with reference to predetermined formulae. The Group has other deferred compensation schemes in place where employees are incentivised based on a variable other than the share price of Discovery Limited, such as embedded value, value of in-force and earnings multiples. Discovery recognises a liability and the related expense is included in employee costs in profit or loss. 18. Trade and other payables Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if payment is due within one year or less from the reporting date. If not, they are presented as non-current liabilities. Trade payables are recognised initially at fair value net of directly attributable transaction costs and subsequently measured at amortised cost using the effective interest method. 19. Contingent liabilities Discovery discloses a contingent liability when: It has a possible obligation arising from past events, the existence of which will be confirmed, only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity, or It has a present obligation that arises from past events but not recognised because: – It is not probable that an outflow of resources will be required to settle an obligation, or – The amount of the obligation cannot be measured with sufficient reliability. 20. Revenue recognition The Group’s primary source of revenue arises on the sale of insurance contracts which are accounted for under IFRS 4 Insurance Contracts and are excluded from the scope of IFRS 15 Revenue from Contracts with Customers. IFRS 15 is applicable to the Group’s revenue from administration business, Vitality income and banking fee and commission income. IFRS 15 requires that once contracts have been identified, the entity identifies the performance obligations in the contract. This is determined on the basis of whether the customer can benefit from the promised good or service individually or together with other readily available resources and whether the performance obligation is distinct in the context of the contract. For the Group, most contracts contained a single performance obligation. The timing of revenue recognition is dependent on whether the entity transfers control over the good or service over time or at a point in time. In determining the appropriate timing for revenue recognition, the Group considers whether the customer benefits as the entity performs. For most revenue types, Group entities provide stand-ready services to customers, where customers benefit as the entity’s services are consumed. In limited instances where revenue is not recognised over time it is recognised at a point in time when control transfers. For revenue recognised over time the stand-ready service is recognised straight line over the term of the contract. In determining the amount of revenue to recognise, the Group considers any uncertainty created through variable consideration contained in the contract, and constrains the recognition of revenue in order to recognise revenue only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty is resolved. The Group also considers the impact of the timing of receiving payments for revenue transactions and determines whether a significant financing component should be taken into account in the measurement of the transaction price. As the Group’s contracts routinely include single performance obligations, there is limited complexity in allocating transaction prices to performance obligations. Payment terms vary across the different revenue types earned by the Group. Where contracts with customers involve a third party, the Group considers whether it is acting as the principal or the agent in the delivery of the promised goods or services to the customer. This assessment is based on whether the Group controls the goods or services before it is transferred to the customer. For certain contracts with customers, Discovery receives income in advance of discharging the related performance obligation. In these instances, the amount is recognised as a contract liability incurred in the acquisition or fulfilment of a contract. Discovery considers whether there are costs incurred for the acquisition or fulfilment of a contract. These costs are recognised as an asset and amortised over the expected period over which performance obligations under the contract are satisfied. Contract costs incurred that are considered to be of a general and administrative nature, that are not explicitly recovered from the customer, are expensed as incurred. Where the transaction price included in a contract is payable less than 12 months from the date of satisfying the related performance obligation, the practical expedient is applied in that a significant financing component is not recognised. Similarly, where costs of obtaining a contract would be amortised over 1 year or less, the costs are not recognised as a separate asset. -- 169 of 217 -- 169 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 20. Revenue recognition continued Fee income from administration business Vitality income Banking fee and commission income Nature of performance obligations Fee income is recognised on health administration and managed care services rendered. Fee income is also generated on asset administration and fees earned on use of intellectual property. In the respective business, these are considered revenue and are seen as single performance obligations in the respective legal entities. These are presented per reporting entity in the segment report shown in note 1. Vitality income includes the fee income that members pay to access the Vitality benefit, as well as various activation fees for activating additional benefits. The performance obligation relates to access to the Vitality programme and partner benefits provided to members. Banking fee and commission income includes banking service fees for banking services. The performance obligation relates to the access to banking and banking services rendered. Commission income relates to the interchange fees which Discovery Bank earns on transactions using debit or credit cards. The performance obligation relates to settlement of transactions via the card network. When does control pass – Point in time (PIT) vs over time Performance obligations to provide administration services are considered stand-ready services. The customer obtains control over the service as the entity makes its services available on an “as and when” basis. As a result, revenue is recognised over time, as the respective entity makes the services available based on the passage of time. Performance obligations to provide access to benefits are considered stand-ready services. The customers obtain benefits when required, over the duration of the contract. As a result, revenue is recognised over time based on the passage of time. The performance obligation associated with the banking fee and commission income passes over time because the client obtains substantially all of the remaining benefits from the service over the period of the month for which the banking fee was charged. When are amounts payable Amounts are billed on health administration and managed care business at the end of the respective month with amounts paid within 30 days. For fees on asset administration business, amounts are disinvested for the units held at the end of the related month. Certain fees, for example, advisor fees are received upfront but are deferred as a contract liability over the expected term of the entity’s performance. Amounts are billed either monthly, payable within 30 days, or billed on activation of the benefit, payable immediately. Banking fees are charged monthly, and payment is immediate. Interchange income is charged at a point of payment and settled daily in batch format. -- 170 of 217 -- 170 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 20. Revenue recognition continued Fee income from administration business Vitality Income Banking fee and commission income Variable consideration and estimates There is no potential for amounts of revenue to vary relating to discounts or rebates on the health administration business. For the asset administration business, fees are determined with reference to assets under management at a point in time. There are no benchmark performance- based fees. The nature of the integrated products that Discovery sells related to the invest business allows for fee discounts and rebates to be determined based on client behaviour. Revenue is estimated and recognised in line with the constraint on variable consideration, only to the extent that it is highly probable that there will not be a significant reversal of revenue already recognised once the uncertainty is resolved. The fee discounts and rebates are determined according to a fixed methodology incorporating policyholder specific information including Vitality status. Discovery has experience in estimating these amounts, which are based on a limited number of outcomes. There is no financing component. There are no adjustments to the transaction price as a result of any variable consideration. There is no significant financing component. There are no adjustments to the transaction price as a result of any variable consideration. There is no significant financing component. Costs to capitalise Where costs are incurred directly to secure a new health administration customer, and the contract is expected to exceed 12 months, the costs are capitalised and amortised over the expected term of the contract. Costs are routinely incurred on the asset administration business related to commission and other incremental costs of entering into the contract. These are capitalised and recognised over the expected duration of the customer relationship. These assets are tested for impairment to the extent that the carrying amount of the asset exceeds the expected remaining net cash inflows from the customer contract. In respect of the Apple watch benefit, Discovery incurs costs upfront to purchase the device and provide it to the customer. These costs are deferred and recognised over the two-year term of the benefit. None. Discovery presents any unconditional rights to consideration separately as a receivable. Discovery assesses a contract asset for impairment in accordance with IFRS 9. An impairment of a contract asset is measured, presented and disclosed on the same basis as a financial asset that is within the scope of IFRS 9. Any impairment losses recognised on any receivables or contract assets arising from Discovery’s contracts with customers, is disclosed separately from impairment losses from other contracts. Insurance premium revenue Insurance premium revenue includes individual life insurance premiums, group life insurance premiums, health insurance premiums and short-term insurance premiums. These are accounted for as described in accounting policy 13. -- 171 of 217 -- 171 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 21. Other non-revenue income 21.1 Investment income Investment income comprises dividends and interest received from assets held at amortised cost and cash and cash equivalents. Discovery recognises dividends when Discovery’s right-to-receive payment is established. This is on the “last day to trade” for listed shares and on the “date of declaration” for unlisted shares. Dividend income includes scrip dividends, irrespective of whether there is an option to receive cash instead of shares. Interest is accounted for on an accrual basis using the effective interest method. 21.2 Net fair value gains on financial assets at fair value through profit or loss Net fair value gains on financial assets at fair value through profit or loss include gains arising from interest, dividends and net realised and unrealised gains on financial assets held at fair value through profit or loss. 22. Leases IDENTIFICATION OF A LEASE At inception of a contract, Discovery assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, Discovery uses the definition of a lease in IFRS 16. Contracts where the service provider has a substantive right to substitute the asset for an alternative asset during the lease term is not regarded as a lease, but instead a service contract. Accordingly, these contracts are not accounted for in accordance with IFRS 16. For Discovery, such contracts include items such as vending machines. 22.1 As a lessee At commencement or on modification of a contract that contains a lease component, Discovery allocates the consideration in the contract to each lease component on the basis of its relative stand-alone prices. However, for the leases of property Discovery has elected not to separate non-lease components and account for the lease and non-lease components as a single lease component. Discovery recognises a right-of-use asset and a lease liability at the lease commencement date. Discovery presents right-of-use assets in ’Property and equipment’ and lease liabilities in ’Borrowings at amortised cost’ in the Statement of financial position. Discovery leases the following assets with a range of lease terms: – Large offices 5 – 15 years – Small offices/Franchise offices (SA only) 1 – 3 years – Computer equipment (e.g. servers) (SA only) 3 – 4 years – Motor vehicles (UK only) 3 years MEASUREMENT LEASE LIABILITY The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the lessee’s incremental borrowing rate. Generally, Discovery uses its incremental borrowing rate as the discount rate. Discovery determines its incremental borrowing rate by obtaining interest rates from various external financing sources and makes certain adjustments to reflect the terms of the lease and type of the asset leased. The incremental borrowing rates were calculated for each legal entity within Discovery that entered into lease arrangements. The incremental borrowing rate considers a base interest rate reflective of the jurisdiction in which the legal entity operates (South Africa, United Kingdom and United States of America), the term of the lease arrangement and the nature of the assets. -- 172 of 217 -- 172 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 22. Leases continued 22.1 As a lessee continued Lease payments included in the measurement of the lease liability comprise the following: Fixed payments, including in-substance fixed payments, less any lease incentives receivable. Variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date. Amounts expected to be payable under a residual value guarantee, and The exercise price under a purchase option that Discovery is reasonably certain to exercise, lease payments in an optional renewal period if Discovery is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless Discovery is reasonably certain not to terminate early. Extension or termination options are included in a number of the building leases across Discovery. These terms are used to maximise operational flexibility in terms of managing contracts. In determining the lease term, management considers all facts and circumstances that create an economic incentive to exercise an extension option, or not exercise a termination option. Extension options (or periods after termination options) are considered in the lease term when there is reasonable certainty that those options will be exercised. The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in Discovery’s estimate of the amount expected to be payable under a residual value guarantee, if Discovery changes its assessment of whether it will exercise a purchase, extension or termination option or if there is a revised in-substance fixed lease payment. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero. RIGHT-OF-USE ASSET The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, including lease incentives received, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset, less any lease incentives received. Discovery receives incentives such as reimbursements for installations or rent-free periods. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term, unless the lease transfers ownership of the underlying asset to Discovery by the end of the lease term or the cost of the right-of-use asset reflects that Discovery will exercise a purchase option. In that case the right-of-use asset will be depreciated over the useful life of the underlying asset, which is determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability. SHORT-TERM LEASES AND LOW-VALUE ITEMS Discovery has elected not to recognise right-of-use assets and lease liabilities for leases of low-value assets and short-term leases. Discovery recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term. Leases of low-value assets relate to those categories of assets which at inception of the lease typically have a value, if bought new, of no more than approximately R70 000. For Discovery, these categories include computer equipment such as desktops, laptops, monitors and related IT peripherals. Short-term leases are those leases with a lease term of less than 12 months. 22.2 As a lessor At inception or on modification of a contract that contains a lease component, Discovery allocates the consideration in the contract to each lease component on the basis of their relative standalone prices. CLASSIFICATION To classify the lease, Discovery makes an overall assessment of whether the lease transfers substantially all of the risks and rewards incidental to ownership of the underlying asset. If this is the case, then the lease is a finance lease; if not, then it is an operating lease. As part of this assessment, Discovery considers indicators such as whether the lease is for the major part of the economic life of the asset, the specialised nature of the asset and the present value of lease payments. -- 173 of 217 -- 173 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 22. Leases continued 22.2 As a lessor continued Discovery leases out portions of its leased property in the form of subleases. Discovery has classified these leases as operating leases. MEASUREMENT As Discovery is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right-of-use asset arising from the head lease, not with reference to the underlying leased asset. If an arrangement contains lease and non-lease components, Discovery applies IFRS 15 Revenue from Contracts with Customers to allocate the consideration in the contract. Discovery recognises lease payments received under operating leases as income on a straight-line basis over the lease term as part of ’other income’. 23. Marketing and administration expenses Marketing and administration expenses include marketing and development expenditure, all other non-acquisition related expenditure and benefits paid under the Vitality programme. These costs are expensed in profit or loss as incurred. 24. Finance costs Finance costs (net of investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets) directly attributable to the acquisition, construction or production of assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. All other finance costs are recognised as an expense in profit or loss on an accrual basis using the effective interest method. In addition, finance costs include any recycled gains or losses from other comprehensive income arising from cash flow hedges of interest rates, amortisation of financing related fees such as loan commitment fees and letter of credit fees as well as modification gains and losses on borrowings. 25. Direct and indirect taxes Direct taxes include South African and foreign jurisdiction corporate tax payable and are disclosed as taxation in profit or loss. Refer to accounting policy 16. Indirect taxes include various other taxes paid to central and local governments, including value-added tax and skills development levies. Indirect taxes are included as part of marketing and administration expenses in profit or loss. 26. Dividend distribution Dividend distribution to Discovery Limited’s shareholders is recognised as a liability in the Group’s financial statements in the period in which the dividends are approved. -- 174 of 217 -- 174 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 27. Non-current assets held for sale Non-current assets, or disposal groups comprising assets and liabilities, are classified as held for sale if it is highly probable that they will be recovered primarily through sale rather than through continuing use. Such assets, or disposal groups, are generally measured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on a disposal group is allocated first to goodwill, and then to the remaining assets and liabilities on a pro-rata basis, except that no loss is allocated to inventories, financial assets, deferred tax assets, employee benefit assets, investment property or biological assets, which continue to be measured in accordance with the Group’s other accounting policies. Impairment losses on initial classification as held for sale or held for distribution and subsequent gains and losses on remeasurement are recognised in profit or loss. Once classified as held for sale, intangible assets and property and equipment are no longer amortised or depreciated, and any equity-accounted investee is no longer equity-accounted. Interest and other expenses attributable to the liabilities of a disposal group classified as held for sale continue to be recognised. Non-current assets and liabilities classified as held for sale are presented separately from the other assets and liabilities in the Statement of financial position. 28. Government grants Discovery obtains government grants, e.g. from the Sector Education and Training Authority (SETA) to access the Skills Development Levies imposed on Discovery’s employees to encourage learning and development in South Africa. Discovery includes government grants in profit or loss using the income approach, including costs for skills programs and deducting these from grants that cover specific expenses in profit or loss. Discovery recognises government grants as income only if they are reasonably assured of receiving them and fulfilling all associated conditions. There are no other forms of government grants from which Discovery has directly benefited, and there are no conditions that Discovery has not fulfilled in recognition of the government grants recognised. 29. Normalised headline earnings Discovery assesses its performance using Normalised Headline Earnings, an alternative non-IFRS profit measure, alongside its IFRS profit. Management considers that Normalised Headline Earnings Per Share (NHEPS) is an appropriate alternative performance measure to enhance the comparability and understanding of the financial performance of Discovery. Non-IFRS measures are not uniformly defined or used by all entities and may not be comparable with similarly labelled measures and disclosures provided by other entities. Discovery has set out its policy to calculate NHEPS below. Discovery calculates headline earnings in accordance with the latest SAICA Circular ’Headline Earnings’. NHEPS is calculated by starting with headline earnings and adjusted to exclude material items that are not considered to be part of Discovery’s normal operations as follows: Once-off transactions, for example restructuring costs, transaction costs related to interest rate derivatives and initial deferred tax assets raised on previously unrecognised assessed losses. Unusual items – Discovery considers items to be unusual when they have limited predictive value or it is reasonable that items of a similar nature would not necessarily arise for several future annual reporting periods. These adjustments include those gains or losses impacting profit or loss associated with changes in economic assumptions used by long-term insurers in the Group to the extent those are recognised in profit or loss, net of any gains or losses on derivatives to offset such changes in economic assumptions, or Income or expenses not considered to be part of Discovery’s normal operations, for example, amortisation of intangibles from business combinations and fair value gains or losses on foreign exchange contracts not designated as hedges. In addition, specified items may be included in NHEPS that may otherwise be included if the income is considered part of Discovery’s normal operations, for example ’gains on disposal of intellectual property’, if the sale arises from the monetisation of intellectual property rights. Management is responsible for the calculation of NHEPS and determining the inclusions and exclusions in accordance with the policy. The Discovery Limited Audit Committee (DLAC) reviews the normalised headline earnings for transparency and consistency. -- 175 of 217 -- 175 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 29. Normalised headline earnings continued During the financial period, Discovery has made the following adjustments in the determination of NHEPS: Adjustment Explanation Changes in economic assumptions in excess of available discretionary margin (in future, this will also include the reversals of economic assumptions recognised in profit or loss) Economic assumptions include changes associated with interest rates as well as currency exchange rates. The adjustment reflects changes in economic assumptions for the time value of money and forex rates and the effect on insurance contracts resulting from changes in the long-term interest rates as well as forex rates. Under IFRS, where there are insufficient discretionary margins to offset losses arising from negative changes in economic assumptions, those losses in excess of the discretionary margin are recognised immediately in profit or loss. In subsequent periods, positive changes in economic assumptions are first recognised separately in profit or loss to the extent that it reverses related losses previously recognised in profit or loss before it increases discretionary margins. The effect of these economic assumptions is unusual and provides little predictive value for future periods. This is because the value is dependent on available discretionary margins at a given point in time and the long-term interest rates which could vary period to period – thereby introducing volatility and inability to be predictive on results during future periods. These adjustments are therefore excluded in assessing the normal business operations of Discovery. Intrinsic fair value changes on specified derivatives to offset changes in economic assumptions Long-term insurance business lines, for example VitalityLife enters into interest rate derivative instruments to offset the impact of changes in economic assumptions on insurance contracts. The adjustment reflects the intrinsic value of fair value gains or losses on these derivative instruments. The intrinsic value of fair value gains or losses on these derivative instruments are excluded from NHEPS to be consistent with the treatment of the changes in economic assumptions recognised in profit or loss. Fair value (gains)/losses on foreign exchange contracts not designated as a hedge The adjustment reflects fair value gains or losses on foreign exchange contracts entered in anticipation of future capital injections in foreign operations, such as PAC book transfer or Ping An Capital injections. These derivative instruments are not designated as a hedge and as a result, the fair value adjustments are recognised in profit or loss. The fair value adjustments of these derivative instruments can result in volatility in profit or loss and is therefore excluded in assessing the normal business operations of Discovery as it relates specifically to a future once-off transaction. Amortisation of intangibles from business combinations The adjustment reflects the amortisation of intangible assets which arose from the purchase of various subsidiaries within Discovery and are recognised in accordance with IFRS 3 Business Combinations. Intangible assets recognised from business combinations provide little predictive value of the earnings from the business, as these assets will not be reacquired, renewed, or replaced once depleted. Discovery also infrequently acquires businesses. The amortisation of these assets is therefore excluded in assessing the normal business operations of Discovery. Annexure B – Group accounting policies continued for the year ended 30 June 2023 -- 176 of 217 -- 176 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 29. Normalised headline earnings continued Adjustment Explanation Deferred tax assets raised on assessed losses The adjustment reflects the initial recognition of deferred tax assets in respect of assessed losses in prior financial periods, after evaluating that there is future taxable income that will arise in the respective business. The initial recognition of this deferred tax asset results in a once-off income recognised in profit or loss. It provides no predictive value in assessing the normal business operations of Discovery. Initial expenses related to the PAC book transfer The adjustment reflects professional fees and legal fees of the book transfer incurred in anticipation of the PAC book transfer. As these expenses relate to a future once-off transaction it provides no predictive value in assessing the normal business operations of Discovery and have therefore been excluded from earnings. Restructuring Costs The adjustment reflects restructuring costs which are once-off costs incurred to restructure specified business areas. These transaction costs are infrequent and therefore excluded in assessing the normal business operations of Discovery. Transaction costs related to interest rate derivatives Transaction costs paid to acquire specified derivative instruments to offset changes in economic assumptions excluded from NHEPS. These transaction costs are infrequent and therefore excluded in assessing the normal business operations of Discovery. Changes in tax balances as a result of use of different tax rates The adjustments reflect the changes in current and deferred tax balances resulting from the use of different tax rates related to items that were excluded from normalised headlines earnings in the current or prior periods. Gain on disposal of intangible assets – Vitality Group International The adjustments include those gains on disposal of intangible assets, e.g. in the AmplifyHealth deal, where Vitality Group International monetised a specified regional right to an initial component of its intellectual property rights via sale as opposed to a licensing arrangement. These gains are considered part of normal operations for Discovery. Annexure B – Group accounting policies continued for the year ended 30 June 2023 -- 177 of 217 -- 177 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts Definitions and Abbreviations The following abbreviations and terms are commonly used within the accounting policy: Abbreviations Meaning CSM Contractual Service Margin DAC Deferred Acquisition Costs DISCOVERY Discovery Group DPF Direct Participation Features DRO Discovery Retirement Optimiser EFCF Expected Fulfilment Cash Flows FINANCIAL RISK The risk of a possible future change in one or more of a specified interest rate, financial instrument price, commodity price, currency exchange rate, index of prices or rates, credit rating or credit index or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract. GMM General Measurement Model IACF Initial Acquisition Cash Flows IFIE Insurance finance income and expense comprises the change in the carrying amount of the group of insurance contracts arising from: the effect of the time value of money and changes in the time value of money, and the effect of financial risk and changes in financial risk IFRS IFRS® Accounting Standards IFRS 4 IFRS 4 Insurance Contracts (effective for Discovery pre-1 July 2023) IFRS 17 IFRS 17 Insurance Contracts (effective for Discovery post 1 July 2023) IFRS 17 margins IFRS 17 margins refers to the contractual service margin plus the risk adjustment ISE Insurance Service Expenses LIC Liability for Incurred Claims LRC Liability for Remaining Coverage OCI Other Comprehensive Income PAA Premium Allocation Approach VFA Variable Fee Approach 30.1 Introduction The effective date of IFRS 17 Insurance Contracts is for reporting periods beginning on or after 1 January 2023, with comparative restatement of the preceding year. IFRS 17 is therefore mandatory for the Discovery Group, effective from 1 July 2023, with comparative restatement of the financial year ended 30 June 2023, including a restatement of the opening Statement of financial position as at 1 July 2022. IFRS 17 is a new accounting standard for insurance contracts that provides guidelines on recognising, measuring, presenting, and disclosing insurance contracts. It was introduced by the International Accounting Standards Board (IASB) in May 2017. IFRS 17 replaces the previous standard, IFRS 4 Insurance Contracts, issued in 2005 as an interim standard with limited prescribed changes to pre-existing insurance accounting practices applied by insurers. IFRS 17 represents a positive step towards enhancing transparency, comparability, and understanding of how insurers earn profits from insurance contracts, namely insurance service result and financial results. Consistent with the core objectives of IFRS 17, Discovery has taken the opportunity to align its financial reporting approach and processes across its various jurisdictions where insurance activities are undertaken. The framework established by IFRS 17 outlines the specific requirements that companies must adhere to when reporting information related to both the insurance contracts they issue and the reinsurance contracts they hold. One of the noteworthy distinctions introduced by IFRS 17 pertains to the level of granularity at which insurance contracts are recognised and measured. Discovery is well-prepared to embrace this enhanced granularity, as it aligns with the Group’s actuarial approach. -- 178 of 217 -- 178 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.1 INTRODUCTION continued IFRS 17 is not limited to insurance companies but also those companies that issue any contract that results in transfer of significant insurance risk. For Discovery, the contracts within the scope of IFRS 17 are almost entirely aligned with those recognised in IFRS 4. Whilst the underlying contractual terms and economic risks and rewards of each insurance contract remain unaltered, IFRS 17 impacts the accounting treatment of insurance contracts and most notably the timing of recognition of insurance related profits and losses for accounting purposes. Importantly, it also separates the insurance related profit or losses between those arising from insurance service results and those arising from financial results. IFRS 17 does not result in a change in the underlying business value of contracts, including: No direct change to cash flows or underlying risk and reward of contracts. Future tax cash flow impacts are expected to be immaterial. Immaterial impact on regulatory or economic solvency, capital position and capital management. The ability to pay dividends unaffected as cash flows and solvency remain unchanged. Immaterial impact on Embedded Value. 30.2 Transition to IFRS 17 and estimated impact Upon first-time adoption, IFRS 17 requires the standard to be applied fully retrospectively as if the standard always applied unless impracticable. If impracticable to do so, the entity can elect to either apply a modified retrospective approach or use the fair value approach. As noted, Discovery is in a position to apply a fully retrospective restatement from inception for all material groups of insurance contracts. Discovery did not measure any of its portfolios using the fair value approach. Note 30.10.1 below contains a summary of those less material instances where a modified retrospective approach was applied. The fully retrospective approach requires that Discovery identify, recognise, and measure groups of insurance contracts as if IFRS 17 had always applied. While this approach brought about significant complexity to the transition project, it has provided Discovery with valuable historical insights as to how results will be impacted by model and assumption changes, changes in the discount rates and significant stress events such as the financial crisis of 2008/09 and the COVID-19 pandemic. Based on the work completed, the restatement is much more pronounced for the long-term insurance business of Discovery Life in SA and VitalityLife in the UK. In contrast, the impact of the retrospective restatement is limited for the short-term businesses except for VitalityHealth where the impact is more significant due to change in the treatment of insurance acquisition costs. Discovery has assessed the estimated impact that the initial application of IFRS 17 will have on its financial statements. The changes resulting from the transition to IFRS 17 can be summarised as follows: Those changes that result in differences to the IFRS 17 margins relative to the IFRS 4 margins. These changes result in concomitant temporary changes in equity. For example, to the extent that changes resulted in the strengthening of contractual service margins that will release to profit in future periods, such changes are mirrored by a reduction in shareholders’ equity upon transition. Other changes, such as remeasurement basis of the expected future cash flows or recognised assets and liabilities from short- term insurance, e.g., deferred acquisition costs. These remeasurements would result in a change in equity on transition without a visible offset of insurance margins but similarly will indirectly result in higher or lower net profits in future periods (for a reduction or increase in equity respectively). In the case of Discovery, increases in insurance margins, most notably CSM, have a far more material impact. Such resulting increases of additional IFRS 17 margins on transition will be available as future profit. The main cause for this significant increase in CSM margins is that Discovery has a more recent and rapidly growing history compared to very long-standing insurers. As Discovery businesses mature, there is a point of convergence where the annual profit recognition under IFRS 4 and IFRS 17 inevitably cross over. -- 179 of 217 -- 179 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.2 Transition to IFRS 17 and estimated impact continued The most significant changes that result in an increase in IFRS 17 margins relative to margins under IFRS 4 can be summarised as follows: The measurement under IFRS 17 includes only those cash inflows and outflows relating directly to the fulfilment of the group of insurance contracts, termed directly attributable expenses. In addition to claims and benefits, these may include certain directly attributable overhead expenses. However, non-directly attributable expenses such as general marketing and sponsorships, allocated group executive and group function costs and research and development activities of new products, are not included in the initial recognition value of the contract. Under IFRS 17, these non-directly attributable expenses are immediately expensed and are therefore not considered when determining the EFCF of the insurance contracts being measured. The immediate expensing of such non-directly attributable expenses increases the available margin on the portfolio compared to the IFRS 4 treatment where such expenses were brought into account when determining the available margins. It should be noted that such expenses are brought into consideration when determining the pricing of products and these increased IFRS 17 margins are therefore similarly available for recognition as profits in future or to absorb adverse changes. Contracts are measured at a more granular level where portfolios are established and as a minimum with annual business cohorts of no more than twelve months apart. Each of these cohorts is further categorised into separate groups based on expected profitability being profitable, profitable at risk, and onerous groups. Losses are immediately expensed when they arise on onerous contracts, effectively eliminating any cross-subsidisation or set-off applied within a portfolio. This immediate write- off of shortfalls on contracts effectively increases the available margin on the remainder of the portfolio, which will be recognised to profit in future. Other items, including, amongst others, the different treatment of certain basis changes and variances through the margin, the different rates at which interest is accreted on the margins, and small differences in the run-off of the margins over time are less material in the case of Discovery. Unlike IFRS 4, IFRS 17 separately recognises the finance related consequences of insurance contracts from the underlying insurance activities. Finance income and expense related to insurance contracts and the changes in the measurement of finance related items are recognised as IFIE either immediately in profit or loss or disaggregated and allocated using a systematic allocation to profit or loss with variances being recognised through OCI. As will be noted below, Discovery has elected to apply the OCI option to certain long-term insurance contracts. The exclusion of certain elements of IFIE from the profit or loss is largely aligned to the existing treatment where Discovery excludes the impact of economic assumptions, net of associated derivatives, from its normalised profit and normalised headline earnings. The use of OCI removes the need for this normalisation after adoption of IFRS 17. Other changes, resulting in a change in equity on transition without a visible offset of insurance margins: The remeasurement of best estimates of the future fulfilment cash flows and measurement and accounting treatment of insurance acquisition cash flows, i.e., deferred acquisition costs, on the short-term business lines and Associated deferred tax and future tax impacts of the changes noted above. -- 180 of 217 -- 180 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.2 Transition to IFRS 17 and estimated impact continued IFRS 17 acknowledges that different companies may manage their insurance contracts differently. As a result, IFRS 17 is principle- based and permits several accounting policy elections. The following is a summary of these accounting elections and specific elections made by Discovery: Election Options Discovery elections Transition approach Three transition approaches IFRS 17 requires full retrospective unless impracticable. If full retrospective is impracticable, then accounting election of modified retrospective, or fair value approach. Given the availability of reliable and accurate data and actuarial models, Discovery is required to apply IFRS 17 fully retrospective to all material groups of insurance contracts. For the remainder of portfolios, when full retrospective was impracticable, then modified retrospective was applied. Discovery has not applied the fair value approach to any groups of insurance contracts. Changes in time value of money (Insurance finance income and expense presentation) Two alternatives: Present all IFIE and IFIE changes in profit or loss. Include IFIE in profit or loss using systematic allocation. Remainder recognised in OCI. The use of the OCI removes the volatility from changes in IFIE (previously economic assumptions) in the measurement of the insurance contract. The amount recognised in OCI is then reclassified to profit or loss using a systematic allocation. Discovery has elected OCI on its long-term life-insurance business lines in Discovery Individual Life and VitalityLife. For the remainder of business lines, the change in measurement of the insurance contracts is offset by a change in the measurement of the assets backing those insurance contracts. Risk adjustment No prescriptive approach is provided under IFRS 17. Discovery uses the confidence level approach. For its long-term businesses and group life insurance, Discovery sets the confidence level at 90%. For its short-term businesses, Discovery sets the confidence level at 75%. Acquisition cost (for portfolios at PAA) Two alternatives: The default under IFRS 17 for contracts with PAA is to defer the insurance acquisitions cash flows and allocate the expense to initial and renewal periods, i.e., Defer acquisition costs and amortise. Entity can elect to immediately expense insurance acquisition cash flows. VitalityHealth applies the default requirement of IFRS 17. This treatment results in a largely similar treatment to the FinRe arrangements VitalityHealth held under IFRS 4. For other insurance portfolios measured using the PAA, Discovery has elected to immediately expense in profit or loss the insurance acquisition cash flows as these are not significant. Reflect time value of money (i.e., discount) in measuring coverage units Two alternatives: Reflect time value of money in measuring coverage units. Don’t reflect time value of money in measuring coverage units. Discovery elected to reflect time value of money in the measurement of coverage units. The discounting of coverage units provides the most reasonable emergence of profit, considering the projected level of future margins on retained business for Discovery. -- 181 of 217 -- 181 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.2 Transition to IFRS 17 and estimated impact continued ESTIMATED TRANSITIONAL IMPACT Based on the restatement work undertaken to date, the transition change is primarily a result of the increased IFRS 17 margins, as represented by the CSM plus the risk adjustment. This adjustment, available for future profit release, falls within the range of R14.5 billion to R15.5 billion pre-tax. Other factors contributing to the change in equity include alterations in the methodology used to determine fulfilment cash flows, difference in short-term business lines such as risk adjustment for non-financial risks, and the tax effects of changes in the measurement of insurance contracts. The concomitant net impact of transition adjustment (after tax) to the balance of the Group’s shareholders’ equity is estimated to be as follows: R million Group total equity 30 June 2022 Audited and previously reported 53 555 IFRS 17 adjustment, net of tax Mainly resulting from the increases in the CSM and available for release to profit in future. Accumulated IFIE recognised in OCI is less than 10% of total impact of shareholders equity (12 000 – 13 000) Group total equity 1 July 2022 Restated 41 555 – 40 555 As mentioned above, the impact of the above reduction in equity is effectively offset by a significant increase in insurance margins, most notably CSM, that is available for release to profit in future years or to absorb any adverse changes. On this basis, the total value created through the insurance activities of the Group remains largely unchanged, however, the timing of recognition of insurance related profits has been deferred. The strengthened IFRS 17 margins result in higher future release of profits and in less volatility due to its ability to absorb negative variances, while the election of OCI results in less volatility as a result of its ability to manage variances in financial risks. The material recognition, measurement and presentation policies of insurance contracts under IFRS 17 are set out below. 30.3 Insurance contracts scope and grouping 30.3.1 DEFINITION AND CLASSIFICATION Insurance contracts are contracts under which Discovery accepts significant insurance risk from a policyholder by agreeing to compensate the policyholder should a specified uncertain future event adversely affect the policyholder. A reinsurance contract transfers significant risk if it transfers substantially all the insurance risk resulting from the insured portion of the underlying insurance contracts, even if it does not expose the reinsurer to the possibility of a significant loss. Discovery determines whether it has assumed significant insurance risk by comparing benefits payable after an insured event with benefits payable if the insured event had not occurred. Insurance and reinsurance contracts can also expose Discovery to financial risk, which is not taken into account in the determination of significant insurance risk. Significant judgements and estimates IFRS 17 does not specify what significant insurance risk is. Discovery’s policy defines significant insurance risk as follows: The possibility that the present value of losses arising on the insurance contract exceeds 10% of the present value of income and receipts collected when applying a worst-case scenario upon inception of the insurance contract. 30.3.2 SEPARATING COMPONENTS WITHIN INSURANCE CONTRACTS IFRS 17 requires an analysis of whether the contract contains components that should be separated from the insurance contract and accounted for under different IFRS Accounting Standards. IFRS 17 requires that cash flows relating to embedded derivatives, cash flows relating to distinct investment components and promises to transfer distinct goods or distinct services, other than insurance contract services, be accounted for separately. Discovery presently has no contracts requiring further separation or a combination of insurance contracts. -- 182 of 217 -- 182 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.3 Insurance contracts scope and grouping 30.3.3 UNIT OF ACCOUNT, AGGREGATION AND RECOGNITION OF INSURANCE AND REINSURANCE CONTRACTS Under IFRS 17, the unit of account is defined as a group of insurance contracts. The manner in which insurance contracts are grouped, affects the timing of profit recognition for insurance services but does not affect the measurement of the estimated cash flows to fulfil the insurance contracts. In terms of IFRS 17, the unit of account is determined by first establishing a portfolio of insurance contracts and then creating separate cohorts within the portfolio based on the date of origination. Each such cohort is further grouped into three groupings based on estimated profitability. Insurance contracts that are subject to similar risks and managed together E.g., whole-of-life insurance, guarantee endowments, household insurance Only contracts issued within a given 12-month period (cohort) can be included in the same group. Annual cohorts are further grouped into one of the following: Portfolio Cohort Groups Onerous at initial Recognition (Onerous) At initial recognition, no significant possibility of becoming onerous (Profitable) Other (Profitable at risk) IFRS 17 Illustration of principles 1: Unit of account At initial recognition, groups of insurance contracts issued are recognised from the earliest of the following: The beginning of the coverage period. The date when the policyholder’s first payment is due or received if there is no due date. When Discovery determines that a group of insurance contracts become onerous. Significant judgements and estimates Discovery uses judgement to determine at what level of granularity Discovery has reasonable and supportable information that is sufficient to conclude that all contracts within a set are sufficiently homogeneous and will be allocated to the same group without performing an individual contract assessment. Discovery performs stress testing on portfolios measured using GMM/VFA. The stresses may differ between portfolios but will correspond to the most significant non-financial stresses currently run as part of the risk appetite work. If any policy that was originally determined to be profitable becomes onerous under any of the three additional stresses calculated, that policy is classified as profitable-at-risk. 30.3.4 MEASUREMENT MODELS IFRS 17 provides three possible measurement models. 1. The default model is the General Measurement Model (GMM). The GMM is typically used for measuring long-term insurance risk and annuity contracts. The basic principles of which are set out below. 2. The GMM is supplemented by the Variable Fee Approach (VFA) for contracts where policyholders have purchased investment- linked insurance contracts integrated with insurance coverage (i.e., insurance contracts with direct participating features). 3. The Premium Allocation Approach (PAA) is a simplified approach of the GMM for short-duration contracts such as group risk, personal lines and private medical insurance. Direct participating contracts are contracts for which, at inception: the contractual terms specify that the policyholder participates in a share of a clearly identified pool of underlying items. Discovery expects to pay to the policyholder an amount equal to a substantial share of the fair value returns on the underlying items; Discovery considers that a substantial share is a majority of returns, and Discovery expects a substantial proportion of any change in the amounts to be paid to the policyholder to vary with the change in fair value of the underlying items. Discovery considers that a substantial proportion is a majority proportion of change on a present value probability-weight average of all scenarios. Within Discovery the unit-linked products and Discovery Optimiser products offered by Discovery Life are examples of insurance contracts with DPFs. -- 183 of 217 -- 183 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.4 Overview of discovery group portfolios, measurement models and accounting policy elections The table below summarises the material insurance contracts Discovery issues and reinsurance contracts it holds. It sets out the measurement model applied and key assumptions and elections. Measurement Model Risk adjustment confidence level 1 Elections on IFIE PAA only – election for treatment of initial acquisition cash flows (IACF) Insurance contract issued and business lines Individual life insurance contracts: Discovery Life and VitalityLife GMM 90% Elected to present changes in IFIE in OCI n/a Insurance-linked investment contracts: General endowments in Discovery Invest Elected to present changes in IFIE in profit or loss Investment contracts: Unit-linked and DRO in Discovery Invest VFA Group life insurance contracts: Discovery Life PAA 90% Elected not to reflect interest for cash flows less than 12 months Elected to immediately expense initial acquisition cash flows (IACF) Car, household and business insurance: Discovery Insure 75% Health insurance: VitalityHealth Consistent with default IFRS 17 requirement, defer IACF and amortise over the initial and renewal periods Reinsurance contracts held Individual life: quota share reinsurance for Discovery Individual Life and VitalityLife GMM 90% Elected to present changes in IFIE in OCI n/a Individual life: excess of loss reinsurance Group life insurance contracts: catastrophe, group continuation and mass lapse treaties PAA 90% Elected not to reflect interest for cash flows less than 12 months Elected to immediately expense initial acquisition cash flows (IACF) Car, household and business insurance: quota share reinsurance and excess of loss insurance 75% Health insurance: quota share reinsurance 1 Risk adjustment was determined using the confidence level technique unless otherwise stated. -- 184 of 217 -- 184 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.5 Contracts measured under the GMM and VFA Under IFRS 17, any company that issues insurance contracts must report those contracts on the Statement of financial position as the total of The expected fulfilment cash flows (EFCF): the current estimates of amounts that the company expects to collect from premiums net of and payout for claims, benefits, and expenses, including an adjustment for the timing and risk of those amounts, and The CSM: the expected profit for providing insurance coverage recognised in profit or loss over the period of insurance coverage. Under IFRS 17, Insurance Contracts are measured as the sum of: the expected fulfilment cash flows (EFCF), representing the present value of current estimates of amounts that the insurer expects to collect from premiums net of and pay out for claims, benefits and expenses, including an adjustment for the risk of those cash flows. Those cash flows for future services is known as “liability for remaining coverage” (LRC) and those cash flows for services already incurred constitutes “liability for insurance claims” (LIC) the contractual service margin (CSM) —, i.e. represents the remaining inherent value of the cohort and is similar to unearned profit for providing future insurance coverage. On initial recognition, for profitable contract, the CSM is the equal and opposite amount of the net cash inflow, resulting in no income or expense arising on initial recognition. + EFCF – Inflow EFCF – Outflow EFCF – Risk adj CSM EFCF – discounting = +Insurance contracts Present value of expected fulfilment cash flows Unearned profit IFRS 17 Illustration of principles 2: General Measurement Model (GMM) 30.5.1 EXPECTED FULFILMENT CASH FLOWS (EFCF) The measurement of a group of insurance contracts includes all future cash flows expected to arise within the contract boundary of each contract in the group. Cash flows are within the contract boundary if they arise from substantive rights and obligations that exist during the reporting period in which Discovery can compel the policyholder to pay premiums or has a substantive obligation to provide services (including insurance coverage and any investment services). EFCF include payments to (or on behalf) of policyholders, insurance acquisition cash flows and other costs incurred in fulfilling contracts. Other costs incurred to fulfil a group of contracts include direct costs and an allocation of fixed and variable overheads directly attributable to fulfilling the group of insurance contracts. The estimates of these future cash flows are based on probability-weighted expected future cash flows. Discovery estimates which cash flows are expected and the probability that they will occur as at the measurement date. When estimating, Discovery uses information about past events, current conditions and forecasts of future conditions. Significant judgements and estimates Discovery applies judgement to determine which cash flows within the boundary of insurance contracts relate directly to the fulfilment of the contracts, including the extent to which fixed and variable overheads are directly attributable to fulfilling insurance contracts.. Discovery primarily uses deterministic projections to estimate the present value of future cash flows, and for some groups, it uses stochastic modelling techniques. The following assumptions were used when estimating future cash flows: Mortality and morbidity rates. Surrender and lapse rates. Economic assumptions/Investment returns. Vitality status assumptions. Expense assumptions. Policy alterations and automatic premium increases. Insurance acquisition cash flows arise from activities of selling, underwriting and commencing a group of contracts that are directly attributable to the portfolio of contracts to which the group belongs. -- 185 of 217 -- 185 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.5 Contracts measured under the GMM and VFA continued 30.5.2 REFLECTING THE TIME VALUE OF MONEY AND DISCOUNT RATES Discounting adjusts the estimates of expected cash flows to reflect the time value of money and the financial risks associated with those cash flows to the extent that the financial risks are not already included in the cash flow estimates. The following table shows which discount rate to apply throughout measuring a group of insurance contracts and the general objective of determining that discount rate. GMM AND VFA Element of measurement model Fulfilment cash flows Current discount rates CSM interest accretion for contracts without direct participation features (i.e., portfolios under GMM). Discount rates are determined on initial recognition of the group, i.e., locked-in at inception. Adjustments to the CSM for changes in the fulfilment cash flows for contracts without direct participation features (i.e., portfolios under GMM). Discount rates are determined on initial recognition of the group, i.e., locked-in at inception. Adjustments to the CSM for changes in the fulfilment cash flows for DPF contracts that do not vary based on the returns on underlying items (i.e., portfolios under VFA), excluding the change in the effect of the time value of money and financial risks. Current discount rates. The “bottom-up” approach is used to derive the discount rate for the cash flows. Under this approach, the discount rate is determined as the risk-free yield, adjusted for differences in liquidity characteristics of the insurance contracts sold. For portfolios of contracts where the insurance contract liability is materially matched with assets, a “top-down” approach is used to derive the discount rate for the cash flows. For Discovery, the risk-free yield curve will be ‘current’ and reflect the risk-free yield curve derived on the last day of the reporting period. The nominal risk-free yield curve is used to discount nominal cash flows, while real cash flows are discounted using the real risk-free yield curve. 30.5.3 RISK ADJUSTMENT The risk adjustment for non-financial risk for a group of insurance contracts, determined separately from the other estimates, is the compensation required for bearing uncertainty about the amount and timing of the cash flows that arise from non-financial risk as Discovery fulfils insurance contracts. It measures the compensation that the entity would require to make it indifferent between: Fulfilling a liability that has a range of possible outcomes arising from non-financial risk and Fulfilling a liability that will generate fixed cash flows with the same expected present value as the insurance contract. A lower risk adjustment would be observed for those insurance contracts with shorter duration, high frequency and low severity type products and narrow probability of distributions. Higher risk adjustment would be observed for insurance contracts that are longer in duration, have a low frequency and high severity and have a wide probability of distributions. IFRS 17 does not prescribe methods for determining the risk adjustment for non-financial risk. Therefore, management’s judgement is necessary to determine an appropriate risk adjustment technique. When applying a confidence level technique, the first step in the process is to calculate the best estimate reserve, where there is an equal chance that the actual amount needed to pay future claims will be higher or lower than the calculated best estimate. The risk adjustment is then calculated such that there is a specified percentage probability that the reserves will be sufficient to cover future claims. For Discovery, the determination of specified percentage has been determined as follows: Significant judgements and estimates Portfolio Methodology Confidence level Life insurance contracts include Discovery LifePlan and VitalityLife whole-of-life and term-life policies Confidence level 90% Investment contracts with DPF include the unit-linked products and the Discovery Retirement Optimiser offered by Discovery Invest Confidence level 90% -- 186 of 217 -- 186 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.5 Contracts measured under the GMM and VFA continued 30.5.4 CONTRACTUAL SERVICE MARGIN (CSM) The CSM represents the future unearned profit. On initial recognition of a group of insurance contracts, if the total of the fulfilment cash flows, including insurance acquisition cash flows: is a net inflow, then the group is profitable. In this case, the CSM is measured as the equal and opposite amount of the net inflow, which results in no income or expenses arising on initial recognition. is a net outflow, then the group is onerous. In this case, the net outflow is recognised immediately as a loss in profit or loss. A loss component is created to depict the amount of the net cash outflow, which determines the amounts that are subsequently presented in profit or loss as reversals of losses on onerous contracts and are excluded from insurance revenue. 30.5.5 SUBSEQUENT MEASUREMENT The carrying amount of a group of insurance contracts at each reporting date is the sum of the liability for remaining coverage (LRC) and the liability for incurred claims (LIC). The LRC comprises the fulfilment cash flows related to services that will be provided under the contracts in future periods and any remaining CSM at that date. The LIC includes the fulfilment cash flows for incurred claims and expenses that have not yet been paid, including claims that have been incurred but not yet reported. IFRS 17 requires a company to update the EFCF at each reporting date, using current estimates of the amount, timing, and uncertainty of cash flows and discount rates. Discovery: accounts for changes to estimates of future cash flows from one reporting date to another, either as an amount in profit or loss or as an adjustment to the expected profit for providing insurance coverage, depending on the type of change and the reason for it; and chooses where to present IFIE either: – all in profit or loss, or – include IFIE in profit or loss using systematic allocation. The remainder of IFIE is recognised in OCI. The treatment can be summarised as follows: Fulfillment cash inflows OCI P/L CSM CSM allocation Financial risk assumptions (e.g., interest rates) Past and current service Future service Reclassify Either Or -- 187 of 217 -- 187 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.5 Contracts measured under the GMM and VFA continued 30.5.5 SUBSEQUENT MEASUREMENT 30.5.5.1 Changes in EFCF Changes in expected fulfilment cash flows from the estimates at the previous reporting date or inceptions of the contracts are recognised as follows: Nature of change Treatment Changes relating to current or past services Recognised in the insurance service results in profit or loss. Changes relating to future services Adjusted against the CSM (or recognised in the insurance service results in profit or loss if the group is onerous). Effects of the time value of money, financial risk and changes therein on estimated future cash flows Recognised as insurance finance income or expenses. Changes in the obligation to pay policyholders an amount equal to the fair value of the underlying items for a group of direct participating contracts (VFA) Recognised in the insurance service results in profit or loss. Accounting policy election: Presentation of IFIE Discovery has elected to disaggregate IFIE for the period in OCI and present in profit or loss IFIE using a systematic allocation on its long-term life insurance business lines in Discovery Life and VitalityLife. For the remainder of business lines, the IFIE and changes therein relating to insurance contracts are presented in profit or loss, offset by the changes in the value of assets backing the insurance contracts. Changes in CSM As noted in policy 30.5.4, the CSM represents the future unearned profit. The movement in the CSM during a financial reporting period can be summarised as follows: Opening CSM 1. Accretion/Unwind of interest 2. New business written during the period 3. Release to p/l using coverage units 4. Changes in assumptions (not IFIE) 5. VFA only – change in the amount of the entity’s share of the fair value of the underlying items Closing CSM Movement in CSM during reporting period IFRS 17 Illustration of principles 4: Subsequent changes in CSM -- 188 of 217 -- 188 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.5 Contracts measured under the GMM and VFA continued 30.5.5 SUBSEQUENT MEASUREMENT continued 30.5.5.1 Changes in EFCF continued The carrying amount of the CSM at each reporting date is the carrying amount at the start of the financial year, adjusted for: 1. Interest accreted on the carrying amount of the CSM during the year. As noted in policy 30.7.4.2, discount rates are determined on initial recognition of the group, i.e., locked-in at inception. 2. The CSM of any new contracts added to the group in the year. 3. The amount recognised as insurance revenue because of the services provided in the year, i.e., release of CSM using coverage units. In determining the coverage units, Discovery has elected to reflect the time value of money in the coverage units using a real rate of return for insurance contracts measured using the GMM. For insurance contracts measured using the VFA, Discovery has elected to reflect the time value of money in the coverage units using a nominal rate of return. 4. The effect of any currency exchange differences on the CSM and changes in fulfilment cash flows that relate to future services, except to the extent that: a. any increases in the fulfilment cash outflows exceed the carrying amount of the CSM, in which case the excess is recognised immediately in profit or loss. b. any decreases in the fulfilment cash outflows are allocated to the loss component, reversing losses previously recognised in profit or loss. 5. For contracts measured using the VFA, the change in the amount of the insurer’s share of the fair value of the underlying item. 30.6. Contracts measured under the PAA As permitted in IFRS 17, Discovery has elected to apply the premium allocation approach (PAA) to measure a group of insurance contracts issued or reinsurance contracts held if, at the inception of the group: The coverage period of each contract in the group of insurance contracts is one year or less or Discovery reasonably expects that the PAA would produce a measurement of the LRC for a group of insurance contracts that would not differ materially from the measurement achieved by applying the GMM. The PAA simplifies the general measurement model. At initial recognition, the insurance contract is measured as: The premiums, if any, received at initial recognition. Minus any insurance acquisition cash flows (applicable only if the group has elected to defer the insurance acquisition cash flows), and Plus/minus non-acquisition assets or liabilities previously recognised for cash flows related to the group of insurance contracts. Where insurance acquisition cash flows are directly attributable to a group of contracts, Discovery allocates costs to that group and the groups that will include renewals of those contracts. Discovery expects to recover part of the related insurance acquisition cash flows through renewals of these contracts. The allocation to renewals is based on how Discovery expects to recover those cash flows. At each reporting date, Discovery revises the amounts allocated to groups to reflect any changes in assumptions that determine the inputs to the allocation method used. Amounts allocated to a group are not revised once all contracts have been added to the group. At each reporting date, if facts and circumstances indicate that an asset for insurance acquisition cash flows may be impaired, Discovery: Recognises an impairment loss in profit or loss so that the carrying amount of the asset does not exceed the expected net cash inflow for the related group and If the asset relates to future renewals, recognises an impairment loss in profit or loss to the extent that it expects those insurance acquisition cash flows to exceed the net cash inflow for the expected renewals, and this excess has not already been recognised as an impairment loss. Discovery reverses any impairment losses in profit or loss and increases the asset’s carrying amount to the extent that the impairment conditions have improved. IFRS 17 permits an accounting policy election on a group-by-group basis: Not to adjust the components of the insurance contracts and onerous contracts for the time value of money (i.e., no discounting). An entity may elect to immediately expense insurance acquisition cash flows when incurred. Annexure B – Group accounting policies continued for the year ended 30 June 2023 -- 189 of 217 -- 189 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.6. Contracts measured under the PAA continued Accounting policy elections For those contracts that apply the PAA, Discovery has elected not to reflect the time value of money in the measurement of the LRC and the LIC when: LRC: On initial recognition of the contract, the time between the insurance service and the related premium is less than a year. LIC: The cash flows are expected to be paid or received in less than one year from the date the claim is incurred. In some instances, claims might be disputed. If the claim is expected to be disputed and settlement deferred beyond 12 months, the exception would not apply. Discovery has elected to immediately expense insurance acquisition cash flows for the following material portfolios: Group Life Discovery Insure – Discovery Insure has the following portfolios: Personal lines for motor and household, Business insurance, Medical gap, trauma cover and travel insurance. AfricaHealth portfolios. Significant judgements and estimates Discovery uses judgement in determining the initial and renewal periods for which the insurance acquisition cash flows are attributed to groups. For VitalityHealth, the initial and subsequent renewal period is set at ten years. 30.6.1 RISK ADJUSTMENT Also refer to policy 30.5.3. For contracts measured under the PAA, the explicit risk adjustment for non-financial risk is estimated to measure the LIC. The risk adjustment will be determined by applying a confidence level technique. For Discovery, the determination of specified percentage has been determined as follows: Significant judgements and estimates Portfolio Methodology Confidence level Discovery Insure personal and business lines, VitalityHealth private medical insurance, AfricaHealth health insurance Confidence level 75% Group Life portfolio Confidence level 90% -- 190 of 217 -- 190 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.7. Reinsurance contracts Groups of reinsurance contracts are established such that each treaty is allocated to the applicable group of reinsurance contracts, which differs to the group to which the underlying insurance contract is included. Discovery concludes that the reinsurance contract’s legal form of a single contract reflects the substance of Discovery’s contractual rights and obligations. A group of reinsurance contracts is recognised, as required under IFRS 17, on the following dates. Reinsurance contracts initiated by Discovery that provide proportionate coverage: The date on which any underlying insurance contract is initially recognised. This applies to Discovery’s quota share reinsurance contracts. Other reinsurance contracts initiated by Discovery: The beginning of the coverage period of the group of reinsurance contracts. Where Discovery recognises an onerous group of underlying insurance contracts on an earlier date and the related reinsurance contract was entered into before that earlier date; in that case, the group of reinsurance contracts is recognised on that earlier date. This applies to Discovery’s excess of loss and stop-loss reinsurance contracts. Reinsurance contracts acquired: The date of acquisition. Discovery applies the same accounting policies to measure a group of reinsurance contracts, adapted where necessary to reflect features that differ from those of the underlying insurance contracts. When a loss-recovery component is created for a group of reinsurance contracts measured under the PAA, Discovery will adjust the asset’s carrying amount for remaining coverage instead of adjusting the CSM. 30.8 Derecognition and modifications Discovery derecognises a contract when it is extinguished – i.e., when the specified obligations in the contract expire or are discharged or the contract is cancelled. Discovery also derecognises a contract if its terms are modified in a way that would have changed the accounting for the contract significantly had the new terms always existed, in which case a new contract based on the modified terms is recognised. If a contract modification does not result in derecognition, Discovery treats the changes in cash flows caused by the modification as changes in estimates of fulfilment cash flows. On derecognition of a contract from within a group of contracts not measured under the PAA: The fulfilment cash flows allocated to the group are adjusted to eliminate those that relate to the rights and obligations derecognised. The CSM of the group is adjusted for the change in the fulfilment cash flows, except where such changes are allocated to a loss component. The number of coverage units for the expected remaining services is adjusted to reflect the coverage units derecognised from the group. If a contract is derecognised because it is transferred to a third party, then the CSM is also adjusted for the premium charged by the third party unless the group is onerous. -- 191 of 217 -- 191 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.9 Presentation and disclosure 30.9.1 OVERVIEW OF PRESENTATION AND DISCLOSURE Portfolios of insurance contracts that are assets and liabilities and portfolios of reinsurance contracts that are assets and liabilities are presented separately in the Statement of financial position. Any assets or liabilities recognised for cash flows arising before the recognition of the related group of contracts (including any assets for insurance acquisition cash flows under ‘Insurance acquisition cash flows’) are included in the carrying amount of the related portfolios of contracts. IFRS 17 requires a company to provide information that distinguishes two ways insurers earn profits from insurance contracts: 1. The insurance service result, which depicts the profit earned from providing insurance coverage and 2. The financial result, which captures the investment income from managing financial assets and insurance finance income and expenses (IFIE) resulting from the insurance rights and obligations. The IFIE reflects the effects of financial variables such as discount rates on the value of insurance rights and obligations. Income and expenses from reinsurance contracts are presented separately from income and expenses from insurance contracts. Income and expenses from reinsurance contracts, other than insurance finance income or expenses, are presented on a net basis as ‘net expenses from reinsurance contracts’ in the insurance service result. Discovery disaggregates changes in the risk adjustment for non-financial risk between the insurance service result and insurance finance income or expenses. The insurance service result includes all changes in the risk adjustment for non-financial risk. The result of insurance performance in the income statement can be summarised as follows: Element Insurance Revenue – GMM/ VFA Expected Insurance Service Expense plus CSM release plus release of risk adjustment. Insurance Revenue - PAA For contracts measured under the PAA, the insurance revenue for each period is the expected premium receipts for providing services in the period. Discovery allocates the expected premium receipts to each period based on the passage of time. Insurance Service expenses Actual claims and directly attributable costs, including past and in-period variances. Net expenses from reinsurance contracts Net expenses from reinsurance contracts comprise an allocation of reinsurance premiums paid less amounts recovered from reinsurers. Discovery has elected to present the income and expenses from a group of reinsurance contracts held as a single amount. Insurance finance income and expense Discovery has elected to disaggregate changes in the risk adjustment for non- financial risk between the insurance service result and insurance finance income or expenses. Discovery has elected to disaggregate IFIE for the period in OCI and present in profit or loss IFIE using a systematic allocation on its long-term life insurance business lines in Discovery Life and VitalityLife. For the remainder of business lines, the change in IFIE of the insurance contracts is presented in profit or loss, offset by the changes in the value of assets backing the insurance contracts. -- 192 of 217 -- 192 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure B – Group accounting policies continued for the year ended 30 June 2023 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.9 Presentation and disclosure 30.9.2 CHANGE IN PRESENTATION AND DISCLOSURE RELATIVE TO IFRS 4 Statement of financial position Assets arising from insurance contracts Assets arising from insurance contracts issued Contract receivables and other receivables Assets arising from reinsurance contracts held Liabilities arising from insurance contracts Liabilities arising from insurance contracts issued Liabilities arising from reinsurance contracts held Other equity (includes reserve for IFIE presented in OCI) Liabilities arising from reinsurance contracts Deferred acquisition costs Insurance receivables, contract receivables and other receivables Reinsurance contracts IFRS 4 IFRS 17 Assets Liabilities Assets Liabilities Equity 1 1 3 4 2 3 Flowchart 1: Changes in Discovery’s presentation in Statement of financial position from IFRS 4 to IFRS 17 1 All insurance cash flows (LRC + LIC), payables and receivables presented net either as a liability or an asset from insurance contracts. 2 Premium debtors are included in the measurement of insurance contracts. 3 All reinsurance cash flows, payables and receivables presented net either as a liability or an asset from reinsurance contracts. 4 New reserve for the cumulative insurance finance income and expense (IFIE) recognised in OCI. -- 193 of 217 -- 193 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Income statement and other comprehensive income 30. New Standards in Interpretation – IFRS 17 Insurance Contracts continued 30.9 Presentation and disclosure 30.9.2 CHANGE IN PRESENTATION AND DISCLOSURE RELATIVE TO IFRS 4 Net premium insurance Insurance premium revenue Reinsurance premiums Insurance Revenue Net finance income/(expense) from insurance contracts issued Net finance income/(expense) from reinsurance contracts held Marketing and administration expenses (non-attributable) Net finance income/(expense) from insurance contracts issued Net finance income/(expense) from reinsurance contracts held STATEMENT OF COMPREHENSIVE INCOME INCOME STATEMENT Accelerated reinsurance premiums Receipts arising from reinsurance Clients and policyholder benefits – Insurance claims recovered from policyholders – Recapture of reinsurance Acquisition costs Marketing and administration expenses Recovery of expenses from reinsurers Net transfer to/from Assets and Liabilities from insurance contracts – change in assets arising from insurance contracts – change in assets arising from reinsurance contracts – change in assets arising from insurance contracts – change in assets arising from reinsurance contracts – economic assumption adjustments net of discretionary margins Reinsurance receipts Claims Operating expenses Changes in margins IFRS 4 IFRS 17 Reclassify over time Insurance service result 1 2 3 Net expenses from reinsurance contracts held Insurance Service Expenses Net insurance financial result 4 Operating expenses 5 4 Net insurance financial result Flowchart 2: Changes in Discovery’s presentation in Income statement from IFRS 4 to IFRS 17. 1 For short-term insurance, the Insurance revenue includes earned revenues. For long-term insurance, the Insurance revenue includes the recognition of CSM, release of risk adjustment and release of expected insurance service expenses (i.e., expected directly attributable costs 2 Insurance service expenses comprise of actual incurred claims and directly attributable expenses, the recognition of onerous contracts. Insurance acquisition cash flows are immediately expensed or amortised. 3 The net expense of reinsurance expenses and reinsurance receipts 4 Changes in assumptions for future services of time value of money, inflation index and foreign exchanges are recognised in period in OCI. The amount is reclassified to profit or loss on a systematic basis over the coverage period. In period, variances are recognised in profit or loss. 5 Includes those expenses and costs not directly attributable to the insurance contract 30.10 Transition IFRS 17 requires the standard to be applied fully retrospectively unless impracticable. If impracticable, the entity can elect to apply a modified retrospective approach or use the fair value approach. As discussed earlier, Discovery has applied the fully retrospective approach for all material groups of insurance contracts. Given some constraints to the availability of reasonable and supportable data, Discovery has elected to apply IFRS 17 in certain circumstances by using the modified retrospective approach. The less material portfolios which applied modifications are noted below. Annexure B – Group accounting policies continued for the year ended 30 June 2023 -- 194 of 217 -- 194 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 30.10 Transition continued 30.10.1 EXCEPTIONS WHERE THE MODIFIED RETROSPECTIVE APPROACH WAS APPLIED Discovery Individual life portfolio Discovery has applied the modified retrospective approach within the Discovery Individual Life portfolio by aggregating contracts issued more than one year apart prior to 2003 into a single group of insurance contracts in respect of insurance contracts issued before June 2003. The application of the full retrospective approach on transition for these groups were determined to be impracticable as Discovery Life does not have the model used nor data of sufficient quality to either retrospectively model business sold before the June 2002 financial year or to identify new business policies sold in the June 2002 financial year. It should be noted that these portfolios or cohorts of business are immaterial in the context as Discovery Life only commenced business in 2000. Discovery Invest portfolios - the unit-linked and DRO portfolio and the general endowments portfolio Discovery has applied the modified retrospective approach within the Discovery Invest portfolios by aggregating contracts issued more than one year apart into a single group of insurance contracts issued before June 2016 for the DRO portfolio and groups of insurance contracts issued before June 2012 for the general endowments and unit-linked portfolio. The application of the fully retrospective approach on transition for these portfolios was determined to be impracticable for Discovery Invest as it did not collect the data of policies sold with sufficient granularity in the periods prior to June 2012. Discovery Invest only commenced trading in 2007. VitalityHealth private medical insurance contracts Discovery applied the modified approach to identify, recognise, and measure assets arising from insurance acquisition cash flows for the VitalityHealth PMI portfolio as of 1 July 2022. It is impracticable to apply the full retrospective approach as eight years ago (of the ten years that DAC is being applied for), the data was not collected with sufficient granularity for the purposes of setting up a deferred acquisition cost reserve, and its omission has an immaterial impact on the equity. 30.11 Implementation progress Work on the finalisation of key policy and methodology decisions is complete. Management has substantially finalised the financial impact assessment to enable the restatement of the comparative opening balance adjustments as at 1 July 2022 and the retrospective reporting periods leading up to the transitional Statement of financial position. The IFRS 17 project has been managed as follows: The Group CFO heads up the IFRS 17 Executive Working Committee (EWC), which comprises the respective Insurance business CFOs, Chief Actuaries, and IT specialists. The IFRS 17 Executive Working Committee is supported by a Technical Advisory Group comprising IFRS Specialists, Actuaries, Financial Managers, and Tax specialists. The Committee also consults with external audit firms where necessary. The EWC is responsible for providing overall strategic direction to the project across the Group and for monitoring progress and interdependencies with other group initiatives. The EWC also provides policy guidance and technical support for the implementation in each of its subsidiaries. The EWC reports to the Group Finance and Capital Committee (FCC) as a sub-committee of the Group Executive Committee and recommends and suggests its final proposals to the IFRS 17 Governance Committee. The IFRS 17 Governance Committee comprises amongst others non-executive directors from the various Actuarial and Audit Committees within the insurance business lines and ultimately makes recommendations to the various Audit Committees and Actuarial Committees that, in turn, make recommendations to their respective Boards. KPMG Inc., as the current joint auditor, and Deloitte & Touche, as the proposed joint auditor following the mandatory audit firm rotation of PwC Inc., have been engaged to provide the external audit assurance for IFRS 17 in their capacity as the external auditors for the financial year ending 30 June 2024, the first financial year that Discovery will apply IFRS 17. A combined assurance approach is being followed whereby group internal and external auditors incrementally test the new IFRS 17 landscape. For the disclosures included within this audited set of Financial Statements, the external auditors, KPMG Inc. and PwC Inc., have performed procedures, including evaluating the decisions made by management and the results to date. These procedures include, but are not limited to, evaluating the transition methodology decisions, product classification, and other policy and methodology decisions relevant to the IFRS 17 results, as well as performing audit procedures over the valuation of portfolios considered material to the disclosures provided. The auditors have reported on the annual financial statements as a whole. PROJECT FOCUS FOR THE NEXT FINANCIAL YEAR Management will focus on the following key areas during the next financial year: Finalisation of the IFRS 17 transitional tax arrangements. Finalise and produce IFRS 17 compliant financial statements for the first interim reporting period for the six months ending 31 December 2023, including restated information for the financial year ended 30 June 2023 and interim reporting period for the six months ended 31 December 2022. External audit of restated balances, models and controls. Management reporting and, where applicable, key performance measures. Finalise business-as-usual future financial and data governance processes and financial reporting controls. Reporting to and educating financial analysts and investors about the application and impact from a Discovery Group perspective. Annexure B – Group accounting policies continued for the year ended 30 June 2023 -- 195 of 217 -- 195 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure C – Directorate REMUNERATION AND FEES Payment to directors and prescribed officers for the year ended 30 June 2023 for services rendered are set out in the table below. It should be noted that these payments reflect cash payments made to directors and prescribed officers during the financial year and therefore all variable pay components are reflective of performance measurements relating to previous periods. The variable pay components relating to the current year under review are physically paid in the following financial year and are analysed in detail in the Group’s annual remuneration report and are more reflective of the performance of the period under review. Payments to directors and prescribed officers for the year ended 30 June 2023 for services rendered are as follows: R’000 Services as directors Basic salary Perfor- mance bonus LTIP2 Provident fund contri- butions Other benefits 1 Total Executive A Gore – 7 987 9 603 8 692 1 198 422 27 902 B Swartzberg – 5 592 13 032 2 522 586 265 21 997 DM Viljoen – 5 995 6 358 4 417 945 303 18 018 HD Kallner7 – 7 472 7 062 23 823 374 228 38 959 NS Koopowitz8 – 21 255 22 734 10 816 118 563 55 486 Dr A Ntsaluba9 – 4 999 5 811 4 961 375 316 16 462 A Pollard10 – 8 968 9 368 6 677 225 388 25 626 Sub-total – 62 268 73 968 61 908 3 821 2 485 204 450 Non-executive ME Tucker3 7 541 – – – – – 7 541 HL Bosman4 1 033 – – – – – 1 033 R Farber5 3 713 – – – – 4 010 7 723 M Hlahla 1 411 – – – – – 1 411 FN Khanyile 1 964 – – – – – 1 964 D Macready 2 087 – – – – – 2 087 Dr TV Maphai 1 651 – – – – – 1 651 T Mboweni 1 391 – – – – – 1 391 M Schreuder 2 033 – – – – – 2 033 B Van Kralingen6 1 901 – – – – 108 2 009 SV Zilwa 2 687 – – – – – 2 687 Sub-total 27 412 – – – – 4 118 31 530 Total 27 412 62 268 73 968 61 908 3 821 6 603 235 980 Less: paid by subsidiaries (27 412) (62 268) (73 968) (61 908) (3 821) (6 603) (235 980) Paid by holding company – – – – – – – 1 “Other benefits” comprise medical aid contributions, travel, other allowances and fees from group subsidiaries. 2 “LTIP” comprises cash-settled and equity-settled incentives. 3 Director’s fees for services rendered are paid in GBP. 4 Director’s fees for services rendered by HL Bosman (retired effective 1 December 2022) were paid to Rand Merchant Insurance Holdings Limited. 5 Director’s fees for services and fees for other consulting services rendered by R Farber were paid in AUD. Director’s fees for consulting services are included as part of other benefits. 6 Director’s fees for services rendered are paid in USD. 7 Transitioned from Group Executive Director to Prescribed Officer with effect from 1 March 2023. The remuneration presented above is for the full financial year. 8 Salary and incentive are paid in GBP. Transitioned from Group Executive Director to Prescribed Officer with effect from 1 March 2023. 9 Stepped down as Executive Director with effect from 1 March 2023. Group Executive 1 March to 30 June 2023. The remuneration presented above is for the full financial year. 10 Salary and incentive are paid in USD. Stepped down as Executive Director with effect from 1 March 2023. Group Executive 1 March to 30 June 2023. -- 196 of 217 -- 196 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure C – Directorate continued REMUNERATION AND FEES continued Payment to directors and prescribed officers for the year ended 30 June 2022 for services rendered are set out in the table below. It should be noted that these payments reflect cash payments made to directors and prescribed officers during the financial year and therefore all variable pay components are reflective of performance measurements relating to previous periods. The variable pay components relating to the current year under review are physically paid in the following financial year and are analysed in detail in the Group’s annual remuneration report and are more reflective of the performance of the period under review. Payments to directors and prescribed officers for the year ended 30 June 2022 for services rendered are as follows: R’000 Services as directors 1 Basic salary Perfor- mance bonus Phantom scheme payments Provident fund contri- butions Other benefits1 Total Executive A Gore – 7 611 8 172 – 1 107 387 17 277 HD Kallner – 5 650 6 891 – 282 174 12 997 NS Koopowitz2 – 19 428 21 286 8 664 81 552 50 011 Dr A Ntsaluba – 4 749 5 216 – 356 290 10 611 A Pollard3 – 7 343 6 684 2 057 122 336 16 542 B Swartzberg – 5 314 5 933 2 532 555 237 14 571 DM Viljoen – 5 019 5 381 2 995 780 183 14 358 Sub-total – 55 114 59 563 16 248 3 283 2 159 136 367 Non-executive ME Tucker4 6 539 – – – – – 6 539 HL Bosman6 1 743 – – – – – 1 743 Dr BA Brink 614 – – – – – 614 SE De Bruyn 591 – – – – – 591 R Farber5 3 219 – – – – 3 633 6 852 MH Hlala 1 102 – – – – – 1 102 FN Khanyile 1 500 – – – – – 1 500 D Macready 1 851 – – – – – 1 851 Dr TV Maphai 1 797 – – – – – 1 797 T Mboweni 209 – – – – – 209 M Schreuder 1 621 – – – – – 1 621 B Van Kralingen7 348 – – – – – 348 SV Zilwa8 2 176 – – – – – 2 176 Sub-total 23 310 – – – – 3 633 26 943 Total 23 310 55 114 59 563 16 248 3 283 5 793 163 310 Less: paid by subsidiaries (23 310) (55 114) (59 563) (16 248) (3 283) (5 793) (163 310) Paid by holding company – – – – – – – 1 “Other benefits” comprise medical aid contributions, travel, other allowances and fees from group subsidiaries. 2 Salary and incentives paid in GBP. 3 Salary and incentives paid in USD. 4 Director’s fees for services rendered are paid in GBP. 5 Director’s fees for services rendered by R Farber were paid in AUD components. 6 Director’s fees for services rendered by HL Bosman were paid to Rand Merchant Insurance Holdings Limited. 7 Director’s fees for services rendered are paid in USD. 8 Participated in Discovery Limited 2015 BEE transaction, which loan outstanding to the Company was fully settled during the 2022 financial year. -- 197 of 217 -- 197 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure C – Directorate continued DIRECTORS’ PARTICIPATION IN LONG-TERM INCENTIVE SCHEMES Discovery’s directors and prescribed officers participate in the various long-term incentive schemes offered by the Group and their participation is disclosed below. Refer to Group note 32 for a detailed description of the various schemes offered. Discovery Limited phantom share scheme Directors and prescribed officers participation as at 30 June 2023: Directors and prescribed officers Outstanding shares Date granted Final vesting date Value at 30 June 2023 R A Gore 12 007 2018/09/30 2023/09/30 1 751 221 HD Kallner 8 053 2018/09/30 2023/09/30 1 174 530 Dr A Ntsaluba 7 078 2018/09/30 2023/09/30 1 032 326 A Pollard 1 640 2018/09/30 2023/09/30 239 194 B Swartzberg 2 819 2018/09/30 2023/09/30 411 151 DM Viljoen 7 597 2018/09/30 2023/09/30 1 108 022 Discovery Limited long-term incentive plan Directors and prescribed officers participation as at 30 June 2023: Directors and prescribed officers Outstanding shares Date granted Final vesting date Value at 30 June 2023 R A Gore 38 200 2019/09/30 2024/09/30 5 571 470 30 434 2020/09/30 2023/09/30 4 438 799 69 707 2020/09/30 2025/09/30 10 166 766 68 786 2021/09/30 2026/09/30 10 032 438 HD Kallner 25 620 2019/09/30 2024/09/30 3 736 677 98 985 2020/09/30 2023/09/30 14 436 962 46 752 2020/09/30 2025/09/30 6 818 779 46 135 2021/09/30 2026/09/30 6 728 790 Dr A Ntsaluba 22 627 2019/09/30 2024/09/30 3 300 148 17 846 2020/09/30 2023/09/30 2 602 839 41 289 2020/09/30 2025/09/30 6 022 001 40 744 2021/09/30 2026/09/30 5 942 512 51 786 2022/11/30 2025/09/30 7 552 988 A Pollard 7 331 2019/09/30 2024/09/30 1 069 226 3 145 2020/09/30 2023/09/30 458 698 22 362 2020/09/30 2025/09/30 3 261 498 22 276 2021/09/30 2026/09/30 3 248 955 83 453 2022/11/30 2025/09/30 12 171 620 7 709 2022/11/30 2027/09/30 1 124 358 B Swartzberg 7 686 2019/09/30 2024/09/30 1 121 003 11 501 2020/09/30 2023/09/30 1 677 421 23 376 2020/09/30 2025/09/30 3 409 390 23 068 2021/09/30 2026/09/30 3 364 468 8 075 2022/11/30 2027/09/30 1 177 739 DM Viljoen 24 170 2019/09/30 2024/09/30 3 525 195 24 797 2020/09/30 2023/09/30 3 616 642 44 105 2020/09/30 2025/09/30 6 432 714 45 197 2021/09/30 2026/09/30 6 591 982 -- 198 of 217 -- 198 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure C – Directorate continued DIRECTORS’ PARTICIPATION IN LONG-TERM INCENTIVE SCHEMES continued The Vitality Group Cash-settled plan Directors and prescribed officers Directors and prescribed officers Outstanding shares Date granted Exercise price USD Final vesting date Value at 30 June 2023 USD A Pollard 36 467 2018/09/30 – 2023/09/30 37 312 139 268 2019/09/30 – 2024/09/30 194 975 153 330 2020/09/30 – 2025/09/30 214 662 167 813 2021/09/30 – 2026/09/30 234 938 B Swartzberg 62 665 2018/09/30 – 2023/09/30 64 118 143 771 2019/09/30 – 2024/09/30 201 279 160 280 2020/09/30 – 2025/09/30 224 393 173 772 2021/09/30 – 2026/09/30 243 281 The VitalityHealth and VitalityLife phantom share schemes Directors and prescribed officers participation as at 30 June 2023: Directors and prescribed officers Outstanding shares Date granted Exercise price GBP Final vesting date Value at 30 June 2023 GBP NS Koopowitz 4 336 2020/03/01 – 2023 192 995 27 430 2022/01/05 – 2024 1 123 533 DIRECTORS’ PARTICIPATION IN SINGLE INCENTIVE PLAN Discovery Limited Single Incentive Plan Directors and prescribed officers participation as at 30 June 2023: Directors and prescribed officers Outstanding shares Date granted Final vesting date Value at 30 June 2023 R A Gore 92 223 2022/11/30 2027/09/30 13 450 725 HD Kallner 67 823 2022/11/30 2027/09/30 9 891 985 Dr A Ntsaluba 55 807 2022/11/30 2027/09/30 8 139 451 A Pollard 91 102 2022/11/30 2027/09/30 13 287 227 B Swartzberg 67 999 2022/11/30 2027/09/30 9 917 654 DM Viljoen 61 054 2022/11/30 2027/09/30 8 904 726 -- 199 of 217 -- 199 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure C – Directorate continued Directors’ interests in shares According to the Register of Directors’ Interests, maintained by Discovery in accordance with the provisions of section 30(4)(d) of the Companies Act, directors and prescribed officers of Discovery have disclosed the following interest in the ordinary shares of the Company at 30 June 2023: Directors and prescribed officers Direct beneficial Indirect beneficial Total 2023 Direct beneficial Indirect beneficial Total 2022 Executive A Gore1 31 372 48 561 559 48 592 931 – 49 046 559 49 046 559 B Swartzberg 2 3 146 461 22 635 115 25 781 576 3 202 227 22 635 115 25 837 342 DM Viljoen 29 850 – 29 850 10 000 – 10 000 HD Kallner4 100 398 – 100 398 100 398 – 100 398 NS Koopowitz4 – 792 004 792 004 – 852 004 852 004 Dr A Ntsaluba5 89 455 – 89 455 80 164 – 80 164 A Pollard5 1 073 099 – 1 073 099 1 193 099 – 1 193 099 Non-executive HL Bosman3 – 164 370 164 370 – 164 370 164 370 R Farber 55 076 – 55 076 55 076 – 55 076 FN Khanyile 1 300 – 1 300 1 300 – 1 300 Dr TV Maphai 1 919 196 505 198 424 1 919 196 505 198 424 SV Zilwa – 680 680 – 680 680 4 528 930 72 350 233 76 879 163 4 644 183 72 895 233 77 539 416 1 Includes 39 300 000 (2022: 39 300 000) ordinary shares which are subject to security. 2 Includes 11 5000 000 (2022: 11 500 000) ordinary shares which are subject to security. 3 Retired effective 1 December 2023 4 Transitioned from Group Executive Director to Prescribed Officer with effect from 1 March 2023 5 Stepped down as Executive Director with effect from 1 March 2023. There has been no change in the directors’ interests in Discovery Limited’s shares between 30 June 2023 and the date of publication of these annual financial statements. -- 200 of 217 -- 200 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure D – Unaudited analysis of shareholders at 30 June 2023 ORDINARY SHAREHOLDERS Number of shareholders % of total shareholders Number of shares % of issued capital Shareholder spread 1 – 1 000 shares 38 753 86.89 5 883 083 0.87 1 001 – 10 000 shares 4 650 10.43 12 676 392 1.88 10 001 – 100 000 shares 878 1.97 27 157 201 4.03 100 001 – 1 000 000 shares 238 0.53 79 460 026 11.81 1 000 001 shares and over 82 0.18 547 969 715 81.41 44 601 100.00 673 146 417 100.00 Public/non-public shareholders Non-public shareholders 19 0.03 178 244 562 26.48 – Directors of the Company, including their associates 9 0.02 75 552 239 11.23 – Employee share trusts 2 0.00 14 045 368 2.09 – Own holdings 1 0.00 680 268 0.10 – Key management personnel and trustees of pension funds 6 0.01 699 089 0.10 – Strategic holdings (more than 10%) 1 0.00 87 267 598 12.96 Public shareholders 44 582 99.97 494 901 855 73.52 44 601 100.00 673 146 417 100.00 Number of shares % Beneficial shareholders’ holding of 5% or more Government Employees Pension Fund (including shares managed by Public Investment Corporation) 87 267 598 12.96 Remgro Limited 51 254 365 7.61 Baillie Gifford & Co Limited 50 465 898 7.50 Adrian Gore 48 592 931 7.22 B PREFERENCE SHAREHOLDERS Number of shareholders % of total shareholders Number of shares % of issued capital Shareholder spread 1 – 1 000 shares 2 611 74.58 305 068 3.81 1 001 – 10 000 shares 756 21.59 2 408 357 30.10 10 001 – 100 000 shares 126 3.60 3 202 255 40.04 100 001 – 1 000 000 shares 8 0.23 2 084 320 26.05 3 501 100.00 8 000 000 100.00 Public/non-public shareholders Public shareholders 3 501 100.00 8 000 000 100.00 Number of shares % Beneficial shareholders’ holding of 5% or more Outsurance Insurance Company Ltd 500 000 6.25 PSG Diversified Income Fund 497 457 6.22 -- 201 of 217 -- 201 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure E – Embedded value statement Report on the review of the Embedded Value Statement of Discovery Limited and its subsidiaries to the Directors of Discovery Limited INTRODUCTION We have reviewed the Embedded Value Statement of Discovery Limited and its subsidiaries (together the Discovery Limited Group) for the year ended 30 June 2023, as set out on pages 202 to 212 of the Discovery Annual Financial Statements for the year ended 30 June 2023 (the Report). The Report is prepared for the purpose of determining the embedded value and performance of Discovery Limited Group. The directors of Discovery Limited are responsible for the preparation and presentation of the Report in accordance with the embedded value basis set out in the Basis of Preparation section of the Report, and for determining that the basis of preparation is acceptable in the circumstances. Our responsibility is to express a conclusion on this Report based on our review. SCOPE OF REVIEW We conducted our review in accordance with the International Standard on Review Engagements ISRE 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity. A review of financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. CONCLUSION Based on our review, nothing has come to our attention that causes us to believe that the Report is not prepared, in all material respects, in accordance with the basis set out in the Basis of Preparation section of the Report. BASIS OF ACCOUNTING AND RESTRICTION ON USE Without modifying our conclusion, we draw attention to the Basis of Preparation section of the Report, which describes the basis of accounting. The Report is prepared for the purpose of determining the value and performance of Discovery Limited Group. As a result, the Report may not be suitable for another purpose. Our report is intended solely for the directors of Discovery Limited and should not be used by any other parties. We agree to the publication of our report in the Discovery Annual Financial Statements for the year ended 30 June 2023, provided it is clearly understood by the recipients of the Discovery Annual Financial Statements for the year ended 30 June 2023 that they enjoy such receipt for information only and that we accept no duty of care to them in respect of our report. PricewaterhouseCoopers Inc. KPMG Inc. Director: Andrew Graham Taylor Director: Mark Danckwerts Registered Auditor Registered Auditor Johannesburg Johannesburg 21 September 2023 21 September 2023 -- 202 of 217 -- 202 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure E – Embedded value statement continued for the year ended 30 June 2023 The embedded value of the Discovery Group consists of the following components: the adjusted net worth attributed to the business at the valuation date; plus: the present value of expected future shareholder cash flows from the in-force covered business; less: the cost of required capital. The present value of future shareholder cash flows from the in-force covered business is calculated as the value of projected future after-tax shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate. The required capital are the assets attributed to the covered business above the amount required to back covered business liabilities, whose distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements. The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the new business written by the Discovery Group, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses and cost of required capital. The value of new business is calculated using the current reporting date assumptions. The embedded value includes the insurance and administration profits of the covered business in the Discovery Group. Covered business includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery Health (“Health”) and Discovery Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality Group, Ping an Health Insurance, Discovery Insure, Discovery Bank and Umbrella Funds, no published value has been placed on the current in-force business. In August 2011, the Discovery Group raised R800 million through the issue of non-cumulative, non-participating, non-convertible preference shares. For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted net worth. From June 2022, the VitalityLife embedded value has been adjusted to allow for the agreement with the Prudential Assurance Company (“PAC”) in May 2022 to defer the transfer of the VitalityLife business on the PAC licence to the Vitality Life Limited licence (“the Part VII transfer”). The 30 June 2023 embedded value results and disclosures were subjected to an external review. -- 203 of 217 -- 203 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure E – Embedded value statement continued for the year ended 30 June 2023 TABLE 1: GROUP EMBEDDED VALUE R million 30 June 2023 30 June 2022 % change Shareholders’ funds 63 974 53 555 19 Adjustment to shareholders’ funds from published basis1 (45 688) (39 764) 15 Adjusted net worth2 18 286 13 791 33 Value of in-force covered business before cost of required capital 83 906 76 077 10 Cost of required capital (4 016) (3 610) 11 Discovery Group embedded value 98 176 86 258 14 Number of shares (millions) 658.4 657.0 Embedded value per share R149.11 R131.29 14 Diluted number of shares (millions) 672.5 668.3 Diluted embedded value per share3 R145.99 R129.07 13 1 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted using the closing exchange rate of R23.99/GBP (June 2022: R20.00/GBP). R million 30 June 2023 30 June 2022 Life net assets under insurance contracts (25 491) (24 793) Vitality Life Limited net assets under insurance contracts (12 051) (8 608) VitalityHealth financial reinsurance asset (4 465) (3 021) VitalityHealth and Vitality Health Insurance Limited deferred acquisition costs (net of deferred tax) (536) (450) VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) (13) (11) Goodwill relating to the acquisition of Standard Life Healthcare and the PAC joint venture (2 969) (2 475) Intangible assets (net of deferred tax) in covered businesses (893) (864) Net preference share capital (779) (779) Reversal of 1 Discovery Place IFRS 16 financial lease accounting 1 333 1 170 Equity settled share based payment mark-to-market adjustment 176 67 (45 688) (39 764) The “equity settled share based payment mark-to-market adjustment” reflects the difference between the provision in the IFRS equity and the mark-to-market value of the equity settled share based payments. -- 204 of 217 -- 204 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure E – Embedded value statement continued for the year ended 30 June 2023 2 The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the embedded value: R million 30 June 2023 30 June 2022 Shareholders’ funds 63 974 53 555 Adjustment to shareholders’ funds (45 688) (39 764) Adjusted net worth 18 286 13 791 Excess of available capital over adjusted net worth 40 336 35 342 Available capital 58 622 49 133 Required capital 41 987 38 658 Excess available capital 16 635 10 475 The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth and the available capital. This includes: – The net preference share capital of R779 million which is included as available capital. – The difference between Vitality Life Limited’s Solvency II Pillar 1 Own Funds and its adjusted net worth. – The difference between Life’s Pillar 1 Own Funds and its adjusted net worth. The following table sets out the required capital for each of the covered businesses: R million 30 June 2023 30 June 2022 Health and Vitality 1 108 1 000 Life and Invest 26 011 25 403 VitalityHealth 4 238 3 164 VitalityLife 10 630 9 091 Total required capital 41 987 38 658 – For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost. – For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement. – For VitalityHealth, the required capital amount was set equal to 1.35 times the Solvency II Pillar 1 Solvency Capital Requirement. – For the VitalityLife business on the PAC licence, the required capital was set equal to 1.5 times the UK Solvency I long-term insurance capital requirement as per the agreement with PAC following the long-term delay of the Part VII transfer. For the business sold on the Vitality Life Limited licence, the required capital was set equal to 1.4 times the Solvency II Pillar 1 Solvency Capital Requirement. Note that for the prior period ended 30 June 2022, the total required capital for VitalityLife was incorrectly reported as R9 751 million resulting in a total required capital of R39 318 million and total excess available capital of R9 815 million. This misstatement has been corrected above, and did not affect the embedded value as at 30 June 2022. 3 The diluted embedded value per share adjusts for treasury shares held in the Discovery Group BEE Share Trust and as part of the Discovery Group’s Long-term Incentive Plan where the impact is dilutive. -- 205 of 217 -- 205 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure E – Embedded value statement continued for the year ended 30 June 2023 TABLE 2: VALUE OF IN-FORCE COVERED BUSINESS R million Value before cost of required capital Cost of required capital Value after cost of required capital at 30 June 2023 Health and Vitality 25 985 (512) 25 473 Life and Invest1 33 301 (1 665) 31 636 VitalityHealth2 12 797 (698) 12 099 VitalityLife 2 11 823 (1 141) 10 682 Total 83 906 (4 016) 79 890 at 30 June 2022 Health and Vitality 24 528 (479) 24 049 Life and Invest1 32 073 (1 509) 30 564 VitalityHealth2 10 658 (583) 10 075 VitalityLife2 8 818 (1 039) 7 779 Total 76 077 (3 610) 72 467 1 Included in the Life and Invest value of in-force covered business is R2 005 million (June 2022: R1 734 million) in respect of investment management services provided on off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth. 2 The value of in-force has been converted using the closing exchange rate of R23.99/GBP (June 2022: R20.00/GBP). TABLE 3: GROUP EMBEDDED VALUE EARNINGS R million 30 June 2023 30 June 2022 Embedded value at end of period 98 176 86 258 Less: embedded value at beginning of period (86 258) (74 645) Increase in embedded value 11 918 11 613 Net change in capital1 – (10) Dividends paid 69 56 Transfer to hedging reserve (76) (309) Employee share option schemes (553) (326) Increase in treasury shares – – Acquisition of subsidiaries with non-controlling interest (6) – Embedded value earnings 11 352 11 024 Annualised return on opening embedded value 13.2% 14.8% 1 The net change in capital reflects share issues (net of costs and proceeds) and an increase (decrease) in treasury shares in the period. -- 206 of 217 -- 206 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure E – Embedded value statement continued for the year ended 30 June 2023 TABLE 4: COMPONENTS OF GROUP EMBEDDED VALUE EARNINGS Year ended 30 June 2023 Year ended 30 June 2022 R million Net worth Cost of required capital Value of in-force covered business Embedded value Embedded value Total profit from new business (at point of sale) (5 213) (302) 6 955 1 440 2 061 Profit from existing business – Expected return 7 196 (33) 1 426 8 589 6 799 – Change in methodology and assumptions1 1 989 172 (7 015) (4 854) 867 – Experience variances 716 68 2 420 3 204 3 124 Impairment, amortisation and fair value adjustment2 (67) – – (67) (52) Increase in goodwill and intangibles (263) – – (263) (418) Other initiatives 3 – – 24 24 (836) Non-recurring expenses (193) – – (193) (130) Acquisition costs 4 (50) – 2 (48) (41) Finance costs (2 848) – – (2 848) (2 318) Foreign exchange rate movements 5 1 365 (312) 4 017 5 070 1 171 Other6 89 1 – 90 (16) Return on shareholders’ funds7 1 208 – – 1 208 813 Embedded value earnings 3 929 (406) 7 829 11 352 11 024 1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the operating and economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to previous embedded value statements). 2 This item reflects the amortisation of the intangible assets reflecting the banking costs, Cambridge Mobile Telematics system spend and capital expenditure in Discovery Group Europe Limited. 3 This item includes the profits of non-covered businesses (including Discovery Insure, Vitality Group and Ping An Health Insurance) and costs of start-up businesses (including Discovery Bank, a commercial offering in Discovery Insure, and an Umbrella Fund offering in Invest). Head office costs which relate to non-covered business are also included in this item. 4 Acquisition costs relate to commission paid on the Life and Invest business and expenses incurred in writing Health and Vitality business that has been written over the period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the value of new business and therefore the costs are not deducted from the value of new business. 5 This item includes foreign exchange gains/(losses) emerging through the income statement, in addition to translation impacts on the cost of required capital and value of in-force. 6 This item includes, among other items, the tangible tax impact from movements in covered business intangible assets, which are excluded from the net worth. 7 The return on shareholders’ funds is shown net of tax and management charges. -- 207 of 217 -- 207 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure E – Embedded value statement continued for the year ended 30 June 2023 TABLE 5: EXPERIENCE VARIANCES Health and Vitality Life and Invest VitalityHealth VitalityLife R million Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force Total Renewal expenses 67 – 32 2 (93) – (16) – (8) Lapses and surrenders 1,2 (4) (78) 1 189 – 372 (161) 218 537 Mortality and morbidity – – 130 (79) (93) – 34 – (8) Policy alterations2 – (5) (521) 163 – – 30 (54) (387) Backdated cancellations – – – – – – – – – Premium and fee income 3 150 – 14 232 218 – 7 61 682 Inflation-linked indexation2,4 – – 4 242 – – (107) 606 745 Economic5 – – 260 284 64 – (2) – 606 Commission – – – – (36) – – – (36) Tax6 110 – 305 (307) (33) – 46 – 121 Reinsurance – – – – 84 – (106) 46 24 Maintain modelling term7 – 335 – 137 – 117 – – 589 Vitality benefits (32) – – – – – (5) – (37) Other8 161 (1) (58) 35 19 – 247 (27) 376 Total 452 251 167 898 130 489 (33) 850 3 204 1 For Health and Vitality, the lapse and surrender experience was driven by the termination of an in-house scheme for the period under review – excluding this impact would have resulted in a positive experience variance for the business. For VitalityHealth, the experience reflects improved retention rates from strong performance across all channels coupled with a continued focus on renewal pricing strategies. Better than expected lapse experience has been observed for the other covered businesses. 2 For Life and Invest, the policy alterations experience relates mainly to acquisition costs on positive servicing, but should be considered in the context of the overall positive lapse and surrender and economic experience variances given its correlation to current economic conditions and the high inflationary environment. 3 Other than higher than expected premium and fee income, this experience variance item includes the impact of positive integration experience for Individual Life, and an increased demand for private medical insurance in the United Kingdom improving premium retention for VitalityHealth. 4 This experience variance relates to premium and benefit increases for inflation-linked policies, net of increase holidays. During the period the actual inflation was higher than expected for those policies passing through an anniversary increase in-period. In previous embedded value statements, this experience variance was included under economic experience. Due to the significance of these experience variances in the current period as a result of the high inflationary environment, this amount has been shown separately. 5 For Life and Invest, the experience includes higher than expected growth in asset values in the Invest business. 6 The tax variance arises due to the timing difference between the expected tax payments and actual payments. 7 For Health and Vitality, Life and Invest and VitalityHealth, the projection term is rebased at each year-end. Therefore, an experience variance arises because the total term of the in-force covered business is effectively increased by twelve months. 8 The key Other experience relates to cash flow timing variances in Life and Invest, profits and losses from companies within the Health, VitalityHealth and VitalityLife segments which are not part of covered business, including the net impact of the VitalityLife swaption program, excluding gains or losses from the hedge which are included in the economic assumption changes item. -- 208 of 217 -- 208 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure E – Embedded value statement continued for the year ended 30 June 2023 TABLE 6: METHODOLOGY AND ASSUMPTION CHANGES Health and Vitality Life and Invest VitalityHealth VitalityLife R million Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force Total Modelling changes 1 41 – (121) 202 – – 48 (190) (20) Expenses 2 – (495) 5 (133) – – – – (623) Lapses 3 – – (170) (1 115) – – – – (1 285) Mortality and morbidity4 – – – – – – 81 (219) (138) Benefit changes – (18) – – – – – – (18) Vitality – – – – – – – – – Tax – – – – – – – (13) (13) Economic assumptions 5 – (1 318) 23 (2 126) – (1 072) 106 (293) (4 680) Premium and fee income6 – 1 084 108 454 – – – – 1 646 Reinsurance and financing 7 – – 1 867 (1 735) – 63 – – 195 Other – – 1 81 – – – – 82 Total 41 (747) 1 713 (4 372) – (1 009) 235 (715) (4 854) 1 For Health and Vitality and Life and Invest, the item reflects refinements to the data and models. For VitalityLife, the item reflects modelling improvements related to commission and reinsurance. 2 For Health and Vitality and Life and Invest, the expense assumption update reflects an alignment to the expense budget for the next financial year. 3 For Life and Invest, the long-term decrement basis was reviewed and updated in line with lower exit rates observed on certain Invest product lines, and a short-term allowance for elevated expected lapse and policy alterations experience on the Life business. 4 For VitalityLife, the mortality basis, with respect to future mortality improvements, and the serious illness cover basis was reviewed. The existing shared value model was reviewed and replaced with a new model to more appropriately capture the impact that shared value has on the business’ underlying demographic basis. 5 For Health and Vitality and Life and Invest, the economic assumptions were updated in line with observed market nominal and real yield risk-free curves at 30 June 2023. For VitalityLife, the item includes the impact of updating the assumptions relative to the Solvency II yield curves and the IFRS interest rates, offset by the net change in the interest rate hedge. For VitalityHealth, the impact of updating the assumptions relative to the Solvency II yield curves results in a reduction to the annuity factor. 6 For Health and Vitality, the premium and fee income item relates to an update of the administration fee income escalations for certain plans recently renewed. For Life and Invest, Invest fee structures were reviewed in response to updated persistency expectations. 7 For Life and Invest, the reinsurance and financing item primarily relates to the impact of financing arrangements, where the future expected cash flows arising from part of the negative reserves are monetised to match other positive policy liabilities. -- 209 of 217 -- 209 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure E – Embedded value statement continued for the year ended 30 June 2023 TABLE 7: EMBEDDED VALUE OF NEW BUSINESS R million 30 June 2023 30 June 2022 % Change Health and Vitality Present value of future profits from new business (at point of sale) 954 958 Cost of required capital (39) (30) Present value of future profits from new business (at point of sale) after cost of required capital 915 928 (1) New business annualised premium income1 4 959 4 185 18 Life and Invest Present value of future profits from new business (at point of sale)2 516 795 Cost of required capital (87) (90) Present value of future profits from new business (at point of sale) after cost of required capital 429 705 (39) New business annualised premium income3 2 965 2 995 (1) Annualised profit margin4 1.8% 3.0% Annualised profit margin excluding Invest business 2.5% 5.3% VitalityHealth5 Present value of future profits from new business (at point of sale) 269 398 Cost of required capital (87) (81) Present value of future profits from new business (at point of sale) after cost of required capital 182 317 (43) New business annualised premium income6 2 001 1 648 21 Annualised profit margin4 1.4% 2.6% VitalityLife7 Present value of future profits from new business (at point of sale) 3 219 Cost of required capital (89) (108) Present value of future profits from new business (at point of sale) after cost of required capital (86) 111 (177) New business annualised premium income 1 124 882 27 Annualised profit margin4 (1.0%) 1.4% 1 Health new business annualised premium income is the gross contribution to the medical schemes. The new business annualised premium income shown above excludes premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as well as premiums in respect of new business written during the period but only activated after 30 June 2023. The total Health and Vitality new business annualised premium income written over the period was R9 051 million (June 2022: R7 548 million). 2 Included in the Life and Invest embedded value of new business is R21 million (June 2022: R54 million) in respect of investment management services provided on off balance sheet investment business. Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the impact of which has been recognised in the value of new business. 3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first premium is due after the valuation date. Invest new business is defined as business where at least one premium has been received and which has not been refunded after receipt. Invest new business also includes Discovery Retirement Optimiser policies to which Life and Invest became contractually bound during the reporting period, including policies whose first premium is due after the valuation date. The new business annualised premium income of R2 965 million (June 2022: R2 995 million) (single premium APE: R1 430 million (June 2022: R1 421 million)) shown above excludes automatic premium increases and servicing increases in respect of existing business. The total new business annualised premium income written over the period, including automatic premium increases of R2 208 million (June 2022: R1 801 million) and servicing increases of R716 million (June 2022: R668 million), was R5 889 million (June 2022: R5 464 million) (single premium APE: R1 499 million (June 2022: R1 492 million)). Single premium business is included at 10% of the value of the single premium. Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans are shown in Table 5 as experience variances and not included as new business. Term extensions on existing contracts are not included as new business. 4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums. 5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation date multiplied by the Margin multiplied by the Annuity Factor less the new business cash flows from point of sale to the valuation date. The assumptions for the Margin and Annuity Factor are shown in Table 8. 6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised premium income shown above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month, as well as premiums in respect of new business written during the period but only activated after 30 June 2023. 7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies whose first premium is due after the valuation date. -- 210 of 217 -- 210 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure E – Embedded value statement continued for the year ended 30 June 2023 Basis of preparation TABLE 8: EMBEDDED VALUE ECONOMIC ASSUMPTIONS 30 June 2023 30 June 2022 Beta coefficient 0.75 0.75 Equity risk premium (%) 3.5 3.5 Risk discount rate (%) – Health and Vitality1 15.125 14.375 – Life and Invest1 15.875 14.875 – VitalityHealth 7.000 5.016 – VitalityLife 7.042 4.997 Rand/GBP exchange rate Closing 23.99 20.00 Average 21.43 20.25 Margin over Expense inflation to derive Medical inflation (%) South Africa 3.00 3.00 Expense inflation (%)2 South Africa – Health and Vitality 7.96 7.85 – Life and Invest 8.13 7.74 United Kingdom 3.75 3.75 Pre-tax investment return (%) South Africa – Cash1 11.75 10.75 – Life and Invest bonds3 13.25 12.25 – Health and Vitality bonds3 12.50 11.75 – Equity1 16.75 15.75 United Kingdom – VitalityHealth risk-free rate 4.38 2.39 – VitalityLife risk-free rate 4.42 2.37 – VitalityLife IFRS interest rate 3.98 2.92 – VitalityLife investment return 4.31 2.00 Long-term corporation tax rate (%) South Africa 27 27 United Kingdom 25 25 VitalityHealth Assumptions – Margin (net of tax and cost of capital) (%) 12.05 12.00 – Annuity Factor 6.28 7.00 Projection term – Health and Vitality 20 years 20 years – Discovery Life – VIF 40 years 40 years – Group Life 20 years 20 years – VitalityLife No cap No cap – VitalityHealth4 20 years 20 years 1 Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds. 2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow weighted average inflation is shown in the table. For the United Kingdom, the expense inflation assumption is aligned with the long-term market view of inflation. 3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown. 4 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor. -- 211 of 217 -- 211 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure E – Embedded value statement continued for the year ended 30 June 2023 The Discovery Group embedded value is calculated based on a risk discount rate using the Capital Asset Pricing Model (CAPM) approach with specific reference to the Discovery Group beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk discount rate proxies the result of a Weighted Average Cost of Capital approach with reference to the capital structure of the Group and the observed beta calculated using daily returns over a long time period. The observed beta is calculated with reference to the ALSI. The assumed beta will only change if the capital structure of the Group and/or the observed beta calculated using daily returns over a long time period suggest the beta assumption should depart significantly from the assumption at the financial year-end. As beta values reflect the historic performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk. Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available, augmented by reinsurance and industry information. The Health and Vitality lapse assumptions were derived from the results of recent experience investigations. The VitalityHealth assumptions were derived from internal experience. VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery Group group information. Renewal expense assumptions were based on the results of the latest expense and budget information. The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding expenses of an exceptional or non-recurring nature. The South African investment return assumptions for Life, Invest, Health and Vitality were set relative to the publicly available JSE risk-free nominal yield curve. The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining the net investment return assumption. The risk-free rate assumption for VitalityHealth and VitalityLife was based on the single interest rate derived from the Prudential Regulatory Authority yield curve. The inflation rate is consistent with the long-term market view of inflation. From 30 June 2018, VitalityHealth calculate the value of in-force at the valuation date as the in-force written premium multiplied by the Margin multiplied by the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed future lapse rates and premium increases. The Margin assumption reflects profit margins after tax and Cost of Capital. The assumptions underlying the Annuity Factor and Margin are set taking into account the current experience in the business at different durations. The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on tangible assets. The Vitality Life Limited and the VitalityLife business on the PAC licence required capital amount is assumed to earn the investment return assumption, which is set based on the return on a portfolio of government and corporate bonds assumed to back the required capital. The Life and Invest cost of required capital is calculated assuming shareholder cash flow is limited to the cash flow available after having met both the required capital amount and an internally defined liquidity target capital requirement of tangible assets. The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”) 107: Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to take into account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 2. -- 212 of 217 -- 212 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure E – Embedded value statement continued for the year ended 30 June 2023 Sensitivity to the embedded value assumptions The risk discount rate uses the CAPM approach with specific reference to the Discovery Group beta coefficient. As beta values reflect the historic performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk. Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. The sensitivity of the embedded value and the embedded value of new business at 30 June 2023 to changes in the risk discount rate is included in the tables below. For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for management action such as risk premium increases where future experience is worse than the base assumptions. TABLE 9: EMBEDDED VALUE SENSITIVITY Health and Vitality Life and Invest VitalityHealth VitalityLife Embedded value % change R million Adjusted net worth2 Value of in-force Cost of required capital Value of in-force Cost of required capital Value of in-force Cost of required capital Value of in-force Cost of required capital Base 18 286 25 985 (512) 33 301 (1 665) 12 797 (698) 11 823 (1 141) 98 176 Impact of: Risk discount rate + 1% 18 286 24 563 (551) 30 350 (1 759) 12 160 (664) 11 106 (1 002) 92 489 (6) Risk discount rate – 1% 18 286 27 555 (467) 36 786 (1 555) 13 501 (737) 12 625 (1 310) 104 684 7 Lapses – 10% 18 054 26 824 (536) 36 226 (1 760) 14 943 (815) 12 579 (1 374) 104 141 6 Interest rates – 1% 1 17 316 25 887 (494) 33 841 (1 636) 13 501 (737) 11 987 (1 454) 98 211 – Equity and property market value – 10% 18 247 25 985 (512) 32 595 (1 658) 12 797 (698) 11 823 (1 141) 97 438 (1) Equity and property return + 1% 18 286 25 985 (512) 33 657 (1 665) 12 797 (698) 11 823 (1 141) 98 532 – Renewal expenses – 10% 18 402 28 602 (473) 33 978 (1 636) 13 925 (698) 12 077 (1 126) 103 051 5 Mortality and morbidity – 5% 18 560 25 985 (512) 35 550 (1 544) 14 876 (698) 12 279 (1 105) 103 391 5 Projection term + 1 year 18 286 26 295 (517) 33 391 (1 667) 12 889 (703) 11 823 (1 141) 98 656 – 1 All economic assumptions were reduced by 1%. 2 The sensitivity impact on the VitalityLife net of tax change in negative reserves is included in the adjusted net worth column. The following table shows the effect of using different assumptions on the embedded value of new business. TABLE 10: VALUE OF NEW BUSINESS SENSITIVITY Health and Vitality Life and Invest VitalityHealth VitalityLife Value of new business % change R million Value of new business Cost of required capital Value of new business Cost of required capital Value of new business Cost of required capital Value of new business Cost of required capital Base 954 (39) 516 (87) 269 (87) 3 (89) 1 440 Impact of: Risk discount rate + 1% 875 (43) 341 (92) 170 (82) (103) (75) 991 (31) Risk discount rate – 1% 1 040 (36) 718 (81) 379 (93) 122 (107) 1 942 35 Lapses – 10% 1 022 (43) 707 (92) 509 (100) 120 (106) 2 017 40 Interest rates – 1%1 960 (38) 508 (85) 379 (93) 90 (123) 1 598 11 Equity and property return + 1% 954 (39) 543 (87) 269 (87) 3 (89) 1 467 2 Renewal expense – 10% 1 094 (37) 567 (85) 399 (87) 41 (85) 1 807 25 Mortality and morbidity – 5% 954 (39) 609 (80) 508 (87) 39 (82) 1 822 27 Projection term + 1 year 970 (40) 521 (87) 284 (87) 3 (89) 1 475 2 Acquisition costs – 10% 985 (39) 686 (87) 317 (87) 172 (89) 1 858 29 1 All economic assumptions were reduced by 1%. -- 213 of 217 -- 213 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Annexure F – Unaudited five-year review for the year ended 30 June 2023 Group 2019 Group 2020 Group 2021 Group 2022 Group 2023 Compound growth % Income statement extracts (R million) Profit from operations 7 536 1 532 5 304 7 858 8 662 4% Headline earnings 5 147 296 2 986 5 204 5 490 2% Abnormal expenses/(income) (112) 3 451 420 612 2 188 Normalised headline earnings 5 035 3 747 3 406 5 816 7 678 11% Diluted normalised headline earnings per share (cents) 771.6 566.7 512.9 877.3 1 160.9 11% Statement of financial position extracts (R million) Total assets 180 233 210 328 246 694 271 224 301 773 14% Shareholders' funds 43 083 44 549 46 415 53 550 63 970 10% Embedded value Embedded value (R million) 71 217 70 834 74 645 86 258 98 315 8% Diluted embedded value per share (R) 108.30 107.71 112.23 129.07 146.20 8% Key ratios Return on average equity (%) 16.4 0.4 7.1 11.0 9.1 Return on average assets (%) 3.9 0.1 1.4 2.1 1.9 Exchange rates Rand/USD – Closing 14.15 17.41 14.28 16.47 18.87 – Average 14.17 15.70 15.42 15.22 17.79 Rand/GBP – Closing 17.98 21.44 19.74 20.00 23.99 – Average 18.32 19.75 20.74 20.25 21.43 Share statistics Number of ordinary shares in issue – Weighted average (000's) 652 295 656 648 656 710 656 901 658 045 – Diluted weighted average (000's) 652 568 661 242 664 073 663 082 661 328 – End of period (000's) 658 291 658 291 665 769 668 963 673 146 Price/diluted headline earnings (times) 19.3 18.3 24.7 14.6 12.6 Share price (cents per share): – High 17 830 15 163 15 738 18 280 15 266 – Low 13 287 5 815 10 047 11 760 10 241 – Closing 14 911 10 455 12 667 12 810 14 585 Market capitalisation (R million) 98 158 68 824 84 333 85 694 98 172 -- 214 of 217 -- 214 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Glossary of terms Abbreviation Meaning AIAV AIA Vitality Proprietary Limited API Annual Premium Income CAE Chief Audit Executive CCIC Capital, Currency and Investment Committee CEO Chief Executive Officer CFC Controlled Foreign Company CFO Chief Financial Officer CGU Cash generating unit CIPC Companies and Intellectual Property Commission CMT Cambridge Mobile Telematics CODM Chief Operating Decision-Maker Companies Act South African Companies Act, 71 of 2008 CRO Chief Risk Officer CSM Contractual Service Margin (unearned profit) DHEL Discovery Holdings Europe Limited DHMS Discovery Health Medical Scheme Discovery Discovery Limited Group DLAC Discovery Limited Audit Committee DMTN Domestic Medium Term Note DRG Discovery Risk Grades DVA Discovery Vitality Australia Proprietary Limited ECL Expected credit losses ESG Environmental, Social, and Corporate Governance FCA Finance Conduct Authority FCC Finance and Capital Committee FEC Foreign Exchange Contracts FGC Financial Guarantee Contracts FinRe Financial Reinsurance – with risk transfer FLR Financial Leverage Ratio FRC United Kingdom Financial Reporting Council FSV Financial Soundness Valuation FVTPL Fair value through profit or loss GIA Group Internal Audit GMM General Measurement Model HAF Head of Actuarial Function IASB International Accounting Standards Board IBNR incurred but not yet reported claims ICA Individual Capital Assessment IFA Insurance Fund Account IFRS International Financial Reporting Standards INSPRU The Prudential Sourcebook for Insurers IRBA South African Independent Regulatory Board of Auditors -- 215 of 217 -- 215 DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023 Abbreviation Meaning JSE Johannesburg Stock Exchange KAM Key Audit Matters LIC Liability for Incurred Claims LRC Liability for Remaining Coverage LTICR Long-term Insurance Capital Requirement LTIP Long-term Incentive Plan MAFR Mandatory audit firm rotation Morbidity Morbidity claims are claims which arise as a result of an impairment of life due to an illness or disability event insured by the policyholder Mortality Mortality claims are claims which arise from the death of an insured life NCD Negotiable certificates of deposits OCI Other Comprehensive Income OCR Outstanding Claims Reserve ORSA Own Risk and Solvency Assessment PA Prudential Authority (South Africa) PAA Premium Allocation Approach PAC Prudential Assurance Company PAHI Ping An Health Insurance Company of China Ltd PRA Prudential Regulatory Authority (United Kingdom) ROEV Return On Opening Embedded Value SA South Africa SAICA South African Institute of Chartered Accountants SAM Solvency Assessment and Management SAP Standard of Actuarial Practice SCR Solvency Capital Requirement SME Small and Medium-sized Enterprises TCFD Task Force on Climate-related Financial Disclosure TRS Total Return equity Swaps UK United Kingdom VFA Variable Fee Approach VGI Vitality Group International Inc. WHT Withholding Tax Glossary of terms continued -- 216 of 217 -- Discovery Limited | +27 11 529 2888 | askthecfo@discovery.co.za | www.discovery.co.za Copyright 2021. Discovery Ltd is the licensed controlling company of the designated Discovery Insurance Group. Registration number: 1999/007789/06. Companies in the Group are licensed insurers and authorised financial services providers. -- 217 of 217 --